{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f2b1d406-70b1-40be-9490-be2ed3e5d55d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from langchain.document_loaders import PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.embeddings import HuggingFaceEmbeddings\n",
    "from langchain_community.vectorstores import LanceDB\n",
    "from langchain_community.embeddings import HuggingFaceEmbeddings\n",
    "import lancedb\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain_openai import ChatOpenAI\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "48f3786f-d47e-4b7a-a6d3-3cf55fef71cd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded 286 pages\n"
     ]
    }
   ],
   "source": [
    "PDF_PATH = \"Kenya-ARV-Guidelines-2022-Final-1.pdf\"\n",
    "\n",
    "loader = PyPDFLoader(PDF_PATH)\n",
    "documents = loader.load()\n",
    "\n",
    "print(f\"Loaded {len(documents)} pages\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "98dd4b72-0a7f-45fe-8299-98b9e39295e5",
   "metadata": {},
   "source": [
    "## Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "fbbd212a-64df-4fcb-9b94-a0970806df10",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Created 1013 chunks\n"
     ]
    }
   ],
   "source": [
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size=800,\n",
    "    chunk_overlap=150,\n",
    "    separators=[\"\\n\\n\", \"\\n\", \".\", \" \"]\n",
    ")\n",
    "\n",
    "chunks = text_splitter.split_documents(documents)\n",
    "print(f\"Created {len(chunks)} chunks\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "0dfead11-828f-468e-86b0-397281847f5c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=' \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 0}),\n",
       " Document(page_content='', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 1}),\n",
       " Document(page_content='  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content=' \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content=' \\n \\ni Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health . \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content=' \\n \\nii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content=' \\n \\niii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix \\nList of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2 \\n2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2 \\n2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4 \\n3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15 \\n4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31 \\n4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34 \\n4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content=' \\n \\nv 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40 \\n4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5 \\n5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7 \\n5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31 \\n5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1 \\n6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7 \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10 \\n8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13 \\n9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1 \\n9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6 \\n9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1 \\n10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content=' \\n \\nvii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2 \\n11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5 \\n11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12 \\n11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1 \\n12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content=' \\n \\nix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15 \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39 \\nFigure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3 \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7 \\nTable 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2 \\nTable 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9 \\nTable 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29 \\nTable 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content=' \\n \\nxi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13 \\nTable 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23 \\nTable 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32 \\nTable 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5 \\nTable 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1 \\nTable 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10 \\nTable 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1 \\nTable 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4 \\nTable 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content=' \\n \\nxiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up. ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9. \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently  \\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?    \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content=' Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ ) ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.  \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.  \\n      \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further . \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia  \\n   \\n \\n \\n \\n \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in  \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic\\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE\\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence  \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event  \\n         \\n         \\n         \\n         \\n         \\n         \\n \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='  \\nAnnexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years \\nweighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3 \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.  \\n   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction  \\n \\n \\n \\n \\n \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)  \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts  \\n \\n   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability  \\n• Potentially lead to \\ndeath  \\nExamples:  \\n• Decline in \\npulmonary \\ncapacity from TB \\nor MAC infection  \\n• Neurologic \\ncomplications \\nfrom cryptococcal \\ninfection  \\n• Loss of vision from \\nCMV retinitis \\ninfection  • Treat the OI and manage the associated \\nsymptoms  \\n• Manage t he IRIS -associated inflammation:  \\no If NOT KS: give 1 to 2 mg/kg prednisone for \\n1 to 2 weeks. Follow with a period of \\nindividualized tapering of the dose  \\no Do not use corticosteroids for the \\nmanagement of KS -related IRIS  \\n• Closely monitor patients on corticosteroid \\ntherapy for:  \\no Hyperglycemia  \\no Hypertension  \\no Mental status changes  \\no Avascular necrosis  \\no Worsening of an existing infection  \\no Predisposition to a new infection (e.g., TB \\nand CMV)  \\n    \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 59 Annex 17: HTS Adult Screening Tool Enhancement  \\n  \\nCounty: …………………………………………. Sub -County Name: ………………………………….  \\n \\nFacility Name:……………………………… Facility MFL Code: ……………………………………  \\n1 Today’s Date                                              Gender                                             AGE  \\n \\n………………………….                            \\n2 Have you ever tested for HIV Before?  \\nIf yes, what was the HIV result?         Positive                      Negative  \\nIf positive, Date of ART initiation. ……………………. (Not eligible for testing)  \\nIf Negative, when is the most recent HIV test?   Months              Years  \\n \\n3 If negative or status unknown, determine  behavioural risk of HIV acquisition  by \\nasking the following questions:  \\n• Unprotected sex within the last 3 months  \\n• Unknown status of the sexual partners  \\n• New sexual partner within the last 3 months  \\n• Multiple sexual partners  \\n• intergenerational relationships  \\n• Symptoms of sexually transmitted infection (refer to MoH syndromic \\nchart) or history of STI  \\n• Pregnancy for females  \\n• Assessing h istory of recurrent illnesses without resolution of symptoms, \\nacute or chronic febrile illness (symptoms ≥ 14 days) and any other \\nconditions suggestive of HIV  \\n4 Possible Risk exposures:  \\n• Defilement  \\n• Traditional /non -medical procedures e.g., scarification, plastic tooth \\nextraction , Circumcision, uvulectomy etc.  \\n5 If Risk noted or clinical assessment suggest HIV, eligible for testing  \\n6. If No risk noted and assessment does not suggest, not eligible  \\nName  Institutions  \\n \\n  \\n M\\nM\\nM  F \\n  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 280}),\n",
       " Document(page_content=\" Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 60 Annex 1 8: List of Contributors and Affiliation  \\n  Name  Affiliation    Name  Affiliation  \\n1 Abraham Katana  CDC  61 Jonah Magare  MOH NASCOP  \\n2 Adrian Gardner  Moi University  62 Jonah Maswai   DoD  \\n3 Agnes Langat  CDC  63 Jonah Onentiah  MOH NASCOP  \\n4 Alice Njoroge  Kajiado County  64 Jonathan Mwangi  CDC  \\n5 Ambrose Juma  MOH NASCOP  65 Joseph Mbuthia  Mater Hospital  \\n6 Anne Marie \\nMacharia  KNH  66 Joseph Nkuranga  UON  \\n7 Anthony Wachira  MOH NASCOP  67 Judith Lusike  CHAI  \\n8 Appolonia Aoko  CDC  68 Julius Kisio  Murang'a County  \\n9 Barbara Mambo  MOH NASCOP  69 Julius Oliech  CDC  \\n10 Brandwell Mwangi  CHAI  70 Justine Odionyi  EGPAF  \\n11 Brenda Opanga  MOH NASCOP  71 Justus Ogada  CHAI  \\n12 Celestine \\nImuuraget  DOD  72 Kenneth Masamaro  CDC  \\n13 Christine Kisia  WHO  73 Lazarus Momanyi  MOH NASCOP  \\n14 Claver Kimathi  Isiolo County  74 Lennah Nyabiage  CDC  \\n15 Collins Etemesi  MOH NASCOP  75 Leonard Kingwara  MOH NHRL  \\n16 Dalton Wamalwa  UON  76 Leonard Soo  USAID  \\n17 Daniel Kimani  CDC  77 Loice Achieng Ombajo  UON  \\n18 Daniel Were  JHPIEGO  78 Margaret Ndubi  UNAIDS  \\n19 Davis Karambi  CHAI  79 Mary Mugambi  MOH NASCOP  \\n20 Deborah Carpenter  CDC  80 Mary Nyangasi  MOH NCCP  \\n21 Deborah Goldstein  USAID  81 Marybeth Maritim  UON  \\n22 Deborah Ikonge  MOH NASCOP  82 Maureen Inimah  MOH NASCOP  \\n23 Dennis Osiemo  USAID  83 Maureen Syowai  ICAP at Columbia \\nUniversity  \\n24 Diana Marangu  UoN  84 Mike Ekisa  Kakamega County  \\n25 Dinah Mamai   CHS  85 Muthoni Karanja  DOD  \\n26 Dorcus Abuya  UNICEF  86 Nancy Bowen  MOH NHRL  \\n27 Doreen Muriithi  JHPIEGO  87 Nandita Sugandhi  ICAP at Columbia \\nUniversity  \\n28 Dorothy Mwagae  MOH NASCOP  88 Natella Rakhmanina  EGPAF  \\n29 Douglas Gaitho  AKUH  89 Nelson Otwoma  NEPHAK  \\n30 Dunstan Achwoka  USAID  90 Newton Omale  MOH NASCOP  \\n31 Edith Apondi  AMPATH Plus  91 Odylia Muhenje  CDC  \\n32 Elaine Abrams   ICAP at Columbia \\nUniversity  92 Pacific Akinyi  MOH NASCOP  \\n33 Elizabeth Irungu  JHPIEGO  93 Patricia Oluoch  USAID  \\n34 Elizabeth Katiku  CDC  94 Patricia Ongwen  JHPIEGO  \", metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 281}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 61 35 Elizabeth Mueni  NMS  95 Philip Kimani  CHAI  \\n36 Elizabeth Onyango  MOH NCD  96 Rogers Simiyu  EGPAF  \\n37 Elizabeth Washika  MOH NASCOP  97 Rose Ayugi  MOH NASCOP  \\n38 Emma Momanyi  CIHEB  98 Rose Wafula  MOH NASCOP  \\n39 Eric Mutua  MOH NASCOP  99 Ruby Fayorsey                  ICAP at Columbia \\nUniversity  \\n40 Evelyn Ngugi  CDC  100  Ruth Kamau  MOH NASCOP  \\n41 Everline Ashiono  USAID Dumisha Afya  101  Ruth Korir  Mathari Hospital  \\n42 Felicistas Makokha  NyaWest RTWG  102  Ruth Musyoki  MOH NASCOP  \\n43 Francis Ndwiga  MOH NASCOP  103  Ruth Nduati  UoN  \\n44 Frank Basiye  CDC  104  Salome Okutoyi  USAID  \\n45 George Siberry  USAID  105  Sarafuina Sikwata  MOH NASCOP  \\n46 Grace Rabut  MOH NASCOP  106  Sarah Masyuko  MOH NASCOP  \\n47 Helen Chun  CDC  107  Shobha Vakil                     ICAP at Columbia \\nUniversity  \\n48 Herb Herwell  CHAI  108  Sospeter Gitonga  MOH NASCOP  \\n49 Herman Wayenga  CDC  109  Steve Oyule  DoD  \\n50 Immaculate \\nMutisya  CDC  110  Susan Njogo  ARC Kenya  \\n51 Irene Mukui  DnDI  111  Teresa Simiyu  USAID  \\n52 Isabella Yonga  USAID  112  Terezah Alwar  UNICEF  \\n53 Ivy Kasirye  WHO  113  Vakil, Shobha  ICAP  \\n54 Jafred Mwangi  MOH NASCOP  114  Valeria Makory  MOH NASCOP  \\n55 James Wagude  NyaWest RTWG  115  Valerie Obare  MOH NASCOP  \\n56 Janet Muema  MOH NASCOP  116  Veronica Irungu  CHS  \\n57 Japheth Gituku  MOH NASCOP  117  Virginia Karanja  CHS  \\n58 Jeremy Penner  UBC  118  Wangui Kamau  KNH  \\n59 Joan -Paula Bor  MOH NCCP  119  Wanjiku Ndegwa  MOH NASCOP  \\n60 John Mungai  CHAI  120  Winifred Nyanya  MOH NASCOP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 282}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 62 Annex 19: List of Participating Organizations and Agencies  \\nContributing Organizations  \\nCenter for Health Solutions  \\nAga Khan University Hospital  \\nAMPATH Plus  \\nARC Kenya  \\nCenter for Disease Control  \\nCIHEB Kenya  \\nClinton Health Access Initiative  \\nCouncil of Governors  \\nDepartment of Defence  \\nDnDI  \\nEGPAF  \\nICAP at Columbia University  \\nJHPIEGO  \\nKenyatta Nati onal Hospital  \\nMater Hospital  Mathari National TRH  \\nMOH Department of NCD  \\nMOH Division of NCCP  \\nMOH NASCOP  \\nMOH NHRL  \\nMOH NLTP  \\nMoi University  \\nNairobi Metropolis Services  \\nNEPHAK  \\nUCSF  \\nUNICEF  \\nUniversity of British Columbia  \\nUniversity of Nairobi  \\nUSAID  \\nWorld Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 283}),\n",
       " Document(page_content=' \\n63 - 264   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 284}),\n",
       " Document(page_content=' \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 285})]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "d7ee6b4d-196c-46af-961c-998bf7ce1250",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content='© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content='by NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content='i Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='Disease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='and treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='health sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health .', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content='ii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='person, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='Financial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content='iii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='List of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content='v 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P),', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content='vii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Annex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='Annex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content='ix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Figure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='Table 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content='xi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Table 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content='xiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='FTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='AIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Support  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='DAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='EDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='FLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='self-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='Consists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='transmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='be screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='important during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='have been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='confirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='after assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='monitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='integrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='and repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='continued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='rifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='immediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='Summary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='pregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='other populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='screening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='In Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='tools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='delivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='blood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='whereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='and injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='infected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='HIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='and be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='Adolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='disclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='unknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='multiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='post -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='correct use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='confidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='During the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='algorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Explain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='members, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Post -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='If the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Child HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Child confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='Results  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='initiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='gestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='Confirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='results and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='consent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='on individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='distinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='HIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='test kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='REPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='after 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='Disclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='in the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='the receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='Integrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='The purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='suppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='which national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='HIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='the provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='Those suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='on ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='Reference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='before confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='management of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='be focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='o Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='psychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='years of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='dermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='concurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='laboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='Creatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='signs or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='treatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='pneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='includes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='presumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='Focus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='may also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='clinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='important during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='Patients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='adolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='Adherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='until complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='negative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='preparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='every contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='service delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='on ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='ART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='standard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='o Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='Initial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='group. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='management of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='and follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='training centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='Family planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='considered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='after birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='continue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='topical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='Dose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='patients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='awaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='special test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='pregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='adolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='infusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='fluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='months apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='Fluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='Patien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='on history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='good as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='Category 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='discordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='appropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='for cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='adherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='cardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='o Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='diuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g.,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='o If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='symptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='consider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='treatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='specialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='nephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='to be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='o Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='depression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='doing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='bothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='program)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='health team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='o Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='an anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='depres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='Patients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='guidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='fit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='with no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='Maintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='key areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='living with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='The following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='immune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='respondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='good, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='and challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='Support structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='All PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='o Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='o Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='Messages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='o Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='malnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='Weight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='care:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='feeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='and risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='Guidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='Age  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='born to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='Standard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='specific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='doses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='Guidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='intermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='an adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='level of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='after which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='patients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='counselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='significantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='emphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='taken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='has not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='Note: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='established that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='for HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='HIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='o Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='HIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='Antiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='PLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='counselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='treatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='the patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='o Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='message  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='ready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='be conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='support of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='C. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='strategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='and Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='of a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='initiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='sessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='volunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='same day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='with the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='confirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='records  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='women: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='confirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='Every provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='MMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='Table 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='medications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='Counselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='patient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='he/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='the next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='status?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='etc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='identified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='another care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='place  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='Treatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='can be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='potential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='is important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='conducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='o Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='enhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='Monthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='days  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='support ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='TWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='line ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='Adherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='attend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='contact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='systems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='scheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='HIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='PCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='weeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='All other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='Infants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='a child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='daily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='Clinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='anti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='available as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='RAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='o There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='these supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='load, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='efavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='first VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='providing enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='and providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='VL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='monitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='Gynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='DRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='medical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='symptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='specifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='hours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='liver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='HBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform )', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='consider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='Action  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='that may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='The goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='Treatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='VL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='(0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='the primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='ABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='results; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='should be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='out inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='of excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='the TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='Table 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='including PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='more intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='receive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='unknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='HIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='prevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='Table 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='cessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='months after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='HIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='Manage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='and 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='prophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='be treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='their own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='women without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='with Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='cessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='AZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='If older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='Table 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='under 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='appropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='Continued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='to eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='can pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='transmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='patients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='LPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='bronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='guidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='reviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='SL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='GeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='o Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='the eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='TB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='the PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='regimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='neuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='ACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='Table 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection);', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='management (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='Table 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='duration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='to EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='algorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='and for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='outcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='discuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Comorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='completion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='consider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='there is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='prevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='HCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='settings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='o Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='smoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR),', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='disease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='TB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='ARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='children. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='Patients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further .', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='ARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='Duration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='assault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='syndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='Breastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='To avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='o With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='The risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='you use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='to determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='STI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='o Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='o Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='in advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='Continuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='months and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='appropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='An “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='Daily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='STI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='initiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='initiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='at high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='suspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='Visit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='for discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='the previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='Pre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='adherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='new HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='optimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='Every effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='received specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='testing by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='and sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='infection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='o Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='HIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='additional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='services.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='People Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='TB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='Treatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='o NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='episodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='lymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='using clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='about HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='immediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='adolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='main points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='your ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='affected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='the ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='and the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='have a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='someone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='them ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='of ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='been a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='understand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='service for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='breakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='Section 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='then you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='strategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='adherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='Cognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='remembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='to the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='possible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='confirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='and how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='come up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='Session 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='since the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='is failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='the table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Describe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Has Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='o Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='o Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='adherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='ABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='RAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='Notes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='tab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='Annexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='EFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='weighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='mg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='liquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='dissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='RTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='approach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='LPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content='Efavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='first 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='been reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='acidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='Decrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='with 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='raised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content='during the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='ddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='disease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine,', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content='Insomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='increased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='increase the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='toxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='Delamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='effect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content='increased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content='exceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='monitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='Increases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content='administered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='interactions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='PIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='starting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content='ATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='If must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='rifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='Delamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content='(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='counselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='Is the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='o High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content='Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " ...]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chunks"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ba71b26d-823c-4e02-8908-cbfecb914560",
   "metadata": {},
   "source": [
    "## Chunking wit LLM"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "e900a4d5-9823-4696-a6cc-ba083918f363",
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "load_dotenv()  # OPENAI_API_KEY from .env\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "fb9afb69-57b6-4955-8e1c-6d294c26b305",
   "metadata": {},
   "outputs": [],
   "source": [
    "from openai import OpenAI\n",
    "\n",
    "openai_client = OpenAI()\n",
    "\n",
    "\n",
    "def llm(prompt, model='gpt-4o-mini'):\n",
    "    messages = [\n",
    "        {\"role\": \"user\", \"content\": prompt}\n",
    "    ]\n",
    "\n",
    "    response = openai_client.responses.create(\n",
    "        model='gpt-4o-mini',\n",
    "        input=messages\n",
    "    )\n",
    "\n",
    "    return response.output_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "7d06a282-8f5b-458a-9448-f0eadea0a9c9",
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_template = \"\"\"\n",
    "Split the provided document into logical sections\n",
    "that make sense for a Q&A system.\n",
    "\n",
    "Each section should be self-contained and cover\n",
    "a specific topic or concept.\n",
    "\n",
    "<DOCUMENT>\n",
    "{document}\n",
    "</DOCUMENT>\n",
    "\n",
    "Use this format:\n",
    "\n",
    "## Section Name\n",
    "\n",
    "Section content with all relevant details\n",
    "\n",
    "---\n",
    "\n",
    "## Another Section Name\n",
    "\n",
    "Another section content\n",
    "\n",
    "---\n",
    "\"\"\".strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "f1162596-6344-4fbb-a8ae-b221823a1c6b",
   "metadata": {},
   "outputs": [],
   "source": [
    "# def intelligent_chunking(text):\n",
    "#     prompt = prompt_template.format(document=text)\n",
    "#     response = llm(prompt)\n",
    "#     sections = response.split('---')\n",
    "#     sections = [s.strip() for s in sections if s.strip()]\n",
    "#     return sections"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "7831d7f8-d676-4b56-9d5e-78844807903d",
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "\n",
    "def intelligent_chunking(text):\n",
    "    splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=800,\n",
    "        chunk_overlap=100,\n",
    "        separators=[\"\\n\\n\", \"\\n\", \".\", \" \"]\n",
    "    )\n",
    "    return splitter.split_text(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f9575d54-ada2-44ba-88c0-c94e14540082",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content=' \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 0}),\n",
       " Document(page_content='', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 1}),\n",
       " Document(page_content='  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 2}),\n",
       " Document(page_content=' \\n  \\n \\n \\n \\n \\n \\n \\n \\n \\n \\n© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.   \\n \\nFor clarifications contact National AIDS and STI Control Program (NASCOP) at P. O. Box 19361 - 00202, \\nNairobi Kenya, T el: +254 (020) 2630867, Email: info@nascop.or.ke, Website: www.nascop.or.ke  \\nThe recommended citation for this document is:  \\nMinistry of Health, National AIDS & STI Control Program. Kenya HIV Prevention and Treatment Guidelines, \\n2022  Edition. Nairobi, Kenya: NASCOP, Aug  2022. Print.  \\n \\n \\n \\nDesign and Layout: Collins Etemesi - NASCOP  \\nISBN: 13 -978 -9966 -038 -31-9\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 3}),\n",
       " Document(page_content=' \\n \\ni Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous \\nprogress in HIV Prevention, Care and Treatment through introduction of better medicines, \\ndiagnostics and patient centered approaches in service delivery, Advanced HIV Disease continues \\nto be a challenge. These guidelines intend to widen access t o key diagnostics and medicines to \\nmanage the most common causes of illness and death. Further, emphasis on integrated delivery \\nof patient -centered HIV, TB, NCDs, mental health and sexual and reproductive health services has \\nbeen included.  \\nThese guidelines  provide key recommendations on  HIV testing services and linkage to prevention \\nand treatment; initial evaluation and follow up of PLHIV; standard package of care for PLHIV; \\nadherence preparation monitoring and support; antiretroviral therapy in infants, c hildren, \\nadolescents and adults; prevention of mother to child transmission of HIV, Syphilis and Viral \\nHepatitis; TB/HIV coinfection; Hepatitis B & C/HIV co -infection; use of ARVs for post and pre -\\nexposure prophylaxis for HIV uninfected populations; and HI V services for people who inject \\ndrugs.  \\nThe guidelines are an important tool meant to be used by service providers at all levels of the \\nhealth sector in Kenya. They are presented in a simplified manner using a public health approach \\nto HIV prevention and treatment.  \\nIt is my hope that this guidance document provides the much -needed framework and impetus to \\nmove towards universal access for HIV services and the agenda of ending AIDS by 2030 as a key \\nnational health strategic objective.  \\n \\n \\nDr. Patrick Amoth , EBS  \\nAg. Director General for Health , \\nMinistry of Health . \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 4}),\n",
       " Document(page_content=' \\n \\nii Acknowledgement s \\n \\nThe 2022 Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in \\nKenya has been a long -awaited document as the revision was greatly affected by the COVID -19 \\npandemic. The document has been updated through the collaborative effort of multiple \\nstakeholders, both individuals and institutions, that contributed to the extensive consultations \\nled by NASCOP HIV Care and Treatment Program.  \\n \\nWith much appreciation, I acknowledge all the institutions, both local and international, \\ngovernment ministries and departments whose staff spent long hours, both virtually and in \\nperson, in the review, writing and finalization of this document.  \\n \\nI take th is opportunity to appreciate the efforts of the Ministry of Health officers at NASCOP and \\nother institutions who coordinated and provided leadership during the review process. \\nCompliments to the guidelines review secretariat and the special task force who worked tirelessly \\nto ensure that the team produced a great quality document. Particular appreciation to the \\nNASCOP team and numerous TA’s who were instrumental in compiling the evidence review and \\ndeveloping the guidelines. Special thanks to the consultant s; Jeremy Penner, Irene Mukui, and \\nHerb Harwell for their dedication to this process.  \\n \\nFinancial support for the review process, printing and launch of this document was provided by \\nthe Global Fund, UNITAID through CHAI, the US government through the Cent ers for Disease \\nControl and Prevention and ICAP at Columbia University through the USAID -funded RISE -Kenya \\nProject, WHO and UNICEF - Kenya.  \\n \\n \\n \\nDr. Rose Wafula  \\nHead, National AIDS & STI Control Program  \\nMinistry of Health\\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 5}),\n",
       " Document(page_content=' \\n \\niii Table of Contents  \\nForeword  ................................ ................................ ................................ ................................ ................................ .......... i \\nAcknowledgements  ................................ ................................ ................................ ................................ ....................  ii \\nTable of Contents  ................................ ................................ ................................ ................................ ........................  iii \\nList of Figures  ................................ ................................ ................................ ................................ ...............................  ix \\nList of Tables  ................................ ................................ ................................ ................................ ................................ ..x \\nAcronyms and Abbreviations  ................................ ................................ ................................ ............................  xiii \\n1. Summary of Key Recommendations  ................................ ................................ ..................  1 \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  ................................ ..... 1 \\n1.2 Initial Evaluation and Follow -up for PLHIV  ................................ ................................ .............................  1 \\n1.3 Standard Package of Care for PLHIV  ................................ ................................ ................................ ...........  2 \\n1.4 Adherence Preparation, Monitoring and Support  ................................ ................................ ................  4 \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  ................................ ....... 4 \\n1.6 Prevention of Mother to Child Transmission of HIV/Syphilis/HBV  ................................ .............  5 \\n1.7 TB/HIV Co -infection Prevention and Management  ................................ ................................ .............  6 \\n1.8 HBV/HIV and HCV/HIV Co -infection Prevention and Management  ................................ .............  7 \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1 \\n2.1.1 Facility -based testing  ................................ ................................ ................................ ................................ ..........................  1 \\n2.1.2 Community –based testing  ................................ ................................ ................................ ................................ ................  2 \\n2.2 HTS strategies  ................................ ................................ ................................ ................................ .......................  2 \\n2.2.1 HIV Self -Testing (HIVST)  ................................ ................................ ................................ ................................ ...................  2 \\n2.2.2 Index Testing  ................................ ................................ ................................ ................................ ................................ ...........  2 \\n2.2.3 Voluntary Counselling and Testing (VCT):  ................................ ................................ ................................ ...............  2 \\n2.2.4 Social Network Strategy (SNS) - ................................ ................................ ................................ ................................ ...... 2 \\n2.3 Package of HI V Testing Services  ................................ ................................ ................................ ...................  5 \\n2.4 Age -Specific HIV Testing Algorithms  ................................ ................................ ................................ ..........  8 \\n2.4.1 Early Infant Diagnosis  ................................ ................................ ................................ ................................ .................  8 \\n2.4.2 Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and Adults  ............  12 \\n2.4.3 HIV testing for Pregnant Women  ................................ ................................ ................................ .......................  14 \\n2.5 Retesting recommendations for HIV negative pe rsons  ................................ ................................ ... 17 \\n2.6 Inconclusive HIV status  ................................ ................................ ................................ ................................ .. 18 \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  ................................ ...............  19 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 6}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\niv 3. Initial Evaluation and Follow up  ................................ ................................ .........................  1 \\n3.1 Introduction  ................................ ................................ ................................ ................................ ...........................  1 \\n3.2 Initial Clinical Evaluation of PLHIV  ................................ ................................ ................................ ..............  1 \\n3.3 Initial Laboratory Evaluation of PLHIV  ................................ ................................ ................................ ...... 4 \\n3.4 Managem ent of Patients Who Present with Advanced HIV Disease  ................................ .............  6 \\n3.5 Follow -up of PLHIV after ART initiation  ................................ ................................ ................................ ... 8 \\n3.5.1 First 6 months after ART initiation  ................................ ................................ ................................ ..............................  9 \\n3.5.2 Differentiated Service Delivery for Patients beyond the 1st 6 months of ART  ................................ ....... 9 \\n3.6 Summary of clinical and laboratory monitoring of PLHIV on ART ................................ .............  11 \\n3.7 Differentiated Care for Chi ldren, Adolescents and Pregnant/ breastfeeding Women  ...... 13 \\n3.8 ART Prescription, Dispensing, and Distribution for clients establishe d on ART  .................  14 \\n4. Standard Package of Care for PLHIV ................................ ................................ ..................  1 \\n4.1 Antiretrovir al Therapy  ................................ ................................ ................................ ................................ ...... 4 \\n4.2 PHDP, GBV/IPV & HIV Education/Counselling  ................................ ................................ ......................  5 \\n4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  ................................ .... 6 \\n4.2.2 HIV Education/Counselling  ................................ ................................ ................................ ................................ ..............  7 \\n4.3 Specific Opportun istic Infection Screening and Prevention  ................................ .............................  8 \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  ................................ ................................ ................................ ................  8 \\n4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  ................................ ................................ ..........  11 \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  ................................ ................................ ...............  11 \\n4.4 Reproductive Health Services  ................................ ................................ ................................ .....................  15 \\n4.4.1 Sexually Transmitted Infections  ................................ ................................ ................................ ................................ . 15 \\n4.4.2 Family Planning and Pre -Conception Counselling  ................................ ................................ .............................  15 \\n4.4.3 Maternal Healthcare  ................................ ................................ ................................ ................................ .........................  18 \\n4.5 Non -communicable Diseas es Screening and Management  ................................ ............................  18 \\n4.5.1 Metabolic Disorders  ................................ ................................ ................................ ................................ ..........................  18 \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  ................................ ......................  23 \\n4.6 Mental Health Screening and Management  ................................ ................................ ..........................  25 \\n4.6.1 Depre ssion  ................................ ................................ ................................ ................................ ................................ .............  25 \\n4.6.2 Alcohol and Drug Use/Addiction  ................................ ................................ ................................ ................................  28 \\n4.6.3 Anxiety ................................ ................................ ................................ ................................ ................................ .....................  31 \\n4.6.4 Stress and stress management  ................................ ................................ ................................ ................................ .... 32 \\n4.6.5 experiences o f Trauma  ................................ ................................ ................................ ................................ ....................  33 \\n4.6.6 Psychosis  ................................ ................................ ................................ ................................ ................................ ................  34 \\n4.6.7 Self -Care  ................................ ................................ ................................ ................................ ................................ ..................  34 \\n4.6.8 Wellbeing  ................................ ................................ ................................ ................................ ................................ ...............  35 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 7}),\n",
       " Document(page_content=' \\n \\nv 4.7 Nutritional Services  ................................ ................................ ................................ ................................ .........  36 \\n4.7.1 Nutritional Assessment, Counselling and Support (NACS)  ................................ ................................ ............  36 \\n4.8 Prevention of Other Infections  ................................ ................................ ................................ ...................  40 \\n4.8.1 Immunizations  ................................ ................................ ................................ ................................ ................................ ..... 40 \\n4.8.2 Malaria  ................................ ................................ ................................ ................................ ................................ .....................  42 \\n4.8.3 Safe Water, Sanitation and Hygien e ................................ ................................ ................................ ..........................  42 \\n5. Adherence Preparation, Monitoring and Support  ................................ ........................  1 \\n5.1 Undetectable = Untransmittable (U=U)  ................................ ................................ ................................ ..... 5 \\n5.1.1 Benefits of U=U  ................................ ................................ ................................ ................................ ................................ ....... 5 \\n5.1.2 Considerations for implem entation of U=U within clinical settings  ................................ ............................  5 \\n5.1.3 Messaging to Patients on U=U  ................................ ................................ ................................ ................................ .........  5 \\n5.1.4 How patients can discuss U=U with others  ................................ ................................ ................................ ..............  6 \\n5.1.5 Counselling patients about other prevention combination interventions  ................................ ................  6 \\n5.1.6 Application of U=U in o ther settings  ................................ ................................ ................................ ............................  6 \\n5.2 ART Adherence Preparation and Support  ................................ ................................ ................................  7 \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  ................................ ................................ ....................  7 \\n5.2.2 ART Treatment Preparation  ................................ ................................ ................................ ................................ ............  7 \\n5.2.3 Age -Specific Tr eatment Preparation and Support  ................................ ................................ .............................  13 \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months of ART  ........ 20 \\n5.3.1 Adherence Monitoring  ................................ ................................ ................................ ................................ .....................  20 \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  25 \\n5.4 Adherence Monitoring, Counselling and Support for Patients with Suppressed Viral Load \\n< 200 copies/ml  ................................ ................................ ................................ ................................ ...... 29 \\n5.5 Adherence Monitoring, Counselling and Support for Patients with Unsuppressed Viral \\nLoad ≥ 200 copies/ml  ................................ ................................ ................................ ...........................  30 \\n5.5.1 Enhanced Adherence Assessments  ................................ ................................ ................................ ...........................  31 \\n5.5.2 Enhanced Adherence Counselling  ................................ ................................ ................................ ..............................  31 \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  ................................ ................................ ..... 34 \\n5.7 Identifying, Tracing, and Supporting Patients who Default from Care  ................................ ..... 35 \\n6. Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  .................  1 \\n6.1 Eligibility for ART  ................................ ................................ ................................ ................................ ................  1 \\n6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7 \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line ART .........................  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 8}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nvi 6.5.2 Changing ARVs Due to Adverse Drug Reactions  ................................ ................................ ................................ .... 9 \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  ................................ ................................ ................................ .. 16 \\n6.5.4 Changing ARVs Due to Treatment Failure  ................................ ................................ ................................ .............  17 \\n7. Prevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  .........  1 \\n7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1 \\n8.1 TB Screening for PLHIV: Intensified Case Finding (ICF)  ................................ ................................ .... 1 \\n8.2. TB Preventive Therapy (TPT)  ................................ ................................ ................................ .......................  9 \\n8.2.1. Indications for TPT  ................................ ................................ ................................ ................................ ..............................  9 \\n8.2.2. Contraindications to TPT  ................................ ................................ ................................ ................................ ..............  10 \\n8.2.3. Dose and Duration of TPT  ................................ ................................ ................................ ................................ .............  10 \\n8.2.4. Follow -up of Patients on TPT  ................................ ................................ ................................ ................................ ...... 11 \\n8.3. Identifying and Managing Drug Toxicities from TPT  ................................ ................................ ...... 11 \\n8.3.1 Peripheral Neuropathy - Suspected drug: INH  ................................ ................................ ................................ ..... 11 \\n8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  12 \\n8.3.3 Managemen t of TPT -associated Rash - Suspected Drugs include Isoniazid (H), Rifapentine (P), \\nRifampicin (R)  ................................ ................................ ................................ ................................ ................................ .................  13 \\n8.4. ART for TB/HIV Co -infect ion ................................ ................................ ................................ ......................  13 \\n9. HBV/HIV and HCV/HIV Co -infection Prevention and Management  .......................  1 \\n9.1 Hepatitis B/HIV Co -infection  ................................ ................................ ................................ ..........................  1 \\n9.1.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  1 \\n9.1.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  1 \\n9.1.3 Treatment  ................................ ................................ ................................ ................................ ................................ .................  2 \\n9.2 Hepatitis C/HIV Co -infection  ................................ ................................ ................................ ..........................  5 \\n9.2.1 Screening  ................................ ................................ ................................ ................................ ................................ ...................  5 \\n9.2.2 Prevention  ................................ ................................ ................................ ................................ ................................ ................  6 \\n9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1 \\n10.3 Eligibility For PEP  ................................ ................................ ................................ ................................ .............  2 \\n10.4 Management and Follow Up ................................ ................................ ................................ .........................  2 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 9}),\n",
       " Document(page_content=' \\n \\nvii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1 \\n11.1.1 Indications for PrEP  ................................ ................................ ................................ ................................ ..........................  1 \\n11.1.2 HIV Risk Assessment  ................................ ................................ ................................ ................................ ........................  1 \\n11.1.3 Criteria for PrEP Eligibility  ................................ ................................ ................................ ................................ ............  2 \\n11.2 Package of PrEP Service  ................................ ................................ ................................ ................................ . 3 \\n11.2.1 Pre -Initiation Che cklist  ................................ ................................ ................................ ................................ ....................  4 \\n11.2.2 Pre -initiation client education  ................................ ................................ ................................ ................................ ..... 5 \\n11.3 Recommended ARVs for PrEP  ................................ ................................ ................................ .....................  5 \\n11.3.1 Schema for follow up for daily oral PrEP  ................................ ................................ ................................ ................  7 \\n11.3. 2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  ................................ ................................ ...........  7 \\n11.4 Managing Clinical and Laboratory Results on Initial and Follow -up Asse ssment  ...............  9 \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  ................................ ................................ ....... 12 \\n11.6 Criteria for Discontinuing Oral PrEP  ................................ ................................ ................................ ..... 12 \\n11.7 Restarting PrEP  ................................ ................................ ................................ ................................ ...............  12 \\n11.8 Improving adherence to PrEP  ................................ ................................ ................................ ..................  13 \\n11.9 Monitoring Sero -conversion among PrEP users  ................................ ................................ ..............  13 \\n12. People Who Inject Drugs (PWID) and HIV ................................ ................................ ....... 1 \\n12.1 Intro duction  ................................ ................................ ................................ ................................ ........................  1 \\n12.3 ART in HIV positive PWID  ................................ ................................ ................................ .............................  4 \\n13. Annexes  ................................ ................................ ................................ ................................ ........  1 \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  ................................ ...........  1 \\nAnnex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  ................................ ..... 2 \\nAnnex 3: Normal Developmental Miles tones in Children  ................................ ................................ .........  3 \\nAnnex 4: Tanner Staging of Sexual Maturity in Adolescents  ................................ ................................ ... 4 \\nAnnex 4 A: Tanner Staging of Sexual Maturity in Girls ................................ ................................ ................................ ... 4 \\nAnnex 4 B: Tanner Staging of Sexual Maturity in Boys  ................................ ................................ ................................ .. 4 \\nAnnex 5: Age -Appropriate Disclosure for Child ren and Adolescents  ................................ ..................  5 \\nAnnex 6: Transitioning from Adolescent to Adult HIV Services  ................................ .............................  6 \\nAnnex 7: 2018 HIV Testing Services Algorithm ................................ ................................ .............................  7 \\nAnnex 8: HIV Education and Adherence Counselling Content Guide  ................................ ...................  8 \\nAnnex 9 A: Enhanced Adherence Counselling Content Guide  ................................ ..............................  16 \\nAnnex 9 B: Case Summary Form  ................................ ................................ ................................ .......................  22 \\nAnnex 9 C: Enhanced Adherence Counselling Form  ................................ ................................ .................  24 \\nAnnex 9 D: Home Visit Checklist  ................................ ................................ ................................ .......................  25 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 10}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nviii Annex 9 E: Management Protocol for Patients Switc hing to 3rd Line ART  ................................ .... 26 \\nAnnex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and \\nChildren 4 Week s of Age and Older  1 ................................ ................................ .............................  28 \\nAnnex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid Formulations for Once -\\nDaily Dosing in Infants and Children 4 Weeks of Age and Older1 ................................ ..... 29 \\nAnnex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \\n4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \\nat Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \\nAnn ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \\nAnnex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34 \\nAnnex 11: Overlapping toxicities between AR Vs ................................ ................................ .......................  35 \\nAnnex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors in Adults  ..... 36 \\nAnnex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  .....................  38 \\nAnnex 12 C: Use of Protease Inhibitors in Adults  ................................ ................................ ......................  39 \\nAnnex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  ................................ ................................ .. 40 \\nAnnex 13 A: Drug -Drug Interactions - NNRTIs  ................................ ................................ ...........................  41 \\nAnnex 13 B: Drug -Drug Interactions – PIs ................................ ................................ ................................ .... 45 \\nAnnex 13 C: Drug -Drug Interactions – INSTIs  ................................ ................................ .............................  52 \\nAnnex 14: Health Facility Assessment to Provide Community ART Distribution  .......................  54 \\nAnnex 15: Creatinine Clearance  ................................ ................................ ................................ .........................  55 \\nAnnex 16: Immune Reconstitution Inflammatory Syndrome  ................................ ..............................  56 \\nAnnex 17: HTS Adult Screening Tool Enhancement  ................................ ................................ .................  59 \\nAnnex 18: List of Contributors and Affiliation  ................................ ................................ ............................  60 \\nAnnex 19: List of Participating Organizations and Agencies  ................................ ................................  62 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 11}),\n",
       " Document(page_content=' \\n \\nix List of Figures  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age  ................................ .. 9 \\nFigure 2.2: Birth Testing Algor ithm  ................................ ................................ ................................ ................................ ....................  11 \\nFigure 2.3: HIV Testing Services Algorithm  ................................ ................................ ................................ ................................ .... 13 \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  ................................ ................................ ................................ ..........................  15 \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test  ............................  20 \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  .............  14 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) ................................ ................................ ..........................  32 \\nFigure 4.3: Management of Severe Acute Malnutrition in Children  ................................ ................................ ....................  38 \\nFigure 4.4: Management of Malnutrition in Adults with HIV  ................................ ................................ ................................ . 39 \\nFigure 5.1: Adherence Preparation, Monitoring and Support  until Viral Load after 3 Months on ART  ...............  2 \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or 3rd Line \\nART  ................................ ................................ ................................ ................................ ................................ ................................ .....................  34 \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  ................................ .......................  35 \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg on First \\nLine ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11 \\nFigure 6.4: Managing Single Drug Substitutions for ART  ................................ ................................ ................................ .........  12 \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  ................................ ................................ ................................ ............  13 \\nFigure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  ................................ ...............................  18 \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm  ................................ ................................ ................................ ...................  5 \\nFigure 8.2: Use of TB -LAM for Diagnosis of TB among PLHIV  ................................ ................................ ................................ .. 8 \\nFigure 11.1 : Package of Service for PrEP  ................................ ................................ ................................ ................................ ............  3 \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  ................................ ................................ ................................ ...............  7 \\nFigure 11.3 Schema for Event -Driven PrEP  ................................ ................................ ................................ ................................ ....... 8 \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ................................ ................................ ...........  8 \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 12}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nx List of Tables  \\nTable 2.1: HTS Recommendations for Different Populations and Settings  ................................ ................................ ........ 3 \\nTable 2.2: Summary of HIV Testing Services Package  ................................ ................................ ................................ ..................  6 \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR Results  ................  10 \\nTable 2 .4: Approaches to Improve Linkage to Treatment and Prevention Services  ................................ ..................  16 \\nTable 2.5: Recommendations for Retesting HIV Negative C lients  ................................ ................................ .......................  18 \\nTable 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  ................................ ...................  2 \\nTable 3.2: Baseline Laboratory Investigatio ns for PLHIV  ................................ ................................ ................................ ...........  4 \\nTable 3.3: Differentiated Care Based on Initial Patient Presentation  ................................ ................................ ...................  7 \\nTable 3.4: Management of patients who are presenting well: WHO Stage 1 or 2, and CD4 count > 200 \\ncell/mm3  ................................ ................................ ................................ ................................ ................................ ................................ ............  8 \\nTable 3.5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  ................................ ......................  9 \\nTable 3.6: Summary of Clinical and Laboratory Monitoring for PLHIV1 ................................ ................................ ..........  11 \\nTable 4.1: Components of the Standard Package of Care for PLHIV  ................................ ................................ ......................  2 \\nTable 4.2: Domains and Components for PHDP Serv ices ................................ ................................ ................................ ............  5 \\nTable 4.2a: Components of screening for GBV/IPV (LIVES)  ................................ ................................ ................................ ...... 7 \\nTable 4.3: Co -trimoxazole Preventive therapy  ................................ ................................ ................................ ................................ . 8 \\nTable 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  ................................ ................................ ................................ .... 9 \\nTable 4.5: Management of Drug -Associated Skin Rash  ................................ ................................ ................................ ................  9 \\nTable 4.6a: Standard Cotrimoxazole Desensitization Regimen (8 days)  ................................ ................................ ..........  10 \\nTable 4.6b: Rapid Cotrimoxazole Desensitization Regimen (6 hours)  ................................ ................................ ..............  10 \\nTable 4.7: Treatment of Cryptococcal Meningitis  ................................ ................................ ................................ ........................  12 \\nTable 4.8: Contraceptive Methods for PLHIV Based on WHO 2018 Medical Eligibility Criteria  ...........................  16 \\nTable 4.9: Pr e-Conception Counselling Messages and Services for PLHIV  ................................ ................................ ...... 17 \\nTable 4.10: Lifestyle Modifications to Prevent and Manage Cardiovascu lar Disease in PLHIV  ............................  19 \\nTable 4.11 : Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  ................................ .... 20 \\nTable 4.12: Type 2 Diabetes Mellitus Screening, Dia gnosis, and Initial Management for PLHIV  .........................  21 \\nTable 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  ................................ ..................  22 \\nTable 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  ...........................  23 \\nTable 4.15: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  ................................ ..........................  26 \\nTable 4.16: CRAFFT Screening Interview for Adolescents  ................................ ................................ ................................ ...... 28 \\nTable 4.17: CAGE -AID Screening Questions for Adults  ................................ ................................ ................................ .............  29 \\nTable 4.18: Addiction Support Based on Stages of Change  ................................ ................................ ................................ ..... 30 \\nTable 4.19: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  ................................ .. 37 \\nTable 4.20: Interpretation of Z -scores for Children  ................................ ................................ ................................ ....................  37 \\nTable 4.21: Interpretation of BMI Results for Adults  ................................ ................................ ................................ .................  40 \\nTable 4.22: Kenya Expanded Program on Immunizations 2016 Schedule  ................................ ................................ ...... 40 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 13}),\n",
       " Document(page_content=' \\n \\nxi Table 4.23: Vaccinations in Adolescents and Adults Living wit h HIV  ................................ ................................ ................  41 \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  ................................ ................................ .................  7 \\nTable 5.2: Components of HIV Education (see Annex 8 for detai led content guide)  ................................ ..................  10 \\nTable 5.3: Adherence Support and Retention Interventions  ................................ ................................ ................................ .. 11 \\nTable 5.4: ART Readiness Assessment Form  ................................ ................................ ................................ ................................ . 13 \\nTable 5 .5: Age -appropriate Involvement of Child/Adolescent in HIV Education and Adherence Counselling\\n ................................ ................................ ................................ ................................ ................................ ................................ ..............................  15 \\nTable 5.6: Unique Considerations for Caregivers, Children and Adolescents  ................................ ................................  16 \\nTable 5.7: Treatment Preparation and Support for Chil dren (≤ 9 years) and Caregivers  ................................ ....... 17 \\nTable 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  ................................ ...........................  18 \\nTable 5.9: Treatment Preparation and Support for Adults  ................................ ................................ ................................ ..... 19 \\nTable 5.10: Adherence Monitoring Strategies  ................................ ................................ ................................ ...............................  21 \\nTable 5.11: Morisky Medication Adherence Scale (MMAS -4) ................................ ................................ ................................  23 \\nTable 5.12: Morisky Medication Adherence Scale (MMAS -8) ................................ ................................ ................................  24 \\nTable 5.13: Adherence Rate Based on Pill Counts  ................................ ................................ ................................ .......................  25 \\nTable 5.14: Adherence Counselling and Support During the First 3 Months of ART  ................................ .................  26 \\nTable 5.15: Assessment for Barriers to Adherence  ................................ ................................ ................................ .....................  27 \\nTable 5.16: Adherence Counselling and Support for Patients with Viral Load < 50 copies/ml  ............................  29 \\nTable 5.17 Viral Load Monitoring Cut -Offs  ................................ ................................ ................................ ................................ ..... 30 \\nTable 5.18: Components of Enhanced Adherence Co unselling Sessions (Annex 9A for detailed content \\nguide)  ................................ ................................ ................................ ................................ ................................ ................................ .................  32 \\nTable 6.1: Special Considerat ions for Timing of ART Initiation  ................................ ................................ ...............................  2 \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and Adults 1 .......................  3 \\nTable 6.3: Use of Alternative ARVs in First -Line Regimens 1 ................................ ................................ ................................ .... 4 \\nTable 6.4: Dosing and Administration of Dolutegravir  ................................ ................................ ................................ ................  5 \\nTable 6.5: Common Significant Adverse Drug Reactions  ................................ ................................ ................................ .........  10 \\nTable 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 ................................ ...........  14 \\nTable 6.7: Management of AZT -Associated Bone Marrow Suppression  ................................ ................................ ...........  15 \\nTable 6.8: Management of Drug -Related Hepatotoxicity  ................................ ................................ ................................ .........  15 \\nTable 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  ................................ ............................  16 \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and Adults, \\nexcluding TB/HIV co -infection 1 ................................ ................................ ................................ ................................ ...........................  19 \\nTable 6.11: Possible Third -line ART in Children, Adolescents and Adults  ................................ ................................ ...... 21 \\nTable 7.1: Essential Package of Antenatal Care  ................................ ................................ ................................ ...............................  1 \\nTable 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 14}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxii Table 7.7: Complementary Foods for Children 6 -24 Months Old  ................................ ................................ ...........................  9 \\nTable 8.1: TB Diagnosis in Children <10 Years Old  ................................ ................................ ................................ ........................  6 \\nTable 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  ................................ ...... 7 \\nTable 8.3: Recommended TPT Regimens for PLHIV  ................................ ................................ ................................ ..................  10 \\nTable 8.4: Grading and Management of DILI  ................................ ................................ ................................ ................................ .. 12 \\nTable 8.5: Management of TPT -Associated Skin Rash  ................................ ................................ ................................ ...............  13 \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st Line ART 1 ... 14 \\nTable 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on 1st Line ART \\n1,2 ................................ ................................ ................................ ................................ ................................ ................................ ..........................  15 \\nTable 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line ART 1 ..............  16 \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  ................................ ...............  2 \\nTable 9.2: Summary of Initial Clinical and Laboratory Evaluation in HIV/HBV Co -infection  ................................ ... 3 \\nTable 9.3: Dose Adjustment of TDF and  3TC in Patients with Impaired Renal Function 1 ................................ .........  4 \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  ................................ ... 6 \\nTable 9.5: Recommended DAA for the Treatment of HCV among PLHIV  ................................ ................................ ............  7 \\nTable 10.1: Recommended ARVs for PEP  ................................ ................................ ................................ ................................ ...........  1 \\nTable 10.2: Recommendations for PEP Management and Follow -up ................................ ................................ ...................  3 \\nTable 10.3 Considerations for special circumstances  ................................ ................................ ................................ ...................  4 \\nTable 11:1 HIV Screening questions  ................................ ................................ ................................ ................................ .....................  2 \\nTable 11.2: Pre -Initiation Assessment Checklist  ................................ ................................ ................................ .............................  4 \\nTable 11.3: Client Education Checklist  ................................ ................................ ................................ ................................ .................  5 \\nTable 11.4: Antiretrovirals for Use in PrEP  ................................ ................................ ................................ ................................ ....... 6 \\nTable 11. 5 Initial & follow up laboratory test  ................................ ................................ ................................ ................................ ... 9 \\nTable 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  ..............................  10 \\nTable 11.7: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ ........................  11 \\nTable 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  ................................ ................................ .............  12 \\nTable 12.1: Comprehensive Package of Harm Reduction for PWID  ................................ ................................ ......................  2 \\nTable 12.2: Summary of ART Recommendations for PWID  ................................ ................................ ................................ ....... 5 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 15}),\n",
       " Document(page_content=' \\n \\nxiii Acronyms and Abbreviations  \\nAbbreviations and Names of Antiretroviral Drugs  Other Acronyms and Abbreviations  \\n3TC  Lamivudine  HTS  HIV Testing Services  \\nABC  Abacavir  ICF  Intensified Case Finding  \\nATV  Atazanavir  IEC  Information, Education and Communication  \\nATV/r  Atazanavir/ritonavir  INH  Isoniazid  \\nAZT  Zidovudine  INSTI  Integrase Strand Transfer Inhibitor  \\nDRV  Darunavir  IPD  In-Patient Department  \\nDRV/r  Darunavir/ritonavir  IPT  Isoniazid Preventive Therapy  \\nDTG  Dolutegravir  IPV Intimate Partner Violence  \\nEFV  Efavirenz  IRIS  Immune Reconstitution Inflammatory \\nSyndrome  \\nETR  Etravirine  ITN  Insecticide Treated Mosquito Nets  \\nFTC  Emtricitabine  IUD  Intrauterine Device  \\nLPV  Lopinavir  KEPI  Kenya Expanded Program of Immunization  \\nLPV/r  Lopinavir/ritonavir  KS  Kaposi’s Sarcoma  \\nNVP        Nevirapine  LEEP  Loop Electrosurgical Excision Procedure  \\nRAL                                Raltegravir  L&D  Labor And Delivery  \\nRTV  Ritonavir  LIVES  Listen, Inquiry, Validate, Enhance Safety and \\nSupport  \\nTDF  Tenofovir Disoproxil Fumarate  LLV  Low Level Viremia  \\nOther Acronyms and Abbreviations  LRF  Laboratory Requisition Form  \\nACE -I Angiotensin -Converting Enzyme Inhibitor  LP Lumbar Puncture  \\nADR  Adverse Drug Reaction  MAC  Mycobacterium Avium Complex  \\nAIDS  Acquired Immunodeficiency Syndrome  MAT  Medically Assisted Therapy  \\nALT  Alanine Transaminase  MCH  Maternal Child Health  \\nALP  Alkaline Phosphatase  MNCH/FP  Maternal, Neonatal and Child Health/Family \\nPlanning  \\nAHI Acute Hiv Infection  MDT  Multi -Disciplinary Team  \\nANC  Antenatal Care  MEC  Medical Eligibility Criteria  \\nA&E  Accident And Emergency  MOH  Ministry of Health  \\nARB  Angiotensin -Receptor Blocker  MSM  Men Who Have Sex with Men  \\nART  Antiretroviral Therapy  MUAC  Mid -Upper Arm Circumference  \\nARV  Antiretroviral Drug(S)  NACS  Nutritional Assessment, Counselling and \\nSupport  \\nAST  Aspartate Transaminase  NASCOP  National AIDS And STI Control Program  \\nBD Twice Daily  NCD  Non -Communicable Diseases  \\nBF Breastfeeding  NHRL  National H IV Reference Laboratory  \\nBMI  Body Mass Index  NNRTI  Non -Nucleoside Reverse Transcriptase \\nInhibitor  \\nBP Blood Pressure  NRTI  Nucleoside Reverse Transcriptase Inhibitor  \\nCAG  Community Art Groups  NSP  Needle and Syringe Programmes  \\nCCC  Comprehensive Care Centre  NRTI  Nucleotide Reverse Transcriptase Inhibitor  \\nCrCl  Creatinine Clearance  OD  Once Daily  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 16}),\n",
       " Document(page_content='Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n \\nxiv CHV  Community Health Volunteer  OI  Opportunistic Infection  \\nCITC  Client -Initiated HIV Testing and Counselling  OPD  Outpatient Department  \\nCM Cryptococcal Meningitis  OST  Opioid Substitution Therapy  \\nCMV  Cytomegalovirus  OVC  Orphans And Vulnerable Children  \\nCNS  Central Nervous System  PCP  Pneumocystis Jirovecii Pneumonia  \\nCPT  Cotrimoxazole Preventive Therapy  PCR  Polymerase Chain Reaction  \\nCrCl  Creatinine Clearance  PEP  Post -Exposure Prophylaxis  \\nCTX  Cotrimoxazole  PrEP  Pre-Exposure Prophylaxis  \\nCYP450  Cytochrome P450  PGL  Persistent Generalized Lymphadenopathy  \\nDAAs  Direct Acting Antiviral Therapies  PHQ -9  Patient Health Questionnaire -9 \\nDBS  Dried Blood Spot  PHDP  Positive Health, Dignity, and Prevention  \\nDICEs  Drop -In-Centres  PI  Protease Inhibitor  \\nDMS  Director of Medical Services  PITC  Provider Initiated HIV Testing and Counselling  \\nDNA  Deoxyribonucleic acid  PLHIV  People Living With HIV  \\nDOT  Directly observed therapy  PLLV  Persistent Low-level Viremia  \\nDS Double strength  PML                                 Progressive Multifocal Leukoencephalopathy  \\nDRT  Drug Resistance Testing  PMTCT                           Prevention of mother -to-child transmission  \\nED - PrEP  Event Driven PrEP  PPE                                  Papular Pruritic Eruptions  \\nEDTA  Ethylenediaminetetraacetic acid  PrEP  Pre-exposure Prophylaxis  \\nECP  Emergency contraceptive pill  PTB  Pulmonary Tuberculosis  \\nEID  Early Infant Diagnosis  PWID  People Who Inject Drugs  \\neMTCT  Elimination of Mother to Child Transmission  NHCSC  National HIV Clinical Support Centre  \\nEPTB  Extra -pulmonary Tuberculosis  RAST  Rapid Assessment Tool  \\nFDA  Food and Drug Administration  RNA  Ribonucleic Acid \\nFBC  Full Blood Count  RPR  Rapid Plasma Reagin  \\nFBS Fasting Blood Sugar  sCrAg  Serum Cryptococcal Antigen  \\nFDC  Fixed Dose Combination  SRH  Sexual and Reproductive Health  \\nFLP  Fasting Lipid Profile  SS  Single Strength  \\nFP  Family Planning  STI  Sexually Transmitted Infection  \\nFTC  Emtriciatabine  TB  Tuberculosis  \\nGIT  Gastro -intestinal tract  TB LAM  Tuberculosis Lipoarabinomannan  \\nGOK  Government of Kenya  TDF  Tenofovir  \\nGBV  Gender -Based Violence  TT Tetanus Toxoid  \\nHb  Hemoglobin  TWG  Technical Working Group  \\nHBV  Hepatitis B virus  ULN  Upper Limit of Normal  \\nHBsAg  Hepatitis B Surface Antigen  UTI Urinary Tract Infection  \\nHCV  Hepatitis C Virus  VIA  Visual Inspection with Acetic Acid  \\nHCW  Health Care Worker  VILI  Visual Inspection with Lugol’s Iodine  \\nHEI  HIV Exposed Infant  VL  Viral Load  \\nHIV  Human immunodeficiency Virus  VMMC  Voluntary Medical Male Circumcision  \\nHIVST  HIV Self-testing  WHO  World Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 17}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 1   \\n1. Summary of Key Recommendations  \\n \\n1.1 HIV Testing Services (HTS) and Linkage to Treatment and Prevention  \\n• HIV testing should be voluntary and conducted ethically in an environment where \\nConsent, Confidentiality, Counselling, Correct results, Connection (linkage) and Creating \\nan enabling environment can be assured  \\n• To optimize access to testing services, HIV testing can be conducted in 2 different settings:  \\n▪ Facility -based  \\n▪ Community -based  \\n• Targeted HIV testing is recommended which involves index client listing of contacts, HIV \\nself-testing and use of HTS screening tool to identify people at risk of HIV infection as \\neligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:  \\n▪ Adults, adolescents, and children five years and older as having a CD4 cell count of \\nless than 200 cells/mm3 or \\n▪ WHO clinical stage 3 or 4 disease  \\n▪ All children younger than five years  \\n● All PLHIV presenting with Advanced HIV Disease (AHD) should be offered a package of \\ncare that includes timely initiation of ART, screening, diagnosis, prophyl axis, and \\nmanagement  of opportunistic infections.  \\n● Frequency of routine VL monitoring:  \\n▪ For PCR positive HEIs: at baseline (at the time of ART initiation)  \\n▪ Age 0 -24 years old: 3 months after ART initiation, and then every 6 months  \\n▪ Age ≥ 25 years old: 3 months after ART initiation, then at month 12, and then annually  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 18}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 2  ▪ Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/breastfeeding), and \\nthen every 6 months until c omplete cessation of breastfeeding  \\n▪ Before any drug substitution (if no VL result available from the prior 6 months)  \\n▪ Three months after any regimen modification (including single -drug substitution)  \\n● PLHIV should receive differentiated care based on initial e valuation (advanced vs. well) \\nand follow up (established vs not established on ART)  \\n \\n1.3 Standard Package of Care for PLHIV  \\nConsists of 8 components:  \\n1. Antiretroviral Therapy  \\n▪ All PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO \\nclinical stage, age, pregnancy status, or comorbidities  \\n▪ ART should be initiated as soon as the patient is ready to start, preferably within \\ntwo weeks from time of HIV diagnosis (except for patients with cryptococcal \\nmeningitis or TB meningi tis) \\n2. Positive Health, Dignity, and Prevention, GBV/IPV & HIV Education and Counselling  \\n▪ All patients should be counselled and supported for disclosure of HIV status; \\npartner/ family testing and engagement; condom use; family planning; sexually \\ntransmitted infections screening; treatment adherence; and pre -exposure \\nprophylaxis for HIV -negative sexual partners  \\n▪ All females aged 15 -49 years and emancipated minors accessing HIV care services \\nshould be screened for Intimate Partner Violence (IPV) as p art of the standard \\npackage of care  \\n▪ All PLHIV should be provided with HIV education and counselling  \\n3. Screening for and Prevention of Specific Opportunistic Infections  \\nCotrimoxazole Preventive Therapy (CPT) is no longer recommended as life -long \\nprophylaxis, and is only recommended in the following sub populations, unless they \\nhave an allergy to sulfur drugs or develop toxicity from CPT  \\n● All HIV Exposed Infants  \\n● HIV infected children < 15 years of age  \\n● All PLHIV > 15 years of age:  \\no Living in malaria -endemic zones  (Refer to the National Guidelines for the \\nDiagnosis, Treatment and Prevention of Malaria in Kenya for the current Kenya \\nMalaria endemicity map)  \\no Presenting with WHO stage 3 or 4 event, or meeting the AHD criteria  \\no Suspected treatment fa ilure  \\n● All Pregnant and Breast -feeding women  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 19}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 3  ▪ When dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4% ≤ 25% for children ≤ 5 years old), and should be discontinued \\nonce a patient achieves viral suppression and a sustained CD4 count of > 200 \\ncell/mm3 (or > 25% for children ≤ 5 years old) for at least 6 months  \\n▪ All PLHIV should be screened for TB at  every visit using the Intensified Case Finding \\n(ICF) tool and assessed for TB Preventive Therapy (TPT) if screened negative for TB  \\n▪ All adolescent and adult PLHIV with a baseline CD4 count of ≤ 200 cells/mm3 should \\nbe screened for cryptococcal infection us ing the serum CrAg test  \\n4. Reproductive Health Services  \\n▪ All PLHIV should be screened for STI at every clinic visit  \\n▪ Pregnancy status should be determined for all women of reproductive age at every \\nvisit and their contraception need determined and met  \\n▪ All HIV p ositive women between the ages of 18 - 65 years should be screened for \\ncervical cancer (HPV testing conducted every 2 years or Annually if using VIA -VILI)  \\n5. Screening for and Management of Non -Communicable Diseases  \\n▪ All PLHIV should be screened for hypertension, diabetes mellitus, dyslipidaemia, \\nand renal disease annually.  \\n▪ Routine screening should be provided for early detection of cervical cancer, breast \\ncancer, bowel cancer, and prostate cancer  \\n6. Mental Health Screening and Management  \\n▪ All PLHIV should receive basic screening for depression  and anxiety  before initiating \\nART, and annually thereafter, and whenever there is a clinical suspicion  \\n▪ All PLHIV should be provided for and linked with support structures to maintain \\ngeneral well -being  addressi ng issues that could affect their mental health  \\n▪ All adults and adolescents should be screened for alcohol and drug use before \\ninitiating ART and regularly during follow -up \\n▪ All caregivers should also receive baseline and follow -up screening for depression \\nand alcohol/drug use  \\n7. Nutrition Services  \\n▪ All PLHIV should receive nutritional assessment, counselling, and support tailored \\nto the individual needs of the patients  \\n▪ All infants irrespective of HIV status should be exclusively breastfed for the first 6 \\nmonths  of life, with timely introduction of appropriate complementary foods after \\n6 months, and continued breastfeeding up to 24 months or beyond  \\n8. Prevention of Other Infections  \\n▪ PLHIV (including children) should receive vaccinations as recommended by the \\nNational  Vaccines and Immunization Program  \\n▪ All PLHIV should receive vaccination for COVID -19 following national guidelines for \\nage and dosing  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 20}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 4  1.4 Adherence Preparation, Monitoring and Support  \\n• The adherence preparation, monitoring, and support that a patient requires should be \\ntailored to their level of adherence and the stage of ART initiation and follow -up \\n• All patients with durable viral suppression (2 consecutive viral load results with < 50 \\ncopies) should be offered messaging on Undetectable=Untrans mittable (U=U).  \\n• Whenever possible, follow -up should be provided by the same care provider or team of \\ncare providers (e.g., same clinician and counsellor) at every visit. This is particularly \\nimportant during the first 3 months in care  \\n• For all children/adol escents, the level of disclosure should be assessed at the first visit. \\nOngoing care should include a plan for age -appropriate disclosure  \\n• All patients are at risk of new or worsening barriers to adherence, so adherence \\nmonitoring, counselling and support s hould continue despite viral suppression  \\n• Every service delivery point that is providing ARVs for patients (whether ART, PEP, or \\nPrEP) must have a functional system for identifying patients who miss appointments and \\nfor taking action within 24 hours of a mi ssed appointment  \\n• In patients failing ART, do not change regimens until the reason/s for treatment failure \\nhave been identified and addressed (which should be done urgently using a case -\\nmanagement approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP  \\n▪ > 4 weeks to < 15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old: TDF + 3TC + DTG  \\n• Children and adolescents who are virally suppressed but are NOT on the preferred first -\\nline ART regimen should be assessed for transition and transitioned to the preferred \\nregimen  \\n• Treatment failure is suspected when a pa tient has a VL ≥ 100 0 copies/ml after at least 3 \\nmonths of using ART. Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml \\nafter assessing for and addressing poor adherence or other reasons for high VL, and then \\nrepeating VL after at least 3 mo nths of excellent adherence to allow for viral re -\\nsuppression  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 21}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 5  • Persistent low -level viremia ( pLLV) is defined as having VL 200 - 999 copies/ml on two \\nor more consecutive measures. These patients are at increased risk of progression to \\ntreatment failure, dev elopment of ARV resistance and death and therefore require a \\nsimilar case management approach as patients with an initial VL ≥ 1,000 copies/ml  \\n• All PLHIV with a detectable VL ≥ 200 copies/ ml (unsuppressed) : assess for and address \\npotential reasons for virem ia, including intensifying adherence support, and repeat the \\nVL after 3 months of excellent adherence  \\n▪ If the repeat VL is < 200  copies/ml ( suppres sed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (suspected treatment failure), prepare for \\nchange to an effective regimen (Figure 5.2 and Table 6.10)  \\n▪ If the repeat VL is 200 - 999 copies/ml (low level viremia),  reassess adherence \\nand other causes of viremia and repeat VL after another 3 months of excellent \\nadherence  \\n1.6 Pre vention of Mother to Child Transmission of HIV/Syphilis/HBV  \\n• Prevention of mother -to-child transmission (PMTCT) of HIV,  Syphilis and Hepatitis B  \\n(triple elimination ) should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal  care interventions  \\n• All pregnant women, unless known positive, should be counseled and tested for HIV, \\nSyphilis (using the HIV -Syphilis dual test) and HBV during their first ANC visit, and if \\nnegative a repeat HIV -Syphilis dual test should be performed in the 3rd trimester.  \\n• Lifelong ART should be initiated in all pregnant and breastfeeding women living \\nwith HIV, regardless of gestational age, WHO clinical stage or CD4 count  \\n• ART should be started as soon as possible, ideally on the same day HIV diagnosis is  made, \\nwith ongoing enhanced adherence support  \\n• The preferred first line ART regimen for pregnant and breastfeeding women is TDF + 3TC \\n+ DTG  \\n• For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 months after \\ninitiation, and then every 6 m onths until complete cessation of breastfeeding  \\n• For HIV positive women already on ART at the time of confirming pregnancy or \\nbreastfeeding, obtain a VL irrespective of when prior VL was done, and then every 6 \\nmonths until complete cessation of breastfeeding  \\n• For pregnant or breastfeeding women with a VL ≥ 200 copies/m l (unsuppressed ): assess \\nfor and address potential reasons for viremia, including intensifying adherence support, \\nand repeat the VL after 3 months of excellent adherence  \\n▪ If the repea t VL is < 200  copies/ml (suppressed) then continue routine \\nmonitoring  \\n▪ If the repeat VL is ≥ 1,000 copies/ml (treatment failure), prepare for change to \\nan effective regimen  \\n▪ If the repeat VL is 200  - 999 copies/ml ( low level viremia ), reassess adherence \\nand other causes of viremia and consult the Regional or National TWG  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 22}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 6  • All HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or \\nfirst contact thereafter; if negative then another DNA PCR at 6 months, and if negative \\nthen  repeat DNA PCR at 12 months.  \\n• All HEI should receive infant ARV prophylaxis consisting of 6 weeks of AZT + NVP and \\nthereafter NVP should be continued until 6 weeks after complete cessation of \\nbreastfeeding  \\n• All infants irrespective of HIV status should be exclusively breastfed for the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond  \\n \\n1.7 TB/HIV Co -infection Prevention and Management  \\n• All healthcare settings should implement TB infection control recommendations to \\nreduce the risk of transmission of TB among patients, visitors and staff  \\n• Symptom -based TB screening using the ICF tool MUST be performed for all PLHIV at \\nevery clinic visit  \\n▪ Patien ts who screen negative should be assessed for and provided with TB \\npreventive therapy (TPT)  \\n▪ Patients who screen positive (presumptive TB) must complete definitive diagnostic \\npathways  \\n• The GeneXpert Ultra MTB/Rif test is the preferred test for diagnosis of T B and \\nrifampicin resistance in all presumptive TB cases  \\n• TB-LAM can be used as an adjunct rapid point -of-care diagnostic test for PLHIV: with \\nadvanced HIV disease (WHO stage 3 or 4 or CD4 count ≤ 200 cells/mm3 (or CD4% ≤ 25% \\nfor children ≤ 5 years)) with presumptive TB, or; any danger signs of severe illness, or; \\ncurrently admitted to hospital  \\n• Patients diagnosed with TB/HIV co -infection should start anti -TB treatment immediately \\nand initiate ART as soon as anti -TB medications are tolerated, preferably within 2 weeks \\n(unless they have TB meningitis, in which case ART should be deferred for 4 to 8 weeks)  \\n• Patients with TB/HIV co -infection who are already on ART should start anti -TB treatment \\nimmediately and continu e ART, making any required adjustments to the ART regimen \\nbased on known drug -drug interactions and monitoring toxicity  \\n• Always assess for ART failure in patients who develop TB after being on ART for ≥ 6 \\nmonths  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 23}),\n",
       " Document(page_content='  \\nSummary of Key Recommendations  \\n1 - 7  1.8 HBV/HIV and HCV/HIV Co -infection Preve ntion and Management  \\n• All HIV positive adolescents and adults should be screened for HBV infection, using serum \\nHBsAg, as part of initial evaluation; children who did not complete routine childhood \\nimmunizations should also be screened for HBV and vaccinat ed if negative.  \\n• PLHIV without evidence of hepatitis B infection (HBsAg negative) should be vaccinated \\nagainst hepatitis B  \\n• The recommended first -line ART for adults with HIV/HBV co -infection is TDF+ 3TC + DTG  \\n• HCV serology should be offered to individuals at  risk of HCV infection  \\n• Direct acting antiviral therapies (DAAs) for treatment of HCV have simplified the \\nmanagement of HIV/HCV co -infection  \\n \\n1.9 ARVs for Post -exposure Prophylaxis (PEP)  \\n• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \\n• The recommended ARV agents for PEP are  \\n▪  <15 years old  \\n▪ < 30 kg: ABC + 3TC + DTG  \\n▪ ≥ 30 kg: TDF + 3TC + DTG  \\n▪ ≥ 15 years old  \\n▪ TDF + 3TC + DTG  \\n \\n1.10 Pre -Exposure Prophylaxis (PrEP)  \\n• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \\ninfection (including the seronegative partner in a discordant relationship)  \\n•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \\npregnancies, therefore, additional protection should be of fered.  \\n• PrEP should only be offered to clients  ≥15 years of age who are sexually active after \\neligibility assessment using  the following parameters:  \\n▪ Laboratory: HIV negative  \\n▪ Medical (for oral PrEP): no contraindication to TDF; no severe renal diseases; wei ght \\n≥ 30 kg  \\n▪ Client readiness: client must be willing to take PrEP as prescribed, and adhere to \\nassociated follow up and HIV testing (at enrollment, at month 1 and thereafter every \\n3 months)  \\n• The recommended ARV regimen for Oral PrEP is TDF/FTC (alternative  TDF/3TC), \\navailable in two dosing strategies:  \\n▪ Daily oral PrEP: TDF (300 mg) + FTC (200 mg) once daily  \\n▪ Event -driven PrEP : Event driven PrEP is where oral PrEP is used in men having sex \\nwith men when an isolated sexual act is anticipated. The dose is two pills of TDF/FTC \\ntaken between 2 and 24 hours (preferably closer to 24h) before the anticipated \\nsexual act; then, a third pill taken 24 hours after the first two pills; and then a fourth \\npill taken 24 hours after the third pill (“2+1+1”).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 24}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n1 - 8  1.11 People Who I nject Drugs (PWID) and HIV  \\n• PWID should be offered regular HIV testing and counselling and be linked to   \\ncomprehensive HIV treatment and prevention services including harm reduction \\ncounselling and support  \\n• The recommended first -line ART for adult PWID is T DF + 3TC + DTG  \\n• PWID should be offered screening, diagnosis, treatment and prevention of STIs as part of \\ncomprehensive HIV prevention and care  \\n• PWID should have the same access to TB prevention, screening and treatment services as \\nother populations at risk o f or living with HIV  \\n• PWID should be screened for HBV (by HBsAg) and HCV (by HCV serology) at first contact  \\n• All PWID should be linked to Needle and Syringe Programs (NSP) to access sterile \\ninjecting equipment  \\n• All PWID should be linked to Medically Assisted Therapy (MAT)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 25}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 1   \\n2. HIV Testing Services and Linkage to Treatment \\nand Prevention  \\nHIV testing services (HTS) provide the first critical link to comprehensive HIV treatment and \\nprevention services such as voluntary medical male circumcision (VMMC), pre -exposure \\nprophylaxis (PrEP), post -exposure prophylaxis (P EP) and other combination HIV prevention \\nservices. In addition, this initial step also provides opportunities to offer other interventions such \\nas sexual and reproductive health services (SRH), TB screening and referral, and substance abuse \\nscreening and r eferral.  \\nHIV testing should be voluntary and conducted ethically in an environment where the six Cs \\nprinciples of Consent, Confidentiality, Counselling, Correct results, Connection (linkage) to care and \\nother appropriate post -test services and creating an  enabling environment are adhered to . \\nTargeted HIV testing  is the major strategic shift, involving index client listing of contacts, HIV self -\\ntesting and use of HIV screening tools to identify people at risk of HIV infection as eligible for \\ntesting, except in the case of PMTCT and key populations.  \\n2.1 Settings fo r HIV Testing  \\nIn Kenya, HTS is delivered in two broad settings: facility -based and community -based settings  \\n2.1.1 Facility -based testing  \\n● The HTS screening tool should be used to facilitate prioritization of testing for persons at risk \\nof HIV infection; those diagnosed with sexually transmitted infections, with multiple sexual \\npartners, key populations, and those with possible or known HIV exposures, such as sexual or \\nneedle sharing partner of a person living with HIV or of a person of unknown HIV status  \\n● Providers should undertake a thorough risk assessment using the validated NASCOP screening \\ntools (Annex 17) to identify clients at risk and those eligible for a HIV test.  \\n● HTS should be offered only to clients who consent  \\n● Clients who are not eli gible for testing should receive HIV prevention messages and be offered \\nservices as appropriate  \\n● Clients who test HIV positive should be linked to care while those who test negative should be \\nlinked to HIV prevention services  \\n● Patients starting HIV care shou ld receive disclosure counselling and support, and be offered \\nfamily, sexual and needle -sharing partner testing  \\nAs much as possible, HIV testing services should be integrated into care pathways at all service \\ndelivery points including adult and pediatric i npatient units, outpatient units, maternal and child \\nhealth clinics, SRH/family planning clinics, TB clinics, specialty clinics, gender -based violence \\n(GBV) care units and service delivery points for key and priority populations.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 26}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 2  2.1.2 Community –based t esting  \\nTargeted community based HTS offers additional opportunities to identify and link people to HIV \\ntreatment and prevention. This setting is especially important for testing children and partners of \\nindex clients through index testing , as well as  outreach to key and priority populations, orphans, \\nand vulnerable children (OVCs), adolescents, youth and targeted testing in workplaces.  \\n2.2 HTS strategies  \\nThe major HTS strategies to identify people living with HIV but unaware of their status are:  \\n2.2.1 HIV Self -Testing (HIVST)  \\n● HIVST allows individuals to collect their own specimen, perform the test, and interpret the \\nresults on their own, conducted either within a health facility, at home or in any other \\nconvenient place.  \\nHIVST can be  conducted with o r without direct assistance by a trained person.  \\n● HIVST is a screening test and is not sufficient to make an HIV -positive diagnosis. A reactive \\n(positive) self -test result should therefore be confirmed using the validated national testing \\nalgorithm by an H TS-trained service provider.  \\n● HIVST should be performed using MoH approved HIV rapid diagnostic test kits that are either \\nblood -based or oral fluid based.  \\n● HIVST may have the greatest benefit in reaching specific populations such as partners of newly \\ndiagnosed PLHIV; partners of pregnant women attending antenatal care (ANC); contacts of \\npatients treated for STIs; hard -to-reach populations such as men, adolescents, and young \\npeople, as well as key populations, such as MSM and sex workers.  \\nHIVST is a scr eening test and does not provide a diagnosis.  \\nAll reactive (positive) self -test results must be confirmed in a health facility according to \\nnationally set standards  \\n2.2.2 Index Testing  referred to as partner testing/partner notification services, is an approach \\nwhereby the exposed contacts (i.e., sexual partners, biological children and anyone with whom a \\nneedle was shared) of an HIV -positive person (i.e., index client), are elicited and offered HIV testing \\nservices  \\n2.2.3 Voluntary Counselling and Testin g (VCT):  This involves provision of targeted HIV \\ntesting to clients who willingly present to HTS facilities for testing for diverse reasons, including \\nself-assessed risk.  \\n2.2.4 Social Network Strategy (SNS) - this involves offering to index clients self -guided options \\nto informally extend links to HIV testing and other services to a broader set of social -, sexual -, \\nand injecting -network members who have an elevated risk of HIV infection. The index client for \\nSNS can either be PLHIV or HIV negative persons wi th increased risk for HIV infection . \\nProviding targeted HTS for different populations and in different settings increases opportunities \\nfor access to knowledge of HIV status and to a range of HIV treatment and prevention services. \\nTable 2.1 summarizes key recommendations for HTS for different sub -populations.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 27}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 3  Table 2.1: HTS R ecommendations for Different Populations and Settings  \\nPopulation  Recommendation  \\nBirth testing of \\ninfants born to \\nknown HIV - \\npositive mothers \\n(Figure 2.2)  ● Birth testing (HIV testing of infants at birth or at first contact within 2 weeks after \\nbirth) can be conducted where feasible and in settings wher e return of results is \\nfeasible within 24 hours and ART  can be initiated immediately*). Infants tested at \\nbirth must be tested at the 6 weeks immunization visit regardless of the results of \\nthe initial test at birth.  \\n● Infants with an initial positive HIV D NA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\nInfants and \\nchildren aged less \\nthan 18 months \\n(Figure 2.1)  ● HIV exposure status of all infants should be established at first contact.  \\n● To establish HIV exposure status of a child less than 18 months of age, conduct HIV \\nantibody testing for mothers with unknown status or who previously tested \\nnegative during antenatal care at the 6 -week immunization visit or first contact. If \\nthe mother declines to be tested or is not available for testing, then conduct a rapid \\nHIV antibo dy test for the child to determine exposure (if antibody test is positive \\nthis confirms HIV exposure)  \\n● When HIV exposure is confirmed, ARV prophylaxis should be started immediately.  \\n● All HEIs should have DNA PCR testing at the 6 -week immunization visit or fi rst \\ncontact thereafter.  \\n● Infants with an initial positive HIV DNA PCR result should be presumed to be HIV \\ninfected and started on ART in line with national guidelines, with a new sample for \\nconfirmatory HIV DNA PCR and baseline viral load taken at the time of ART \\ninitiation (ART initiation is based on the initial HIV DNA PCR result)  \\n● All HEI with initial HIV negative results should continue infant ARV prophylaxis \\nand be followed as HEIs, including additional PCR testing at 6 months and 12 \\nmonths, and antibody  testing at 18 months and every 6 months during \\nbreastfeeding, and at 6 weeks after complete cessation of breastfeeding  \\nChildren older \\nthan 18 months \\ntill age 9 years \\n(Figure 2.3)  ● Conduct HIV testing and counselling for all children of adults living with HIV as \\nsoon as possible after confirming the HIV positive status of the adult. Within health \\nfacilities, testing should be conducted at in -patient wards, nutrition clinics, and all \\nhigh HIV burden settings.  \\nAdolescents and \\nyoung people  \\n(10 - 24 years) \\n(Figure 2.3)  ● Targeted HIV testing services should be offered to adolescents and young people \\nwho are screened and found eligible for HIV test. HIV prevention services should \\nbe offered to clients who test negative while those who test positive should be \\nlinked to HIV care.  \\n● Adolescents aged above 10 years, should be tested with the written consent of a \\nparent or guardian, and are also required to give assent.  \\n● Adolescents who are e mancipated minors irrespective of age, can give their own \\nconsent.  \\n● All adolescents should be counselled on the potential benefits and risks of \\ndisclosure of their HIV status and empowered and supported to determine if, \\nwhen, how and to whom to disclose.  \\n● For sexually active adolescents, HIV testing and counselling should be offered to \\ntheir partners and children where appropriate.  \\n● All uncircumcised adolescent males who test HIV negative should be counselled \\nabout the prevention benefits of VMMC and linked t o VMMC services if they agree  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 28}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 4  Table 2.1 Cont.  \\nPregnant and \\nbreastfeeding \\nwomen  ● During the first ANC visit, HIV testing of pregnant women should be done \\nusing a dual test for HIV and syphilis, unless the woman is known to be living \\nwith HIV.  \\n● Women who test negative for both HIV and Syphilis should be offered a repeat \\nHIV-Syphilis dua l test in the third trimester.  \\n● Prevention services should be offered to all pregnant and breastfeeding \\nwomen who test HIV negative. They should be screened for eligibility and \\nwillingness for PrEP.  \\n● At labor and delivery, HIV testing should be done for all women with \\nunknown HIV status and those who previously tested negative (even if tested \\nnegative in the third trimester).  \\n● All breastfeeding mothers (unless known HIV positive) should be counselled \\nand tested at the 6 -week infant immunization visit. The HIV  test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding.  \\n● For mothers considered to be at high risk of HIV infection, retesting \\npostnatally should be done every 3 months; these include mothers \\ncategorized as key popul ation; in a HIV discordant relationship, or having \\nongoing sexual or injecting behavior that places her at risk, including new or \\nmultiple sexual partners.  \\n● Mothers should be counselled on the schedule for repeat HIV testing in \\npregnancy and postnatal as p art of routine ANC and postnatal education.  \\n● All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV testing during the first contact should be offered HIV counselling and \\ntesting in subsequent visits with appropriate referral and li nkage for \\nprevention, care, and support services.  \\n● All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (assisted disclosure), case management and \\nfollow -up. It should also include linkage to general ca re for ANC, delivery and \\npost -natal care  \\n● All spouses/partners as well as children of pregnant and breastfeeding \\nwomen testing HIV positive should be offered HIV testing and counselling.  \\nSexual partners & \\nchildren of index \\nclients (HIV positive \\nperson who is newly \\ndiagnosed or already \\nin HIV care)  ● All PLHIV enrolled into HIV care should receive disclosure counselling and \\nbe supported to disclose their HIV status (assisted disclosure)  \\n● HIV testing and counselling (facility -based or community -based) should be \\nencouraged for all partners including  sexual partners, needle sharing \\npartners, and children of index clients, with appropriate linkage to \\ntreatment and prevention services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 29}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 5  Table 2.1 Cont.  \\nKey and vulnerable \\npopulations  ● Conduct HIV testing and counselling for all clients from key and vulnerable \\npopulations presenting to the health facility irrespective of the reason for \\ntheir visit, or through targeted outreach and testing at key and vulnerable \\npopulation service delivery points (e.g., drop -in centers).  \\n● Key populations that test negati ve should be retested quarterly.  \\n● Link all who test HIV positive to treatment and prevention services.  \\n● Prevention services should be recommended, including consistent and \\ncorrect use of condoms and use of sterile needles and syringes.  They should \\nbe scree ned for eligibility and willingness for PrEP.  \\n● All uncircumcised males who test HIV negative should be counselled on the \\nprevention benefits of VMMC and linked to VMMC services if they consent  \\nTargeted HIV testing \\nand counselling of \\nadults  ● All adults eligible for testing should be offered HTS and encouraged to know \\ntheir HIV status and the status of their partners.  \\n● For those that test negative, re -testing is recommended if there is a new risk \\nexposure.  \\n● HIV positive adults should be counseled for  immediate ART initiation.  \\n● Link all adults identified as HIV positive to treatment and prevention services.  \\n● Clients who are not eligible for testing should receive HIV prevention \\nmessages and be offered services, as appropriate.  \\n● All males who test HIV nega tive should be counselled on the prevention \\nbenefits of VMMC and linked to VMMC services if they consent  \\n \\n2.3 Package of HIV Testing Services  \\nAn HIV testing and counselling session consists of:  \\n● A pre -test session  \\n● HIV testing  \\n● Assessment for other health -related conditions or needs (while HIV tests are running)  \\n● A post -test session (including index testing)  \\n● Referral and linkage to other appropriate health services (as part of the post -test session)  \\nThe HIV testing service package is summarized in Tab le 2.2.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 30}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 6  Table 2.2: Summary of HIV Testing Services Package  \\nPre- Test Counselling  \\nPre-test counselling may be provided to an individual or a couple presenting for HTS.  Group information \\ncan also be offered during pre -test.  \\nThe objectives of the pre -test counselling session are to:  \\n− Provide information on the benefits of knowing one’s H IV status, including outcomes for people \\non ART and undetectable = Untransmittable  (U=U).  \\n− Provide an explanation for the HIV testing process including time the session will take, \\nconfidentiality, and interpretation of test results  \\n− Obtain informed consent for HIV testing.  \\n− Explore the client’s risk of HIV infection.  \\n− Discuss the importance of disclosure to partners and other family members.  \\n− Explain the benefits of couple testing and partner services/index testing.  \\nProvide information on available post -test se rvices, including referrals for prevention or HIV care services  \\nPerform test.  \\nThe goal of HIV testing is to:  \\n• Provide accurate HIV diagnosis as per the nationally approved testing algorithm  \\n• Provide same day HIV test results  \\nDuring the 15 minutes as you wait for the test results:  \\n− Discuss Combination Prevention e.g., PrEP, PEP, Risk Reduction, STI treatment, condom \\ninformation and demonstration, VMMC, Elimination of Mother to Child Transmission of HIV \\n(eMTCT)  \\n− Screen, provide information and referrals for; Intimate Partner Violence (IPV), STI and cancer \\nscreening, Tuberculosis (TB), Family planning/c ontraceptive needs, etc.  \\n− Establishing number of sexual contacts and biological children for the purpose of index testing.  \\n− Document in the HTS, Lab, referral and linkage register (MOH 362).  \\nDiscuss further on index testing and HIVST as you perform the secon d and the third test, as per the national \\nalgorithm, for the clients who test positive with the screening test  \\nPost -test counselling  \\n− Check if the client is ready for results and help them to interpret.  \\n− Check what the client understands by the results.  \\n− Allow the client to share his/her initial reactions and verbalize their initial feelings.  \\n− Explore and acknowledge client’s immediate feelings and concerns.  \\nOffer necessary support  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 31}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 7  Table 2.2 Cont.  \\nNEGATIVE RESULT  \\n− Explain test results.  \\n− Review implications of being HIV negative.  \\n− Support clients to develop a risk reduction \\nplan (see HTS operational manual)  \\n− Provide information on methods to prevent \\nHIV acquisition.  \\n− Provide male and/or female condoms, \\nlubricant, and guidance on their use.  \\n− Emphasize on importance of knowing the \\nstatus of sexual partners and information \\nabout the availability of partner and couples \\ntesting services.  \\n− Referral and linkage to relevant HIV \\nprevention services  \\nExplain the need for repeat testing for people \\nwho tes t negative but report risky behavior \\nwithin the prior  4 weeks (i.e., unprotected sex \\nwith a partner of unknown status or Known HIV \\npositive status); if they test HIV negative again \\nafter 4 weeks  and are at  ongoing risk of HIV \\nacquisition , they should be ad vised to return for \\ntesting every 3 months  POSITIVE RESULT  \\n− Review implications of being HIV positive.  \\n− Help the index client to cope with emotions arising \\nfrom the diagnosis.  \\n− Discuss immediate concerns and help for the client \\nto decide who in his or her social network may be \\navailable to provide immediate support.  \\n− Discuss positive living.  \\n− Provide clear information on ART and its benefits \\nfor maintaining health and reducing the  risk of HIV \\ntransmission, as well as where and how to access \\nART  \\n− Refer clients who turn HIV positive to CCC for \\nlinkage to treatment.  \\n− Revisit index testing and HIVST to determine \\npartner notification plan/approach (refer to HTS \\noperational manual and APN S operational Manual).  \\n− Discussion of the risks and benefits of disclosure to \\npartners; couples counselling should be offered to \\nsupport mutual disclosure.  \\nEncourage and offer HIV testing for sexual partners, \\ninjecting partners, biological children, and oth er family \\nmembers, which can be done through couples testing, \\nfamily testing and/or assisted partner notification \\nservice.  \\nAssessment of other health related conditions  \\nAssess risk for sexually transmitted infections (STIs) and opportunistic infections that would also require \\nmanagement  \\nReferral and linkage to care  \\nObtain accurate locator information from the index client (physical location, phone number)  \\nPhysically escort the client for re -testing and linkage to ART  \\nDocument the outcomes of partner follow up(s)  \\nPost -Test Counseling in the Era of Test -and -Treat  \\nPost -test counselling should, at a minimum, include three key messages that being the ART treatment \\npreparation process for all PLHIV:  \\n− Treatment (called antiretroviral therapy or ART) is available and is recommended for everyone \\nwith HIV.  \\n− Starting treatment as soon as possible (preferably within two weeks from testing positive for \\nHIV) reduces the chance of your illness getting worse or of passing HIV to others. If  you take your \\nART properly and do not miss pills you can expect to live a long and productive life  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 32}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 8  2.4 Age -Specific HIV Testing Algorithms  \\n2.4.1  Early Infant Diagnosis  \\n2.4.1.1 Confirmation of HIV infection in HIV Exposed Infants and Children < 18 Months Old  \\nHIV expo sure  of an infant or child can occur in utero, at labour and delivery and through breast \\nmilk. Confirmation of HIV infection should immediately follow.  \\nAll HIV exposed infants (HEI) should be tested with DNA PCR within 6 weeks of age or first contact \\nthere after; if negative then another DNA PCR at 6 months, and if negative then repeat DNA PCR at \\n12 months.  \\nIf the HEI develops symptoms suggestive of HIV as per WHO staging criteria, an additional DNA \\nPCR test should be conducted immediately.  \\nAn antibody test  should be performed for all HEI at 18 months of age and every 6 months thereafter \\nduring breastfeeding, and at 6 weeks after complete cessation of breastfeeding (Figure 2.1).  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 33}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 9  \\nEstablish  HIV   of Infants  and  Children\\n< 18 months\\n•  Mother known HIV \\n•  HTS  for mothers  with  unkn own HIV \\n•  Rapid antibod y test on infant/child  if mother s HIV cannot  be \\nEstablish HIV infection for HIV Exposed Child at 6 weeks or at first \\ncontact  (includes child with negative DNA PCR result at birth)\\n• Collect a DBS for HIV DNA PCR test 1\\n• Start/continue infant  ARV prophylaxis\\n• Start CPT At L&D, MNCH/F P, \\nIPD, A&E,  CCC & \\nHIV DNA PCR test NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -upHIV DNA PCR test POSITIVE\\nChild presumed HIV infected\\n• Discontinue infant ARV prophylaxis\\n• Start ART\\n• Offer comprehensive care including \\ncontinuation of CPT\\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.  1Conduct DNA PCR  at 6 months of age or soonest contact \\nthereafter (or earlier if child develops symptoms \\nsuggestive of HIV -as per WHO staging criteria)1\\nConfirmatory HIV DNA \\nPCR test POSITIVE\\nChild confirmed HIV \\ninfected\\n• Continue ART and \\ncomprehensive care \\nand routine under -5 \\ncareConfirmatory HIV DNA PCR \\ntest NEGATIVE\\nChild presumed HIV infected\\n• Continue ART \\n• Collect and send a DBS \\nto NHRL and manage \\nas per the results from \\nNHRLHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Conduct DNA PCR at 12 months of age  or \\nsoonest contact till 18 months of age (or earlier if \\nchild develops symptoms suggestive of HIV -as \\nper WHO staging criteria) 1\\nHIV DNA PCR result NEGATIVE\\nChild HIV -exposed\\n• Continue HEI follow -up\\n• Continue routine under -5 care\\n• Conduct HIV Antibody test at 18 months of age \\n• If breast feeding, do HIV antibody test every 6 months while breast \\nfeeding and 6 weeks after complete cessation of breastfeeding \\nIf HIV antibody test  is negative\\nChild HIV negative \\n• Stop CPT * \\n• Review at age 2 years and document vital status \\n• Continue routine  unde r-5 If HIV antibody test  is positive \\nChild confirmed HIV infected\\n• Start  ompre hensive  \\n• Continue CPT\\n• Continue routine  unde r-5 \\n1 Where Point of Care DNA PCR is available - EID should be done using the whole blood at the facility. \\nFor baseline viral load testing – If available, use point of care machine for viral load; If there is no point of care \\nmachine to do viral load - Take a plasma and send it to the VL testing laboratory\\n* Only after final antibody test negativeChild is HIV unexposed\\n  \\nFigure 2.1 Algorithm for Early Infant Diagnosis in Infants and Children < 18 months of age   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 34}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 10  Presumptive Diagnosis of Severe HIV Disease in Children under 18 Months  \\nOccasionally, children less than 18 months of age present to hospital with severe illness; and a rapid \\nHIV antibody test confirm s HIV exposure. Lack of immediate availability of HIV DNA PCR results \\nfor confirmation of HIV could result in undue delay in starting life -saving ART. In such children, a \\npresumptive diagnosis of HIV infection can be made using the criteria in Table 2.3. A RT can be \\ninitiated while awaiting HIV DNA PCR results to confirm HIV infection.  \\nTable 2.3: Presumptive Diagnosis of HIV in children <18 months while awaiting DNA PCR \\nResults  \\nHIV antibody test positive AND symptomatic with;  \\n 2 or more of the following:  \\n● Oral candidiasis/thrush  \\n● Severe pneumonia  \\n● Severe sepsis  \\nOR any of the of following:  \\n● Any WHO Clinical Stage 4 condition  \\n● Recent maternal death (if likely to have been HIV -related) or advanced HIV disease in \\nmother  \\n● Child’s CD4% < 2 5% \\n \\n2.4.1.2  Birth Testing  \\nBirth testing is defined as HIV testing (with DNA PCR) at birth or around birth for infants born to \\nHIV-positive mothers. Birth testing has the potential to improve survival for infants who are \\ninfected during pregnancy, around labour and delivery by ident ifying them early for rapid ART \\ninitiation. Do not use cord blood for birth testing as this could result in false positive results.  \\nA DNA PCR test can be offered at birth or around birth where feasible.  \\nALL children initially tested at birth should be rete sted at 6 weeks of age and the EID \\nalgorithm followed (Figure 2.2.)  \\nConsiderations for providing birth testing:  \\nBirth testing may be prioritized for newborns who are at high risk of HIV acquisition including \\nthose born to:  \\n● Mothers who seroconvert during p regnancy.  \\n● Mothers who have unsuppressed or unknown viral loads during delivery.  \\n● Mothers who received a HIV positive diagnosis for the first time at or after 28 weeks \\ngestation or during labour and delivery  \\n● Mother on ART for less than 12 weeks prior to delivery  \\nBirth testing should be offered where this is feasible:  \\n● DNA PCR results can be returned the same  day e.g., where on site point of care is available.  \\n● ART regimens recommended for neonates as per national guidelines are available and can \\nbe initiated immed iately.  \\n● Follow -up of the newborn is done to ensure no lost to follow -up. ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 35}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 11  \\nInfant of known HIV positive mothers at birth (or \\nwithin 2 weeks of birth)\\n• Collect DBS for DNA PCR\\n• Start infant ARV prophylaxis immediately after \\nbirth.  \\nHIV DNA PCR positive HIV DNA PCR Negative \\n• Initiate ART immediately\\n• Book for follow up at 2 weeks of age. \\n• Offer comprehensive care for HIV infected child. \\n• Collect new sample for confirmatory HIV DNA \\nPCR, baseline viral load and CD4%.• Continue infant ARV prophylaxis and follow up \\nfor HIV exposed infants. \\n• Repeat DNA PCR test at 6 weeks. Follow the EID \\nalgorithm. \\nConfirmatory DNA PCR positive/ \\ndetectable Viral load \\n• Continue ART \\n• Provide comprehensive care. Confirmatory DNA PCR negative \\n• Continue ART \\n• Collect DBS for repeat PCR at 6 weeks of age \\nand manage as per EID algorithm \\n• Collect new sample send to NHRL. Manage as \\nper NHRL results \\nFigure 2.2: Birth Testing Algorithm  \\n \\n2.4.1.3  Use of Point of Care testing for Children  \\nPoint -of-care testing occurs at the health facility where care is being provided, with results being \\nreturned to the patient or caregiver on the same day as sample collection. Point of care DNA PCR \\ntesting for early infant diagnosis of HIV can reduce the turnaround time for testing and return of \\nresults and allow imme diate initiation of ART among infants.  Point of care DNA PCR testing can be \\nused to diagnose HIV infection as well as to confirm positive results.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 36}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 12  2.4.2  Diagnosis of HIV Infection in the Older Child (≥ 18 months), Adolescents and \\nAdults  \\n● Serial testing,  using approved rapid HIV antibody testing kits, is used to diagnose HIV infection \\nin children older than 18 months, adolescents, and adults, and (refer to Figure 2.3)  \\n● An HIV -positive diagnosis will be made using three consecutive reactive assays . This thr ee-\\ntest strategy as well as retesting aims to ensure that at least a 99% Positive Predictive Value \\n(PPV) is maintained, and false positive misdiagnosis is avoided.  \\n● Offer adequate information to all clients and obtain consent prior to the HIV test (verbal \\nconsent is adequate but should be documented by the health care worker in client records). \\nFor children below the age of 14 year who are not emancipated minors, a written consent from \\nthe guardian is recommended.  \\n● Individuals 15 years and older and emancipa ted minors can provide self -consent.  \\n● Clients who test positive should be linked to care and treatment. Counselling support, index \\nand family testing should be offered to these clients.  \\n● Clients who test negative should be counselled on HIV risk reduction b ehaviors and linked to \\ncombination HIV prevention services (such as VMMC, RH/FP, condoms, PrEP, etc.) depending \\non individual risk profile. Table 2.5 provides recommendations for re -testing those who test \\nHIV negative.  \\nHIV testing algorithm for children >1 8months, adolescents and adults.  \\nFigure 2.3 illustrates the serial testing algorithm. An HIV -positive diagnosis will be made using \\nthree consecutive reactive assays (Figure 2.3). All individuals are first tested on Assay 1 (A1). \\nAnyone with a non -reactive test result (A1−) is reported HIV -negative.  Individuals who are \\nreactive on Assay 1 (A1+) will then be tested on a separate and distinct Assay 2 (A2). Individuals \\nwho are reactive on both Assay 1 and Assay 2 (A1+; A2+) will then be tested on a separate an d \\ndistinct Assay 3 (A3). A positive HIV diagnosis is given when Assay 3 is reactive (A1+; A2+; A3+).  \\nIf Assay 3 is nonreactive (A1+; A2+; A3−), the status should be reported as HIV -inconclusive, and \\nthe individual should be asked to return in 14 days for retesting.   \\nIndividuals who are reactive on Assay 1 but non -reactive on Assay 2 (A1+; A2−) should be repeated \\non Assay 1. If repeat Assay 1 is non -reactive (A1+; A2−; repeat A1 –), the status should be reported \\nas HIV -negative.  If repeat Assay 1 is reactive (A1+; A2 –; repeat A1+), the status should be reported \\nas HIV -inconclusive, and the individual asked  to return in 14 days for retesting.   All clients with \\nHIV positive results will be referred to a Comprehensive Care Clinic for retesting prior to \\ninitiation of ART  \\nNOTE:  The three -test algorithm will be implemented after identification of the specific \\nassay. Meanwhile, the current algorithm continues being in use (Annex 7). Guidance will \\nbe issued before implementation.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 37}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 13  \\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYS. \\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ART\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.3: HIV Testing Services Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 38}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 14  Results interpretation  \\nRESULTS  INTERPRETATION  \\nA1- HIV-NEGATIVE  \\nA1+; A2+; A3+  HIV-POSITIVE  \\nA1+; A2 -; Repeat A1+  HIV-INCONCLUSIVE (retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative   \\nA1+; A2 -; Repeat A1 - HIV-NEGATIVE  \\nA1+; A2+; A3 - HIV- INCONCLUSIVE (Retest after 14 days). If reactivity \\nremains the same after 14 days, the individual should be \\nreported as HIV -negative  \\n \\n2.4.3  HIV testing for Pregnant Women  \\nFor pregnant women, the HIV/syphilis dual test should be used as the A1 test (Figure 2.4). The dual \\ntest kit is recommended for:  \\n● Pregnant women during their first ANC, unless the woman is known to be living with HIV.  \\n● For those who test negative for both HIV and Syphilis repeat testing should be conducted \\nin the third trimester using the HIV and syphilis dual test.  \\n● Partners accompanying pregnant women for the first -time during ANC  \\nHIV/Syphilis dual test should not be used for retesting women on ART or with  known positive HIV \\nstatus, or women diagnosed with syphilis during pregnancy.  \\nSee Figure 2.4 for the full algorithm when considering HIV and syphilis (TP) results concurrently.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 39}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 15  \\nTEST A1 (HIV/Syphillis)\\nHIV TEST A1 SYPHILIS TEST A1\\nREPORT NEGATIVE HIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE \\nRETEST IN 14 DAYS.\\nREPORT HIV POSITIVE AND REFER TO THE SECOND TESTER AT CCC/MCH\\nHIV TEST A1\\nNON -REACTIVE REACTIVE\\nREPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSHIV TEST A2\\nNON -REACTIVE REACTIVE\\nHIV TEST A1 HIV TEST A3\\nNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVE REPORT INCONCLUSIVE AND \\nRETEST IN 14 DAYSINITIATE ARTNON -REACTIVE REACTIVE NON -REACTIVE REACTIVE\\nREPORT NEGATIVEREPORT POSITIVE AND \\nTREAT FOR SYPHILLIS\\nNote: \\n• The use of DNA PCR as a supplemental assay is no longer recommended\\n• For inconclusive HIV status, if reactivity remains the same after 14 days the individual should be \\nreported as HIV -negative and advised to retest after 3 months \\nFigure 2.4 Dual HIV/syphilis Testing Algorithm  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 40}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 16  RESULTS  INTERPRETATION  \\nA1 HIV -, Syphilis Test (TP) - HIV negative, syphilis negative  \\nA1 HIV -, Syphilis Test (TP)+  HIV negative, syphilis positive  \\nA1 HIV+, Syphilis Test (TP) - Syphilis negative and proceed with A2 for HIV  \\nA1 HIV+, Syphilis Test (TP)+  Syphilis positive and proceed with A2 for HIV  \\nA1 (HIV+); A2+; A3+  HIV-positive  \\nA1(HIV+); A2 -; Repeat A1+  HIV-inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nA1(HIV+); A2 -; Repeat A1 - HIV-negative  \\nA1(HIV+); A2+; A3 - HIV- inconclusive (retest after 14 days). If reactivity remains the same \\nafter 14 days, the individual should be reported as HIV -negative  \\nTable 2.4: Approaches to Improve Linkage to Treatment and Prevention Services  \\nkey area  Action  \\nInformation  ● Quality post -test counselling should include information about the nature and \\navailability of additional HIV -related services, description of the next steps in \\ntreatment and prevention including entire treatment plan and follow -up visits \\nand schedule.  \\n● The benefits of immediate assessment and early initiation of ART should be \\nemphasized.  \\n● Involve the patient in the decision -making process regarding treatment and \\nprevention (espe cially where and when to start ART)  \\nDisclosure  ● Disclosure to a trusted ‘significant other’ promotes linkage and adherence to \\ntreatment.  \\n● Encourage and help the patient to discuss HIV status with a trusted friend or close \\nrelative.  \\n● Encourage adolescents to identify and invite a supportive adult or friend to \\nsupport them.  \\n● For children, HIV status should be disclosed to children by age 12 years and the \\nprocess can start when a child is as young as 7 years old.  The health care provider \\nor the pa rent/caregiver/guardian can disclose to the child with appropriate \\nguidance and training. The aim of disclosure to children is to start to involve them \\nin the management of their own health and reduce stigma associated with HIV  \\nBarriers to \\nLinkage  ● During post -test counselling, identify and address any barriers to linkage  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 41}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 17  Table 2.4 Cont.  \\nSystems to \\nFacilitate \\nLinkage  ● The HTS provider is responsible for linkage into care.  \\n● Same day enrolment into care is expected. monitor linkage to treatment initiation \\nwithin 14 days of diagnosis, however allow follow up of clients to 90 days of a \\nHIV-positive diagnosis  \\n● For HIV negative clients link to HIV prevention services based on assessed risk  \\n● Linkage should be done to on -site treatment and prev ention services through \\npatient escorts. Where this is not possible (due to patient preference or the \\nservices are not available), the testing facility should book the appointment with \\nthe receiving facility and follow -up to ensure the patient registers at  the receiving \\nfacility. Provide the patient with referral information, referral form and contact \\ndetails of the facility.  \\n● Deploy retention and loss -to-follow up tracking system to ensure linkage is \\nsuccessful. These include enlisting the help of peer or b uddy systems, SMS \\nreminders, phone calls and community outreach workers to escort HIV positive \\nclients to enrolment.  \\n● Early preparation and assessment for ART, with early initiation of ART \\nstrengthens engagement in care.  \\nCare \\nCoordination \\nand \\nIntegration  ● Coordinate and treat mother -baby pairs, partners, and families together. \\nIntegrate common services offered to PLHIV (TB diagnosis and treatment, \\nSRH/FP, cervical cancer screening, nutrition etc.)  \\n● Where referrals are necessary, such referrals should be coor dinated \\n(communication and documentation between referring and receiving service \\ndelivery points)  \\nLinkage Register  ● Maintain a linkage register at all testing points in the facility and community.  \\n● Track and report on progress with linkage monthly  \\n● Discuss linkage at MDT meetings.  \\n \\n2.5 Retesting recommendations for HIV negative persons  \\nRetesting in this context refers to testing that occurs later after the initial test is negative.  \\nThe purpose of retesting is to:  \\n● Monitor the effectiveness of HIV prevention interventions  \\n● identify and treat new HIV infections as early as possible when prevention efforts fail.  \\nThe following are the recommendations for HIV retesting in different populations and settings in \\nKenya:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 42}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 18  Table 2.5: Recommendations for Retesting HIV Negative Clients  \\nScenario/population  Recommendation for retesting  \\nGeneral population  All general population to be screened every 2 years \\nusing the approved NASCOP HTS screening tool and \\nthose eligible get tested  \\nKey populations (FSW, MsM, TG, \\nPWID)  Re-test every 3 months  \\nNegative partner in discordant  \\n \\n Retest HIV negative partner at the initiation of ART for the \\nHIV positive partner, at 6months and 12 months once \\nviral suppression is achieved.  \\nRetest a nnually if the positive partner remains virally \\nsuppressed.  \\nPregnant women  Test in first trimester or first contact; Re -test in the third \\ntrimester and, during labour and delivery.  \\nBreastfeeding mothers  Re-test 6 weeks after delivery, at 6 months then every 6 \\nmonths until complete cessation of breast feeding.  \\nFor mothers considered to be at high risk of HIV \\ninfection, retesting postnatally should be done every 3 \\nmonths  \\nPersons who had a most recent \\n(e.g., less than one month) high \\nrisk exposure to  HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich National testing guidelines apply  \\nSTI symptomatic patients or \\npatients with symptoms \\nsuggestive of acute HIV  Test at initial presentation and re -test at 4 weeks, after \\nwhich national te sting guidelines apply  \\nIndividuals on Pre -exposure \\nprophylaxis (PrEP)  Test at initiation of PrEP; Retest at month one, and then \\nevery 3 months  \\n2.6 Inconclusive HIV status  \\nAn HIV -inconclusive test status means that individuals had discrepant results on the test (for \\nexample, first test reactive, second test nonreactive, third test reactive) and so could not be given \\nan HIV -positive or HIV -negative diagnosis.  \\nInconclusive results are rare, but they may occur when  \\ni) cross -reactivity exists between kits or patient -related factors,  \\nii) the tester or test kit makes an error; and/or  \\niii) individuals are seroconverting and in the window period, when infection cannot be \\ndeterm ined.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 43}),\n",
       " Document(page_content='  \\nHIV Testing Services and Linkage to Treatment and Prevention  \\n2 - 19  The window period is the time from exposure to HIV infection to when the body produces enough \\nHIV antibodies to be detected by an HIV antibody test. This time can vary across different types of \\ntests, where some tests may be able to detect antibodies earli er than another test, which can lead \\nto discrepant test results.  \\nAll people with an inconclusive HIV status should be encouraged to return in 14 days for retesting. \\nReceiving inconclusive results could be confusing and stressful for clients and may be dif ficult for \\nthe provider to explain. During post -test counselling, the provider needs to take time to explain \\ncarefully what an HIV -inconclusive status means, stating that it is neither HIV -positive nor HIV -\\nnegative, and that retesting in 14 days is needed to establish the correct diagnosis. Because \\ndefinitive diagnosis cannot be made on the day of testing, and immediate referral to HIV care or \\nART initiation is not appropriate, providers need to help clients make a clear plan for follow -up and \\nschedule an a ppointment for retesting. Also, clients should be informed about prevention options \\nand how to stay HIV -negative, as well as about the availability and benefits of ART.  \\nThose suspected of having an acute HIV infection1 – for example, if they report or pre sent with \\nsymptoms associated with acute HIV infection – should be followed up closely. This is a period of \\nhigh infectiousness due to high viral load, and clients need to be informed how to protect their \\npartners. Individuals at high ongoing risk of HIV c an be informed about PrEP and encouraged to \\ndiscuss options depending on their final HIV status when they come back for retesting.  \\n \\n2.7 Approach to Patients on ART with a Discrepant HIV Test Result  \\nHIV testing should not be performed to patients who are al ready enrolled into HIV care and \\non ART.  However, some patients self -refer for HIV antibody testing without disclosing that they \\nare known HIV positive and on ART. Figure 2.5 provides recommendations on managing patients \\nwho have a non -reactive antibody te st while on ART.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 44}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n2 - 20  \\nEducation/counselling  for patients who are on ART and present with a new negative HIV antibody test\\n• The new HIV antibody test may be a  false negative    the patient may still be HIV -infected but their antibody \\nlevels may be suppressed as a result of effective ART. This is more common for patients who start ART very \\nsoon after HIV infection\\n• Those with prior history of detectable viral loads, positive DNA PCR results, or low CD4 counts are almost \\nalways truly HIV positive\\n• Continue their ART until a special test is performed (a new sample for DNA PCR) at the National HIV \\nReference Laboratory (NHRL)\\n• Stopping ART before HIV status is confirmed could result in a rapid rise in viral load, decline in CD4, and \\nincreased risk of developing an opportunistic infection or dying\\n• Draw a sample for DNA PCR  and send to the NHRL  (preferably a whole blood EDTA sample following \\ncold -chain protocols within 24 hours of collection; DBS is acceptable if EDTA is not possible)\\n• Specify that this is a sample for confirming HIV status  of a patient who is on ART, and provide the dates \\nand results for all prior antibody tests, DNA PCR tests, and RNA viral load tests in the request form\\nIf HIV DNA PCR sample is positive\\n• This confirms the patient is HIV positive\\n• Provide additional counseling on the \\nreasons why the antibody test may have \\nbeen falsely negative and discourage the \\npatient from any repeat antibody testing\\n• Emphasize that the patient  s ART is \\nworking and the need for continued \\nexcellent adherenceIf HIV DNA PCR sample is negative\\n• The patient may be HIV negative, or it could be that the \\npatient is  HIV positive but the HIV DNA levels have been \\nsuppressed below the testing limit (this is more common if \\na DBS sample was used)\\n• Inform the patient that they may still be HIV positive and \\nneed to be monitored closely for an additional 6 months \\nbefore confirming they are HIV negative\\n• Inform the patient that ART should be stopped immediately\\n• They should return for HIV viral load performed at 1 \\nmonth, 3 months, and 6 months after stopping ART \\n(samples for HIV viral load should be sent to the designated \\nVL/EID network laboratory assigned to the requesting \\nfacility with all past details) \\nFigure 2.5: Managing Patients on ART Who Present with a New Negative HIV Antibody Test', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 45}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 1   \\n3. Initial Evaluation and Follow up  \\n \\n3.1 Introduction  \\nAll PLHIV are eligible for ART irrespective of CD4 cell count or percentage, WHO clinical  stage, age, \\npregnancy status, or comorbidities. ART should be initiated as soon as the patient is ready to start, \\npreferably within two weeks from time of HIV diagnosis.  \\nIn order to provide targeted services based on clinical presentation, during the init ial evaluation \\nall PLHIV should be categorized as presenting with advanced HIV disease (AHD) or as presenting \\nwell (Table 3.3). Patients with advanced disease require more intensive evaluation for and \\nmanagement of OIs, and once ART is started, they are at  higher risk of developing immune \\nreconstitution inflammatory syndrome (IRIS, Annex 16).  \\nSimilarly, after at least 6 months on ART, PLHIV should be categorized as being either established \\nor not established on ART (clinically, virologically, and psychosoci ally) to best meet the specific \\nneeds of each patient for treatment and follow -up and improve patient outcomes through provision \\nof targeted differentiated care. Differentiated care minimizes inconvenience and unnecessary \\nfrequent follow -up, thus reducing costs and time related to clinic visits. It also allows resources to \\nbe focused on those patients who require additional attention.  \\n3.2 Initial Clinical Evaluation of PLHIV  \\nAll patients enrolling into HIV care should have a complete medical history taken, a thorough \\nphysical examination and appropriate laboratory investigations. Findings from this initial \\nevaluation should be documented legibly in a retrievable health record management format \\n(electronic or paper -based) to facilitate long -term follow -up of the patient. Table 3.1 summarizes \\nimportant aspects of the initial medical history and physical examination for PLHIV.  \\nThe initial visit provides the opportunity to establish a meaningful patient -provider relationship; \\nthe clinician should elicit concerns  and expectations with open, non -judgmental, and clear \\ncommunication.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 46}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 2  Table 3.1: Initial Clinical Evaluation for PLHIV (History and Physical Examination)  \\nHistory  Details for History taking  \\nCurrent and past \\nmedical history  ● Presenting complaints/current symptoms  \\no Also inquire about symptoms due to co -existing HIV -related and non -HIV-\\nrelated disease and co -morbidities that will require immediate intervention  \\n● History of TB and TB contacts  \\nComplete the Intensified Case Finding (ICF) tool  \\n● Date of first positive HIV test  \\n● Past and current co -morbidities (e.g., TB, cryptococcal meningitis, hypertension, \\ndiabetes, kidney, and liver disease)  \\no Document history of TB  \\n● Current medications,  \\no Establish current medications (prescription, non -prescription, and \\nherbal) likely to interact with ARVs  \\no Document ARV exposure history including previous or current ARV use \\n(including for PMTCT, PEP, PrEP, and ART)  \\n● Drug allergies, especially sulpha allergy  \\n● History of hospitalizations  \\no Establish reasons for hospitalizations  \\n● Family history of chronic disease or cancer  \\nEstablish nutritional history and adequacy of nutritional intake and household food \\nsecurity  \\nPsychosocial \\nhistory  ● Education, employment, family, marital status  \\n● Establish possible presence of mental health concerns  \\no Including past treatment for mental illnesses and any current \\nsymptoms of depression  \\n● Assess for disclosure and presence of self -stigma  \\no Encourage disclosure to trusted close relations and sexual partners  \\n● Substance use screening including alcohol, tobacco, miraa (khat), marijuana, \\nnarcotics, injection drug use (use the CRAFFT screening tool for adolescents and \\nthe CAGE -AID screening tool for adults to screen for alcohol and drug use \\ndisorders – see Tables 4.15 and 4.16)  \\n● Establish and document social support structures  \\n● Link to additional facility and community support resources, including \\npsychosocial support groups, peer mentors, harm reduction services for PWIDs, \\netc. \\nElicit and begin to address possible barriers to adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 47}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 3  Table 3.1 Cont.  \\nSexual and \\nreproductive \\nhistory  History  \\n● History of STIs  \\n● Current symptoms of STIs  \\n● Sexual practices  \\no Determine HIV status and disclosure to sexual partner(s)  \\no ART status of sexual partner/s  \\n● Pregnancy history and age of all living children  \\n● Menstrual history, family planning and plans for pregnancy  \\n● History of cervical cancer screening  \\n● Vaccination history (including COVID -19 vaccine)  \\nDiscuss:  \\n● Secondary prevention and avoidance of re -infection with STIs  \\n● Pregnancy intention and contraception needs  \\nEncourage contact tracing and HIV testing for sexual partners and all children < 15 \\nyears of age of HIV -infected women or whose mothers’ HIV status is unknown  \\nVital signs, and \\nanthropometric \\nmeasurements  ● Measure and record weight, height, MUAC (in children and pregnant women), \\ntemperature, pulse rate, BP, respiratory rate, and pulse oximetry  \\n● Calculate BMI as: Weight (kg)/ Height2(m); Use z -scores for children  \\n● Monitor growth trends for children  \\nGeneral \\nexamination  Examine the following:  \\n● Conjunctiva and palms for pallor or jaundice; swollen lymph nodes (cervical, \\naxillary, inguinal); mouth for Kaposi’s sarcoma (KS) lesions, oral hairy \\nleucoplakia, candidiasis, tooth decay; skin (for drug eruptions, herpes zoster, \\ndermatitis, pruritic papular eruptions (PPE), folliculitis, fungal infections, \\nmolluscum, and KS)  \\n● Assess developmental milestones for children  \\nSystemic \\nexamination  ● Central Nervous System  \\n● Mental State Examination (for mental status)  \\n● Abdomen   \\n● Respiratory  \\n● Cardiovascular  \\n● Genitourinary/ anorectal system (for ulcers, discharge, condylomata/warts, \\nprostate examination for men ≥ 45 years of age). Speculum examination with \\ncervical cancer screening for females  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 48}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 4  Table 3.1 Cont.  \\nSummary  List differential diagnosis and management plan for each problem (including \\ninvestigations, treatment, referrals, and follow -up) \\n● Assign and document the WHO Clinical Stage and manage presenting \\nillnesses  \\n● Growth and developmental milestone must be assessed and used for WHO \\nstaging in children  \\nDifferentiate between patients with advanced disease versus those who are clinically \\nwell, to guide acuity of follow -up \\n3.3 Initial Laboratory Evaluation of PLHIV  \\nThe comprehensiveness of laboratory tests will depend on presence and/or type of suspected \\nconcurrent illness. Table 3.2 summarizes the recommended baseline laboratory investigations for \\nall PLHIV. Additional investigations should be based on clinical indicati on. ART should not be \\ndelayed if a laboratory test is not available.  \\nTable 3.2: Baseline Laboratory Investigations for PLHIV  \\nHIV  \\nSpecific  Test  Comments  \\n● Confirm and \\ndocument positive \\nHIV test result  ● Positive status should be reconfirmed prior to ART \\ninitiation for all patients  \\n● Refer to current HIV testing algorithm  \\nCD4 cell count  ● For all patients  (CD4% for children ≤ 5 years old)  \\n● If CD4 ≤ 200 cells/mm3 in PLHIV >5 years, th en \\nlaboratories should automatically perform a serum \\ncryptococcal antigen (sCrAg) on the same sample to screen \\nfor cryptococcal infection  \\n● TB-LAM should also be conducted   \\nViral load (HIV -1 RNA)  ● Baseline viral load (VL) is recommended for infants after \\n1st PCR test is positive. Specimen for baseline VL can be \\ndrawn at the time of initiating ART; obtaining a VL should \\nnot delay ART initiation  \\nSerum Cryptococcal  \\nAntigen (sCrAg)  ● Obtain serum CrAg If CD4 ≤ 200 cells/mm3 in patients >5 \\nyears  as reflex testing by the laboratory  \\n● If positive, manage as per the cryptococcal meningitis \\nscreening algorithm (Figure 4.1)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 49}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 5  Table 3.2 Cont.  \\nOthers  Hb (preferably full  \\nblood count if available)  ● All patients especially if on AZT  \\n●  \\nPregnancy Test  ● Pregnancy status should be determined for all women of \\nreproductive age (based on history of last menstrual period, \\nand if uncertain, irregular, or delayed then a urine pregnancy \\ntest should be performed)  \\nTB- LAM  ● Conduct TB -LAM  on a urine sample if CD4 ≤ 200 cells/mm3 \\nin PLHIV >5 years, and if CD4% ≤ 25% in children < 5 years  \\n● Seriously ill patients  \\nUrinalysis (for protein  \\n& glucose)  ● All patients  \\nCreatinine  o All patients, especially those starting TDF. Calculate \\nCreatinine Clearance (CrCl), (Annex 15)  \\nSyphilis serology \\n(VDRL, TPHA, or RPR)  ● All patients with a history of being sexually active  \\nGlucose  ● All patients  \\nPlasma lipid profile  ● All patients  \\nHBsAg  ● All adolescent and adult patients (plus children who did not \\ncomplete routine childhood immunizations)  \\nHCV antibody  ● PWID or for patients with history of injection drug use  \\nALT  ● Not recommended as baseline investigation unless there is a \\nspecific clinical reason (e.g., patient with history of hepatitis, \\nsigns or symptoms of liver disease, or risk of liver disease - \\nalcoholics, HBV or HCV infection, hepatotoxic drugs such as \\nfluconazole, etc.)  \\nHPV testing  ● For women of reproductive age between 25 -49 years \\nconducted at baseline and every two years (refer to cancer \\nscreening guidelines)  \\n \\nIt is not possible for ALL facilities providing ART to offer all the laboratory tests recommended for \\nHIV treatment. If a facility does not have on -site capacity to carry out any test, arrangements \\nshould be made to transport specimens to a local or regional reference laboratory.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 50}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 6  3.4 Management of Patients Who Present with Advanced HIV Disease  \\nThe World hea lth organization (WHO) defines AHD for adults, adolescents, and children five years \\nand older as having a CD4 cell count of less than 200 cells/mm3 or WHO clinical stage III or IV \\ndisease. All children younger than five years living with HIV who are not al ready receiving ART and \\nnot clinically stable are considered to have AHD.  \\nAdvanced HIV Disease can occur in various settings including PLHIV newly presenting to care, \\nthose returning to care after treatment interruption and those on ART who have experienc ed \\ntreatment failure.  \\nPLHIV with AHD have immune suppression with reduced ability to fight opportunistic infections \\n(OI), other infectious and non -infectious diseases, and are therefore at increased risk of morbidity \\nand mortality. AHD is also associated with increased health -care costs, use of more health -care \\nservices and more frequent monitoring needs. Leading causes of mortality among adults with AHD \\ninclude immune reconstitution inflammatory syndrome, tuberculosis (TB), severe bacterial \\ninfections, cryptococcal disease, histoplasmosis, toxoplasmosis, and Pneumocystis Jirovecii \\npneumonia amongst others.  \\nCD4 testing criteria to diagnose AHD and determine eligibility for package for care:   \\n• New clients initiating ART:  \\no CD4 testing should be c onducted as a baseline test for ALL PLHIV  \\n• Patients who are treatment experienced:  \\no PLHIV ≥5 years of age and who had previously initiated ART and are reinitiating after >3 \\nmonths).  \\no Individuals who have documented persistent unsuppressed viral load (two viral load VL \\n>1,000 within 3 -6 months).  \\nPackage of Care for AHD  \\nAll PLHIV presenting  with Advanced HIV Disease (AHD) should be offered a package of care that \\nincludes timely initiation of ART, screening, diagnosis, prophylaxis, and management of \\nopportunistic infections.  \\nTable 3.3 provides a summary of definitions of well versus advanced disease and package of care \\nfor each at enrolment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 51}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 7  Table 3.3: Differentiated Care Based on Initial Patient Presentation  \\nAdults, adolescents, and children ≥ 5 years who Present with Advanced HIV Disease: WHO Stage \\n3 or 4, or CD4 count ≤ 200 cell/mm3  \\nAll children younger than five years at enrollment into care  \\nPackage of Care  ● Standard Package of Care (Chapter 4)  \\n● Intensive management of presenting illnesses and malnutrition  \\n● Priority for identification, management, and prevention of OIs, \\nincluding.  \\no GeneXpert ultra for TB diagnosis for all PLHIV with presumptive TB \\n(Figure 8.1)  \\no TB-LAM (Figure 8.2), in addition to GeneXpert ultra, for PLHIV with \\npresumptive TB who  \\n▪ Have CD4 ≤ 200 cells/mm3 and if CD4% ≤ 25% in children < 5 \\nyears  \\n▪ Have signs of severe illness, or  \\n▪ Are currently admitted to hospital  \\no Cryptococcal antigen screening for adolescents and adults with CD4 \\n≤ 200 cells/mm3 or clinical suspicion of meningitis (any age) (Figure \\n4.1)  \\no Cotrimoxazole Preventive Therapy (CPT)  \\no TB Preventiv e Therapy (TPT)  \\n● Immediate ART initiation unless they are suspected to have TB, TB \\nmeningitis, or cryptococcal meningitis;( Table 6.1)  \\n● Close monitoring for development of immune reconstitution \\ninflammatory syndrome (Annex 16)  \\nFocus of ART Preparation \\nCounselling  ● Immediate ART start is required to prevent further damage to the \\nimmune system.  \\n● Starting ART soon will decrease risk of disease progression, including \\nwasting and other infections  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression.  \\n● More frequent visits or hospitalization may be required to stabilize \\nacute medical conditions and address psychosocial and other concerns  \\n● Referral for management of co -morbidities or concurrent infections \\nmay also be needed  \\nManagement of Opportunistic Infections in Patients with AHD  \\nCryptococcal Disease (CM)  \\nCryptococcal disease is one of the most important opportunistic infections among peop le living \\nwith AHD and is a major contributor to mortality.  \\nEarly diagnosis and treatment of cryptococcal meningitis is key to reducing mortality from \\ncryptococcal disease. Health -care professionals should have a low threshold for suspecting \\ncryptococcal meningitis among people with advanced HIV disease.  \\nScreening, prevention and treatment of  cryptococcal meningitis is described in Section 4.33.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 52}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 8  Tuberculosis (TB)  \\nTB is the most frequent life -threatening OI and a leading cause of death among PLHIV. TB remains \\nthe leading cause of mortality among PLHIV, despite substantial scale -up of ART, accounting for \\n30% of the AIDS -related deaths reported.  \\nScreening, prevention  and treatment of TB is described in Chapter 8.  \\nTable 3. 4: Management of patients who are presenting well : WHO Stage 1 or 2, and CD4 count \\n> 200 cell/mm3  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nFocus of ART Preparation \\nCounselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment \\nPreparation Counselling  • ART is the most important treatment to maintain good health and an \\nactive life  \\n• Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n• ART will reduce the risk of transmitting HIV to others  \\n \\n3.5 Follow -up of PLHIV after ART initiation   \\nFollow -up of patients on ART is determined by the duration the patient has been on treatment, how \\nwell they understand the treatment and their response to AR T. Follow -up includes scheduled \\nclinical appointments, unscheduled clinical assessments for patients with concerns/complaints, \\nroutine and as -needed laboratory monitoring.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 53}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 9  3.5.1 First 6 months after ART initiation  \\nAfter ART initiation, patients need to be monitored closely for development of adverse drug events, \\nidentify and address barriers to adherence, and development of IRIS. A reasonable follow -up \\nschedule for most patients is 2 weeks and 4 weeks after ART initiation (Table 3. 5 and 3. 6).  \\nWhen possi ble, follow -up for a particular patient should be provided by the same care provider or \\nteam of care providers (e.g., same clinician and same counsellor) at every visit. This is particularly \\nimportant during the first 6 months in care.   \\n3.5.2 Differentiat ed Service Delivery for Patients beyond the 1st 6 months of ART  \\nFollow up of patients beyond 6 months of ART is described in table 3. 5. It also  provides the criteria \\nfor determining if a patient is established on ART.  \\nIn summary:  \\n● Patients who are not established on ART require closer follow -up.  \\n● Patients who are established on ART require less frequent facility follow -up, with up \\nto six months b etween clinical appointments  \\n \\nTable 3. 5: Differentiated Follow -up of Patients Beyond the First 6 Months of ART  \\nPatients NOT established on ART  \\nPatients with any of the following:  \\n● On treatment for < 6 months  \\n● Any active OIs (including TB) in the previous 6 months  \\n● Poor or questionable adherence to scheduled clinic visits in the previous 6 months.  \\n● Most recent VL ≥ 200 copies/ml  \\n● Children < 2 years  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Case management to address reason/s for not being established on ART  \\nFocus of \\nCounselling  ● ART is the most important treatment to maintain good health and an active life  \\n● ART will reduce the risk of transmitting HIV to others   \\nFrequency of \\nFollow -up ● Every 1 -3 months, based on clinical judgment  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● If VL is detectable at 3 months they will need additional assessments for \\nand management of the reason/s for detectable viral load, with close \\nfollow -up until viral suppression is achieved (Chapter 5).  \\n● Patients with confirmed viral suppression can be followed up every 3 -6 \\nmonths based on patient preference and clinician judgment, with \\nadditional unscheduled visits any time the patient has a concern.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 54}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.  \\n● The client’s category can change at any time so there is a need for a reassessment at each \\nvisit. Clients should be categorized at every visit and managed based on their status.  \\nPackage of \\nCare  ● Standard Package of Care  \\n● Re-assessment of criteria at every clinical visit  \\nLocation of  \\nServices  ● Clinical review and ART prescription from any ART service delivery point; all \\nfacility levels  \\n● Distribution of ART between clinical appointments, which can be facility -based \\nor community -based  \\nFocus of  \\nCounselling  ● Encourage patient to continue with what is working  \\n● Reminders that any significant life event or change in daily routine could \\ninterfere with adherence  \\nFrequency of  \\nFollow -up ● Clinic appointments to be made at 6 months intervals  \\n● ART should be offered as refills lasting 3 months,  (through fast -track pick -up at \\nfacility or through community -based distribution). Patients on injectab le \\ncontraception should be provided FP through a fast -tracked process between \\nclinic follow -up visits; oral contraceptives and condoms should be distributed \\nwith ART  \\n● Additional visits as required to address any medical or psychosocial concerns  \\n● Closer follow -up may be arranged based on patient preference  \\n*  Children below 2 years are excluded as they require frequent dose adjustment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 55}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 11  3.6 Summary of clinical and laboratory monitoring of PLHIV on ART  \\nTable 3. 6 summarizes the recommended minimum routine follow -up schedule for PLHIV.  \\nAdditional clinical and laboratory follow -up should be performed whenever clinically indicated  \\nTable 3. 6: Summary of Clinical and Laboratory Monitoring for PLHIV1 \\n Initial  \\nVisit  ART  \\npreparation  Week  \\n(After \\nART)   \\nMonths (after ART)   \\n≥ 6 months  \\n \\nAppointment2,3   \\nEvery week4  \\n2  \\n4  \\n2  \\n3  \\n4  \\n5  \\n6 Every 1 -6 \\nmonths \\ndepending \\non stability  \\nHistory and \\nphysical exam5 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each \\nclinical visit  \\nAdherence \\nassessment and \\nsupport6 ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  ✔  At each visit  \\nTB Screening  ✔  Every visit, using ICF screening tool  \\nCD4 count  ✔  ● Baseline, and then only if patient develops treatment failure (to assess \\nfor risk of OIs), or if defaults from care (off ART) for at least 6 months  \\n● For patients on prophylaxis using dapsone (documented CTX allergy), \\nrepeat CD4 every 6 months until CD4 >200 cells/mm3 for two \\nconsecutive measures 6 months apart and VL undetectable, after which \\ndapsone and CD4 monitoring can be discontinued  \\nHIV Viral Load   ● For PCR positive HEIs: baseline at the time of ART initiation  \\n● Age 0 -24 years: at month 3, then every 6 months  \\n● Age ≥ 25 years: at month 3, then month 12, then annually thereafter if \\nsuppressed  \\n● For all: before any drug substitution for patients on ART for a t least 6 \\nmonths with no valid VL, at month 3 after regimen modification, and \\nthen as per population group  \\n● Any patient with a detectable VL during routine monitoring, follow viral \\nload monitoring algorithm (Figure 6.6)  \\nHIV Viral Load \\n(pregnant/ \\nbreastfeeding)   ● If on ART at time of confirming pregnancy: VL done at confirmation of \\npregnancy (regardless of when previously done), then every 6 months \\nuntil complete cessation of breastfeeding  \\n● If starting ART during pregnancy or breastfeeding, VL at 3 months after \\ninitiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 56}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 12  Table 3. 6 Cont.  \\nCrAg  ✔  Baseline for adults and adolescents with CD4 ≤ 200 cells/mm3 (as reflex \\ntesting by laboratory), then only if there is clinical suspicion of CM  \\nHb ✔  Baseline, then symptom directed; if on AZT, baseline then weeks 2, 4, and \\n12 \\nPregnancy \\nStatus  ✔  At every visit for women of reproductive age (by history +/ - urine \\npregnancy test)  \\nUrinalysis \\n(protein & \\nglucose)  ✔  Baseline, then annually if on TDF  \\nCreatinine  ✔  Baseline, then annually if on TDF  \\nGlucose  ✔  Baseline, then annually  \\nPlasma lipid \\nprofile  ✔  Baseline, then annually  \\nHBsAg  ✔  Baseline, followed by immunization for all patients who screen \\nnegative (after viral suppression is confirmed)  \\nSyphilis \\nserology \\n(VDRL, \\nTPHA, or \\nRPR)  ✔  Baseline, then annually in those at risk and as part of routine ANC profile  \\nDrug \\nResistance  \\nTesting   DRT recommended once treatment failure confirmed on a DTG - or PI -based \\n1st line regimen, or confirmed treatment failure on 2nd line or subsequent \\nregimens  \\nALT   Not recommended for routine baseline or follow -up unless specific clinical \\nindication  \\nCervical \\nCancer  All women should be screened for cervical cancer following the national guidelines.  \\nUsing HPV screening conducted every 2 years for HIV positive women in their \\nreproductive age (or annually if using VIA -VILI)  \\nHCV  Baseline for PWIDs or with a history of injection drug use  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 57}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 13  Table 3. 6 Cont.  \\n1 Recommended investigation should not delay ART initiation.  \\n 2This is the recommended appointment schedule. Clinicians and patients should be encouraged to \\nschedule additional appointments as needed. Patients should be encouraged to return to the HIV \\nclinic for unscheduled appointment whenever  an acute issue arises, instead of seeking care at \\nanother facility. Early after initiation of ART, and after any regimen modification , every \\nappointment should include:  \\n− Continued adherence counselling and support (started at the initial visit)  \\n− Assessment of adherence and correct storage of medication  \\n−  Assessment for and management of early side effects of the drugs, and patient counselling \\non the same  \\n3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \\nmonthly appointments until month 6.  \\n4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \\nwithin 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \\nthey should be followed up every week until ART initiation to address whatever issues are \\ndelaying ART initiation, for ongoing management of acute medical issues and for treatment \\npreparation and ART r eadiness assessment.  \\n4Refer to table 3.1 for detailed history and physical examinations.  \\n5children and adolescents, weight and height should be measured and recorded at every visit, \\nwith weight -based dosing of ARVs confirmed at every visit.  \\nIn adults, weig ht and height should be measured at the initial visit to determine nutritional status \\nand calculate the BMI, and thereafter, weight should be measured at every visit.  \\n6The first 2 -4 visits are critical for assessing and supporting adherence to ART, managi ng adverse \\ndrug reactions, and treating any acute illnesses including IRIS. Adherence should be assessed at \\nevery contact with the clinic. See Chapter 5 for specific adherence preparation, monitoring and \\nsupport procedures for each visit  \\nRequired laboratory tests are highly recommended for patient monitoring, but are not a pre -\\nrequisite for ART initiation.  \\nTargeted laboratory tests may be necessary to identify and manage inter -current diseases or \\nadverse drug reactions.  \\n3.7 Differentiated Care for Children, Adolescents and Pregnant/ breastfeeding \\nWomen  \\nChildren, adolescents, pregnant and breastfeeding women, and key populations face unique \\nchallenges in retention  and viral suppression and  hence may benefit more from different iated \\nservice delivery models  adapted to their needs.  \\nChildren:  Children’s care is dependent on family and care giver dynamics. Family centered \\napproaches to care where clinic visits for parents/caregivers and the child are synchronized, \\nshould be used.  A ssessment and categorization to determine establishment on ART should be \\nconducted for pairs and follow -up tailored to their situations. Weight -based dose adjustments \\nshould be incorporated in both the facility and community models (e.g., by using portable  weighing \\nscales if out of the health facility) to determine optimal doses for ARVs at each review.  Aligning \\nappointments with school calendar should be considered to avert disruption of treatment and \\nlearning of the child.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 58}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 14  Adolescents:  Adolescents requi re psychosocial support, ongoing adherence assessments and \\ncounselling which should be aligned with clinic visits, community follow -up as well as school \\ncalendar.  Considerations should be factored in during the clinical encounters with more focus to \\nthose  with adherence and viral suppression challenges. Adolescents and Youth Friendly services \\nthat incorporate life skills and extracurricular activities should be integrated where feasible.  \\nPregnant/breastfeeding women:  Pregnant and breastfeeding women who h ave been established \\non ART should have their HIV clinic appointments synchronized with Antenatal Care visits and with \\nfollow -up of the HIV -exposed infant. Those initiated on ART during pregnancy may need close \\nfollow up to support them in adherence, reten tion and achieving viral suppression. Breast feeding \\nwomen and their babies will have their clinical visit aligned with the immunization clinics schedule. \\nPsychosocial support groups are encouraged for both pregnant and breastfeeding mothers \\nincluding peer  to peer support.  \\n3.8 ART Prescription, Dispensing, and Distribution for clients established on \\nART  \\nPatients who are established on ART should be offered ART  refills of up to 3 months. The refill of \\nother associated commodities such as cotrimoxazole, TPT a nd condoms should be aligned to the \\nART refill schedule. Clients established on ART should receive their ART, CPT, family planning, and \\nany other chronic medicines through a distribution system that minimizes the burden on them \\n(travel costs, waiting times , inconvenience) and burden on the health facility (personnel time, \\nspace constraints, etc.). This must be on a voluntary basis (i.e., the client can choose to remain in \\nstandard care if they prefer).  \\nThe health facility is responsible for ART prescription , dispensing, and distribution for all patients \\nenrolled into care. ART distribution for patients established on ART can take place at the health \\nfacility or through a community distribution system, depending on patient preference and health \\nfacility syste ms and resources. The point of ART dispensing should be based on client ability \\nto access treatment with ease.  Models for ART refills include:  \\n● Facility -based  \\no Fast track facility -based refills  \\no Facility -based ART distribution groups  \\n● Community -based  \\no Community -based ART distribution groups  \\no Community ART distribution points  \\no Community pharmacy distribution  \\nFacility -based Fast Track System for ART Refills  \\nThe facility -based fast track system for ART  refills is a simple model implemented at the health \\nfacility. The client is still required to come to the clinic every 3 months for ART refill, however the \\nrefill appointments require minimal or no waiting time at the clinic.   Refer to DSD operational \\nmanual for detailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 59}),\n",
       " Document(page_content='  \\nInitial Evaluation and Follow up  \\n3 - 15  Facility -based ART Distribution Group  \\nFacility -based ART Distribution Groups are a model for ART distribution, whereby a group of \\nPLHIVs meet at a designated location within their health facility for drug refills and dispense \\ndrugs to their peers within the group while ensuring peer support and treatment literacy.  ART \\nrefills are done through the group every 3 months and  each client is required to attend their \\nclinical review appointment e very 6 months.   \\nThis model may provide clients with psychosocial support if they are not already part of a support \\ngroup. This may also be more convenient for clients who are in urban settings and would not wish \\nto be enrolled in a community -based group. F acility -based groups can be peer or HCW led.  \\nCommunity -based ART Distribution Models  \\nClients may receive ART refills through community -based distribution. All clients may also benefit \\nfrom home visits such as for adherence monitoring and support, on a case -by-case basis.  \\nClients can receive their ART refill through community -based models such as:  \\n● Community -based ART distribution groups  \\n● Community ART distribution points  \\n● Community pharmacy distribution  \\nBefore implementing a community -based ART distribution program, a health facility should work \\nwith the CHMT to design a program that meets the criteria listed in Annex 14, and the plan \\napproved by the County HIV Technical Working Group before implementation. Refer to DSD \\noperational manual for det ailed information on community models.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 60}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 61}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 1   \\n4. Standard Package of Care for PLHIV  \\n \\nAll PLHIV should receive a package of services that are known to promote health, improve the \\nquality of life, prevent further HIV transmission, and prevent HIV disease progression and \\nmortality.  \\nThe standard package of care for PLHIV in cludes: antiretroviral therapy; Positive Health, Dignity \\nand Prevention (PHDP) services; screening and providing support in cases of gender -based \\nviolence (GBV) or intimate -partner violence (IPV); HIV education/counselling; screening and \\nprevention of spec ific opportunistic infections; reproductive health services; screening for and \\nmanagement of non -communicable diseases; mental health screening and management; \\nnutritional services; and prevention of other infections (Table 4.1).  \\nThe standard package of ca re should always be applied using a patient - and family -\\ncentered approach  in PLHIV management.  Patient -centered care includes: considering the \\nindividual patient’s health needs; eliciting and addressing the patient’s concerns and expectations; \\ninvolving th e patient’s (and their family and friends as appropriate) in decision -making, and; \\nrespecting the patient’s values and preferences. Family -centered care identifies, engages and \\nprovides care to all HIV -positive family members, prevents new infections among  family members \\nat risk, and promotes family support and awareness.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 62}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 2  Table 4.1: Components of the Standard Package of Care for PLHIV  \\nComponent of Standard Package of Care Sub components  \\nAntiretroviral therapy (ART)  ● ART initiation  \\n● Adherence assessment, counselling and support  \\n● Monitoring (clinical and laboratory)  \\nPositive health, dignity and prevention \\n(PHDP); gender -based violence (GBV) \\nand intimate -partner violence (IPV) \\nscreening; and HIV \\neducation/counselling  ● Disclosure  \\n● Index testing  \\n● Condom use  \\n● Family planning  \\n● STI screening, prevention, and treatment  \\n● Adherence counselling and support  \\n● Pre-exposure prophylaxis for HIV -negative sexual partners  \\n● GBV/IPV screening and support  \\n● HIV education/counselling  \\nSpecific opportunistic infection screening \\nand prevention  ● Cotrimoxazole preventive therapy  \\n● Tuberculosis (TB)  \\no Intensified case finding  \\no TB preventive therapy  \\no ART for TB/HIV co -infected patients  \\n● Cryptococcal meningitis  \\nReproductive health services  ● Sexually transmitted infections screening and management  \\n● Family planning and pre -conception services  \\n● Maternal healthcare  \\n● Cervical cancer screening  \\nNon -communicable diseases (NCD) \\nscreening and management  ● Hypertension  \\n● Diabetes mellitus  \\n● Dyslipidemia  \\n● Chronic kidney disease  \\n● Other NCDs  \\nMental health screening and management  ● Depression  \\n● Anxiety  \\n● Stress  \\n● Trauma  \\n● Alcohol and drug use/addiction  \\n● Self-care and wellbeing  \\nNutritional services  ● Assessment  \\n● Counselling and education  \\n● Management and support  \\nPrevention of other infections  ● Immunizations  \\n● Malaria  \\n● Safe water, sanitation and hygiene  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 63}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 3  Table 4.1 Cont.  \\nStandard Package of Care for HIV -Exposed and HIV -Infected Infants  \\n● Determine HIV status at first contact through HTS/EID and link to HIV care  \\n● Provide ARV prophylaxis for all HEIs and ART for all HIV -infected children ( confirming correct \\nweight -based dosing of ARVs at every visit ); perform clinical and laboratory assessment  \\n● Provide nutritional assessment, counselling and support (NACS, Section 4. 7) and monitor growth and \\ndevelopment of the child (Annex 3)  \\n● Ensure that all immunizations are provided following the national schedule (Section 4.8.1)  \\n● Clinical assessment at every visit, treat infections early, identify, manage and report adverse drug \\nreactions aggressively and refer appropriately where specialized care is required.  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TB Preventive Therapy \\n(TPT), deworm every 6 months (starting at 1 year of age) and provide supplemen tal Vitamin A every 6 \\nmonths (starting at age 6 months)  \\n● Educate the caregiver on all aspects of care for the child including infant feeding, immunizations, \\npersonal hygiene, HIV education/counselling, adherence, availability of support for child disclosure , \\nand follow -up requirements  \\n● Adherence assessment, counselling and support  \\n● Provide age -appropriate psychosocial support for the family and child and refer to community -based \\nsupport programs as appropriate  \\n● Ensure that the caregiver and family members are r eceiving appropriate care, support and treatment  \\n● Provide intensive case management for mother/infant pair until 2 years postpartum; identify \\ndefaulters and prioritize this population for tracking  \\n● Enroll in Orphans and Vulnerable Children (OVC) program for social protection and other services.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 64}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 4  Table 4.1 Cont.  \\nStandard Package of Care for Adolescents Living with HIV  \\nClinical care  \\n● Provide immediate linkage to HIV care  \\n● Provide ART to all HIV -infected adolescents  \\n● Perform clinical and laboratory assessment  \\n● Clinical assessment at every visit, treat infections early and refer appropriately where specialized care \\nis required  \\n● Screen for opportunistic infections and provide prophylaxis (cotrimoxazole, TPT)  \\n● Provide NACS and monitor growth and  development  \\n● Provide/refer for HPV vaccine  \\nAdherence and psychosocial support  \\n● Perform a baseline and regular subsequent psychosocial assessment  \\n● Assess for and support disclosure of HIV status to the adolescent (Annex 5)  \\n● Enroll in age -appropriate psychosoci al support groups  \\n● Provide treatment literacy  \\n● Provide life skills counselling  \\n● Provide adherence counselling  \\n● Support appropriate transition into adult HIV treatment and prevention  \\n \\nPrevention of HIV transmission  \\n● Encourage index testing and support for disclosure  \\n● Assess for and manage drug and alcohol use  \\n● Perform a sexual risk assessment and STI screening and treatment, and linkage of sexual partner to \\nPrEP where applicable  \\n● Assess for and manage IPV  \\n● Provide reproductive health services, including pregnan cy screening, pregnancy intention assessment, \\nfamily planning and linkage to PMTCT for pregnant adolescents  \\nReferrals, linkages and support for continuum of care  \\n● Provide intra -facility & inter -facility referrals as needed for specialized care  \\n● Link with youth community groups, targeting youth both in and out of school  \\nOther services  \\nlegal centers, paralegal services, gender -based violence recovery centers, educational institutions, \\nbursary/scholarship programs, income generating activities, constituency development funds, vocational \\ntraining centers for skills development, etc.  \\n4.1 Antiretroviral Therapy  \\nART is recommended for all PLHIV, regardless of WHO stage, CD4 count, age, pregnancy status, \\nor comorbidities/co -infections. O nce a diagnosis of HIV infection is confirmed, ART should be \\ninitiated as soon as possible (preferably within 2 weeks), once patient readiness has been \\ndetermined. Other sections of these guidelines deal with initial evaluation and monitoring \\n(Chapter 3), patient preparation and adherence support (Chapter 5), and specific recommended \\nART regimens (Chapter 6).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 65}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 5  4.2 PHDP, GBV/IPV & HIV Education/Counselling  \\nPHDP (Positive Health, Dignity and prevention) is a framework that emphasizes the health and \\nrights of P LHIV, including reducing risk of onward transmission of HIV.  Within PHDP are 7 core \\ndomains of services that should be provided at the health facility to PLHIV and caregivers (Table \\n4.2). Complementary community -based PHDP should also be implemented.  \\nTabl e 4.2: Domains and Components for PHDP Services  \\nPHDP Domain  Components  \\nDisclosure of HIV status  ● Assessment of disclosure status, particularly to sexual partners  \\n● Assisted disclosure  \\nNote: for children and adolescents, it is also necessary to evaluate for and \\nsupport age -appropriate HIV disclosure to the child/adolescent (Annex 5)  \\nIndex testing and \\nengagement  ● HIV testing of sexual and drug injecting partners  \\n● HIV testing of other family members at risk  \\n● Enrolment of positive partners/family members into HIV care  \\n● Engagement of negative partners and family members in care and \\nsupport for index patient, and PrEP as appropriate  \\nCondom use  ● Risk reduction counseling  \\n● Correct and consistent condom use  \\n● Provision of condoms at every visit  \\nFamily planning  ● Assessment of pregnancy intention  \\n● Pre-conception counselling  \\n● Dual contraception until ready for pregnancy  \\n(See Section 4.4.2 for specific clinical guidelines)  \\nSexually transmitted \\ninfections (STI)  ● Screening for symptoms of STIs  \\n● Prevention of STIs  \\n(See Section 4.4.1 for specific clinical guidelines)  \\nTreatment adherence  ● Benefits/importance of:  \\no Adherence to clinical care  \\no Adherence to ART  \\n● Messaging on Undetectable=Untransmissible (U=U)  \\n (Chapter 5)  \\nPre-exposure prophylaxis  ● Assess HIV -negative sexual partners for PrEP  \\n(Chapter 11)  \\nAdditional services that should be offered to PLHIV beyond the above components include screening for GBV and IPV \\nand HIV education/counseling services.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 66}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services  \\n• A questionnaire, with standard questions where providers can document responses,  \\n• Providers offer first -line support (LIVES)  \\n• Providers have received training on how to ask about GBV and Violence Against Children  \\n• Private setting, confidentiality ensured  \\n• A system for referrals or linkages to other services within the facility is in place  \\nIf any of these minimum requirements is mis sing, GBV and Violence Against Children  services are \\nconsidered inadequate, and providers should ensure to have these systems in place before \\nconducting routine enquiry or universal screening  \\nAll clients accessing HIV care services should be screened for a ny form of violence \\nincluding  IPV as part of the standard package of care for PLHIV.  \\nThe following script can be used for screening:  \\n “Many people do not realize that violence can lead to various serious health problems. Many \\npeople have problems with thei r husbands, partners or other people in their lives. Sometimes the \\npeople who love us can hurt us. Has this ever happened to you?”  \\nHas your partner ever:  \\n1. Insulted you or made you feel bad about yourself?  \\n2. Belittled or humiliated you in front of other people?   \\n3. Did things to scare or intimidate you on purpose  \\n4. Threatened to hurt you or someone you care about?  \\n5. Slapped you or thrown something at you that could hurt you?  \\n6. Kicked, dragged, beat you up?  \\n7. Chocked or  burned you on purpose?  \\n8. Threatened to use or actually used a gun, knife or other weapon against you?  \\n9. Physically forced you to have sexual intercourse when you did not want?  \\n10. Did you ever have sexual intercourse you did not want because you were afraid of w hat \\nhe might do?  \\n11. Forced you to do something sexual that you found degrading or humiliating?  \\nIf a survivor answers yes to any of these questions provide them with LIVES and do a mental \\nassessment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 67}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 7  Table 4.2a: Components of screening for GBV/IPV (LIVES)  \\nListen  Listen to the client closely, with empathy and without judging  \\nInquire  Assess and respond to the client’s various needs and concerns  \\nValidate  Show the client that you understand and believe them. Assure the client that they \\nare not to blame  \\nEnhance safety  Discuss a plan to protect the client from further harm if violence occurs again  \\nSupport  Support the client by helping them to access information, services and social \\nsupport  \\nSupportive messages that may be helpful include:  \\n● “What happened to you is not your fault”  \\n● “Many women/men are in the same situation as you”  \\n● “You are not to blame.”  \\n● “Everybody deserves to feel safe at home if you feel like you are in immediate danger, we can \\ninvolve the police or local administration “  \\nMen, the  elderly, and children suffer different forms of violence and should be assessed if there \\nis any clinical suspicion. Key populations are particularly vulnerable to abuse, including MSM, \\ntransgender, and prisoners. For children art and play therapy is used during history taking and \\npsychological assessment.  \\n4.2.2 HIV Education/Counselling  \\nAll PLHIV and caregivers should receive focused education about HIV and its treatment to \\nempower them to succeed in management of the infection. Self -management is critica l to the \\nsuccessful treatment of any chronic illness, including HIV. Key messages for HIV education and \\nadherence counselling are described in Chapter 5 of these guidelines.  \\nIn addition, psychosocial counselling and support for PLHIV and caregivers should include:  \\n● Mitigation of fear, anger, self -stigma and discrimination  \\n● Alleviation of grief, bewilderment and stress among partners and family members  \\n● Behavior changes in support of healthy living and prevention of further HIV transmission  \\n● Skills -building on how to live a healthy and productive life  \\n● Identification and treatment of depression and substance abuse  \\nHIV education and counselling can be offered in multiple settings, including: facility -based \\nindividual, couples, family, and/or gro up counselling, and through community -based counselling \\nand peer support groups.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 68}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 8  4.3 Specific Opportunistic Infection Screening and Prevention  \\n4.3.1 Cotrimoxazole Preventive Therapy (CPT)  \\nCPT is no longer recommended as life -long prophylaxis, and is only recommended in the \\nfollowing sub populations, unless they have an allergy to sulfur drugs or develop toxicity from \\nCPT:  \\n● HIV exposed infants  \\n● HIV infected children and adolescents <15 years of age  \\n● PLHIV > 15 years of age:  \\no Living in malaria -endemic zones * \\no Presenting with WHO stage 3 or 4 event, or meeting the criteria AHD  \\no Suspected treatment failure  \\n● All Pregnant and Breast -feeding women  \\nFor HIV exposed and infected infants, CPT should start at 6 weeks of age. CPT is effective in AHD, \\nand preventing specific OIs for patients with low CD4 counts (PCP and toxoplasmosis), as well as \\nreducing the risk of common bacterial infections, sepsis, diarrhea illness and malaria.  \\n*Refer to the National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya for the \\ncurrent Kenya Malaria endemicity map  \\nTable 4.3: Co -trimoxazole Preventive therapy  \\nSub -Population  Starting/Restarting criteria  Ending criteria  \\nHIV exposed Infants  All infants, starting 4 -6 weeks \\nafter birth  Child is confirmed HIV -negative  \\n \\nHIV-infected children \\nand adolescents ≤ 15 \\nyears old  All children  Attains 15 years of age  \\nPLHIV > 15 years old  Suspected treatment failure  \\nWHO Clinical Stage 3 and 4  Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\nHIV-positive \\nPregnant and \\nbreastfeeding women  All Clinically stable:  \\no On ART for at least 12 months  \\no Showing no signs or symptoms of \\nWHO Clinical Stage 2,3 or 4  \\no Not pregnant or breastfeeding  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 69}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 9  Table 4.4: Daily Dose of Cotrimoxazole Preventive Therapy  \\nWeight (kg)  If using oral suspension  \\n(240mg per 5ml)  If using single \\nstrength tablet 480 \\nmg (SS)  If using double strength \\ntablet 960 mg (DS)  \\n1 – 4 2.5 ml  ¼ SS tab  -- \\n5 – 8 5 ml  ½ SS tab  ¼ DS tab  \\n9 – 16 10 ml  1 SS tab  ½ DS tab  \\n17 – 30 15 ml  2 SS tabs  1 DS tab  \\n> 30  20 ml  2 SS tabs  1 DS tab  \\nAdult (any weight)   2 SS tabs  1 DS tab  \\nNote: If CrCl 15 -30 ml/min then use 50% of normal recommended dose; if CrCl < 15 ml/min then CTX should \\nbe avoided  \\nDuring pregnancy, CPT should be initiated irrespective of the gestational age and should \\ncontinue throughout pregnancy and breastfeeding. Additional intermittent preventive \\ntherapy (sulfadoxi ne-pyrimethamine (SP)) for malaria is not required for women already \\non CPT.  \\nCotrimoxazole can cause anaemia and neutropenia in some patients, as well as a skin rash.  \\nManagement of Patients with Cotrimoxazole Allergy  \\n● A rash may occasionally develop, usually about 7 -14 days following initiation of CPT. It \\nis often a relatively mild maculopapular rash with or without pruritus. Infrequently, rash \\nmay develop with severe exfoliation of the skin and Stevens -Johnson syndrome. Rash \\nseverity should b e assessed, with management based on severity (Table 4.5)  \\n● Desensitization is effective in the majority of patients with mild to moderate rash (Table \\n4.6a). The rapid desensitization regimen (Table 4.6 b) can be used in situations where \\ntreatment for PCP is needed  \\nTable 4.5: Management of Drug -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue CTX; close monitoring; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop CTX; symptomatic treatment with antihistamines +/ - \\ntopical steroids (NOT oral steroids); trial of desensitization \\nafter symptoms completely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated fever; \\nany % of body surface area  Stop CTX; admission to hospital for supportive management (IV \\nfluids, wound care, pain control, infection control, monitoring \\nfor super -infection); patient should NEVER be re -challenged \\nwith CTX or other sulfa -containing drugs;  document and \\nreport adverse event and issue patient alert card  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 70}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 10   \\n \\n Cotrimoxazole Desensitization Protocols (for patients who have fully recovered from \\nmoderate reaction)  \\nTable 4.6a: Standard Cotrimoxazole \\nDesensitization Regimen (8 days)  Table 4.6b: Rapid Cotrimoxazole \\nDesensitization Regimen (6 hours)  \\n \\nDay  \\nDose of TMP/SMX Suspension  \\n(40/200 mg per 5ml)  \\nDay 1 0.5 ml  \\nDay 2 1 ml \\nDay 3 2 ml \\nDay 4 3 ml \\nDay 5 4 ml \\nDay 6 5 ml \\nDay 7 1 SS tablet  \\nDay 8 2 SS tablets/1 DS tablet per day  \\nNote: For children, continue up until they have \\nreached their recommended weight -based dosage  \\n  \\nHour  \\nDose of TMP/SMX Suspension \\n(40/200  mg per 5ml) \\nHour 0 0.5 ml \\nHour 1 1 ml \\nHour 2 2 ml \\nHour 3 3 ml \\nHour 4 4 ml \\nHour 5 5 ml \\nHour 6 1 SS tablet \\nNote: The rapid desensitization protocol should \\nnot be used for children because the cumulative \\ndosage will be too high  \\n \\n \\nDapsone as a Substitute for CPT  \\nIn situations of severe allergy to cotrimoxazole or when desensitization is not successful, \\ndapsone can be used instead of CTX. It is primarily effective as prophylaxis against PCP but does \\nnot have the other prophylactic benefits of cotrimoxazole.  \\nNote:  \\nDapsone will contribute to anaemia in most patients, and causes haemolytic anaemia in some \\npatients, so pati ents should have a baseline Hb before starting dapsone and Hb monitored every \\n1-2 weeks for the first couple of months.  \\nWhen dapsone (as a substitute for CPT) is being used as PCP prophylaxis, it is only \\nrecommended for patients in WHO Stage 4 and/or with  absolute CD4 count ≤ 200 \\ncells/mm3 (or CD4 % ≤ 25% for children ≤ 5 years old), and should be discontinued once \\na patient achieves a sustained CD4 count of > 200 cells/mm3 (or > 25% for children ≤ 5 \\nyears old) for at least 6 months.  \\nDapsone is NOT recomme nded during breastfeeding.  \\nDose of Dapsone  \\n● Available as 25 mg and 100 mg tabs  \\n● Children: 2 mg/kg once daily (maximum dose: 100 mg) OR 4 mg/kg once weekly \\n(maximum dose: 200 mg)  \\n● Adults: 100 mg once daily  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 71}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 11  4.3.2 Tuberculosis (TB) Prevention and Management for PLHIV  \\nAll PLHIV should be screened for TB at every visit using the Intensified Case Finding (ICF) tool.  \\nAll PLHIV older than 12 months of age who screen negative for TB should be provided with TB \\nPreventive Therapy (TPT) unless they have a s pecific contraindication.  All patients who receive \\na full course of TPT should have this clearly documented in their file (Section 8.2)  \\nFor PLHIV who have presumptive TB, GeneXpert ultra is the preferred testing platform to \\nconfirm the diagnosis, with TB -LAM used as an adjunct bedside test when indicated, while \\nawaiting GeneXpert ultra -results. All PLHIV qualify for ART, including patients with HIV/TB co -\\ninfection.  \\nChapter 8 provides specific guidelines for ICF, TPT, use of GeneXpert ultra and TB -LAM, and ART \\nfor patients with TB/HIV co -infection.  \\n4.3.3 Cryptococcal Meningitis (CM) Screening and Treatment  \\nAll adult and adolescent PLHIV with a baseline CD4 count of ≤ 200 cells/mm3   should be \\nscreened for cryptococcal infection (Figure 4.1). This should be a  reflex test performed by the \\nlaboratory as soon as the low CD4 count is noted, rather than requiring the clinician to order a \\nspecial test for screening.  \\nPLHIV, including children and adolescents, should receive cryptococcal screening if clinically \\nsuspec ted. For patients who are symptomatic for meningitis but screen serum CrAg negative, \\nalternative diagnoses for sub -acute meningitis should be explored, such as TB meningitis. All \\npatients with clinical meningitis should be assessed and managed at a facilit y that can perform \\nlumbar punctures.  \\nWhenever performing CSF CrAg for patients with symptomatic meningitis, CSF GeneXpert \\nultra for TB should be performed at the same time, as well as urine for TB -LAM . \\nFluconazole use during first trimester of pregnancy in creases the risk of birth defects. All \\npregnant women who screen positive with serum CrAg should be offered a lumbar puncture \\n(irrespective of symptoms) to determine if they have cryptococcal meningitis. If the CSF CrAg is \\npositive, they should be treated with 2 weeks of amphotericin B for induction (without \\nfluconazole), while consulting Uliza!  Hotline (0726 460 000; ulizanascop@gmail.com) to discuss \\nconsolidation/maintenance. Pregnant women with negative CSF CrAg should start ART \\nimmediately (without pre -emptive fluconazole therapy) and be monitored for symptoms of CM.  \\nTable 4. 7 provides detailed guidance on the use of amphotericin, fluconazole, flucytosine (once \\navailable), and therapeutic lumbar punctures for the treatment of symptomatic cryptococcal \\nmen ingitis  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 72}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 12  Table 4. 7: Treatment of Cryptococcal Meningitis  \\nTarget \\npopulation  Regimen  Induction (2 \\nweeks)1,2 Consolidation \\n(8 weeks)  Maintenance  When to start  \\nART  \\nAdults  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole \\n1,200 mg/day  Fluconazole6  \\n800 mg/day  Fluconazole 200 \\nmg/day for at \\nleast 1 year and \\nuntil CD4 count  \\n> 200 cells/mm3 \\nfor two measures  \\n6 months apart \\nAND VL is \\nundetectable  Defer ART until \\nafter completing  \\n5 weeks of CM \\ntreatment and \\nsymptoms have \\nresolved  Alternative  Fluconazole,3,4,5,6  \\n1,600 mg daily  Fluconazole6 \\n800 mg daily  \\nChildren and \\nadolescents  Preferred  Ampho B 1.0 \\nmg/kg/day + \\nFluconazole 12 \\nmg/kg/day (up \\nto max 800 \\nmg/day)  Fluconazole 6 -\\n12 mg/kg/day \\nup to  \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\nAlternative  Fluconazole3,4,5 \\n12 mg/kg/day \\n(up to max \\n1,600 mg/  \\nday)  Fluconazole 12 \\nmg/kg/day up \\nto \\n800 mg/day  Fluconazole  \\n6mg/kg/day up \\nto 200 mg/day  \\n1Amphotericin B should always be used for induction when available. If it is not possible to complete 2 weeks \\nof induction with ampho due to availability, toxicity or monitoring, then use a shorter duration of ampho and \\ncomplete the 14 -day induction period with the alternative regimen  \\n2Once available, flucytosine may become part of the  preferred and alternative induction regimens, given \\n100mg/kg per day divided into four doses per day  \\n3Fluconazole requires a dose adjustment for impaired renal function; when CrCl ≤ 50 ml/min then use 50% \\nof the standard recommended dose  \\n4Fluconazole shou ld not be used with rifabutin -based TB treatment  \\n5When using high -dose fluconazole check ALT after one week of treatment and based on symptoms \\nthereafter  \\n6Fluconazole is contraindicated in the first trimester of pregnancy. Amphotericin can be used. Please consult \\nexpert or National or Regional TWG.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 73}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 13  Managing and Monitoring for Amphotericin B Therapy  \\nAdults  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B given with 1 litre of 5% dextrose. Add one to two tablets of 8 mEq \\nKCl orally twice daily. An additional one 8 mEq KCl tablets twice daily may be added in \\nthe second week. Include magnesium supplementation at 250 mg tablets of magnesium \\ntrisilicate twice daily (or 4 mEq tablets of magnesium chloride t wice daily)  \\nAdolescents and Children  \\n• Give 1 L of normal saline with 20 mmol of KCl over 2 -4 hours before each controlled \\ninfusion of Ampho B. Darrows or Ringer’s solutions can also be used  \\nNote: Avoid KCl replacement in patients with pre -existing renal imp airment or \\nhyperkalemia  \\n \\nManaging hypokalaemia and raised creatinine levels  \\n• Obtain a routine baseline and twice weekly potassium and creatinine:  \\n- If K < 3.3 mmol/L, administer 1 L of normal saline with KCl 40 mmol in normal saline \\nor 1 -2 tablets of 8mEq KCl every 8 hours. Add magnesium. Monitor potassium daily  \\n- If creatinine level increases > 2 -fold from baseline, omit dose of Ampho B, increase \\nhydration to 1 L every 8 hours. If there’s improvement, re -start Ampho B at 0.7 \\nmg/kg/day on alternate days. If n o improvement, discontinue Ampho B, give \\nfluconazole 1,600 mg/day to complete induction. Monitor creatinine daily  \\nTherapeutic lumbar punctures are a critical component of the management of CM and \\nshould be standard of care:  \\n• For all patients with symptomati c CM: perform daily therapeutic lumbar punctures:  \\n- If opening pressure is ≤ 40 cm: draw off enough CSF to reduce pressure to 20 cm  \\n- If opening pressure is > 40 cm: draw off enough CSF to reduce pressure by 50%  \\n- Continue daily LPs until pressure is normal for 3 consecutive days  \\n- Restart LPs if symptoms return  \\nIf measuring intracranial pressure is not possible (even using a giving set and tape measure), \\nthen perform daily therapeutic LPs until severe headache subsides, removing 10 -20 ml of CSF \\neach tim e \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 74}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 14  \\nNewly diagnosed HIV -infected adult or adolescent\\nCD4   200 cells/mm3\\nAutomatic/reflex CrAg \\nscreening\\nSerum CrAg POSITIVE Serum CrAg NEGATIVE\\nSymptom Screen: Progressive headache, fever, \\nmalaise, neck pain, confusion\\nSymptomatic: Admit and do \\nLumbar puncture to obtain CSF \\nfor CrAg and geneXpert• Asymptomatic1: Offer presumptive treatment for possible early CM with \\nfluconazole 1,600 mg per day for 2 weeks, followed by fluconazole 800 \\nmg per day for 8 weeks, followed by fluconazole 200 mg per day for at \\nleast 1 year and until CD4 count >200 cells/mm3 for two measures 6 \\nmonths apart and VL is undetectable (LDL <200copies/ml )\\n• Defer ART for 5 weeks2\\n• Monitor closely and perform LP if symptoms develop\\nNB: Lumber puncture for CSF CrAg is strongly recommended for pregnant \\nwomen irrespective of symptoms3\\nCSF CrAg positive: Treat for cryptococcal \\nmeningitis with amphotericin, fluconazole \\nand therapeutic LPs (Annex 7)\\nDefer ART until completed 5 weeks of \\ntreatment and has resolution of \\nsymptoms2• CSF CrAg negative: Offer pre -emptive therapy for non -meningeal \\ndisease with fluconazole 800 mg per day for 2 weeks, followed by \\nfluconazole 400 mg per day for 8 weeks, followed by fluconazole \\n200 mg for at least 1 year and until CD4 count >200 cells/mm3 for \\ntwo measures 6 months apart and VL is undetectable (LDL \\n<200copies/ml )\\n• Defer ART until completed 5 weeks of treatment and has \\nresolution of symptoms2\\nLP is recommended for all sCrAg positive patients irrespective of symptoms with management based on LP results. If \\nLP is not available to rule out meningeal disease then patients should be treated for possible CM, even if \\nasymptomatic\\nPatients with cryptococcal meningitis are at high risk of developing life-threatening IRIS;  deferring ART has \\nshown to improve survival for these specific \\nFluconazole use during pregnancy increases the risk of birth defects. All pregnant women who screen positive with \\nserum CrAg should be offered a lumbar puncture (irrespective of symptoms) to determine if they have cryptococcal \\nmeningitis\\nNote: \\n• Fluconazole requires a dose adjustment for impaired renal function; when CrCl      ml/min then use 50% of the \\nstandard recommended dose\\n• Fluconazole should not be used with rifabutin -based TB treatment\\n• When using high -dose fluconazole check ALT after one week of treatment and based on symptoms thereafter• No cryptococcal treatment required\\n• Initiate ART within 2 weeks \\nFigure 4.1: Routine Screening for Cryptococcal Meningitis for HIV -infected Adults and Adolescents  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 75}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 15  4.4 Reproductive Health Services  \\n4.4.1 Sexually Transmitted Infections  \\nScreening for syphilis using VDRL, TPHA, or RPR should be performed as a baseline investigation \\nfor all adolescent and adult PLHIV. Pregnant women should be screened for Syphilis during the \\nfirst ANC visit and 3rd trimester.  \\n \\nAll PLHIV should be assessed for symptoms of STIs using the National Algorithm s for Treating \\nCommon STI Syndromes (Kenya National guidelines for management and control of STIs, 2018. \\nAnnex 4). Sexual partners should be treated as well.  \\n \\nRisk reduction counselling and provision of condoms is an integral part of STI treatment.  \\n \\nPatien ts who have persistent signs and symptoms of STIs after syndromic treatment should \\nundergo diagnostic evaluation for definitive diagnosis and treatment.  \\n \\nAt initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \\nchlamydi a (following treatment recommendations of vaginal/urethral discharge syndrome as \\nper national STI guidelines), with presumptive treatment every quarter.  \\n \\n4.4.2 Family Planning and Pre -Conception Counselling  \\nPregnancy status should be determined for all wom en of reproductive age at every visit (based \\non history of last menstrual period and, if uncertain, irregular, or delayed, then a urine pregnancy \\ntest should be performed).  \\n \\nPregnancy intention should be determined for all women of reproductive age and the ir partners \\nso that appropriate family planning or pre -conception counselling can be provided.  \\n \\nFor patients who do not have an immediate desire to become pregnant, dual contraception \\n(defined as condoms plus another form of effective contraception) should  be provided \\nimmediately with follow -up appointments scheduled to ensure no interruption in contraception \\nprovision. Table 4.8  outlines contraception options for PLHIV based on the ARVs they are using.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 76}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 16  Table 4.8 : Contraceptive Methods for PLHIV Based on  WHO 2018 Medical Eligibility Criteria  \\nContraceptive Method  ARVs Being Used  Anti -TB \\nNRTI \\n(any)  NNRTI  \\nPI/r \\n(any)  INSTI  \\nRifampicin or \\nRifabutin  EFV \\nor \\nNVP  ETR  RAL  DTG*  \\nIM medroxyprogesterone (DMPA; Depo \\nProvera)  1 1 1 1 1 - 1 \\nNorethisterone enanthate (NET -EN; \\nnorethindrone)  1 2 1 2 1 - 2 \\nImplants  1 2 1 2 1 - 2 \\nCombined oral contraceptive (pill)  1 2 1 2 1 - 3 \\nIntrauterine \\ndevice (IUD)  Initiation  ● Category 2 for asymptomatic or mild HIV disease (WHO Stage 1 \\nor 2, or any WHO Stage once they are stable on ART)  \\n● Category 3 for women with advanced and symptomatic HIV \\ndisease UNTIL they are stable on ART and asymptomatic  \\nContinuation  Category 2 for all women regardless of symptomatic HIV (do not \\nrequire IUD to be removed)  \\nCondoms  No restrictions; use encouraged in combination with a hormonal \\ncontraception method or IUD as part of dual FP to prevent STI/HIV \\ntransmission  \\nEmergency contraceptive pill (ECP)  No restrictions; can be started up to 5 days after intercourse  \\nSterilization  No reason to deny; delay in case of acute HIV -related infection  \\nFertility awareness -based (FAB) methods  Can use if menstrual cycle is regular, although reliability is not as \\ngood as hormonal contraceptive methods or IUD. Encoura ge to use \\nin combination with condoms to prevent STI/HIV transmission  \\nLactational amenorrhoea method (LAM)  Effective for women who are less than 6 months post -partum, are \\nexclusively breastfeeding, and have not resumed menses. Encourage \\nto use in combinat ion with condoms to prevent STI/HIV \\ntransmission  \\nSpermicides and diaphragm  Use is not recommended; may increase risk of HIV transmission  \\nCategory 1: No restriction for the use of the contraceptive method  \\nCategory 2: Advantages of using the method generally outweigh the theoretical or proven risks  \\nCategory 3: The theoretical or proven risks usually outweigh the advantages of using the method  \\n*DTG was not included in the WHO 2018 MEC Guidelines, however, drug interactions between DTG and \\nhormonal con traception have not been identified  \\nFor patients who intend to become pregnant, the key pre -conception messages and services are \\npresented in Table 4. 9. \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 77}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 17  Table 4. 9: Pre -Conception Counselling Messages and Services for PLHIV  \\nScenario  Key Counselling Messag es Pre-conception Services (in \\naddition to the Standard Package of \\nCare for PLHIV)  \\nAll \\nwomen/couples \\nwith intention to \\nconceive  ● All PLHIV qualify for ART, with \\ninitiation preferably within 2 weeks \\nof HIV diagnosis  \\n● Deferring pregnancy until confirmed \\nviral suppression reduces risk of \\nvertical transmission to the baby, \\nimproves infant outcomes, and \\nreduces risk of cross -transmission to \\nthe sexual partner  \\n● Unprotected sex should be limited to \\ndays when ovulation is expected \\n(based on basal tempe rature \\nmonitoring, fertility calendar based \\non menstrual cycles, and/or fertility \\ncalendar app)  \\n● Routine ANC and delivery by a \\nskilled birth attendant improves \\noutcomes for mother and baby  ● ART for all PLHIV, including those \\nintending to become pregnant  \\n● Baseline investigations  \\no Hb (with management of \\nanaemia)  \\no Syphilis screening  \\no Cervical cancer screening  \\n● STI symptom screening  \\n● Nutritional assessment, \\ncounselling, and support  \\n● Folic acid supplementation  \\n● Standard VL monitoring (Figure \\n6.6)  \\n● PrEP for the HIV -negative partner  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: male \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV positive \\npartner  \\n● Discuss use of PrEP for the HIV-negative partner (Chapter 11)  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as sperm washing and artificial insemination  \\nAdditional \\nmessages for \\ndiscordant \\ncouples: female \\npartner HIV \\npositive  ● Defer unprotected sex until confirmed viral suppression in the HIV -positive \\npartner  \\n● Discuss use of PrEP for the HIV -negative partner (Chapter 11)  \\n● Discuss self -insemination during the peri -ovulatory period, where \\nappropriate/as preferred  \\n● In situations where viral suppression is challenging, consider specialist referral \\nfor additional options such as artificial insemination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 78}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 18  4.4.3 Maternal Healthcare  \\nMaternal healthcare begins with preconception counselling (Table 4. 9), and continues \\nthroughout pregnancy and breastfeeding. The standard package of antenatal and postnatal \\nservices in the context of HIV is described in Chapter 7 of these guidelines.  \\n4.5 Non -communicable Diseases Screening and Management  \\n4.5.1 Metabolic Disorders  \\nScreening, prevention and management of specific NCDs are included in the standard package of \\ncare for PLHIV because of their associated high morbidity and mortality. PLHIV are at higher risk \\nfor cardiovascular, liver and kidney disease because o f the chronic inflammatory state associated \\nwith HIV infection itself, and also as a side -effect of some of the ARVs.  \\nThe modifiable risk factors for cardiovascular disease include tobacco use and exposure to \\ntobacco smoke, unhealthy diets, overweight/obe sity, physical inactivity, harmful use of alcohol, \\nhypertension, diabetes, hyperlipidemia, infections such as rheumatic fever and HIV. Advancing \\nage, sex, race/ethnicity and family history are non -modifiable risk factors associated with \\ncardiovascular dise ases  \\nHIV and other chronic diseases require health systems that support chronic care and  \\nadherence; their management should be integrated at the health facility, including at the \\nprimary care level.  \\nLifestyle modifications are always the first line of prev ention and management for \\nhypertension, diabetes mellitus (DM), and dyslipidaemia (Table 4. 10). These are \\nrecommended for all patients to prevent these NCDs and should be integrated into routine HIV \\ntreatment and prevention. Recommendations for screening, diagnosis, and initial management \\nof hypertension, type 2 DM, dyslipidaemia, and chronic kidney disease (CKD) are provided in \\nTables 4.1 1-4.14. \\nFor comprehensive guidelines on prevention, diagnosis and management of diabetes and \\ncardiovascular diseases, re fer to Kenya National Clinical Guidelines for the Management of \\nDiabetes  and Kenya National Guidelines for Cardiovascular Diseases Management , respectively.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 79}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 19  Table 4. 10: Lifestyle Modifications to Prevent and Manage Cardiovascular Disease in PLHIV  \\nSmoking Cessation  \\n● Smoking cessation has multiple short -term and long -term benefits, including  \\no Reduced premature aging/wrinkling of skin  \\no Improved fitness and quicker recovery from common infections  \\no Reduced risk of respiratory infections and chronic lung disease  \\no Reduced risk of high blood pressure, diabetes, kidney disease, heart disease, and stroke  \\no Improved infant outcomes (for pregnant women)  \\no Reduced risk of cancers: lung, bladder, breast, mouth, throat, esophagus  \\no Better response to ART (better viral suppression)  \\no Reduced risk of developing TB or dying from TB  \\n● Tobacco dependence treatment and cessation programs should combine behavioral/counseling \\nsupport with pharmacotherapy treatment where necessary and available. For further details on \\ncessation interventions, refer to the Kenya National Guidelines for Tobacco Dependence \\nTreatment  \\nRefer to Table 4.1 8 for tips to assist a client to quit smoking  \\n \\nDietary Changes and Weight Loss  \\n● Weight loss to maintain a healthy BMI (nutritionists to be engaged in patient care)  \\n● Drink 8 glasses of water per day  \\n● Reduce/abstain from alcohol  \\n● Cut down sugar intake  \\n● Cut down red meat intake  \\n● Cut down consumption of fatty foods, fat for flavoring, and fried foods  \\n● Increase intake of whole grain s, vegetables, fruit, and beans  \\n● Increase intake of fish  \\n● Consume less than 5 g (just under a teaspoon) of salt per day  \\n \\nPhysical Activity  \\n● Active lifestyle with moderate -intensity physical activity  \\n● 30 minutes of aerobic activity such as brisk walking, at least 5 days per week  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 80}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 20  Table 4.1 1: Hypertension Screening, Diagnosis, and Initial Management for Adult PLHIV  \\nScreening  \\n● BP should be measured and recorded for every adult at every visit  \\nDiagnosis  \\n● Hypertension requiring intervention is defined as BP ≥ 140/90 mmHg on at least 3 different occasions  \\nAdditional Investigations for patients with hypertension  \\n● Urinalysis: to assess for kidney disease and diabetes  \\n● Creatinine, Na, K: to assess for kidney disease  \\n● Blood glucose: to assess for diabetes  \\n● Full blood count: anaemia may indicate chronic kidney disease  \\n● Lipid profile: dyslipidemia is a cardiovascular risk factor  \\n● ECG: to assess for cardiac pathology including cardiomegaly, ventricular dysfunction, ischemic heart \\ndisease, etc.  \\nManagement (treatment target is BP < 140/90 mmHg)  \\n● If baseline BP is 120 -139/80 -89 (pre -hypertension)  \\no Lifestyle modification, along with monthly BP monitoring  \\n \\n● If baseline BP is 140 -159/90 -99 \\no Lifestyle modification (Table 4.9) for up to 6 months, along with monthly BP monitoring  \\no If does not meet treatment target with lifestyle modifications, then add drugs to lifestyle \\nmodification  \\no In PLHIV without  kidney disease or diabetes, first -line antihypertensive therapy is a thiazide \\ndiuretic s uch as hydrochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD) OR a \\ncalcium channel blocker such as amlodipine starting at 2.5 mg OD (maximum 10 mg OD)  \\no In PLHIV with kidney disease or diabetes the first antihypertensive should be an ACE -I or ARB  \\nsuch as enalapril 2.5 -10 mg OD (maximum dose is 20 mg BD); or, losartan 50 mg OD (maximum \\ndose is 100 mg OD), with referral to a physician if available  \\no Introduce one drug at a time. If the target blood pressure is not reached within one month after \\ninitia ting therapy, the dosage of the initial medication should be increased. Titrate to maximum \\nrecommended dosage (if tolerated) before adding an additional drug  \\no If inadequate response once dose has been titrated, an additional agent may be required e.g., \\nhydr ochlorothiazide starting at 12.5 mg OD (maximum dose 25 mg OD)  \\no If inadequate response to two agents, consider consultation with or referral to a physician  \\no Note: Calcium -channel blockers have known drug interactions with PIs and NNRTIs and \\nshould be used with caution (Annex 13). ACE -I and thiazide diuretics do not have significant \\ninteractions with ARVs  \\n \\n● If baseline BP ≥ 160/100 mmHg  \\no Initiate lifestyle modifications and introduce anti -hypertensive medications concurrently  \\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 81}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 21  Table 4.1 2: Type 2 Diabetes Mellitus Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Blood glucose (fasting or random) should be evaluated at baseline for all PLHIV, then annually if \\nbaseline screening is normal; urine dipstick for protein and glucose can be used if blood glucose \\ntesting is not available  \\nDiagnosis  \\n● Diabetes Mellitus is defined as fasting blood sugar ≥ 7.0 mmol/L, or random blood sugar ≥ 11.1 \\nmmol/L, or HbA1c > 6.5%, or oral glucose tolerance test ≥ 11.1 mmol/L  \\n● Abnormal results should be repeated to confirm the diagnosis, particularly for patients without \\nsymptoms of diabetes (such as polyuria, polydipsia, polyphagia, weight loss)  \\n \\nManagement (treatment target is HbA1c ≤ 7.0% or FBS 4 -7 mmol/L)  \\n● For patients with pre -diabetes (abnormal results but does not meet criteria above for diabetes) \\nmonitor FBS or HbA1c every 3 months and encourage lifestyle modifications (Table 4. 10) \\n \\n● For patients with diabetes, monitor HbA1c (or FBS if HbA1c is not available) every 3 months  \\n \\n● Lifestyle modification (weight loss, nutritional support to manage portion sizes and calculate \\nglycaemic index of various foods to hel p with control of blood sugar) for 3 -6 months  \\n \\n● If does not meet treatment target with lifestyle modifications then add drugs  \\no Metformin  \\n▪ Obtain baseline Creatinine; do NOT use metformin if creatinine clearance < 45 ml/min  \\n▪ Start with low dose (500 mg OD or BD) and titrate up every 1 -2 weeks until reaches 1 g BD (or \\nmaximum tolerated dose if less than 1 g BD)  \\n▪ Note:  DTG may increase metformin plasma levels: monitor blood glucose levels; dose reduction \\nof metformin may be required, and maximum daily dose of met formin should be 1g  \\no If does not meet treatment targets with metformin for 3 -6 months at maximum tolerated dose then \\nconsider adding drug from another class (such as sulphonylureas (gliclazide)) and/or specialist \\nconsultation. Some patients may require insu lin. \\no At every visit: A thorough history (to elicit features of hypoglycemia, other cardiovascular disease \\nrisk factors, neuropathy, diabetic foot ulcers) and a physical exam (for BP, neuropathy, foot ulcers)  \\n \\n● Additional routine screening for patients with diabetes  \\no Annual ophthalmology examination for diabetic retinopathy  \\no Annual urinalysis: start on an ACE -I/ARB if proteinuria develops (even if BP normal)  \\nNote : patients with DM are at increased risk of developing TB  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 82}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 22  Table 4.12: Dyslipidemia Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Fasting lipid profile should be evaluated at baseline for all PLHIV, then annually if baseline screening \\nis normal  \\nDiagnosis  \\n● Dyslipidemia is defined as high fasting total cholesterol (>5.2 mmol/L), LDL (>3.4 mmol/L) or \\ntriglycerides (>2.2 mmol/L)  \\nManagement  \\n● Lifestyle modification for 3 -6 months (Table 4. 10) \\n● If the patient is on an ARV known to cause or exacerbate dyslipidemia (primarily LPV/r & EFV) then \\nconsider a single -drug substitution to a more lipid -friendly drug (such as ATV/r or DTG) as the \\ntreatment of choice before adding a lipid -lowering drug. Rule out treatment failure before making \\nsingle -drug substitutions (Figure 6.4)  \\n● If patient does not meet treatment  target with lifestyle modifications, then add drugs  \\no Atorvastatin: starting dose of 10 mg OD (maximum dose 20 mg once daily if patient is on a PI/r; \\nmaximum dose 80 mg once daily if not on a PI/r)  \\no Simvastatin and lovastatin are contraindicated in the presence of PI/r  \\no Allow at least 3 months before repeating fasting lipids and titrating dose  \\nOnce targets achieved can monitor lipids every 6 -12 months  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 83}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 23  Table 4.13: Chronic Kidney Disease Screening, Diagnosis, and Initial Management for PLHIV  \\nScreening  \\n● Urinalysis (for protein) and serum creatinine should be evaluated at baseline for all PLHIV and \\nmonitored annually  \\nDiagnosis  \\n● Impaired renal function is defined as creatinine clearance < 90 ml/min, or dipstick proteinuria ≥ 1 \\n(see Annex 15 for CrCl calculations)  \\n● Abnormal results should be repeated to confirm diagnosis  \\n● Chronic kidney disease is defined as evidence of kidney damage that persists for at least three \\nmonths  \\nManagement  \\n● Management depends on the cause of the renal impairment; additional investigations and/or \\nspecialist consultation may be required  \\n● Consultations with a physician is recommended  \\n● Treat dehydration promptly and aggressively  \\n● If on TDF -containing regimen, substitute with another ARV if C rCl<50 ml/min (see Section 6.5), \\nwith the exception of patients with HBV/HIV co -infection (Table 9.3 for renal dose adjustments of \\nTDF and 3TC for patients with HIV/HBV co -infection)  \\n● Avoid nephrotoxic drugs (e.g., aminoglycosides and NSAIDS)  \\n● Evaluate for a nd treat hypertension  \\n● All NRTIs except ABC require dose adjustments for renal impairment, depending on the severity \\n(Table 6.6 for specific dose adjustments). NNRTIs, PIs, and INSTIs do not require dose adjustments \\nfor impaired renal function  \\nNote: DTG may  cause a small rise in serum creatinine levels but this does NOT represent a \\ndecline in renal function, close monitoring is recommended.  \\nPatients at higher risk for renal disease and for developing TDF -associated renal toxicity include \\nthose with: pre-existing renal disease, hypertension, diabetes mellitus, severe wasting (weight \\nbelow 60 kg in adults), age > 45 years, WHO stage 3 or 4, CD4 < 200 cells/mm3, high HIV viral \\nload, and concomitant nephrotoxic agents.  \\nGlomerular disease directly related to HIV infection, commonly known as HIV -associated \\nnephropathy (HIVAN) is an important cause of chronic kidney disease among PLHIV.  \\nPrevention, early identification, and management of kidney disease is important to reduce \\nthe burden of dialysis and other c omplications.  \\n4.5.2 Cancer Prevention, Early Detection and Management among PLHIV  \\nPLHIV have a substantially higher risk for many cancers, mainly due to a weakened immune \\nsystem which impairs control of oncogenic viral infections. A high prevalence of thes e infections \\nand other modifiable risk factors (such as smoking, alcohol use, unhealthy diet and physical \\ninactivity) contributes to the elevated risk. PLHIV are far more likely than the general population \\nto be diagnosed with Kaposi Sarcoma, non -Hodgkin l ymphoma and other cancers (cervical, anal, \\nliver, lung and oral/throat) hence the importance of prioritizing screening and early diagnosis \\nprograms in this group.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 84}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 24  4.5.2.1 Specific Interventions for Cancer Control in PLHIV  \\nFour interventions are important f or cancer control among PLHIV:  \\n● Achieve viral suppression:  uncontrolled viral replication is a major risk factor for \\ncancer. All PLHIV should initiate ART, and be supported and monitored to achieve long -\\nterm viral suppression in order to reduce risk for can cer, and to improve treatment \\noutcomes for many cancers  \\n● Primary prevention through avoidance of modifiable risk factors  \\no Smoking cessation  \\no Avoidance of harmful use of alcohol  \\no Regular physical activity  \\no Healthy diets  \\no Vaccination: vaccination against Human Papillomavirus for girls 9 -14 years old are \\neligible in Kenya, Hepatitis B Vaccine for newborns and high -risk groups  \\n● Secondary prevention through screening and early diagnosis  \\no Screening: application of simple tests to detect cancer in asymptomatic individuals  \\n▪ Cervical cancer: all women LHIV who have been sexually active up to 49 years \\nold (25 -49 years in the general population), through either visual inspection \\nwith acetic acid (VIA) or PAP smear annually, or HPV testing every 2 years  \\n▪ Breast cancer: mammogram annually from 40 -55 years; mammogram every \\ntwo years from 56 -74 years; screening for younger women can be performed \\non an individual basis based on family history or other risk factors. Clinical \\nbreast exam can be used where mammogr am is not available  \\n▪ Prostate cancer: serum prostate specific antigen (PSA) annually for men 40 \\nyears and above; digital rectal examination can be used if PSA is not available, \\nand for all men with urinary symptoms  \\n▪ Colorectal cancer: fecal occult blood test ing of stool (guaiac or FIT) annually for \\neveryone 45 -75 years old, or colonoscopy every 10 years  \\n▪ Oral cancer: visual examination for everyone above 40 years with history of \\ntobacco use, known HPV infection or immunosuppression  \\no Early diagnosis: prompt diag nosis of cancer in symptomatic individuals  \\n▪ Breast: lump, asymmetry, skin changes, nipple changes, blood -stained \\ndischarge  \\n▪ Cervix: post -coital bleeding, excessive vaginal discharge  \\n▪ Colon and rectum: change in bowel habits, unexplained weight loss, anemia, \\nblood in stool  \\n▪ Oral: white or red lesions, growth, ulceration  \\n▪ Naso -pharynx: nosebleed, permanent blocked nose, deafness, lymph nodes in \\nupper neck  \\n▪ Larynx: persistent hoarseness of voice  \\n▪ Stomach: upper abdominal pain, indigestion, weight loss  \\n▪ Skin: irregular growths, lesions, or non -healing sores  \\n▪ Bladder: painful or frequent urination, blood in urine  \\n▪ Prostate: difficulty (long time) in urination, frequent nocturnal urination  \\n▪ Retinoblastoma: white spot in the pupil, convergent strabismus (in a child)  \\n▪ Testis: swelling of one testicle  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 85}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 25  ● Tertiary prevention : Cancer management, prevention of complications and treatment \\nof side effects and secondary cancers  \\nNote: For screening, diagnosis, and management recommendations refer to national \\nguidelines for prevent ion and management of cancers. For individual patient \\nmanagement, referral to regional and national hospitals with capacity for comprehensive \\noncology services may be warranted.  \\n4.6 Mental Health Screening and Management  \\nPLHIV are susceptible to psychological disturbances due to HIV itself and perceptions regarding \\nHIV in their environment. Some of the most common psychological disturbances include \\ndepression and suicide, anxiety, internalized stigma, post -traumatic stress disorder, cognitive \\ndifficulties such as dementia, and perceived lack of social support. Any of these can significantly \\ninterfere with a patient’s sense of well -being and their adherence. Depression and alcohol/drug \\naddiction are the most significant and are reviewed in this sect ion. For any patient with other \\nsuspected mental health disorders, such as anxiety, psychosis or post -traumatic stress disorder, \\nconsider formal screening and/or referral to a specialist.  \\n4.6.1 Depression  \\nDepression is one of the most common psychiatric il lnesses in the world, and chronic illness \\n(including HIV) is a strong risk factor for depression. PLHIV are 3 -6 times more likely to suffer \\nfrom depression than the general population, with significant disability and poorer treatment \\noutcomes if it is not identified and managed. Depression can be a significant contributing factor \\nto poor adherence and HIV treatment failure.  \\nAll PLHIV should receive basic screening for depression upon enrollment and thereafter \\nannually using the following two questions:  \\n● Duri ng the past two weeks have you often been bothered by feeling down, depressed, or \\nhopeless?  \\n● During the past two weeks have you often been bothered by little interest or pleasure in \\ndoing things?  \\nAll patients who answer “yes” to either or both of the questi ons above, and all patients with a \\ndetectable viral load after 3 or more months on ART (whether or not they had achieved viral \\nsuppression in the past), should undergo a more thorough screening for depression using the \\nPHQ -9 screening tool, with management  guided by the PHQ -9 score (Table 4.1 5). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 86}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 26  Table 4.1 5: Patient Health Questionnaire -9 (PHQ -9) for Depression Screening  \\nPHQ -9 Depression Screening                               Name:  _________________________    Date: __________________  \\nAsk the patient the questions below for each of the 9 symptoms and circle the response for each question. After asking all \\nquestions, add the points for each column  at the bottom. The total score is the sum of the column totals. Interpretation \\nand management recommendations are provided at the bottom of the table.  \\nQuestion:  “Over the last 2 weeks, how often have you been \\nbothered by any of the following problems?”  Not at all  Several days  More than \\nhalf the days  Nearly every \\nday \\n 1. Little interest or pleasure in doing things  0 1 2 3 \\n2. Feeling down, depressed, or hopeless  0 1 2 3 \\n3. Trouble falling or staying asleep, or sleeping too much  0 1 2 3 \\n4. Feeling tired or having little energy  0 1 2 3 \\n5. Poor appetite or overeating  0 1 2 3 \\n6. Feeling bad about yourself, or that you are a failure, or that \\nyou have let yourself or your family down  0 1 2 3 \\n7. Trouble concentrating on things (linked with patient’s usual \\nactivities, such as reading the newspaper or listening to a radio \\nprogram)  0 1 2 3 \\n8. Moving or speaking so slowly that other people could have \\nnoticed. Or the opposite, being so fidgety or restless that you \\nhave been moving around a lot m ore than usual  0 1 2 3 \\n9. Thoughts that you would be better off dead or of hurting \\nyourself in some way  0 1 2 3 \\nTotal ____ = (add the points from each column)  0 +___  +___  +___  \\n \\nInterpretation of PHQ -9 Score and Recommended Management  \\nTotal Score  Provisional \\nDiagnosis  Recommended Management  \\n0-4 Depression unlikely  Repeat screening in future if new concerns that depression has developed  \\n5-9 Mild depression  ● Provide counselling support and continue to monitor; refer to mental \\nhealth team if available  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\n10-14 Moderate depression*  ● Provide supportive counselling (refer to a psychologist if available)  \\n● If patient is on EFV, substitute with a different ARV after ruling out \\ntreatment failure (Figure 6.4)  \\nand  \\n● Begin antidepressant medication (or, if unfamiliar with use of \\nantidepressants, then refer to an experienced clinician)  \\nand  \\n● Refer to a medical officer, psychiatrist, or mental health team if available  15-19 Moderate -severe \\ndepression*  \\n20-27 Severe depression*  \\n*Symptoms should be present for at least 2 weeks for a diagnosis of depression and before considering treatment with \\nantidepressant medication. Severe depression may require patients to start on anti -depressants immediately  \\nDepression is a known adverse drug reaction with EFV although it is often mild and temporary. Patients on \\nEFV who develop any persistent symptoms of depression should be switched to another ARV aft er ruling \\nout treatment failure (Figure 6.4).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 87}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 27  Supportive Counselling for Depression  \\nPatients with mild depression should receive supportive counselling, which includes  \\n● Psycho -education on the following key messages  \\no Depression is common and can happen to anyone  \\no Depressed people often have exaggerated negative opinions about themselves, \\ntheir life and their future  \\no Effective treatment is possible  \\n● Counseling on self -management  \\no Continuing ART as prescribed  \\no Continuing activities that they used to find interesting/pleasurable  \\no Maintaining a regular sleep cycle  \\no Keeping physically active  \\no Participating in community/social events  \\no Returning to clinic if any thoughts of self -harm occur  \\n● Addressing psychosocial stressors  \\no Explore potential stressors in the patient ’s life  \\no Assist in problem -solving to reduce stressors  \\no Assess for and manage intimate partner violence  \\n● Reactivation of or referral to social networks, including peer support groups  \\n● Regular follow -up until symptoms improves and are stable  \\n \\nPharmacological Management of Depression  \\nPatients with moderate depression or worse should be treated with supportive counselling plus \\nan anti -depressant medication.  \\nFluoxetine is an antidepressant and does not have significant drug interactions with ARVs.  \\n● Starting dose for an adult is usually 20 mg once taken daily in the morning (can start with a \\nlower dose for patients who frequently have side -effects from medications). Dose can be \\ntitrated up by 20 mg every 2 -4 weeks as needed, up to a maximum of 80 mg p er day.  \\n● Common side -effects include GI upset, headaches, insomnia, and disturbances of the \\nmenstrual cycle. These usually resolve after 1 -2 weeks of continued use.  \\n● Full effect is not achieved until around 4 weeks of continued use. Once symptoms of \\ndepres sion resolve, antidepressants should be continued for at least another 6 months.  \\n● If/when the patient is ready to discontinue antidepressant therapy it should be discontinued \\nas a weekly taper (e.g., if the maintenance dose is 60mg then taper to 40mg, then 30mg, then \\n20mg, then 10mg and then stop), with close monitoring for recurrence of symptoms.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 88}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 28  4.6.2 Alcohol and Drug Use/Addiction  \\nAlcohol and other drug use are common among the general population and among PLHIV. \\nAlcohol and drug use can be a significant contributing factor to poor adherence and HIV \\ntreatment failure.  \\nAll adults and adolescents should be screened for alcohol and drug use before initiating ART and \\nevery year using the following three questions:  \\n● During the past 12 months, did you  drink any alcohol (more than a few sips)?  \\n● During the past 12 months, did you smoke any marijuana?  \\n● During the past 12 months, did you use anything else to get high?  \\nPatients who answer “yes” to any of the questions above, and all patients with a detectable  viral \\nload after 3 or more months on ART (whether or not they had achieved viral suppression in the \\npast), should undergo a more thorough screening.  \\nFor adolescents, use the CRAFFT screening tool (Table 4.1 6). For adults, use the CAGE -AID \\nscreening tool (Table 4.1 7). Anyone who screens positive on these tools should have further \\nassessment and management by clinical staff, ideally with experience in managing alcohol and \\ndrug use disorders. Table 4.1 8 gives some general guidance on management of addictions . The \\nNational Protocol for Treatment of Substance Use Disorders in Kenya provides more in -depth \\nguidance.   \\nTable 4.1 6: CRAFFT Screening Interview for Adolescents  \\nCRAFFT Screening for Alcohol and Drug Use Disorders for Adolescents  \\nAsk the patient the six questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients . Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you ever ridden in a Car driven by someone (including yourself) \\nwho was “high” or had been using alcohol or drugs?    \\n2. Do you ever use alcohol or drugs to Relax, feel better about yourself, or \\nfit in?    \\n3. Do you ever use Alcohol or drugs while you are alone?    \\n4. Do you ever Forget things you did while using alcohol or drugs?    \\n5. Do your Family or Friends ever tell you that you should cut down on \\nyour drinking or drug use?    \\n6. Have you ever gotten into Trouble while you were using alcohol or \\ndrugs?    \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 89}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 29  Table 4.1 7: CAGE -AID Screening Questions for Adults  \\nCAGE -AID Screening for Alcohol and Drug Use Disorders for Adults  \\nAsk the patient the four questions below. Each question requires a yes/no response. Answering Yes to two \\nor more questions indicates an alcohol or drug use problem and requires further assessment and \\nmanagement.  \\n“I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your \\nanswers confidential”  \\nQuestion  No Yes \\n1. Have you felt you should Cut down on your drinking or drug use?    \\n2. Have people ever Annoyed you by criticizing your drinking or drug use?    \\n3. Have you ever felt bad or Guilty about your drinking or drug use?    \\n4. Have you ever had a drink or used drugs first thing in the morning to \\nsteady your nerves or to get rid of a hangover ( Eye opener)?    \\nIf referral to the mental health team is not immediately possible for those who screen positive, or as a \\nstarting point in supporting a patient while referral is being made, an assessment of whether the patient \\nwants to quit and targeted messages/support based on their stage of quitting may be benefi cial (Table \\n4.17). The National Protocol for Treatment of Substance Use Disorders in Kenya provides additional \\nresources for assessments and interventions.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 90}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 30  Table 4.1 8: Addiction Support Based on Stages of Change  \\nStage of Change  Counselling Approach  \\nPre-contemplation: not \\ncurrently considering \\nquitting; no immediate \\ndesire to quit  ● Acknowledge that not everyone is ready to think about quitting  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from their alcohol or drug \\nuse (their motivation for continuing to use)  \\n● Explore why other people might think it is a good idea to quit  \\nContemplation: not sure if \\nhe/she wants to quit, or \\nthinking about quitting but \\nwith no immediate plan to \\nquit  ● Acknowledge that not everyone is ready to quite immediately  \\n● Clarify that it is their decision  \\n● Listen to them describe the benefits they get from the alcohol or drug use \\n(their motivation for continuing to use)  \\n● Listen to them describe the negative effects o f their alcohol or drug use \\n(their motivation for considering quitting)  \\n● Discuss any ideas they have on how they could go about quitting  \\nPreparation: would like to \\nquit within the next month  ● Congratulate them on their decision to quit  \\n● Listen to them describe the benefits they expect to get from quitting  \\n● Discuss any plan they have to try quitting  \\n● Discuss the challenges they may face with quitting  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Encourage small ste ps towards quitting (e.g., avoiding situations that \\ntrigger use)  \\n● Acknowledge that they have the strength to succeed  \\nAction: actively trying to \\nquit, or has recently quit \\n(within past 6 months)  ● Listen to their experience with quitting  \\n● Congratulate them on the steps they have taken so far  \\n● Problem -solve with them on overcoming challenges, including identifying \\nsupport systems  \\n● Review the long -term benefits of quitting  \\nMaintenance: has quit (more \\nthan 6 months ago) and \\nwants to remain abstinent  ● Congratulate them on their success so far  \\n● Discuss potential for relapse and how to deal with it  \\n● Review the long -term benefits of maintaining abstinence from drug or \\nalcohol use  \\nRelapse  ● Acknowledge that relapse is common  \\n● Evaluate what triggered the relapse  \\n● Reassess motivation to quit and barriers to quitting  \\n● Problem -solve with them on overcoming challenges and what additional \\nsupport systems and strategies can be used  \\nAs indicated in the introduction of this section on mental health (Section 4.6), the following are \\nkey areas of concern in mental ill health and there needs to be a high index of suspicion in order \\nto identify these often -debilitating conditions that negatively affect an individual’s ability to cope \\nwith the tasks  of daily living. The last to items in this section contribute towards building \\nresilience which positively affects an individual’s mental health enabling them to positively \\ninteract with their environments   and live more meaningful lives.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 91}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 31  4.6.3 Anxiety  \\nAnxiety and other anxiety related disorders are mental health conditions that are often \\ncharacterized by experiences of one or several of the following:  \\n− Feelings of nervousness  \\n− Fear, or worry that interfere with the ability to sleep or otherwise function  \\n− A lack of appetite  \\n− Tremulousness and or frank trembling  \\n− Sweating and clamminess  of hands  \\n− Other symptoms may include a racing heart (rapid heartbeat ), difficulty breathing,  \\nheadaches, difficulty falling asleep, and difficulty concentrating.  \\nConcerns around anxiety, especially within the context of living with HIV or caring for persons \\nliving with HIV may reveal themselves during the history taking. These manifestations need to be \\ntaken seriously and addressed with sincerity and compassion.  \\nMany of these may require basic reassurance and support or even just a listening ear during the \\nevaluation session. These will go a long way in alleviating many patient’s anxieties and conc erns. \\nA quick screening tool can be used to assess whether the anxiety demonstrated or identified may \\nrequire further attention.  \\nThe Generalized Anxiety Disorder Assessment (GAD -7) is a seven -item instrument that is used to \\nmeasure or assess the severity of generalized anxiety disorder (GAD). Each item asks the \\nindividual to rate the severity of his or her symptoms over the past two weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 92}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 32  \\nOver the last 2 weeks,  how \\noften have you been bothered \\nby the following problemsNot at all Several daysMore than half \\nthe daysNearly every \\nday\\n1. Feeling nervous, anxious or \\non edge\\n2. Not being able to stop or \\ncontrol worrying\\n3. Worrying too much about \\ndifferent things\\n4. Trouble Relaxing\\n5. Being so restless that it is \\nhard to sit still\\n6. Becoming easily annoyed or \\nirritable\\n7. Feeling afraid as if \\nsomething awful might \\nhappen\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3\\n0 +1 +2 +3 \\nFigure 4.2: Generalized Anxiety Disorder Assessment (GAD -7) \\nThe following cut -offs correla te with level of anxiety severity:  \\n• Score 0 -4: Minimal Anxiety  \\n• Score 5 -9: Mild Anxiety  \\n• Score 10 -14: Moderate Anxiety  \\n• Score greater than 15: Severe Anxiety  \\nTreatment options can then be explored including referral to psychologists, psychiatrists for \\npossible  psychotherapy and medication if required  \\n4.6.4 Stress and stress management  \\nThis is a feeling of emotional or physical tension. The symptoms include ache and pains, \\npalpitations, exhaustion, insomnia, headache,  dizziness or shaking, digestive problems, we ak \\nimmune system, muscles tension or jaw tension.  \\nMany patients may experience these symptoms individually or in clusters and they interfere with \\nthe lives they are living. Sources of stress may be from difficulties in understanding issues around \\nHIV, from  addressing different concerns within themselves, from their significant others, from ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 93}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 33  their workplaces. These issues could be social, financial or environmental concerns and may be \\nsevere enough to negatively impact their lives. The stress may be so severe  as to be observed by \\nanyone interacting with the individual and may manifest in their behaviour and the symptoms \\nthey complain about. It is important for the health care worker to be calm, and assured as they \\naddress the patient’s concerns around stress. Further, a  screening tool can be used to assess the \\nneed for referral to more specialized mental health workers to provide much needed support.  \\n4.6.5 experiences of Trauma  \\nTrauma results from exposure to an incident or series of events that are emotionally disturbing \\nor life -threatening with lasting adverse effects on the individual’s functioning and mental, \\nphysical, social, emotional, and/or spiritual well -being. Past traumatic experiences in PLHIV must \\nbe addressed for their wellbeing.  \\nAssessi ng for Trauma - Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) \\nThe Primary Care PTSD Screen for DSM -5 (PC -PTSD -5) is a screening tool designed to identify \\npersons with probable PTSD. Results of the screening should be considered \"positive\" if the \\nrespondent  answers \"yes\" to any 3 items in the questions listed below. Those screening positive \\nshould have further assessment with a structured interview for PTSD, preferably performed by a \\nmental health professional who has experience in diagnosing PTSD.  \\n“Sometim es things happen to people that are unusually or especially frightening, horrible, or \\ntraumatic. ” For example:  \\n1. A serious accident or fire  \\n2. A physical or sexual assault or abuse  \\n3. An earthquake or flood  \\n4. A war  \\n5. Seeing someone be killed or seriously injured  \\n7. Having a loved one die through homicide or suicide  \\n“If you have ever experienced this type of event, please answer the following in the past month, \\nhave you ” \\n• Had nightmares about the event(s) or thought about the event(s) when you did not want \\nto? \\n• Tried hard not to think about the event(s) or went out of your way to avoid situations that \\nreminded you of the event(s)?  \\n• Been constantly on guard, watchful, or easily startled?  \\n• Felt numb or detached from people, activities, or your surroundings?  \\n• Felt guil ty or unable to stop blaming yourself or others for the events(s) or any problems \\nthe event(s) may have caused?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 94}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 34  4.6.6 Psychosis  \\nPsychosis is a mental disorder characterized by a disconnection from reality.  \\nPsychosis may occur as a result of a psychiatri c illness such as schizophrenia. In other instances, \\nit may be caused by a health condition, medication or drug use.  \\nSigns and Symptoms of psychosis  \\n• Marked behavioural changes  \\n• Neglecting usual responsibilities related to work, school, domestic or social activities  \\n• Agitated, aggressive behaviour, decreased or increased activity  \\n• Fixed false beliefs not shared by others in the person’s culture  \\n• Hearing voices or seeing things that are not there  \\n• Lack of realization that one is having mental health problems  \\nTreatment may include medication and talk therapy.  \\n4.6.7 Self -Care  \\nOverall, in the context of mental health, taking up self -care strategies will help individuals live \\nboth more responsibly, and more satisfactorily as this helps boost both physical and mental \\nhealth.  \\nSelf-care strategies include the following;  \\n− Getting regular exercise  \\n− Eating healthy, regular meals and staying well hydrated  \\n− Making sleep a priority. Many people struggle with this but just getting regular sleep with \\na constant waking and sleeping time contribute tremendously to good self-care  as well as \\ngood, well rested physical and mental health  \\n− Taking up a relaxing activity  \\n− Setting goals and priorities.  \\nThis allows for being realistic in one’s expectation in life and formulat ing realistic strategies to \\nachieve one’s goals  \\nPracticing gratitude  \\nReminding oneself that things that one is grateful for. The more specific one is, the easier it is to \\neven be grateful for them. Listing them down is a good way of getting such clarity  \\nFocusing on positivity  \\nThe calls for appreciating the good and positive things that have happened, are going on and are \\nplanned for in one’s life. The things to look forward to. This strategy also calls for the identification \\nand challenging of negative and unhelpful thoughts. Good friends and counsellors, as well as other \\nhealth workers with mental health skills can assist in this.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 95}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 35  Staying connected  \\nThis is extremely important. Increasingly in the present world disconnection is leading to more \\nand more phy sical and mental ill health. Staying connected with family and friends as well as \\nspiritual support systems enable  one to better manage their lives as they work towards being as \\nmentally healthy as possible.  \\n4.6.8 Wellbeing  \\nAccording to the WHO, mental hea lth is a state of well -being in which an individual realizes his or \\nher own abilities, can cope with the normal stresses of life, can work productively and is able to \\nmake a contribution to his or her community.  \\nSupport structures for wellbeing:  \\nThe suppor t structures for wellbeing are available at different levels of implementation which are:  \\n• Individual counselling  \\n• Group therapy  \\n• Networks of organizations providing support to different categories of populations in \\ndifferent age sets such as adolescents, me n, women etc.  \\nHealth workers in facilities should take the initiative to set up/ maintain these structures and \\nestablish referral systems for clients in need of these services. Referral for PLHIV should include \\nservices that address issues that potentially could affect the mental health of PLHIV such as social \\nand financial issues.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 96}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 36  4.7 Nutritional Services  \\nGood nutrition is a critical component of management of HIV because it contributes to: reducing \\nrisk and frequency of other infections; delaying progression from HIV infection to AIDS; a healthy \\nappearance and weight; gaining strength, maintaining and building muscle, and having energy to \\nremain active, and reducing side effects of ART.  \\n4.7.1 Nutritional Assessment, Counselling  and Support (NACS)  \\nAll PLHIV should receive nutritional assessment, counselling, and support  \\nAll PLHIV should receive nutritional assessment, counselling, and support tailored to the \\nindividual needs of the patients, including:  \\n● Nutrition assessment and diagnosis (timed with routine clinic visits, preferably monthly for \\nthe first year of life, and then quarterly up to 14 years old, and then every 3 -6 months)  \\no Anthropometric (Tables 4.1 9, 4.20 and 4.2 1 provide interpretation and required acti ons \\nfor anthropometric results for children and adults)  \\no Biochemical (investigations as listed in Table 3.2 for baseline and Table 3.5 for follow -up \\ninvestigations)  \\no Clinical (physical examination as described in Table 3.1 for initial evaluation)  \\no Dietary (24 -hour recall for food type/frequency and household food security)  \\no Environmental and psychosocial  \\no Functional (ability to care for self, bedridden, etc.)  \\n● Counselling and education  \\no Benefits of maintaining good nutritional status for a person living with HIV \\no Mother infant and young child nutrition (MIYCN) including exclusive breastfeeding  \\no Reassuring the client that it is possible to  \\no Attain/maintain good nutritional status  \\no Look well and live a healthy life  \\no Identifying locally available foods they can access given their own context, food safety \\nand food preparation  \\no Helping the client to plan meals and snacks with a variety of foods in order to meet their \\nenergy and nutrient needs and treatment plans  \\no Identifying any constraints, the client may face and f ind ways to minimize them  \\no Helping the client to understand the potential side effects and food interactions of the \\nmedicines they are taking, and help the client identify ways to manage these side effects  \\no Exploring with the client the cause(s) of poor appetite and appropriate responses (type \\nof food, disease, pain, depression, anxiety, or side effects of medications)  \\no Counsel on critical nutrition practices  \\nMessages: Critical Nutrition Practices (CNPs)  \\n1. Have periodic nutritional status assessments  \\n2. Increase energy intake through a balanced diet  \\n3. Maintain high levels of sanitation and food hygiene  \\n4. Practice positive living behaviors  \\n5. Carry out physical activity or exercises  \\n6. Drink plenty of clean, safe water  \\n7. Seek prompt treat ment for all opportunistic infections and manage diet -related symptoms  \\n8. Manage drug -food interactions and side effects  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 97}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 37  Support  \\no Therapeutic and supplementary foods to treat clinical malnutrition (food by prescription, \\ntherapeutic feeds, fortified blended flour): Figures 4. 3 and 4. 4 provide malnutrition \\nmanagement recommendations for adults and children; Table 4. 10 provides specific \\nnutritional recommendations for patients with non -communicable diseases  \\no Exclusive breastfeeding for the first 6 months of life; complementary foods for children \\naged 6 - 24 months with continued breastfeeding to prevent malnutrition (Table 7.7 \\nprovides complementary feeding recommendations)  \\no Micronutrient supplements to prevent vitamin and mineral deficiencie s \\no Food security and linkage to HIV sensitive social protection such as household food \\nsupport, home -based care, agricultural extension services, and economic strengthening \\nand livelihood support  \\nSome aspects of nutrition support (such as prescription of th erapeutic and supplementary foods) \\nshould be provided by a trained healthcare professional, however all aspects should be promoted \\nand supported at the community level.  \\nTable 4.1 9: Interpretation of MUAC Results for Children and Pregnant/Lactating Women  \\nMUAC Level by Age (cm)  Classification  Action to Take  \\n6-59 \\nmonths  5-9 yrs.  10-17 yrs.  \\n< 11.5  < 13.5  < 14.5 cm  Severe acute \\nmalnutrition  Irrespective of clinical signs, admission \\n(referral) for stabilization/therapeutic \\nrehabilitation  \\n11.5–12.5  13.5 -14.5  14.5 -18.5  Moderate acute \\nmalnutrition  Admission for supplementary feeding is \\nrecommended  \\n12.6–13.5    Mild acute \\nmalnutrition  Nutritional education and counselling  \\n> 13.5    Normal  Education and counselling of caregivers  \\nPregnant and Breastfeeding Women  \\n≤ 23  Malnourished  Provide nutritional support (Figure 4.3)  \\n> 23  Normal  Education and counselling  \\nTable 4. 20: Interpretation of Z -scores for Children  \\nRatio  Indicator   Z-score  Severity  \\nWeight/Age  Underweight  < - 3 Severe  \\nHeight/Age  Stunting  - 3 to - 2 Moderate  \\nWeight/Height  Wasting*  > - 2 to - 1 Mild  \\n> - 1 Normal  \\n*Children with weight/height z -score of -2 or less should be supported with therapeutic/supplementary \\nfoods    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 98}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 38   \\nScreening\\nMeasure  anthropometry and check bilateral\\nPitting oedema\\nMedical History and Physical examination:\\n-  Evaluate nutritional status and health condition\\n-  Check for medical complications\\n-  Perform appetite test\\nIf SAM without  medical \\ncomplication and passed appetite \\ntestIf SAM with  medical complication \\nand/or failed  appetite test\\nMedical complication developed, decreased \\nappetite, weight loss or stagnant weight, \\noedema increase or no decreaseAdmission to \\nOutpatient careAdmission to \\nInpatient care\\nReferral for continuing treatment in out patient \\ncare:\\nAppetite returning (passed appetite test)\\nOedema decreasing,\\nMedical complication resolvingTreatment Treatment\\nSAM Treatment completed (based on discharge criteria):\\nDischarge to home or refer for supplementary feeding and other services\\n that address underlying causes of malnutritionTREATMENTADMISSION\\n \\nFigure 4. 3: Management of Severe Acute Malnutrition in Children  \\n Other medical complications that necessitate hospitalization  \\nIn addition to severe bilateral pitting oedema (+++), marasmic \\nkwashiorkor and poor appetite, the following complications \\nnecessitate inpatient care:  \\n✔ Intractable vomiting  \\n✔ Convulsions  \\n✔ Lethargy  \\n✔ Unconsciousness  \\n✔ Lower respiratory tract infection  \\n✔ High fever  \\n✔ Severe dehydration  \\n✔ Severe anaemia  \\n✔ Hypoglycaemia  \\n✔ Hypothermia  \\n✔ Eye signs of vitamin A deficiency  \\n✔ Skin lesions  \\nThe following complications require referral of patient for further \\nmedical evaluation:  \\n✔ No appetite (failed appetite test)  \\n✔ IMCI danger signs  \\n✔ Increase in or newly developed bilateral pitting oedema  \\n✔ Weight loss because of diarrhoea (r e-feeding or of other \\norigin)  \\n✔ Weight loss for three consecutive weeks  \\n✔ Static weight (no weight gain) for five consecutive weeks  \\n✔ Other signs of failure to respond to treatment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 99}),\n",
       " Document(page_content=' Standard Package of Care for PLHIV  \\n 4 - 39 \\nA. Weight loss score\\n<5% – Low Risk\\n5-10% – Moderate Risk\\n>10% – High RiskUnplanned % weight loss in the last 1 -3mnthsB. Opportunistic Infections score\\nNo opportunistic infection\\nSub acute OI – Moderate Risk\\nAcute OI – High RiskOpportunistic infections statusC. Food intake score\\nAdequate Intake\\nLow intake – Moderate Intake\\nNausea/Vomiting Non/Fasted \\nfor >5 days – High RiskFood Intake/barriersD. Food Security score\\nLittle or No H/H Hunger = 0 -1\\nModerate H/H Hunger= 2 -3 (High Risk)\\nSevere H/H Hunger= 4 -6 (High Risk)Household hunger score a\\nPregnant & Postpartum women\\nMUAC (cm)<19\\n(SAM)\\n19.0 - 20.9\\n(MAM)\\n21.0 - 23.1\\n(HIGH \\nRISK)\\n>23.1\\n(NORMAL)Nutritional anemia (Hb < 11g/dl) – \\ndeficiency  of iron, folate, Vit. B12;\\nBitot spots due to Vitamin A \\ndeficiency; Pellagra due to vitamin \\nB1 deficiencyMicronutrient deficiency/diseases Other Adults\\nBMI (Kg/m2) b< 16\\n(SAM)\\n16 – 18.5\\n(MAM)\\n18.6 - 21.9\\n(HIGH \\nRISK)\\n22 – 24. \\n(NORMAL)\\nSEVERE MALNUTRITION (SAM)\\nSAM with medical complications \\nand cannot eat ( Clinical status or \\nfailed appetite test)\\nActions  c\\ni. Initiate Phase I therapeutic \\nfeeding until stable (Inpatient – \\nrescue phase feeding)Clinically stable, able to eat and \\ngood appetite\\nActions  c\\n i.  Initiate Phase II therapeutic \\nfeeding for nutritional \\nreconstitution\\nii.  Nutrition counselling & \\neducation\\niii.  Review (in or out patients) \\nweekly\\niv.  Transition to supplemental \\nfeeding upon recovery from \\nSAMActions  c\\ni. Nutrition counselling & \\neducation\\nii. Initiate supplemental \\nfeeding\\niii.  Multiple micronutrient \\nsupplementation\\niv.  Review monthly\\nv.  Post -discharge review every \\n2-3monthsMODERATE MALNUTRITION \\n(MAM)\\nActions  c\\ni.  Nutrition \\ncounselling & \\neducation\\nii.  Repeat nutrition \\nscreening every 2 -3 \\nmonthsNORMAL/LOW RISK\\nActions  c\\ni.   Nutrition counselling & \\neducation\\nii.   Multiple micronutrient \\nsupplementation\\niii.   Review nutrition status \\nand risk factors every \\n2-4 weeks until stable\\niv.  Repeat nutrition \\nscreening every 2 -3 \\nmonths once stable\\n v.  For pregnant or \\npostpartum mothers \\nenroll on FBPNORMAL/HIGH RISK\\nRefer food insecure \\nclients for livelihood\\na Refer to household food security assessment tool\\nb For overweight and obese, refer for counselling\\nc Implement local clinical policy and protocol\\nNUTRITIONAL \\nINTERVENTIONSNUTRITIONAL \\nDAIGNOSISNUTRITIONAL \\nASSESSMENT\\nRefer non responders for \\nfurther clinical assessment \\nand management \\nFigure 4. 4: Management of Malnutrition in Adults with HIV', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 100}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 40 Table 4.2 1: Interpretation of BMI Results for Adults  \\nBMI Level  Classification  Action to Take  \\n< 16 Severe \\nmalnutrition  • Refer for facility -based therapeutic intervention; rehabilitation with \\ntherapeutic foods; counselling on intake issues and possible metabolic issues  \\n• Screen for TB  \\n16.0 –18.4 Mild/moderate \\nmalnutrition  ● Nutritional counselling and supplementary feeding  \\n● Screen for TB  \\n18.5 –25.0 Normal/ \\nrecommended  Nutritional counselling, consistent exercise to build muscles  \\n25.1 –30 Overweight  Nutritional counselling to reduce energy intake; aerobic physical activity to \\nreduce weight  \\n>30 Obese  Counselling to change lifestyle and reduce energy intake; aerobic physical activity \\nto reduce weight  \\n4.8 Prevention of Other Infections  \\n4.8.1 Immunizations  \\nAll children, regardless of HIV status, should be immunized following the full KEPI schedule, \\nwith a few exceptions for infants with severe immunosup pression (Table 4.2 2). For infants \\nliving with HIV and HEIs, an earlier dose of measles vaccines should be given at 6 months of age.  \\nTable 4.2 2: Kenya Expanded Program on Immunizations 2016 Schedule  \\nAge  Vaccines  \\nBirth  OPV1, BCG2 \\n6 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n10 weeks  OPV3, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10), Rotavirus  \\n14 weeks  IPV, Pentavalent (DPT -HepB -HiB), Pneumococcal (PCV10)  \\n6 months  Measles/Rubella (MR) - for HIV exposed and infected infants; Vitamin A  \\n9 months  Measles/Rubella (MR); Vitamin A; Yellow Fever4 \\n18 months  Measles/Rubella (MR); Vitamin A  \\n10 years (girls only)  HPV (2 doses at 6 months apart in the general population; 3 doses for \\nPLHIV, at month 0, 1 -2, and 6)  \\n11-12 years  Tdap (tetanus, diphtheria and pertussis)  \\n1Give OPV to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppressio n (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery  \\n2Give BCG to all infants at birth or within the first two weeks of life. If missed in the neonatal period and the child \\nhas symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) then \\ndefer BCG until virally suppressed on ART and with immune system recovery . Do not give BCG vaccine to babies \\nborn to smear positive mothers. Investigate to rule out TB, give TPT then vaccination d one two weeks after \\ncompletion of TPT  \\n3If HIV+ with symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe immunosuppression (CD4% < 25%) \\nthen use IPV instead of OPV  \\n4Yellow fever vaccine is only routinely used in certain counties as specified by National Vaccines and Immunization \\nProgram; defer yellow fever vaccine if symptoms of advanced HIV disease (WHO Stage 3 or 4) or severe \\nimmunosuppression (CD4% < 25%), until virally suppressed on ART and with immune system recovery  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 101}),\n",
       " Document(page_content='  \\nStandard Package of Care for PLHIV  \\n4 - 41 PLHIV may have an inadequate response to immunizations, particularly before they achieve full \\nviral suppression. The ideal timing, dose, and frequency of re -immunizations for children on ART \\nare not well known. Providers will receive specific guidance or r evaccination from the National \\nVaccines and Immunization Program and NASCOP.  \\nRecommended vaccinations for adolescents and adults living with HIV are listed in Table 4.2 3. \\nTable 4.2 3: Vaccinations in Adolescents and Adults Living with HIV  \\nInfection  Vaccine  Live  \\n(Y/N)  Course  Comments  \\nCOVID -19 Various  N Variable  Follow national guidelines on dosing for the \\nspecific vaccine available  \\nHepatitis B  Subunit  N 4 doses (at  \\n0, 1, 2 and 6 \\nmonths)  Use double dose if non -adjuvanted; use standard \\ndose if adjuvanted  \\nPneumococcus  Conjugate  N 1 dose (PCV  \\n13)  \\nPreferable to polysaccharide  \\nPolysaccharide  N 1 dose  Use if >65 years and with co -morbidity other \\nthan HIV  \\nHuman \\nPapillomavirus \\n(HPV)  Virus -like \\nparticles   \\nN 3 doses (at \\nmonths 0, 1 -\\n2, and 6)  All girls at 9 -14 years old  \\nInfluenza  Inactivated  N 1 dose  Annually  \\nHepatitis A  Inactivated  N 2 - 3 doses  3 doses if CD4 count < 350 cells/mm3 at 0, 1 and \\n6 months. If CD4 count > 350 cells/mm3, give 2 \\ndoses at 0 and 6 months. For those at continued \\nrisk, one booster dose every 10 years  \\nAdditional Vaccines for Special Circumstances  \\nYellow fever  Live attenuated  Y 1 dose  Use only in patients <60 yrs of age and  CD4 > \\n200 cells/mm3 \\nTyphoid  Polysaccharide  N 1 dose  Give the ViCPS parenteral. Repeat every 3 years  \\nCholera  Subunit  N 2 doses  As indicated (usually in epidemics). 2 oral doses \\nof the non -replicating vaccine given 1 -6 weeks \\napart with a single booster dose at 2 years from \\nprimary vaccination  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 102}),\n",
       " Document(page_content='  \\nGuidelines on Use of Antiretroviral Drugs for Tre ating and Preventing HIV Infection in Kenya  \\n \\n4 - 42 4.8.2 Malaria  \\nChildren and adults living with HIV suffer heavier parasitaemia and more malaria morbidity with \\nadvanced HIV disease. Further, people with advanced immunosuppression are at risk of failure \\nof anti -malarial treatment. In pregnancy, there is increased risk of placental malaria,  severe \\nanaemia, premature delivery and perinatal mortality. Drug interactions between ARVs and \\nantimalarial drugs may further complicate management.  \\nRecommendations for malaria prevention for PLHIV include:  \\n● Offer cotrimoxazole preventive therapy (CPT) for  protection against malaria infection \\n(Table 4. 3: Co-trimoxazole Preventive therapy)  \\n● In areas of stable malaria transmission, PLHIV should have access to insecticide treated \\nmosquito nets (ITNs) or indoor residual spraying to reduce exposure to mosquito bi tes \\nand therefore malaria transmission  \\n● PLHIV travelling from non -malarious zones to malaria endemic areas should sleep under \\nITNs  \\n● Pregnant women with HIV living in areas of stable malaria transmission who are not able \\nto take CPT should be given at least t hree doses of sulfadoxine -pyrimethamine (SP) \\nintermittent preventive treatment for malaria as part of routine antenatal care  \\nNote:  SP should not be given to women who are taking CPT  \\n● PLHIV on CPT who develop fever should not be treated for an unconfirmed presumptive \\ndiagnosis of malaria. Laboratory confirmation of malaria should be obtained prior to \\ninitiation of anti -malarial therapy  \\n● PLHIV with malaria should receive standard antimalarial therapy according to national \\nguidelines.  Those on CPT should not be given sulfa -containing anti -malarial drugs. \\nPatients on ART receiving anti -malarial therapy should be monitored closely for adverse \\ndrug reactions  \\n4.8.3 Safe Water, Sanitation and Hygiene  \\nDiarrheal illnesses are common causes of morbidity and  mortality among PLHIV. These diseases \\nare often due to lack of access to safe drinking water, improper disposal of human and animal \\nwaste, and poor personal hygiene, leading to contamination of food and water.  \\nRecommendations for prevention of faecal -oral ly spread illnesses include:  \\n● Offer CPT for protection against some GI infections (Table 4.3: Co -trimoxazole \\nPreventive therapy)  \\n● Hand washing with soap and water after handling human or animal faeces, after using \\nthe toilet, and before food preparation or eating  \\n● Facilities for proper disposal of human waste.  \\n● Training on household -based water treatment methods and water storage containers \\nthat prevent direct hand contact with drinking water  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 103}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 1  \\n5. Adherence Preparation, Monitoring and \\nSupport  \\n \\nThe individual and population benefits of ART are dependent on high levels of adherence to the \\nprescribed medication, the accompanying medical advice and the follow -up plans. Adherence -\\nenhancing strategies should be implemented beginning at the point of HIV di agnosis (as part of \\npost -test counselling and linkage), continued during initial evaluation, and thereafter during the \\nentire follow -up period for ART.  \\n \\nTo avoid treatment failure and the need to switch patients to 2nd or 3rd line ART, it is key to have \\nan adherence support strategy in place before ART initiation, anticipating common and individual \\nbarriers to good adherence. Prevention of treatment failure starts at the time of HIV diagnosis. \\nThis is particularly important with the current recommendation t hat all PLHIV qualify for ART, \\nand ART should be initiated within 2 weeks of diagnosis. Adherence preparation must begin at \\ntime of HIV testing, and close follow -up is required after ART initiation.  \\n \\nThe adherence preparation, monitoring, and support that a patient requires should be tailored to \\ntheir level of adherence, the stage of ART initiation, and the follow -up stage that they are at (Figure \\n5.1).  \\n \\nWhenever possible, follow -up should be provided by the same care provider or team of care \\nproviders (e.g ., same clinician and same counsellor) at each visit. This is particularly important \\nduring the first few months of HIV care.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 104}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated \\ncare based on initial presentation (advanced disease vs \\nwell)\\n• Book follow -up appointment for week 2 and 4 to \\nreview adherence and side -effects\\n• Continue adherence support plan• Weekly appointments  to review clinical \\nstatus, barriers to ART initiation, and provide \\nongoing HIV education and counselling\\n• Provide standard package of care\\n• Re-assessment of ART readiness at every \\nvisit, until ready (target is within 2 weeks)\\nFollow -up with adherence monitoring at every \\nvisit (Table 5.10) and counselling based on \\nlevel of adherence (Table 5.14) until first VL at \\n3 months\\nVL undetectable ( LDL <200copies/ml )\\n• Ongoing adherence assessment and \\ncounselling (Table 5.16)\\n• Continue routine VL monitoring as per \\nthe population groupVL       copies/ml\\n• Suspect poor adherence\\n• Assess for barriers to adherence (Table 5.15)\\n• Follow VL algorithm with enhanced \\nadherence assessment and interventions and \\nassessment for other causes of viremia \\n(Figure 6.6) \\nFigure 5.1: Adherence Preparation, Monitoring and Support until Viral Load after 3 Months on \\nART  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 105}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 3 Adherence is most difficult during the first few months of treatment: the patient is not yet in the \\nhabit of taking their medications every day, they are not familiar with common side -effects, and \\nthey have more challenges with disclosure and stigma,  all of which can interfere with adherence. \\nPoor adherence within the first few months of therapy is also the most risky period for \\ndevelopment of resistance mutations, when the viral load is still high.  \\n \\nFor these reasons, adherence preparation, monitorin g and support must be emphasized \\nduring the first few months of ART until the patient achieves full virological suppression,  \\nafter which adherence monitoring and support can continue at lower intensity.  \\n \\nPatient preparation and counselling should be a coll aborative process between the provider and \\nthe patient or caregiver, to enable the patient to initiate and continue lifelong treatment. This is \\nbest done when the same adherence counsellor follows an individual patient throughout the \\npreparation, initiatio n, and early ART period.  \\n \\nART can be initiated concurrently with the first adherence counselling session, even during \\nthe enrolment visit, especially for infants and for pregnant women. This may also apply to \\npatients with a good understanding of HIV and A RT and strong motivation for immediate \\nART initiation.  \\n \\nEach member of the multidisciplinary team should have the requisite training to provide \\ntreatment education and offer appropriate support to address potential barriers to adherence. \\nTreatment preparat ion and support can be offered at triage, consultation, pharmacy or any other \\nclinic station where confidentiality and privacy are assured and providers are adequately trained. \\nIt should also be incorporated into health talks, peer support group activities , and group \\ncounselling sessions.  \\n \\nBefore commencement of a counseling session, the counselor should ensure that adequate space is available \\nto conduct the counseling, that confidentiality can be maintained, and that tools such as psychosocial \\nassessment f orms, treatment literacy flip charts, PHDP flip charts, and tools to document the counseling \\nsessions are available.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 106}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 4 Persons living positively (adolescent and adult peer educators who can share personal \\nexperiences when needed) should be engaged to support patient education as indicated in the \\noperational guidance below.  \\nOperational Guidance: Meaningful Involvement of People Living with HIV  \\nFor best patient outcomes, PLHIV themselves should be engaged to lead facility -based and \\ncommunity -based HIV ed ucation and support systems. They are often referred to as “peer \\neducators”, “mentor mothers”, and “lay health workers” in these roles. PLHIV have successfully and \\nsignificantly contributed to: improving identification of people at risk for HIV or infected  with HIV; \\nincreasing linkage from testing to treatment; reducing onward transmission of HIV; providing \\npsychosocial support, and improving adherence and retention to care and ART.  \\n \\nIdentifying PLHIV to offer peer -led patient support:  \\n● PLHIV on ART for ≥ 1  year  \\n● Good adherence and undetectable VL  \\n● Positive attitude and interest in supporting peers  \\n \\nPreparing and supporting PLHIV to play a role in patient support systems:  \\n● Must be trained for the role they are expected to provide  \\n● Must have job aids and IEC material appropriate for their role  \\n● Must be supervised by healthcare professionals  \\n \\nPotential roles for PLHIV include  \\n● Supporting HIV self -testing  \\n● Providing HIV testing services  \\n● Acting as peer linkage supporters  \\n● Leading or contributing to facility -based or community -based support groups  \\n● Providing individual or group HIV education  \\n● Providing individual or group adherence counselling  \\n● Distribution of ART refills for stable patients  \\n \\nCompensation for PLHIV who contribute to patient support systems  \\n● Recognition (e.g., ID badges; certificates of service; acknowledgement at community forums)  \\n● Training opportunities with certification  \\n● Financial compensation (e.g., salaries; stipends; transportation allowances)  \\n● Priority consideration for em ployment opportunities  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 107}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 5 5.1 Undetectable = Untransmittable (U=U)  \\nART adherence resulting to durable viral suppression eliminates risk of sexual transmission of \\nHIV and is key to HIV epidemic control. Adoption of the Undetectable equals Untransmittable \\n(U=U) campaign is posed to revolutionize HIV treatment among PLHIV and fortify treatment -for-\\nprevention strategies. Multiple studies have showed that durable viral suppression of <50 \\ncopies/ml eliminates risk of sexual transmission of HIV. (Table 5. 17 Viral load cut -offs)  \\nThe framework of U=U offers a unique opportunity to dismantle HIV stigma and discrimination, \\nemphasizes the critical importance of antiretroviral therapy (ART), daily adherence, and \\ncontinuous engagement in medical care for  PLHIV.  \\nDefinitions:  \\n● Durably Undetectable: 2 consecutive viral load results of <50 copies/ml  \\n● Untransmittable: The finding established by various clinical trials and observational \\nstudies, that people who maintain an undetectable viral load have minimal HIV virus in their \\nblood and other body fluids secretions that they have “effectively no risk” of passing HIV to \\nothers through sex.  \\n5.1.1 Benefits of U=U  \\n● Diminish stigma associated with having HIV  \\n● Reduce barriers to HIV testing and treatment  \\n● Incre ase interest in starting and staying on ART  \\n● Improve self -esteem by removing the fear of being contagious  \\n● Support healthy sexuality regardless of HIV status  \\n● Reduce sex partners’ concerns  \\n5.1.2 Considerations for implementation of U=U within clinical setting s \\n● Viral load monitoring as per the recommended intervals for various populations  \\n● Continuous adherence monitoring and support at all clinical visits  \\n● STI screening at all visits  \\n● Messaging on U=U should be provided for all PLHIV as part of treatment literacy  \\n5.1.3 Messaging to Patients on U=U  \\n● Keeping your HIV undetectable helps you live a long and healthy life  \\n● To get your HIV to an undetectable level and to keep it undetectable, take antiretroviral \\nmedicines as prescribed  \\n● It may take up to 6 months o f taking HIV treatment medicines to bring your HIV viral load \\ndown to an undetectable level  \\n● If you are durably suppressed and you are taking your medications as prescribed, you can \\nbe sure you will not pass HIV through sex  \\n● People who keep their HIV at an undetectable level will not pass HIV to others through sex  \\n● If you stop taking HIV medicines, your HIV can rebound to a detectable level within 1 to 2 \\nweeks, and you may pass HIV to your sex partners  \\n● Keeping your HIV at durably suppressed level helps you sa fely conceive a child with your \\npartner  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 108}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 6 5.1.4 How patients can discuss U=U with others  \\n● Counsel patients to share information about the research on U=U as follows:  \\no In recent research studies that involved thousands of couples, no one who was on \\nHIV treatment and whose HIV was durably undetectable passed HIV to their HIV -\\nnegative sex partner  \\n● Advise patients that they can share the following personal information with current or \\npotential sex partners:  \\no When they last had a viral load test and if their viral load was undetectable  \\n● Individuals should tell their partner(s) that their HIV is undetectable only if they have \\ntaken HIV medicines consistently since their last test with an undetectable viral load  \\n5.1.5 Counselling patients about other preven tion combination interventions  \\n● PrEP:  PrEP is a safe and effective daily pill that prevents HIV infection. The partner without \\nHIV may decide to take PrEP if they:  \\no Are unsure that their partner’s HIV viral load is undetectable, especially if their \\npartner has only recently started ART  \\no Have mo re than 1 sexual partner  \\no Feel more secure with the added perception of protection provided by PrEP  \\n● PEP:  After a possible HIV exposure (e.g., Occupational exposure or if a sex partner with HIV \\nhas not consistently taken ART and is not virally suppressed), t he immediate initiation of \\nemergency PEP can prevent HIV infection  \\n● Condom use:  Condoms protect against other STIs, such as gonorrhea, chlamydia, and \\nsyphilis, and help prevent pregnancy.  \\nCounsel patients to find a prevention strategy that works for them:  \\n● If an individual who does not have HIV is unsure if their partner has an undetectable level of \\nvirus or is anxious about acquiring HIV, care providers should encourage that person to \\nchoose a prevention strategy that works for them, whether that is use of P rEP, emergency \\nPEP, condoms, or a combination of these strategies  \\nNote: Care providers should emphasize that no one should ever be compelled to have \\nsex without condoms  \\n5.1.6 Application of U=U in other settings  \\n● Breastfeeding:  Studies demonstrate that ART greatly reduces the risk of transmission \\nthrough breast milk. However, research has not established that people whose HIV is \\nundetectable do not transmit virus during breastfeeding. Prophylaxis should be provided \\nto HIV expose d infants during the breastfeeding period as per the guidelines regardless \\nof the viral load status  \\n● Injection drug use:  Studies demonstrate that ART greatly reduces the risk of \\ntransmission through sharing of injection drug use. However, research has not \\nestablished that people whose HIV is undetectable do not transmit virus through needle \\nsharing. All people who inject drugs should only use their own needles and not share \\nneedles or other paraphernalia with others  \\n● Needle stick injuries:  Research has not es tablished that people with undetectable viral \\nload do not transmit HIV to people who are stuck by needles containing their blood. HIV \\nPEP should be provided as per the guidelines  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 109}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 7 5.2 ART Adherence Preparation and Support  \\nPreparation for ART begins at the t ime of HIV diagnosis and continues until initiation of ART.  \\n5.2.1 Treatment Preparation as Part of HIV Testing Services  \\nWith the current treatment guidelines recommendation that all PLHIV qualify for ART, post -test \\ncounselling by the HTS provider should no w include three key messages that begin the ART \\ntreatment preparation process for all PLHIV  \\n● Treatment (called antiretroviral therapy (ART)) is available and is recommended for \\neveryone with HIV  \\n● Starting treatment as soon as possible (preferably within two weeks of testing positive \\nfor HIV) reduces the chance of your illness getting worse or of passing HIV to others  \\n● If you take your ART properly and do not miss pills you can expect to live a long and \\nproductive life  \\n \\n5.2.2 ART Treatment Preparatio n \\nART treatment preparation involves HIV education and counselling, including identifying likely \\nbarriers to adherence, a discussion of strategies and support systems to overcome possible \\nbarriers to adherence, and an individualized adherence plan, as summ arized in Table 5.1. The \\neducation and counseling sessions should be documented in patient charts.  \\nTable 5.1: Treatment Preparation and Adherence Counselling Guide  \\nHIV Education  \\n• Ask the patient what they know about HIV  \\n• Ask the patient what they know about treatment for HIV  \\n• Correct/clarify as needed, ensuring you cover:  \\no Modes of transmission and importance of testing partners/children  \\no HIV effect on the immune system and health  \\no HIV viral load and its relationship to health and to HIV transmission  \\no Goals of ART  \\no Relationship between adherence and viral suppression, treatment failure, and drug \\nresistance  \\no Consequences of drug resistance  \\n• Ensure the patient understands by asking them to explain it back to you  \\nBarriers to Adherence  \\n• Ask the patient what they think will be most difficult about taking ART every day  \\n• As the patient what they think will be most difficult about attending all clinic appointments  \\n• Discuss common reasons patients have trouble with excellent adherence and identify which may \\nbe most relevant for them, including:  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 110}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and \\ndifficulty sleeping.  These side effects \\nalmost always resolve with continued \\nuse)  \\no Pill burden  \\no Poor patient -provider relationship  \\no Inadequate HIV education  \\no Cost of care (direct and indirect)  \\no ARV supply -chain limitations (stock -outs, \\nor low stock levels resulting in small refill \\nquantities)  \\nIndividualized Adherence Plan  \\n● Ask the patient what they can do to ensure excellent adherence  \\n● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \\no Number of pills, frequency, food requirements/restrictions  \\no Common side effects  \\no Important drug interactions  \\n● Work with the patient to make an individualized adherence plan, which may include:  \\no Disclosing their HIV status to a close friend or family member who can help support their \\ntreatment; bringing their treatment buddy to clinic with them or to a session with a \\ncounsellor to learn more about HIV  \\no Disclosing their HIV status to household members so they do not have to hide pill -taking  \\no Combining pill taking with a consistent activity in their daily routine  \\no Keeping the ARVs in a place that they are lik ely to see every day  \\no Setting a daily alarm on their phone/watch/clock  \\no Connecting with a support group for additional counseling/education/support  \\no Getting treatment for alcohol or drug use  \\no Getting treatment for depression or other psychiatric illness  \\n● Discuss what to do if:  \\no Develops side effects  \\n▪ Discuss common and serious adverse events for their specific regimen  \\n▪ Encourage patient to return to clinic for any side effects rather than stopping ART  \\no Forgets to take a dose: take it late rather than skipping the dose completely  \\no Travels without their ART: go to the nearest health facility or call clinic for guidance  \\n● Ask the patient to summarize their individualized adherence plan  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 111}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 9 Table 5.1 Cont.  \\nOngoing Support at Subsequent Visits  \\n● Review the patient’s HIV knowledge  \\n● Review the patient’s motivation to take ART  \\n● Elicit any concerns the patient may have about their ART, side effects, visit schedule, or health  \\n● Review the ART dosing schedule and ask about any missed pills  \\n● Explore barriers to adherence that were previously identified or new ones that have developed  \\n● Explore any recent or expected changes in their life or daily routine  \\n● Discuss their individualized adherence plan and if any changes are required  \\n \\nHIV Education and Counselling  \\nHIV education should be a standard component of the enrolment visit. Prior to ART initiation, all \\npatients/caregivers must be provided with enough information to make an informed choice about \\nART initiation and adherence (Table 5.2), including for patients who initiate ART during the \\nenrolment visit. A detailed content guide for HIV education and adherence counselling is provided \\nin Annex 8. This information can be provided through group or individual counselling. The ART \\nReadiness Assessment an d the management plan should be completed for each patient \\nindividually (Table 5.4).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 112}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 10 Table 5.2: Components of HIV Education (see Annex 8 for detailed content guide)  \\nComponent  Questions to be Covered  \\n \\nHIV ● What is HIV  \\n● How is HIV transmitted  \\n● Why should partners and family members be tested for HIV  \\n \\nViral load  ● What is viral load  \\n● How often is viral load measured  \\n● What do viral load measurements mean, including the goal of achieving viral suppression  \\n \\n \\nCD4 cells  ● What are CD4 cells  \\n● How are CD4 cells affected by HIV  \\n● What happens when CD4 cells decrease  \\n● How often is CD4 cell count measured  \\n \\n \\n \\nAntiretroviral \\ntherapy (ART)  ● What is ART  \\n● What are the benefits of ART  \\n● When is ART started  \\n● Does ART cure HIV  \\n● Can you still give HIV to others while taking ART  \\n● How long is ART taken  \\n \\n \\nTreatment failure  ● What happens if you stop taking ART  \\n● What happens if you do not take ART regularly  \\n● What happens if the viral load increases  \\n● What happens in treatment failure  \\n \\nART side effects  ● What are the side -effects of ART  \\n● What should you do if you notice any side effects  \\n \\n \\n \\nAdherence  ● What is adherence  \\n● How should ART be taken  \\n● What usually interferes with good adherence  \\n● What might make it difficult for you to take your ART as prescribed  \\n● What can help you take ART as prescribed  \\n● What happens if you miss an appointment  \\nOther medications  ●  What other medications will you take, in addition to ART (e.g., CPT, TPT)  \\n \\nNutrition  ● Why is nutrition important  \\n● What can you do to improve your nutrition  \\n \\nFollow -up ● How often will you need to come for clinic visits?  \\n● What will we be checking for during your clinic visits  \\nAdherence Support  \\nPsychosocial support for PLHIV and their families is essential for their well -being and good health \\noutcomes. HIV affects virtually every aspect of one’s life, as well as the lives of those close to them. \\nPLHIV need psychological and social support to deal with various issues that are common to \\nchronic illness as well as those that are unique to HIV. These include sti gma, bereavement, self -\\nimage, loss of earning capacity, life skills, and chronic illness, among others. Providing \\npsychosocial support entails identifying any needs that they may have and addressing them. In \\nsome cases, some of these needs can be anticipat ed and addressed even before they come to play \\nin the individual’s life.  \\nThe individualized patient management plan should include establishing appropriate adherence \\nsupport interventions (Table 5.3).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 113}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 11 Table 5.3: Adherence Support and Retention Intervention s \\nStandard Adherence Support Interventions  \\nStructural \\ninterventions  ● Conduct a baseline psychosocial assessment to explore the various aspects of \\nthe client’s life that may influence their adherence to treatment and \\nprevention, and their general well -being. This teases out issues that need to \\nbe explored in detail during the counselling session e.g., disclosure, family \\nplanning, living circumstances etc.  \\n● Use a multidisciplinary team approach to develop and implement treatment \\nplans for each patien t \\n● Engage peer educators to lead HIV education and support services  \\n● Adequately prepare and assess the patient’s readiness to initiate and continue \\nwith ART  \\n● Implement a system for identifying and taking action when patients miss an \\nappointment  \\n● Formalize a sy stem for providing health talks and treatment literacy classes \\nfor patients  \\n● Formalize a system for linking patients to community -based resources, \\nincluding: community support groups, religious groups, CBOs, groups \\nsupporting income -generating activities, o rganizations providing food \\nsupport, NEPHAK, child welfare societies, community health volunteers/units, \\nschools, children’s homes etc.  \\n \\nHIV \\neducation \\nand \\ncounselling  ● Remind the patient about HIV disease, how ART works, the importance of \\nhigh -level adherence and the consequences of non -adherence  \\no Risk of ill health caused by HIV  \\no Role of ART in restoring and maintaining good health  \\no Link between adherence and viral load, CD4 and health  \\no Side effects of medications and how to avoid, recognize and manage them. \\nManage side effects aggressively  \\no Address misconceptions and beliefs about HIV and ART  \\n● Discuss and agree on a treatment plan with the patient. Gain commitment \\nfrom the patient to follow through  \\n● Discuss use of alcohol and drugs and  how to prevent these from affecting the \\ntreatment plan  \\n● It is important to maintain a non -judgmental attitude, establish trust with \\nparents/caregivers, and involve the child as they mature  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 114}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 12 Table 5.3 Cont.  \\nDisclosure and \\nstigma  ● Respect patient privacy and confidentiality  \\n● Discuss with the patient the role of disclosure to close family \\nmembers/trusted friend in promoting adherence  \\n● Offer to facilitate disclosure  \\n● For children/adolescents, discuss age -appropriate disclosure with the \\ncaregiver and off er to support the process (Annex 5)  \\n● Conduct stigma assessment and support appropriately  \\n \\nTreatment \\nsupporter  ● Encourage the patient to identify a treatment supporter/buddy who will \\nprovide the patient with encouragement and social support and even remind \\nthe patient to take medication  \\n● Invite the treatment supporter to at least one of the adherence counselling \\nsessions  \\n● Obtain consent from the patient to contact the treatment supporter if needed  \\nSupport group  ● Link the patient to psychosocial support groups and other community -based \\nsupport mechanisms (preferably through direct introduction)  \\no Support groups give confidence and encouragement and promote positive \\nattitude towards HIV status and may promote disclosure  \\no Support groups offer opportunities for additional counselling and \\nexperience sharing and are an avenue for developing/strengthening life \\nskills  \\no Some support groups engage in economic empowerment activities  \\no Support groups can be used for ART distribution to improve  convenience \\nto the patient  \\n● Develop population -specific support groups when possible (e.g., youth \\ngroups with peer educators for adolescents; children’s clubs; caregiver \\nsupport groups)  \\n● MDT members should be patrons to the support groups, to guide activiti es in \\nline with intended objectives  \\n \\nSMS reminder \\nsystem  ● Enroll patients into an automated SMS reminder system with their consent  \\n● Review the type of messages the patient may receive, the frequency of \\nmessages, and any actions the patient should take when receiving the \\nmessage  \\n● Ensure the system and messages maintain patient privacy and confidentiality  \\nOther reminder \\nstrategies  ● Encourage patient/caregiver to set a specific time of day to take ART, and to \\nassociate ART time with a specific event/s in their daily schedule  \\n● Encourage patient/caregiver to set an alarm on their phone  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 115}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 13 5.2.3 Age -Specific Treatment Preparation and Support  \\nTreatment preparation must be customized to the patient’s age, gender, needs and clinical status: \\nfor patients who present with advanced/symptomatic disease, the focus is on getting better; for \\npatients who present clinically well, the focus is on staying healthy. Specific needs for children, \\nadolescents, caregivers, pregnant and breastfeeding women and men should also be taken into \\nconsideration.  \\nThe HIV education and counselling sessions should be provided at every visit until the patient is \\nready and wi lling to start ART, as determined using the ART Readiness Assessment Form (Table \\n5.4). Each repeat session should begin with a review of what the patient remembers from the \\nprevious session as well as any key issues the counsellor documented in the patient ’s chart, so the \\nsession can be customized to meet their needs. ART preparation should not take more than 1 -2 \\nweeks except for special circumstances such as with uncontrolled mental health issues or \\nuntreated drug addictions. However, once the patient has initiated ART, continued HIV education, \\ncounselling and adherence support must be provided. The counselling sessions should preferably \\nbe conducted by the same counsellor, peer educator, social worker, nurse, community health \\nvolunteer, and/or clinician wh o is professionally certified to counsel based on a certified \\ncurriculum, and they possess the requisite competencies to provide quality counselling. In order \\nto prepare children and adolescents for ART, the counsellor should be trained in providing \\npsycho social support to this age group.  \\nTable 5.4: ART Readiness Assessment Form  \\nCriteria  Y N* \\nA. Psychosocial/Knowledge Criteria (applies to patients and caregivers)  \\n1. Understands the nature of HIV infection and benefits of ART?    \\n2. Has screened negative for alcohol or other drug use disorder, or is stable on \\ntreatment (see Section 4.6)    \\n3. Has screened negative for depression or other psychiatric illness, or is stable on \\ntreatment (see Section 4.6)    \\n4. Is willing to disclose/has disclosed HIV status, ideally to a family member or close \\nfriend?    \\n5. Has received demonstration of how to take/administer ART and other prescribed \\nmedication?    \\n6. Has received information on predictable side effects of ART and understands what \\nsteps to take in case of these side effects?    \\n7. For patients dependent on a caregiver: is the caregiver committed to long -term \\nsupport of the patient, daily administration of ART, and meets the criteria above?    \\n8. Other likely barriers to adherence have been identified and there is a plan in place \\nto address them (e.g., frequent travel for work, plan to deal with unexpected travel, \\ndistance from clinic, etc.)?    \\n9. Has the Patient/caregiver provided accurate locator information and contact details?    \\n10. Patient/caregiver feels ready to start ART today?    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 116}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 14 Table 5.4 Cont.  \\nB. Support Systems Criteria (applies to patients and caregivers)  \\n1. Has identified convenient time/s of day for taking ART, and/or associated \\ndose/s with daily event/s?    \\n2. Treatment supporter has been identified and engaged in HIV education, or will \\nattend next counselling session?    \\n3. Is aware of support group meeting time/s?    \\n4. If facility has SMS reminder system: Has enrolled into SMS reminder system?    \\n5. Other support systems are in place or planned (e.g., setting phone alarm, pill box)?    \\nC. Medical Criteria (applies to patients)  \\n1. Newly diagnosed with TB: defer ART until patient tolerates anti -TB medication; \\ninitiate ART as soon as possible preferably within 2 weeks; for TB meningitis \\ndelay ART for 4 to 8 weeks); monitor closely for IRIS    \\n2. Newly diagnosed cryptococcal meningitis (CM), or symptoms consistent with CM \\n(progressive headache, fever, malaise, neck pain, confusion): defer ART until \\ncompleted 5 weeks of CM treatment, or until ruling out CM as the cause of \\nsymptoms; monitor closely f or IRIS    \\n*If the response to any of the psychosocial criteria or support systems criteria is “No”: develop a \\nstrategy to address the issue as quickly as possible and consider assigning a case manager. ART \\nmay be initiated with adequate adherence support while the criteria is being addressed, on a \\ncase -by-case basis  \\n \\nAt each visit up until ART initiation, every patient should be assessed for readiness to \\nstart ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \\nwhether and when to start ART.  \\nSpecial Considerations when Counselling Children and Adolescents  \\nChildren and adolescents depend on caregivers to support their adherence so there are special \\nconsiderations for adherence preparation and support. All topics covered in the HIV Education \\nand Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \\ncaregiver, with involvement of the child/adolescent as appropriate based on the stage of \\ndisclosure and their developmental stage (Tab le 5.5).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 117}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 15 Table 5.5: Age -appropriate Involvement of Child/Adolescent in HIV Education and \\nAdherence Counselling  \\nAge  Counselling Approach  \\n< 6 years old  The counselling sessions will focus on engaging all of the child’s \\ncaregivers  \\n6-12 years old  Both the caregiver and the child will be involved. The counselling will \\nfocus on the caregiver; younger children can be given a paper and pen \\nand asked to draw their family, school, etc., and talk about their \\nexperiences. Disclosure of HIV status to the child s hould commence by 5 \\nyears of age and be completed by 10 -12 years of age (Annex 5)  \\n> 12 years old with \\ncaregiver present  Most of the counselling can focus on the adolescent, who is often fully \\nresponsible for medication administration. However, it is neces sary to \\nkeep the caregiver coming and involved in supporting the adolescent. A \\nrecommended approach is to start with the caregiver alone, then see the \\ncaregiver and adolescent together, and then see the adolescent alone. \\nUse the HEADSSS tool* to facilitate  discussion  \\n> 12 years old \\nwithout the \\ncaregiver present  Use the HEADSSS tool* to facilitate discussion. Negotiate involvement \\nof a treatment supporter  \\n* HEADSSS assesses: Home; Education/Employment; Activities; Drugs; Sexuality; \\nSuicide/depression/self -image; Safety  \\n \\nIn addition to the standard HIV Education and Adherence Counselling topics, unique issues need \\nto be addressed for caregivers, children and adolescents (Table 5.6).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 118}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 16 Table 5.6: Unique Considerations for Caregivers, Children and Adolescents  \\nCaregiver Barriers to Adherence  \\n• Frequently changing or multiple simultaneous caregivers  \\n• Loss or grief  \\n• Absent or sick caregiver  \\n• Poor understanding of HIV management due to inadequate counselling, elderly, or illiterate \\ncaregiver  \\n• Depression, alcohol and other drug use  \\n• Living far from the health facility  \\n• Economically unstable  \\n• Lack of affection between caregiver and child  \\n• Lack of support systems for the caregiver  \\nChild/Adolescent Barriers to Adherence  \\n• Level of disclosure (is the child/adolescent aware of their HIV status?)  \\n• Lack of understanding of disease/treatment  \\n• Developmental stage and emotional state  \\n• Child refusal to swallow medicine (do not allow refusal to take medicines: all activities should \\nbe stopped for the child until the dose is swallowed)  \\n• Stigmatization and discrimination  \\n• Low self -esteem  \\n• Depression  \\n• Defiance related to a troublesome caregiver -child relationship  \\n• Inadequate structures at school (day or boarding) to support adherence  \\n• Lack of support systems for the child/adolescent  \\nTreatment Barriers to Adherence  \\n• Large volumes of syrups  \\n• Bad taste of syrups  \\n• Pill burden  \\n• Confusing regimens combining syrups and tablets  \\n• Side effects  \\n• Dose adjustment requirements as the child grows  \\nFor all children/adolescents, the level of disclosure should be assessed at first visit and the \\nmanagement plan should include a plan for age -appropriate disclosure (Annex 5). Treatment \\npreparation and support se ssions should be customized to the patient’s age (Tables 5.7 -5.9).  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 119}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 17 Table 5.7: Treatment Preparation and Support for Children (≤   years) and Caregivers  \\nVisit  Standard of Care  \\nAt \\nenrolment \\ninto care  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible \\npsychological, emotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones (Annex 3) to rule out growth \\nretardation, developmental challenges such as autism, deafness and any other \\nphysical challenge. Any child with developmental challenges should be referred for \\nappropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in a child. In \\nthe absence of a caregiver, link the child to a community health volunteer or a peer \\neducator while a more permanent solution is sought, and link with Department of \\nChildren and Social Protection  \\n• The child and their caregiver, if also infected, should be enrolled in the sa me clinic, \\nand have appointments booked on the same clinic day for family -centered care  \\n• Provide HIV education and counselling to caregiver (and child as appropriate for age, \\nTable 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence s upport interventions (Table 5.3), \\nincluding linkage to pediatric and caregiver support groups  \\n• Discuss benefits of disclosure of HIV status of the child and formulate a disclosure \\nplan for children aged 5 years and above (Annex 5)  \\n• Conduct readiness assessme nt to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the caregiver demonstrate how they \\nmeasure and administer the ART)  \\n• Conclude the session by agreeing on a t reatment and follow -up plan  \\n• Where ART is initiated book the child to return within two weeks. Those unwilling to \\ninitiate should return weekly for further counselling on barriers to initiation  \\n• Identify referral needs and link as appropriate  \\n• Document sessi on in the patient’s chart  \\nTwo weeks \\nafter ART \\nInitiation  \\n • Review and reinforce the messages delivered at enrolment; confirm the caregiver’s \\nunderstanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patien t’s chart  \\nFour weeks \\nafter ART \\nInitiation, \\nand further \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\ncaregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 120}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 18 Table 5.8: Treatment Preparation and Support for Adolescents (10 -19 years)  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto care  Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n• Perform a psychosocial assessment at enrolment to evaluate for possible psychological, \\nemotional and social adherence boosters and barriers  \\n• Assess growth and developmental milestones to rule out growth retardation, \\ndevelopmental challenges such as autism, deafness and any other physical challenge. \\nAny adolescent with developmental challenges should be referred for appropriate care  \\n• Identify the primary caregiver as soon as possible after diagnosis of HIV in an \\nadolescent. Adolescents older than 15 years and emancipated minors may not have or \\nmay not want the presence of a caregiver. In this case, the clinical team should explore \\nalternative options to support the adolescent until they are ready to disclose to their \\ncaregivers/guardian or identify someone to disclose to. The alterna tive options include \\nadolescent mentors, peer educators, social worker, nurses or community health \\nvolunteers as may be appropriate.  An adolescent can have both private and joint \\nsessions with the caregiver when deemed appropriate  \\n• The health provider shou ld explore Sexual and Reproductive Health (SRH) \\nunderstanding, fears and needs of the adolescent and prioritize interventions as \\nappropriate. SRH counseling should be introduced in a one -to-one session with the \\nadolescent. The care giver can be excused fro m the sexual and reproductive health \\nsession to enable adolescent to open up during the session  \\n• The adolescent and their caregiver, if also infected, should be enrolled in the same \\nclinic, and have appointments booked on the same clinic day for family -cent ered care  \\n• Provide HIV education and counselling to caregiver (and adolescent as appropriate for \\nage, Table 5.5) as outlined in Table 5.2  \\n• Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to adolescent and car egiver support groups  \\n• Discuss with the caregiver the benefits of disclosure of HIV status to the adolescent (if \\nnot aware of status) and formulate a disclosure plan for adolescents (see Annex 5 for \\nage-appropriate disclosure)  \\n• Conduct readiness assessment to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n• Review ART dosing and timing (including having the adolescent and/or caregiver \\ndemonstrate how they measure and administer the ART)  \\n• Conclude the session by agreeing on a treatment and follow -up plan  \\n• Where ART is initiated, book the adolescent to return within two weeks. Those \\nunwilling to initiate should return weekly for further counselling on barriers to \\ninitiation  \\n• Identify referral needs and li nk as appropriate  \\n• Document session in the patient’s chart  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 121}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nTable 5.9: Treatment Preparation and Support for Adults  \\nVisit  Standard of care  \\nAt \\nenrolment \\ninto HIV \\ncare  \\n Use the 5As (Assess, Assist, Advice, Agree, Arrange)  \\n● Perform a psychosocial assessment to evaluate adherence boosters and barriers e.g., \\nmental, emotional and social status assessments; refer for appropriate care if mental \\ndisorder diagnosed  \\n● Identify a treatment buddy (family member, friend, peer educator, community health \\nvolunteer, etc.) and involve them in HIV education and adherence counselling  \\n● Provide HIV education and counselling to patient  \\n● Identify and establish appropriate adherence support interventions (Table 5.3), \\nincluding linkage to a support g roup  \\n● Discuss benefits of disclosure of HIV status to a trusted family member/friend; how to \\ndisclose; and establish a disclosure plan  \\n● Discuss importance of child and sexual partner testing as well as assisted partner \\nnotification services (aPNS)  \\n● Discus pr evention methods such as condoms, PrEP, PEP, STI screening and treatment  \\n● Conduct an assessment of readiness to initiate ART (Table 5.4); ART should be initiated \\nsame day or the date of initiation agreed upon  \\n● Review ART dosing and timing  \\n● Conclude the sessi on by agreeing on a treatment and follow -up plan  \\n● Where ART is initiated, book the patient to return within two weeks. Those unwilling \\nto initiate should return weekly for further counselling on barriers to initiation  \\n● Document session in the patient’s cha rt ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 122}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure the disclosure plan,  and progress in aPNS  \\n● Document the session in the patient’s chart  \\n \\n5.3 Adherence Monitoring, Counselling and Support During the First 3 Months \\nof ART  \\n5.3.1 Adherence Monitoring  \\nOnce ART has been initiated, adherence should be assessed non-judgmentally by a trained \\nprovider during each visit (Table 5.10).  The objectives of this assessment are to evaluate and \\nreinforce the patient’s adherence to ART, to elicit any barriers to the same, and to develop a plan \\nwith the patient/caregiver to address any of the barriers identified. These may include incorrect \\nknowledge of HIV infection and ART, unsupportive psychosocial factors, difficult home or school \\nenvironment, substance use and poor motivation for taking medication. Patients/caregivers ne ed \\nto be counselled on the importance of being honest about their adherence in order for the \\nhealthcare team to serve them better.  \\nAdherence monitoring requires a combination of interventions. At every clinical visit, the MMAS -\\n4 should be administered as w ell as pill counts. MMAS -8 should be administered any time a \\nhealthcare worker suspects adherence problem (e.g., patients with suspected or confirmed \\ntreatment failure; patient who misses an appointment).  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 123}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 21 Table 5.10: Adherence Monitoring Strategies  \\nAdher ence \\nMonitoring \\nStrategy  Technique  Frequency  \\nSubjective (self -reported adherence)  \\nMorisky \\nMedication \\nAdherence Scale -4 Use Table 5.11 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Every patient, every visit  \\nMorisky \\nMedication \\nAdherence Scale -8 Use Table 5.12 to assess adherence using a \\nstandardized questionnaire, and take action \\nas required  Any time a healthcare worker \\nsuspects adherence problems \\n(e.g., patients with suspected or \\nconfirmed treatment failure; \\npatient who misses an \\nappointment)  \\nAdherence \\nMonitoring \\nStrategy  Technique  Frequency  \\nObjective  \\n \\n \\n \\nPill counts  Ask the patient to bring all their pills with \\nthem to follow -up visits. Calculate how many \\npills should be remaining based on the \\nprevious prescription date and amount \\nprescribed, and compare to how many pills \\nare actually remaining. Excess pills are \\nassumed to be missed doses. Use Table 5.13 to \\ncalculate adherence rate and take action as \\nrequired  ● At every visit until confirmed \\nviral suppression  \\n● Any time a healthcare worker \\nsuspects adherence problems  \\n \\nPharmacy refill \\nrecords  Compare drug pick -up date with expected \\ndate of pick -up (based on number of pills \\ndispensed at last visit). If drug pick -up date is \\nlater than expected, it is assumed the patient \\nis missing doses equivalent to the number of \\ndays late  ● At every drug pick -up \\n● Any time a healthcare worker \\nsuspects adherence problems  \\nViral load  Follow the viral load monitoring algorithm \\n(Figure 6.6). Undetectable VL is the best \\nconfirmation of adequate adherence  ● Age 0 -24 years: at 3 months after \\nART initiation and then every 6 \\nmonths  \\n● Age ≥ 25 years: at month 3 after \\nART initiation and month 12 \\nthen annually  \\n● For pregnant and breastfeeding \\nwomen: at fir st ANC visit if \\nalready on ART, or 3 months \\nafter ART initiation if starting \\nART during pregnancy, and then \\nevery 6 months  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 124}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 22 Table 5:10 Cont.  \\n \\n \\nHome visit  Observe where and how a patient stores and takes \\ntheir medications and assess if they have extra \\nmedications because of missed doses. Home visits \\nmay also provide a better understanding of a \\npatient’s living situation and specific barriers to \\nadherence. Unscheduled home visits may be more \\nrevealing, but should only be conducted if the  patient \\nconsente d to home visits previously (preferably at \\nthe time of enrolment or initiation)  For patients with suspected or \\nconfirmed treatment failure, \\npatients who default from care, \\nor any time the MDT feels a \\nhome visit will contribute to \\npatient management  \\n \\nAccurately assessing adherence requires clinicians to develop a collaborative and non -\\njudgmental relationship with patients.  This is best done when one provider follows an \\nindividual patient longitudinally. The key to asking patients about their adherence is not in the \\nspecifics of the tool used but in taking the time to ask about adherence regularly and doing so in \\nan open and truly inquisitive manner. Otherwise, many patients will simply state what they \\nbelieve the clinician wants to hear: perfe ct adherence.  \\nEvery provider in each ART service delivery point should receive training and gain confidence in \\nassessing adherence and providing adherence support and counselling to the majority of patients \\nwho do not have significant barriers to adherence . However, patients with significant adherence \\nchallenges and multiple barriers to adherence should be referred to providers with additional \\ntraining and time to offer dedicated and enhanced adherence support and counselling. Involving \\nexperienced colleagu es at the same health facility should be done as soon as a concern is \\nidentified, and the patient should be discussed by the MDT to generate as many solutions as \\npossible. Consultation with Mental Health Teams or regional or national mentors may be require d \\nfor complex situations.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 125}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 23 Table 5.11: Morisky Medication Adherence Scale (MMAS -4) \\nMMAS -4: Ask the patient each question below. Circle the corresponding score for each response. \\nAfter completion of all questions, add up all the points that you have circle d for the total score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1  0 \\nTotal Score (sum of all items)   \\nInterpretation of MMAS -4 Score  \\nMMAS -4 \\nScore  Adherence \\nRating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n3-4  \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 126}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 24 Table 5.12: Morisky Medication Adherence Scale (MMAS -8) \\nMMAS -8: Ask the patient each question below. Circle the corresponding score for each \\nresponse. After completion of all questions, add up all the points that you have circled for the \\ntotal score.  \\nQuestion  Yes No \\n1. Do you ever forget to take your medicine?  1 0 \\n2. Are you careless at times about taking your medicine?  1 0 \\n3. Sometimes if you feel worse when you take the medicine, do you stop taking it?  1 0 \\n4. When you feel better do you sometimes stop taking your medicine?  1 0 \\n5. Did you take your medicine yesterday?  0 1 \\n6. When you feel like your symptoms are under control, do you sometimes stop \\ntaking your medicine?   \\n1  \\n0 \\n7. Taking medication every day is a real inconvenience for some people. Do you ever \\nfeel under pressure about sticking to your treatment plan?   \\n1  \\n0 \\n8. How often do you have difficulty remembering to take all your medications? \\n(Please circle the correct number)  \\n  A. Never/Rarely  \\n  B. Once in a while  \\n  C. Sometimes  \\n  D. Usually  \\n  E. All the time  Points: A. 0  \\nB. ¼ C. ½ D. ¾ \\nE. 1 \\nTotal Score (sum of all items)  \\nInterpretation of MMAS -8 Score  \\nMMAS -8 Score  Adherence Rating  Action Required  \\n0 Good  Continue with routine monitoring, counselling and support  \\n \\n \\n1-2  \\n \\nInadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Follow up in 2 -4 weeks  \\n \\n \\n \\n3-8  \\n \\n \\nPoor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to adherence (Table 5.15)  \\n● Engage treatment supporter in adherence counselling \\nsessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 127}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 25 Table 5.13: Adherence Rate Based on Pill Counts  \\nMissed Doses per Month  % Of \\nMedications \\nTaken  Adherence  \\nRating  Action Required (see Table 5.10 for \\nmore details)  For once -\\ndaily \\nregimen  For BD  \\nregimen  \\n1 dose  1-3 doses  ≥ 95%  Good  Continue with routine monitoring, \\ncounselling and support  \\n2-4 doses  4-8 doses  85-94%  Inadequate  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Follow up in 2 -4 weeks  \\n≥ 5 doses  ≥ 9 doses  < 85%  Poor  ● Discuss as an MDT  \\n● Assign a case manager  \\n● Assess for and address barriers to \\nadherence (Table 5.15)  \\n● Engage treatment supporter in \\nadherence counselling sessions  \\n● Implement DOTs  \\n● Follow up in 1 -2 weeks  \\n \\n5.3.2 Adherence Counselling and Support During the First 3 Months of ART  \\nAll patients recently initiated on ART need careful adherence monitoring and support to \\nensure they achieve virological suppression.  This is particularly important in the context of \\nrapid ART initiation. The intensity of counselling and support are dependent on the patients’ level \\nof adherence as assessed by the methods described i n section 5.2.1.  \\nTable 5.14 summarizes adherence counselling and support for patients from the time of ART \\ninitiation until the 3 -month viral load results are available. For patients who have inadequate or \\npoor adherence, Table 5.15 describes the assessmen t for barriers to adherence.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 128}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 26 Table 5.14: Adherence Counselling and Support During the First 3 Months of ART  \\nNo adherence concerns (based on adherence assessment and healthcare team opinion)  \\nCounselling: Group or \\nIndividual, at every visit (can be \\ndone by any member of the \\nhealthcare team, including the \\nclinician)  ● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART \\nadministration (dosing, timing, frequency) and address any \\ngaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can address them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver ’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Encourage the patient/caregiver to continue with the support \\nsystems discussed and implemented already  \\n● Encourage introduction of additional standard support \\nsystems (Table 5.3), including supporting disclosure as needed  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, at \\nevery visit until adherence is \\ngood (preferably by someone \\ntrained on adherence \\ncounselling)  ● Assess for and address potential barriers to adherence \\n(Table  5.15)  \\n● Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) \\nand address any gaps  \\n● Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n● Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or \\nengage another care team member who can addr ess them  \\n● Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt \\nadherence  \\n● Update patient locator and contact information  \\nSupport  ● Review effectiveness of support systems they already have in \\nplace  \\n● Encourage introduction of additional standard and enhanced \\nsupport systems (Table 5.3), including supporting disclosure as \\nneeded, assigning a case manager and considering DOTs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 129}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 27 Table 5.15: Assessment for Barriers to Adherence  \\nTheme  Assessment  \\nAwareness of  \\nHIV status  ● Has the patient/caregiver accepted HIV status?  \\n● For children/adolescents: is age -appropriate disclosure underway/complete?  \\n \\n \\nUnderstanding  \\nof HIV infection \\nand ART  ● How HIV affects the body and risk of transmission to sexual partners and \\nchildren during pregnancy and breastfeeding  \\n● ART and how it works  \\n● Understanding of side effects and what to do in case of side effects  \\no “Have you experienced any side effect since your last visit? Has this \\naffected the way you take your medicine?”  \\n● Benefits of adherence  \\n● Consequences of non -adherence including drug resistance and treatment \\nfailure  \\n \\nDaily routine  ● Review the patient’s/caregiver’s daily routine: “Tell me about your typical day”  \\n● Review how the patient takes medicine or how the caregiver administers it  \\no “Please tell me how you take each of your medicines?”  \\no “How does taking your medicine fit into your daily routine?”  \\n● If the patient’s/caregiver’s daily routine conflicts with medication schedule, \\nwork with t hem to find a new medication schedule that will be more \\nappropriate  \\n● Remind the patient/caregiver to take/give missed or delayed doses as soon as \\nhe/she remembers (up to 12 hours late if on a once -daily regimen, or up to 6 \\nhours late if on a twice - daily re gimen). The next dose should be taken at the \\nusual time  \\n● “What do you do in case of visits or travel?”  \\n● Remind the patient/caregiver to plan travel well, pack sufficient medicine; but \\nshould their medication get finished before they return, advise them to vi sit the \\nclosest ART centre and show their appointment card to get a refill  \\n● For orphans it is critical to assess who the primary caregiver is and their \\ncommitment  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 130}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 28 Table 5.15 Cont.  \\n \\n \\nPsychosocial \\ncircumstance  Home environment:  \\n● “Who do you live with?”  \\n● “Who is aware of your HIV status? Are there people in your life with whom you’ve \\ndiscussed your HIV status and ART use?”  \\no Discuss the usefulness of enlisting the support of family members, friends \\nor a treatment supporter/buddy in reminding them to take medication (for \\nchildren/adolescents, this includes teachers and/or supportive peers at \\nschool); offer assisted disclosure  \\no Encourage the patient to identify and bring a treatment supporter during \\nthe next visit  \\n● Support system (treatment buddy, psychos ocial support groups, etc.)  \\n● Any recent losses, grief  \\n● Changes in relationships with family members/friends  \\n● Screen the patient/caregiver for alcohol and substance abuse (Tables 4.15 and \\n4.16)  \\no Discuss impact on ability to remember to take medication  \\no Explore m otivation to stop and offer support/referral  \\no Encourage limiting use and planning ahead so as not to forget to take \\nmedication  \\n● Screen for intimate partner violence (Section 4.2.1)  \\n● Stigma and discrimination  \\no “Does it bother you people might find out about your HIV status?”  \\no “Do you feel that people treat you differently when they know your HIV \\nstatus?”  \\n● Discuss if stigma is interfering with taking medication on time or with keeping \\nclinic appointments  \\n● Beliefs: has the patient tried faith healing? Has th e patient ever stopped using \\nmedication because of religious beliefs?  \\nMental Health  \\nScreening  ● Screen patient/caregiver for depression using the PHQ -9 (Table 4.14) and \\nmanage/refer as required  \\n● Screen for other psychiatric conditions such as anxiety, post -traumatic stress \\ndisorder or psychosis, or refer to a mental health worker for assessment  \\nReferrals  ● Establish if the patient has been referred to other services (including nutrition, \\npsychosocial support services, other medical clinics, substance use treatment, \\netc.)  \\n● Did he/she attend the appointments? What was his/her experience? Do the \\nreferrals need to be re -organized?  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 131}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 29 5.4 Adherence Monitoring, Counselling and Support for Patients with  \\nSuppressed Viral Load < 200 copies/ml  \\nOnce a patient has confirmed viral suppression (with VL < 50 copies/ml or below the Lower \\nDetection Limit (LDL)) this is confirmation of adequate adherence to ART. The patient can be \\nreassured that they will do well if they continue to adhere. Ho wever, all patients are at risk of new \\nor worsening barriers to adherence, so adherence monitoring, counselling and support should \\ncontinue despite viral suppression, but at a lower intensity and frequency unless concerns are \\nidentified (Table 5.16). These  patients should also be educated on and assessed for qualification \\nas “stable patient” services such as less frequent facility visits, fast -track or community -based ART \\ndistribution, etc. (Table 3.5).  \\nTable 5.16: Adherence Counselling and Support for Pati ents with Viral Load < 50 copies/ml  \\nNo adherence concerns (based on adherence assessment or healthcare team opinion)  \\nCounselling: Group or \\nindividual, every visit \\n(can be done by any \\nmember of the \\nhealthcare team, \\nincluding the clinician)  • Elicit any concerns the patient/caregiver has about ART, other \\nmedications, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily  routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Encourage the patient/caregiver to continue with the support systems \\nthat are in place already  \\nInadequate or poor adherence (based on adherence assessment or healthcare team opinion)  \\nCounselling: Individual, \\nat every visit until \\nadherence is good \\n(preferably by someone \\ntrained on adherence \\ncounselling)  • Assess for and address potential barriers to adherence (Table \\n5.15)  \\n• Review patient/caregiver HIV knowledge (Table 5.2, Annex 8) and \\naddress any gaps  \\n• Review patient/caregiver understanding of ART administration \\n(dosing, timing, frequency) and address any gaps  \\n• Elicit any concerns the patient/caregiver has about ART, other \\nmedicatio ns, visit schedule, or health. Address any concerns or engage \\nanother care team member who can address them  \\n• Explore any major recent or expected changes in the \\npatient’s/caregiver’s life or daily routine that could disrupt adherence  \\n• Update patient locator and contact information  \\nSupport  • Review effectiveness of support systems the patient already has in \\nplace  \\n• Encourage introduction of additional standard and enhanced support \\nsystems (Table 5.3), including supporting disclosure as needed, \\nassigning a case manager and considering DOTs  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 132}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 30 Table 5.17 Viral Load Monitoring Cut -Offs  \\nClinical \\nDefinition  Category  Lab Value  Interpretation  Guidance  \\n• Suppressed  • LDL  \\n \\n \\n• Low Risk \\nLLV  • <50 \\nCopies/ml  \\n \\n• 50 – 199 \\nCopies/ml.  • Treatment Goal  \\n \\n \\n• Stable Client, \\nUntransmissible  • Continue Management  \\n \\n \\n• Continue management, \\nremind client of \\ntreatment goal  \\n• Enroll  in DSD  \\n \\n• Unsuppressed  • High Risk \\nLLV  • 200 -199 \\nCopies/ml  • Increased risk \\nof progression \\nto treatment \\nfailure  • Step down from DSD, \\ninstitute EAC, repeat VL \\nafter 3 months of \\nexcellent adherence  \\n \\n• Suspected \\nTreatment \\nFailure  • ≥1000 \\nCopies/ml  • Client at \\nincreased risk \\nof morbidity \\nand mortality  • Enroll Client in \\nspecialized clinic if \\navailable  \\n• Conduct EAC  \\n• Refer to VL algorithm  \\n \\n \\n5.5 Adherence Monitoring, Counselling and Support for Patients with \\nUnsuppressed Viral Load ≥ 200 copies/ml  \\nTreatment failure should be suspected whenever a patient has been on ART for at least 3 months \\nand has: a viral load ≥ 200 copies/ml; a decline in CD4 count or; a ny new or worsening clinical \\ncondition. Treatment failure is confirmed as per the viral load monitoring algorithm (Figure 6.6). \\nPoor adherence is often the most important factor in developing treatment failure, though there \\ncan be other causes. Adherence m ust be thoroughly assessed and all issues must be addressed \\nbefore switching patients to the next line of ART. Do not change regimens until the reason/s \\nfor treatment failure have been identified and addressed, and a repeat VL is ≥ 1,000 \\ncopies/ml after 3 months of excellent adherence . For patients with high -risk  persistent low -\\nlevel viremia (VL 200 - 999 copies/ml after additional assessment and intervention), consult the \\nRegional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nh csc.nascop.org/clinicalform ). \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 133}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 31 5.5.1 Enhanced Adherence Assessments  \\nAs soon as treatment failure is suspected the patient/caregiver should be discussed by the facility \\nmulti -disciplinary team to develop a plan for assessing barriers to adherence (includin g \\nscheduling a home visit), and assessing other potential causes of treatment failure (e.g., \\ninadequate dosing/dose adjustments, drug -drug interactions, drug -food interactions, impaired \\nabsorption e.g., chronic severe diarrhoea).  \\nAll patients with suspecte d or confirmed treatment failure should have a thorough assessment of \\npotential barriers to adherence (Table 5.15).  \\nIf the patient has a caregiver, treatment buddy, and/or spouse/partner who is enrolled in HIV \\ncare, that person’s file should also be review ed to confirm their most recent viral load results and \\nadherence.  \\n5.5.2 Enhanced Adherence Counselling  \\nAdherence assessment and enhanced adherence counselling should begin as soon as a detectable \\nviral load ( ≥ 200 copies/ml) is received, preferably within 2 weeks.  \\nThe goal of Enhanced Adherence Counselling is to assess possible barriers to adherence in a non -\\njudgmental way and to help the patient construct an adherence plan with concrete objectives. It \\nis important not to focus solely on k nowledge of HIV and ART but also to review psychological, \\nemotional, and socio -economic factors that may contribute to poor adherence. In addition, \\nexploring the patient’s motivation for taking medication often highlights reasons for poor \\nadherence.  \\nAt lea st three sessions of Enhanced Adherence Counselling, spaced 2 -4 weeks apart, are \\nrecommended as the minimum number of sessions, but additional sessions can be added as \\nneeded (Table 5.1 8). If the adherence is evaluated as adequate, a repeat viral load is d one after \\nthree months of excellent adherence, and another Enhanced Adherence Counselling session is \\nconducted to discuss the viral load results. A detailed content guide for Enhanced Adherence \\nCounselling is provided in Annex 9.  \\nIt is preferable to have t he patient go through all adherence counselling sessions with the same \\ncounsellor in order to provide continuity, and that the session is documented to ensure follow -up \\nof all issues identified.  \\nIf adequate adherence cannot be achieved then consult with a senior clinician, discuss as an MDT, \\nor consult the Regional or National TWG.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 134}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 32 Table 5.1 8: Components of Enhanced Adherence Counselling Sessions (Annex 9A for detailed \\ncontent guide)  \\nEnhanced Adherence Counselling Sessions: Overview  \\n \\nSession 1  • Review understanding of viral load (VL) and discuss why the patient’s VL is \\nhigh  \\n• Review common cognitive, behavioral, emotional and socio -economic barriers \\nto adherence  \\no Stigma and non -disclosure  \\no Loss or grief  \\no Treatment literacy  \\no Medications: dosage, timing, storage  \\no Side effects  \\no Discuss risk reduction (e.g., for substance abuse)  \\no Motivation  \\no Mental health screening (screen for depression using PHQ -9, Table 4.14)  \\no Discuss patient’s support systems  \\n● Assist patient to develop adherence plan to address the ide ntified issues  \\n \\nSession 2  ● Review adherence plan from the first session and discuss any challenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n \\n \\nSession 3  ● Review adherence plan from the first and second session and discuss any \\nchallenges  \\n● Identify other possible gaps and issues emerging  \\n● Assist patient to modify the adherence plan to address the identified issues  \\n● Decision on repeat VL based on current adherence  \\no If the adherence is good: plan repeat VL testing after three months of good \\nadherence and explain possible ways forward, emphasizing role of the \\npatient and the health facility  \\no If adherence challenges persist: consult with a senior clinician, discuss as \\nan MD T, or consult the Regional or National TWG before repeating the VL  \\n \\nSession to \\nDiscuss \\nRepeat Viral \\nLoad Results  ● Discuss result of the second VL test  \\n● Plan the way forward:  \\no If VL now < 200 copies/ml: continue current regimen with ongoing \\nenhanced adherence; repeat VL after 6 months  \\no If VL ≥ 1,000: prepare patient for change of regimen (Figure 5.2)  \\no If VL is 200 -999 copies/ml: perform another assessment for causes for \\nviremia and address any issues identified; repeat viral load after an \\nadditional 3 months of excellent adherence  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 135}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 33 Table 5.1 8 Cont.  \\nOther Enhanced Adherence Support Interventions (for patients failing or at high -risk of failing \\ntreatment)  \\nCase \\nmanagement  • Assign a case manager to all children and adolescents (those not achieving \\noptimum treatment outcomes); pregnant women, orphans, patients with alcohol \\nand substance abuse, patients with mental illness, patients with suspected or \\nconfirmed treatment failure, and any patients who the healthcare team feels has \\npoor adheren ce or is at high risk of defaulting from care  \\n• The case manager is the link between the patient and the MDT  \\n• Roles  of the case managers include:  \\no Coordinating multidisciplinary management for patients under case \\nmanagement  \\no Following up on appointment -keeping for their patients  \\no Organizing patient reminders (SMS, calling the day before) and other support \\nsystems  \\no Ensuring appropriate defaulter tracing  \\no Coordinating home visits to their patients  \\nDirectly \\nobserved \\ntherapy  • Patients with suspected treatment failure should have DOTs to ensure good \\nadherence before a viral load is repeated to confirm treatment failure  \\n• DOTs involve a healthcare provider, family member, treatment supporter or any \\ntrained peer observing the patient ingesting th eir prescribed ART on a daily basis  \\n• DOTs can be tapered off once the patient adopts consistent adherence -enhancing \\nbehaviours  and barriers to adherence are overcome  \\nHome visits  • Observe where and how a patient stores and takes their medications, and assess if \\nthey have extra medications because of missed doses  \\n• Home visits may also provide a better understanding of a patient’s living situation \\nand specific barriers to adherence  \\n• Unscheduled home visits may be more revealing, but should only be conducted if \\nthe patient consented to home visits previously (preferably at the time of enrolment  \\nor initiation)  \\nMonthly “high \\nviral load” \\nclinics  • Patients with suspected treatment failure should be booked for dedicated monthly \\nhigh viral load clinics  \\n• Children and adolescents in school who are unable to attend clinic monthly may \\nattend dedicated monthly clinics during mid -term and school holidays (at least \\nevery 6 weeks)  \\n• Comprehensive clinical and psychosocial evaluation should be conducted at e ach \\nvisit, appropriate investigations done and any opportunistic infections treated  \\n• Enhanced adherence counseling sessions should be conducted at each visit  \\n• Support groups for patients with viremia can be timed with “high viral load” clinic \\ndays  \\nSpecial \\nsupport \\ngroups  • For health facilities with several patients who are failing treatment or who are on \\n2nd line ART, special support groups can be established so these patients can work \\nthrough their adherence challenges together  \\n• Community support groups can also be engaged and linked to the facility for \\nsupporting patients with adherence challenges  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 136}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 34 Adherence support systems will need to be adapted to patients’ specific needs and the context \\n(Table 5.1 8). Special attention needs to be given to children, a dolescents, pregnant and \\nbreastfeeding women, patients with mental health disorders and substance users.  \\n5.6 Treatment Preparation for 2nd Line or 3rd Line ART  \\nAfter confirming treatment failure and making the decision to start 2nd line or 3rd line ART (ba sed \\non discussion as an MDT, and in consultation with the Regional or National HIV Clinical TWG), the \\npatient requires targeted counselling and education to prepare them for the new regimen and to \\nsupport ongoing adherence (Figure 5.2).  \\nReview patient file\\nAssess patient  s \\nknowledge and \\nunderstanding\\nProvide patient education\\nConstruct adherence plan\\nEnsure monthly \\ncounselling follow -up \\nsessionsEnsure a monthly follow -up counselling session during \\nclinic visits for the first 6months after initiating the new \\nregimen\\n• Follow up on problems identified during the previous \\nsessions\\n• Assess patient  s adherence and explore any reasons for \\npoor adherence. Identify strategies to overcome these \\nbarriers\\nRepeat VL after 3 months on new regimen\\n• If VL undetectable: adherence counselling every \\n3months\\n• If VL is detectable: discuss as MDT and consult Clinical \\nTWG• Confirm patient  s willingness to start new regimen\\n• Ensure that the patient understands the treatment plan \\n(drug regimen, dosing schedule, dietary restrictions, \\npotential side effects, what to do when missing doses or \\nexperiencing side effects)\\n• Prepare for situations that could impair good \\nadherence, and encourage disclosure of poor adherence\\n• Plan sessions with the pharmacist on medication \\nadherence, and nutritionist on nutritional aspects• Strengthen key messages on HIV and viral load\\n• Provide information on 2nd/3rd line ART: more complex \\nto take (more pills, twice -a-day dosing), very limited \\noptions if this fails\\n• Provide simple take -home IEC materials on 2nd  or 3rd  \\nline ART management• HIV, viral load and ART\\n• The importance of good adherence and potential \\nproblems of non -adherence\\n• Reasons for switching to 2nd or 3rd line ART: treatment \\nfailure with repeated high viral load• Review the patient file and all problems identified \\nduring Enhanced Adherence Counselling sessions\\n• Confirm all the barriers to adherence have been \\naddressed during Enhanced Adherence Counselling, if \\nnot – address remaining barriers before considering \\nchanging regimens\\n \\n \\nFigure 5.2: Adherence Counselling and Education for Patients Preparing to Initiate 2nd Line or \\n3rd Line ART  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 137}),\n",
       " Document(page_content='  \\nAdherence Preparation, Monitoring and Support  \\n5 - 35 5.7 Identifying, Tracing, and Supporting Patients who Default from Care  \\nEvery service delivery point that is providing ARVs for patients (whether ART, PEP, or PrEP) must \\nhave a functional system for identifying patients who miss appointments and for taking action \\nwithin 24 hours of a missed appointment (Figure 5.3).  \\nEnter date of next appointment/TCA for each patient into the \\nappointment diary\\n• As patients arrive at the service delivery point their name should be \\nchecked off in the appointment diary for that day\\n• All patients who had appointments booked for the day but did not \\nattend clinic should be recorded in the patient follow -up register\\n• Patient/caregiver should be called within 24 hours of missed \\nappointment\\n• If no response, treatment buddy should be called\\n• Several attempts at phone tracing should be made if no response \\ninitially\\n• Update the patient follow -up register with phone call findings\\nPatient does not return \\nwithin time agreed upon \\nduring phone call, but still \\nable to reach by phonePatient returns to clinic \\nwithin 7 days, or returns \\non date agreed during \\nphone callUnable to reach by phone, \\nand does not return to \\nclinic within 7 daysPatient dead, transferred \\nout, or declines further \\ncontact: update patient \\nrecords/ registers with \\noutcome\\nReturns to clinic\\n• Assess for and address potential barriers to adherence \\n(Table 5.14) \\n• Review patient/caregiver HIV knowledge (Table 5.1, \\nAnnex 6) and address any gaps\\n• Elicit any concerns the patient/caregiver has about ART, \\nother medications, visit schedule, or health. Address any \\nconcerns or engage another care team member who can \\naddress them\\n• Explore any major recent or expected changes in the \\npatient s/caregiver  s life or daily routine that could disrupt \\nadherence\\n• Review effectiveness of facility and community support \\nsystems the patient already has in place\\n• Encourage introduction of additional standard  and \\nenhanced support systems (Table 5.2), including \\nsupporting disclosure as needed, assigning a case manager \\nand considering DOTs\\n• Review ART Readiness Assessment Form for re -initiation \\nof ART• Prioritized home visit, based on\\no Patient type (pregnant and \\nbreastfeeding women, child, co -\\nmorbidity)\\no Proximity to clinic\\n• Complete the home visit form\\n• Update the patient follow -up register with \\nhome visit findings\\n• Update appointment diary if agrees to \\nreturn to clinic\\nUnable to trace or does not return to clinic on \\nscheduled appointment date\\n• Discuss as MDT and develop follow -up/ \\nmanagement plan\\n• Update patient records/registers with \\noutcome\\n \\nFigure 5.3: Ident ifying, Tracing and Supporting Patients who Default from Care  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 138}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 36  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 139}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 1  \\n6. Antiretroviral Therapy in Infants, Children, \\nAdolescents, and Adults  \\nART, while very effective in managing HIV disease, does not cure HIV infection. The goal of ART is \\nto suppress viral replication with the aim of reducing the  patient’s VL to undetectable levels. \\nUninterrupted ART with ongoing strict adherence will help maintain undetectable VL levels \\nthereby preventing damage to the body’s immune system, reducing AIDS -related morbidity and \\nmortality and the risk of sexual and vertical transmission of HIV.  \\n6.1 Eligibility for ART  \\nAll individuals with confirmed HIV infection are eligible for ART irrespective of CD4 \\ncount, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other cri teria.  \\n6.2 Timing of ART Initiation  \\nART should be started in all patients as soon as possible, preferably within 2 weeks of \\nconfirmation of HIV status, and even on the same day as testing positive for HIV if they are ready.  \\nART Readiness Criteria (Table 5.4) can be used to help determine any issues that need to be \\naddressed around the time of ART initiation. Same -day ART initiation (on the same day as testing \\nHIV-positive) has additional benefits for HIV prevention (e.g., for pregnant and breastfee ding \\nwomen, and the HIV positive partner in a discordant relationship), and is associated with \\nimproved retention, viral suppression, and survival. Special considerations for timing of ART \\ninitiation are listed in Table 6.1.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 140}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 2 Table 6.1: Special Considerat ions for Timing of ART Initiation  \\nPopulation  Timing of ART Initiation  Additional Notes  \\nPregnant and \\nbreastfeeding \\nwomen  Support ART initiation on the \\nsame day as testing positive for \\nHIV Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nInfants (< 12 months \\nold)  Support ART initiation on the \\nsame day as testing positive for \\nHIV. Treatment should \\ncommence following a first \\npositive PCR test. ALWAYS take a \\nsample for a confirmatory PCR \\ntest as soon as the first positive \\nPCR result is received, but do not \\ndelay ART initiation for the \\nsecond PCR result  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\ncaregiver preparation  \\nPatients with strong \\nmotivation to start \\nART immediately  Support ART initiation as soon as \\nthe patient feels ready, preferably \\non the same day as testing \\npositive for HIV  Intensive adherence counselling, \\nsupport and close follow -up \\nrequired because of limited time for \\npatient preparation  \\nPatients with newly \\ndiagnosed TB  Start anti -TB treatment \\nimmediately and initiate ART as \\nsoon as anti -TB medications are \\ntolerated, preferably within 2 \\nweeks. For TB meningitis delay \\nART for 4 to 8 weeks  Monitor closely for IRIS (Annex 16)  \\nPatients with \\ncryptococcal \\nmeningitis  Defer ART until after completing \\n5 weeks of CM treatment  Monitor closely for IRIS (Annex 16)  \\n \\nPatients for whom \\nadherence will be \\nparticularly \\nchallenging  Start ART as soon as possible \\nwhile implementing additional \\nsupport systems (e.g., optional \\nenrolment of a PWID into a MAT \\nprogram; psychiatric treatment \\nfor a patient with mental illness; \\nenrolment into an OVC program \\nfor orphans etc.)  A case manager should be assigned \\nto all patients with complex \\nadherence challenges  \\nAll other patients  Start ART as soon as possible, \\npreferably within 2 weeks, \\nand even on the same day as \\ntesting positive for HIV if they \\nare ready  Continued adherence monitoring \\nand support is recommended after \\nART initiation for all patients  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 141}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 3 6.3 First -Line ART for Infants, Children, Adolescents and Adults (including \\nPregnant and Breastfeeding Women)  \\nThe recommendations below apply to patients who are starting ART for the first time. Preferred \\nand alternative first line regimens are shown in Tables  6.2 and 6.3. ARVs for infant prophylaxis \\nare presented in the PMTCT chapter in Tables 7.3 to 7.6.  \\nAll patients must have their weight documented at every visit. Children and adolescents \\nless than 15 years must have correct weight -based dosing of ARVs conf irmed at every visit.  \\nInfants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.  \\nTable 6.2: Preferred First -line ART Regimens and Dosing for Children, Adolescents and \\nAdults 1 \\nAge  Weight  Preferred \\nRegimen  Dosing2 (correct weight -based dosing must \\nbe confirmed at every visit)  \\nBirth to 4 \\nweeks  Any  AZT + 3TC + NVP3 Refer to Annex 10 for weight -based dosing  \\n> 4 weeks to \\n< 15 years  < 30 kg  ABC + 3TC + DTG4 Refer to Annex 10 for weight -based dosing  \\n≥ 30 kg  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n≥ 15 years  Any  TDF + 3TC + \\nDTG5,6 TDF/3TC/DTG (300/300/50mg): 1 tab once \\ndaily  \\n1 Patients currently on first -line regimens that are not included in the indicated preferred (Table 6.2) \\nor alternative (Table 6.3) regimens should be considered for regimen optimization as per Section \\n6.5.1  \\n2 See Annex 10 for weight -based dosing of all single -drug and fixed -dose combination formulations  \\n3 Infants who initiate ART at less than 4 weeks of age should initiate on AZT+3TC+NVP irrespective of \\nprevious ART exposure; metabolism of other ARVs is not well known for this age group. As soon as \\nthese infants become 4 weeks old, they should switch to ABC/3TC+DTG (dosing included in Annex \\n10). Consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000, \\nulizanascop@gmail.com) in case of pre -term infants  \\n4 Once adolescents reach 30 kg, if virally suppressed they should be considered for transition as per \\nFigure 6.2  \\n5 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n6 DTG/3TC dual therapy may be considered for HBV -negative pa tients once fixed -dose combinations \\nare available  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 142}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 4 Table 6.3: Use of Alternative ARVs in First -Line Regimens 1 \\nAge  Weight  Scenario and ARV \\nAffected  Alternative ARV to Use  \\nBirth to 4 \\nweeks   \\nAny  NVP: Develops \\nhypersensitivity reaction  Use RAL granules or LPV/r granules \\n(over 2 weeks of age) or defer ART until \\n4 weeks of age, then start ABC+3TC+DTG  \\nAZT: Infant Hb < 9.5 g/dL  Defer ART until 4 weeks of age, then \\nstart ABC+3TC+DTG  \\n> 4 weeks \\nto < 15 \\nyears   \\n \\n< 30 kg  ABC: Develops ABC \\nhypersensitivity reaction2 Use AZT (if Hb ≥ 9.5 g/dL); if Hb < 9.5 \\ng/dL consults Regional or National HIV \\nClinical TWG (call Uliza Hotline 0726 \\n460 000; ulizanascop@gmail.com)  \\nDTG: Unable to tolerate  Use LPV/r at standard weight -based BD \\ndosing, if 4-in-1 available this is \\npreferred  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Increase DTG dosing frequency to twice \\ndaily for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to once daily \\ndosing3 \\n \\n \\n \\n≥ 30 kg  \\n \\n TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n≥ 15 years  Any  TDF: Impaired renal \\nfunction (CrCl ≤ 50 \\nml/min)  Use ABC4,5 or TAF (once available)  \\nDTG: Unable to tolerate  Use EFV (for PWID use ATV/r)  \\nDTG: Currently on \\nrifampicin -containing \\nanti -TB \\nmedications  Give TDF/3TC/DTG FDC morning + DTG \\n50mg evening for duration of rifampicin -\\ncontaining TB treatment and for an \\nadditional 2 weeks after TB treatment is \\ncompleted, then revert to TDF/3TC/DTG \\nFDC OD 3 \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 143}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 5 Table 6.3 Cont.  \\n1 For other scenarios that are not covered in this table, discuss as an MDT and consult the Regional or \\nNational HIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2 ABC hypersensitivity reaction (AHR) is rare in the Kenyan population. Table 6.9 provides the \\ndefinition and management of AHR  \\n3 The additional 2 weeks of higher -dose DTG is to counter the ongoing liver enzyme induction effect \\nof rifampicin, which continues for a short period after TB treatment is completed  \\n4 TAF may become the preferred NRTI once fixed -dose combinations are available  \\n5 DTG/3TC dual therapy may be considered for HBV -negative patients once fixed -dose combinations \\nare available  \\n6.4 Dosing and Administration of Dolutegravir (DTG)  \\nDTG is preferred in first line ART (in combination with other ARVs) for children, adolescents and \\nadults. DTG is well tolerated, highly efficacious, has a high genetic barrier to resistance and fewer \\ndrug -drug interactions.  \\nTable 6.4: Dosing and Administration of  Dolutegravir  \\nRecommended Dosing of DTG  \\n● < 20 kg body weight: Use weight -based dosing with dispersible 10mg DTG tablets as per Annex 10  \\n● ≥ 20 kg body weight: DTG 50 mg film -coated tablet once daily, preferably as a morning dose. It is also \\navailable as part of FDC. Those unable to swallow the film coated tablets whole refer to Annex 10  \\n● For patients taking rifampicin: Increase DTG dosing frequency to twice daily for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily. (The additional 2 weeks of higher -dose DTG is to counter the ongoing liver \\nenzyme induction effect of rifampicin, which continues for a short period after TB treatment is \\ncompleted)  \\n● For patients w ith suspected or confirmed INSTI resistance (e.g., patients with prior history of failing a \\nRAL -based regimen): use DTG twice daily  \\n● DTG can be taken with or without food  \\nCommon Side Effects of DTG  \\n● The most common side effects of DTG are headache, nausea and diarrhea. These side effects usually \\nresolve after continued use for 1 -2 weeks. It is critical to inform patients / caregivers about these \\npotential side effects and their temporary nature, and encourage them to continue their ART and \\nconsult a HCW if concerned.  \\n● Some patients on DTG are more likely to develop insomnia. This may be reduced by taking DTG as a \\nmorning dose, or by taking DTG with a low -fat meal or on an empty stomach.  \\n● DTG may cause a small rise in serum creatinine levels bu t this does NOT represent a true decline in \\nrenal function.  \\n● Integrase inhibitors, including DTG, are associated with increased weight gain. Counsel patients about \\nhealthy eating and physical activity and the benefits of maintaining a healthy weight.  \\n● All ad verse events should be reported through the national pharmacovigilance mechanism. \\n(http://www.pv.pharmacyboardkenya.org/ ) ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 144}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 6 Table 6.4 Cont.  \\nPregnancy Safety of DTG  \\n● DTG is safe during pregnancy and breastfeeding. Pregnancy intention should be discussed with all \\nwomen initiating ART regardless of regimen. Women who do not wish to become pregnant should be \\noffered appropriate family planning counseling and methods.  \\nImportant Drug Interactions with DTG  \\n● Rifampicin  \\no Rifampicin lowers DTG levels: increase DTG to 50 mg twice daily for patients on rifampicin who \\nare > 20 kg in body weight. Children <20 kg taking DTG who require rifampicin should increase \\ntheir weight -appropriate DTG dose to twice daily.  \\no There are no significant drug interactions between DTG and other currently used anti -TB \\nmedications (including for MDR -TB) \\n● Mineral supplements, including: antacids containing calcium, zinc, magnesium or aluminum; iron \\nsupplements; prenatal vitamins (which contain iron and calcium)  \\no These supplements decrease the absorption of DTG: administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements  \\no Dose separation is not required for calcium and iron supplements (including prenatal vitamins) if \\nDTG is taken with a meal  \\no It is critical to educate patients about this important drug interact ion because many patients get \\nthese supplements and antacids over -the-counter without informing their healthcare provider  \\n● Carbamazepine, phenobarbital, phenytoin  \\no These anticonvulsants decrease DTG levels: use a different anticonvulsant if available  \\no If DTG must be co -administered with these drugs then increase to DTG to twice daily, although \\nthere is little data to guide this  \\no If valproic acid is available this can be used with DTG without dose adjustment  \\n● Metformin  \\no DTG increases levels of metformin; the levels of DTG are not affected: use a lower dose of \\nmetformin (often 50% of usual dose) and monitor glycemic control. Use a maximum daily dose of \\nmetformin 1 g  \\n● Other drug -drug interactions with DTG  \\no See Annex 13C  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 145}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 7 6.5 Monitoring and Changing ART  \\nThe objectives of clinical and laboratory monitoring during ART are to identify and treat inter -\\ncurrent illnesses, assess for and manage adverse drug reactions, and evaluate response to \\ntreatment. Routine laboratory monitoring recommendations are described in Table 3.5; however, \\nadditional investigations should be ordered whenever there is clinical suspicion for which a \\nlaboratory test result may alter patient management.  \\nIndications for changing ART include optimizing therapy for patients who have undetectable viral \\nload, managing adverse drug reactions or toxicity, drug -drug interactions, co -morbidities and \\ntreatment failure.  \\n6.5.1 Optimizing Therapy for Patients who have suppressed viral load on First Line \\nART  \\nPatients who are virally suppressed o n first line ART may benefit from regimen optimization even \\nif they are currently tolerating their regimen well and have no drug -drug interactions requiring a \\nchange. Regimen modifications may be done for age/weight transitions among children and \\nadolescen ts <15 years and to simplify a regimen, prevent long -term toxicity and improve cost -\\neffectiveness. Dolutegravir has been shown to have superior tolerability and efficacy compared to \\nefavirenz and lopinavir and is now preferred as part of first line ART for  children, adolescents and \\nadults. While most adults in Kenya have switched over to a DTG -containing regimen, proactive \\nswitching of children is now also recommended with the availability of a pediatric dispersible \\ndolutegravir tablet.  \\nChildren and adolesc ents with suppressed viral load on first line ART and not on the \\nrecommended first line regimen as per Table 6.2 should be considered for optimization as \\nper Figures 6.1 and 6.2, such as when children grow and enter a new weight band.  This also \\nincludes PL HIV who recently initiated non -standard therapy (less than 3 months ago, before the \\nfirst VL is due). Decisions on regimen modification should be made following discussion with the \\npatient/caregiver.  \\nAlways discuss the possibility of new side effects when changing to a new ARV,  particularly \\nside effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \\nnew ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 146}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 8 \\nChildren weighing < 30  kg on a first line ART regimen OTHER than ABC/3TC + DTG\\nVL within last 6 months < \\n200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL   200 copies/ml\\n• Switch to ABC/3TC + DTG using the \\nweight -based dosing from Annex 10A -B\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia and \\nproviding enhanced adherence counselling\\n• If current regimen contains ABC: Switch to \\nAZT/3TC + DTG\\n• If current regimen contains AZT: Switch to \\nABC/3TC + DTG\\n• Use the weight -based dosing from Annex 10A -B\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do not \\nwait for DRT results for making the regimen modification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still   200  copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200  copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 147}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 9 \\nChildren and adolescents weighing      kg or       years old on a first line ART regimen OTHER \\nthan TDF/3TC/DTG\\nVL within last 6 months \\n< 200 copies/ml (LDL)\\nNo VL result within last 6 \\nmonths\\nVL within last 6 months   \\n200  copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Switch to TDF/3TC/DTG (300/300/\\n50mg) 1 tab once daily\\n• Schedule clinical appointment at 2 weeks \\nafter regimen change to review \\nadherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen \\nmodification followed by routine viral \\nload monitoring\\n• Switch regimen while assessing for reasons for viremia \\nand providing enhanced adherence counselling\\n• Switch to TDF/3TC/DTG (300/300/50mg) 1 tab once \\ndaily\\n• For all patients on PI/r or DTG containing regimens: \\nsummarize case for TWG and take sample for DRT  – do \\nnot wait for DRT results for making the regimen \\nmodification\\n• Schedule clinical appointment at 2 weeks after regimen \\nchange to review adherence, side effects and any other \\nconcerns\\n• Repeat VL 3 months after regimen modification\\n• If VL still       copies/ml then consult the \\nregional or national TWG\\n• If VL now < 200 copies/ml then continue routine \\nviral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml (LDL) \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg or ≥ 15 years \\nold on First Line ART  \\n6.5.2 Changing ARVs Due to Adverse Drug Reactions  \\nPatients starting ART should be educated on the potential side effects of ART and all ot her \\nprescribed medication.  ADRs can have a significant impact on patient adherence and must be \\nidentified early and managed aggressively. All ADRs should be reported to the Pharmacy and \\nPoisons Board using existing pharmacovigilance tools \\n(http://www.pv.pharmacyboardkenya.org/ ). Pharmacovigilance is particularly important for \\nmonitoring ADRs associated with any new ARVs that enter the national supply chain, as rare \\nADRs may appear in routine care, whi ch were not observed in the highly selected patients \\nparticipating in clinical trials.  \\nThe most common significant ADRs associated with ARVs that may require a drug substitution \\nare summarized in Table 6.5. General principles for managing ADRs are outlined  in Figure 6.3. \\nManaging specific ADRs is described in Tables 6.6 to 6.9.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 148}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 10  Table 6.5: Common Significant Adverse Drug Reactions  \\nARV \\nAgent   Adverse Drug Reaction   High Risk Situations/Comments  \\n NRTIs  \\n  ABC  ABC hypersensitivity \\nreaction (see Table 6.9)  Do not re -challenge  \\n \\n \\n \\nAZT  Anaemia, neutropenia  \\n(See Table 6.7)  Risk factors: CD4 count < 200 cells/mm3; BMI < 18.5 (or \\nbody weight < 50 kg); anaemia at baseline; concurrent use \\nof other drugs with similar ADR (cotrimoxazole, \\ngancyclovir, ribavirin)  \\nLactic acidosis  Risk factors: Pregnancy; obesity  \\nLipoatrophy  Risk factors: Low CD4 count  \\nTDF  Renal dysfunction  \\n(See Figure 6.5)  Risk factors: Underlying renal disease; age > 60 years; BMI \\n< 18.5 (or body weight < 50 kg); diabetes; hypertension; \\nconcomitant PI use or nephrotoxic drug  \\nAvoid in patients with CrCl< 50ml/minute unless no \\nsuitable alternative such as required to treat HIV/HBV co -\\ninfection if TAF is not available  \\nTAF  Weight gain  Risk factors: women; concomitant use of INSTIs  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight (Table 4.9)  \\nNNRTIs  \\nAll \\nNNRTIs  Rash  \\n(NVP>>EFV>ETR)  Manage rash as per Table 4.4 \\n \\nEFV  CNS side -effects  Risk factors: Pre -existing psychiatric disorder  \\nGynaecomastia  Switch from EFV to an alternative, and consult if \\ngynecomastia does not improve  \\nNVP  Hepatotoxicity  \\n(See Table 6.8)  N/A.  \\nPIs \\nAll PIs \\nboosted \\nwith  \\nRTV  GI intolerance \\n(LPV/r>DRV/r>ATV/r)  Consult for recommendation on alternative regimen (R -\\nTWG or Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\nDyslipidaemia \\n(LPV/r>DRV/r>ATV/r)  Risk factors: Obesity; sedentary lifestyle; diet high in \\nsaturated fats and cholesterol  \\nATV/r  Hyperbilirubinemia  This only requires drug substitution if cosmetic effect of \\njaundice is likely to interfere with patient adherence  \\nDRV/r  Rash/hypersensitivity  Risk factors: sulfa allergy  \\nINSTIs  \\nAll \\nINSTIs  Weight gain  Risk factors: women; concomitant use of TAF  \\nProvide advice on healthy eating and physical activity to \\nmaintain a healthy weight  \\nRash/hypersensitivity  Consult (Uliza Hotline 0726 460 000, \\nhttps://nhcsc.nascop.org/clinicalform ) \\n DTG   Insomnia   Give in the morning; if no improvement then try giving \\nwith low fat meal or on empty stomach  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 149}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 11  \\nAlternative explanations for toxicity must be excluded before concluding a reaction is secondary to an ARV.\\nConsider other medications and herbal remedies and diseases including opportunistic infections, immune \\nreconstitution inflammatory syndrome (IRIS), or other illnesses\\n2. Evaluate concurrent medications & any concurrent new \\nor pre -existing condition Establish whether adverse \\nevent is due to:  \\n• other drugs or drug -drug interaction\\n• other medical condition\\n• Inter -current illness or IRIS\\nAdverse Drug Reaction \\nidentifiedPresentation due to other \\nmedical condition\\n3.  Determine seriousness of adverse event Manage condition, continue ART\\nLife-threatening  \\n(Grade 4) Severe\\n(Grade 3) Moderate \\n(Grade 2)Mild \\n(Grade 1)\\nImmediately discontinue\\nALL drugs, including ARVs  \\nand manage the medical \\nevent. The patient often \\nrequires hospitalization \\nWhen the patient is stabilised, \\nreintroduce ARVs using a \\nmodified regimen (substitute \\nthe offending drug) *Substitute the offending \\ndrug without \\ndiscontinuing ART *. \\nMonitor the patient \\ncloselyContinue ARVs as long as \\nfeasible,  offer \\nsymptomatic relief if \\nappropriate. If no \\nimprovement consider \\nsingle drug substitution*Continue ARVs, offer \\nsymptomatic relief (if \\nappropriate)\\nPatients identified with ADR, review the patient progress at every clinic visit and \\ndocument their outcomes \\nReport suspected/confirmed adverse drug events by filling the Pharmacovigilance\\nform or online at www.pv.pharmacykenya.org1. Patient/caregiver \\nreports  possible \\nadverse eventHistory or clinical \\nassessment suggest \\nadverse eventLab tests indicate \\npossible problem \\nrelated to ART\\n1. At every clinic  visit the patient on ART should be monitored clinically for toxicities using history \\n(history of symptoms that suggest toxicity) and physical examination (relevant signs). Patients should be asked \\nspecifically about ADR known to be associated with their current ART. laboratory assessment may be \\nused to confirm specific  \\n2.  Evaluate concurrent medications and establish whether the toxicity is attributable to an ARV, or to a non-ARV \\nmedication taken at the same time. Consider  other disease processes concurrent infectious processes or \\n3.  All toxicities should be graded. Manage the adverse event according to \\n* Follow single-drug substitution algorithm (Figu re \\n \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 150}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 12  \\nPatients with specific reason for stopping an ARV  1\\nVL within last 6 months < \\n200 copies/ml\\nNo VL result within last 6 \\nmonths 1\\nVL within last 6 months   \\n200 copies/ml\\nCollect sample for VL\\nVL       copies/ml\\n• Proceed with single drug substitution\\n• Schedule clinical appointment at 2 weeks after regimen change \\nto review adherence, side effects and any other concerns\\n• Repeat VL 3 months after regimen modification followed by \\nroutine viral load monitoring\\n• Do NOT  change the current regimen unless \\nimmediate change required for clinical reasons1\\n• Follow viral load monitoring algorithm (Figure 6.6)\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml \\n1 If an ARV must be changed for clinical reasons (adverse \\ndrug reaction; drug -drug interaction; co -morbidity; etc) \\nbefore viral load results available, Urgently consult Uliza \\nHotline (0726 460 000) or Regional or National TWG\\n \\nFigure 6.4: Managing Single Drug Substitutions for ART  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 151}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 13 \\nAt every clinic visit, assess for risk of kidney disease:\\n•  Age > 60 years\\n•  Concurrent HIV associated diseases (such as TB and other OIs)\\n•  Concurrent diabetes, hypertension, viral hepatitis\\n•  Concomitant use of nephrotoxic drugs (e.g. aminoglycosides, \\namphotericin and boosted PIs)\\n•  Wasting, low BMI\\n•  CD4 count < 200 cells/mm3\\nIf any risk factor present\\nObtain a dip stick urinalysis and serum creatinine and calculate \\ncreatinine clearance (CrCl in ml/min, see Annex 15)1\\n4,5CrCl   29\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 72 \\nhours, monitor CrCl \\nmonthly 2CrCl    90 \\nTDF 300 mg OD: re -\\nassess creatinine and CrCl \\nat 1 month, 3 months and \\nbi-annually thereafter if \\nnormal3CrCl = 50 -89\\nTDF 300 mg OD, monitor \\nmore closely for decline in \\nrenal function (monthly \\nduring the first year, and 3 \\nmonthly thereafter if CrCl \\nremains stable4,5CrCl = 30 -49\\nAVOID: if there is no \\nsuitable alternative; give \\nTDF 300 mg every 48 \\nhours, monitor closely \\nwith monthly CrCl for the \\nfirst year, and 3 monthly \\nthereafter if stable\\n1 DTG may cause a small rise in serum creatinine levels but this does NOT represent a true decline in renal function\\n2 Obtain biannual serum Cr and CrCl in patients at risk of renal disease and a CrCl      ml/min\\n3 Patients with a CrCl      ml/min do not require TDF dose adjustment.\\n4 Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case TAF or TDF should \\nbe used). If HBV  negative and on first line ART, substitute TDF with  ABC, TAF or DTG + 3TC dual therapy. If prior ART \\ntreatment failure or any other scenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000).  \\n5 3TC also requires dose adjustment once CrCl < 50 ml/min\\n* For patients with decreased renal function, assess for other causes of renal impairment and refer to physician for review \\nFigure 6.5: Managing TDF -Associated Kidney Toxicity  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 152}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 14 Table 6.6: ARV, CTX and Fluconazole Adjustments in Renal and Hepatic Impairment1 \\nDrug  CrCl (ml/min)  Haemodialysis  Liver impairment  \\n15 - 50 <15  \\n \\nABC   \\nNo change  Reduce adult dose to 200 mg BD for \\nmoderate to severe liver impairment. \\nAVOID in severe hepatic impairment  \\nAZT  No change  300 mg/day  300 mg/day  Reduce dose by 50% or double \\ninterval of administration in \\nmoderate to severe impairment  \\nTDF2 AVOID unless \\nHBV+2 AVOID unless \\nHBV+2 300 mg every 7 \\ndays  No change  \\nTAF  No change  AVOID unless \\nHBV+2 No dose adjustment - \\nAdminister after \\ndialysis  No change  \\n3TC  150 mg OD  150 mg OD  75 mg OD  No change  \\nLPV  No change  No change, use with caution in \\nmoderate to severe impairment  RTV  \\nATV  \\nDRV  \\nRAL  No change  \\n No change in mild to moderate \\nimpairment. Use with caution in \\nsevere impairment  DTG  \\nEFV  No change  \\n Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nNVP  No change  AVOID  \\nETV  No change  Use with caution in severe liver \\nimpairment  \\nCTX  If CrCl > 30 ml/min then no dose adjustment \\nrequired; if 15 -30 ml/min then use 50% of normal \\nrecommended dose; if CrCl < 15 ml/min then CTX \\nshould be avoided  Use with caution in mild to moderate \\nliver impairment. AVOID in severe \\nimpairment  \\nFluconazole  If CrCl ≤ 50 ml/min then use 50% of normal \\nrecommended dose (no dose adjustment required \\nfor CrCl > 50 ml/min)  Use with caution  \\n1 Patients with evidence of renal or hepatic impairment should have access to regular monitoring of renal \\nand liver function  \\n2 TDF and renal impairment:  \\n● In acute kidney injury (AKI), interrupt TDF administration until the cause of AKI is established and \\ncorrected.  \\n● Avoid the use of TDF in patients with CrCl < 50ml/min unless in HIV/HBV coinfection (in which case \\nTAF or TDF should be used). For patients wit h HBV co -infection, the benefit of TDF or TAF for treating \\nHBV often outweighs the risks of renal impairment, so more severe levels of renal impairment are \\ntolerated. See Table 9.3 for TDF and TAF dose adjustments for patients with HBV/HIV co -infection. \\nThese patients should be managed in consultation with an experienced clinician  \\n● If HBV negative and on first line ART, substitute TDF with ABC, TAF or DTG + 3TC dual therapy, \\nfollowing the single drug substitution algorithm (Figure 6.4). If prior ART treatmen t failure or any other \\nscenario consult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 153}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 15 Table 6.7: Management of AZT -Associated Bone Marrow Suppression  \\nTest  Result  Action  \\n \\nHb (g/dL)  > 8.5 (and decrease \\nfrom pre -AZT \\nbaseline)  Retain AZT, repeat Hb at week 1, 2, 4 and 12 (if accessing \\nfollow -up Hb is difficult then consider substituting to an \\nalternative ARV immediately)  \\n≤ 8.5  Switch from AZT to an alternative ARV  \\n \\nNeutrophils  \\n(x 109/L) 1.0 – 1.5 (and decrease \\nfrom pre -AZT baseline, \\nif available)  If receiving cotrimoxazole consider withholding unless \\nessential. Retain AZT, repeat at week 1, 2, 4 and 12 (if \\naccessing follow -up neutrophils is difficult then \\nconsider s witching to an alternative ARV immediately)  \\n≤ 1.0  Switch from AZT to an alternative ARV  \\nNote:  \\n● Patients with baseline Hb of < 9.5 g/dL should not be initiated on AZT; patients who develop \\nanaemia while on AZT should be managed as per this table  \\n● AZT -associated bone marrow suppression occurs early in the course of treatment, usually within \\n3 months of initiating ART  \\n● All patients with anaemia and/or neutropenia, whether on AZT or not, should be evaluated for \\nother likely causes of anaemia/neutropenia and managed appropriately  \\n \\nTable 6.8: Management of Drug -Related Hepatotoxicity  \\nALT  <2.5 x Upper Limit of Normal (ULN)  2.5 – 5 x ULN  > 5 x ULN  \\nAction  Retain regimen, repeat in 2 weeks  Retain regimen, \\nrepeat in 1 week  Discontinue offending drug/s  \\nConsult senior clinician for \\nnext step  \\nNote: All patients with acute increase in liver enzymes should be evaluated for other likely causes of \\nhepatitis/hepatotoxicity and managed appropriately  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 154}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 16 Table 6.9: Diagnosis and Management of Abacavir Hypersensitivity Reaction  \\nDiagnosis  \\nWithin 3 weeks of initiating an ABC -containing regimen , patient develops any 2 of the following \\nsymptom groups concurrently  \\n• Fever  \\n• Erythematous and/or pruritic rash  \\n• Respiratory symptoms (shortness of breath and/or sore throat and/or cough)  \\n• GI symptoms: nausea and/or vomiting and/or diarrhea  \\n• Extreme fatigue and/or body pain preventing normal activities  \\nAND: there is not a more likely alternative explanation for the symptoms  \\nManagement  \\n• Stop ABC immediately and substitute with an alternative ARV  \\n• Patient must NEVER be re -challenged with ABC – a single dose could result in a fatal \\nhypersensitivity reaction  \\n• Clearly mark file and educate patient about avoiding ABC in future  \\n• Issue an Adverse Event alert card  \\nNote:  \\n• ABC hypersensitivity reaction is rare in our population: always consider other more likely possible \\ndiagnoses  \\n• Symptoms generally get worse within hours after each dose of ABC  \\n \\n \\n6.5.3 Changing ARVs Due to Drug -Drug Interactions  \\nPatients must be asked about other medications (including non -prescription and herbal \\nmedicine) they are taking at every visit. Some common drugs have specific drug -drug interactions \\nthat may require dose adjustment or substitution o f the ARV or the other interacting drugs. \\nCommon medications that interact with specific ARVs include: rifampicin, rifabutin, antacids, \\nmultivitamin/mineral supplements, methadone, several anti -fungal, anti -convulsant, calcium -\\nchannel blockers, some anti -depressants, some statins, and some anti -malarial. Annex 13 \\nprovides common drug -drug interactions and management recommendations. It is \\nrecommended practice to check for interactions whenever a new medicine is started.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 155}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \\nViral load is the test of choice for monitoring response to ART and identifying treatment failure. \\nFirst VL should be performed 3 months after ART initiation for all PLHIV.   \\nTreatment failure should be suspected when a new or recurrent HIV -associ ated condition \\nindicating severe immunodeficiency (WHO stage III or IV condition) develops after at least 6 \\nmonths on ART. Treatment failure should always be confirmed with VL testing.  \\nFrequency of routine VL monitoring for specific populations is:  \\n● Age 0-24 years old: at 3 months after ART initiation and then every 6 months  \\n● Age ≥ 25 years old: at 3 months after ART initiation, then at month 12 and then \\nannually  \\n● Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 \\nmonths after ART initiation (if ART initiated during pregnancy/ breastfeeding), and \\nthen every 6 months until cessation of breastfeeding  \\n● Before making any drug substitution (if no VL results from the prior 6 months)  \\n● Three months after any regimen modification (includin g single -drug substitutions), \\nand then as per population group  \\n● For any patient with a detectable VL follow the viral load monitoring algorithm \\n(Figure 6.6)  \\n \\nInterpreting Viral Load Results and Defining Treatment Failure (Figure 6.6)  \\nThe goal for ART is t o achieve sustained viral suppression defined as below the Lower Detection \\nLimit (LDL), < 50 copies/ml is considered as suppressed.  See Table 5.17  \\nPersistent low -level viremia (PLLV) is defined as having between 200 -999 copies/ml on \\ntwo consecutive measures.  These patients are at increased risk of progression to treatment \\nfailure, development of resistance and death and therefore require a similar case management \\napproach as patients with VL ≥ 1,000 copies/ml, and consultation with the Re gional or National \\nHIV Clinical TWG (Uliza Hotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ).  \\nTreatment failure is suspected when a patient has a high VL ≥ 1,000 copies/ml after at least \\n3 months of using ART.  Treatment failure is only confirmed when VL is ≥ 1,000 copies/ml after \\nassessing for and addressing poor adherence or other reasons for high VL, and then repeating VL \\nafter at least 3 months of enhanced adherence to allow for viral re -suppression.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 156}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 18 \\nSchedule for routine viral load testing1 \\n• Age 0 -24 years old: at month 3, then every 6 months \\n• Age      years old: at month 3, then month 12 and then annually \\n• Pregnant or breastfeeding: at confirmation of pregnancy (if already on ART) or 3 months after ART initiation (if ART initiate d during \\npregnancy/breastfeeding), and then every 6 months until complete cessation of breastfeeding \\n• Before any drug substitution (if no VL result available from the prior 6 months) \\n• Three months after any regimen modification (including single -drug substitutions) \\nVL < 200 copies/ml\\n VL 200 – 999 copies/ml\\n VL         copies/ml\\nIncreased risk of progression to \\ntreatment failure\\nSuspected treatment \\nfailure\\n• Discuss patient in MDT \\n• Assign a case manager \\n• Assess for and address likely causes of non -adherence2 \\n• Provide enhanced adherence support/intervention as appropriate (Section \\n5.4 of guidelines for enhanced adherence protocol) \\n• Assess for other causes of viremia and manage as needed3 \\n• Support daily witnessed ingestion by treatment buddy or healthcare worker\\n• After 3 months of excellent adherence, repeat VL \\nVL < 200 copies/ml (LDL)\\nVL 200 – 999 copies/ml\\nVL         copies/ml\\n• Continue ART regimen\\n• Routine adherence \\ncounselling and monitoring\\n• Routine VL monitoring\\n• Reassess adherence and other \\ncauses of viremia2,3\\n• Repeat VL after another 3 months of \\nexcellent adherence\\nConfirms treatment failure: \\n• Begin treatment preparation for new regimen and \\ncontinue failing regimen until adherence \\npreparation completed \\n• Continue enhanced adherence support \\n• Take sample for CD4 count and assess for and \\nmanage any OIs \\n• If failing a DTG or PI based regimen a DRT is \\nrecommended in consult ation with the  regional or \\nNational HIV Clinical TWG or call Uliza Hotline \\n       (0726 460 000)  \\n• Schedule clinical appointment at 2 weeks after \\nregimen change to review adherence, side effects \\nand any other concerns \\n• Repeat VL 3 months after regimen modification \\nConsult Regional or National HIV \\nClinical TWG or call Uliza Hotline \\n(0726 460 000)\\nVL 200 – 999 copies/ml\\n1. As part of treatment preparation, patients should be informed that \\nviral load is the recommended method of monitoring ART. VL results \\nshould always be discussed with patients, even when they are \\nundetectable. Goals of treatment and definition of success should be \\ndiscussed and adherence messaging reinforced \\n2. Common causes of poor adherence include: stigma, non -disclosure, \\ntravel, toxicities, alcohol or drug use, mental health disorder, religious \\nbeliefs, inadequate treatment preparation, chaotic lifestyle, lack of \\nsupport systems, and poor patient -provider relationship \\n3. Other common causes of treatment failure (beyond adherence) \\ninclude: inadequate dosing/dose adjustments, drug -drug \\ninteractions, drug -food interactions, impaired absorption (e.g. \\nchronic severe diarrhoea)  \\n Figure 6.6: Viral Load Monitoring of Patients on ART (1st Line or 2nd Line)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 157}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 19 Non -adherence is the most frequent cause of treatment failure. As per the viral load \\nmonitoring algorithm, adherence issues must be addressed BEFORE confirming \\ntreatment failure.  \\nDaily witnessed ingestion by a treatment buddy or healthcare worker is recommended to confirm \\nexcellent adherence before repeating the VL. All adherence issues must be resolved before \\nswitching to a new regimen otherwise the patient will quickly fail the n ew regimen as well, and \\nsoon run out of viable ART options. An exception to this may be when the regimen itself is \\nthe primary cause of poor adherence  (e.g., side effects from one of the ARVs are not \\nmanageable such as severe diarrhea with LPV/r that does not improve with symptom \\nmanagement), in which case the regimen may need to be modified to allow for perfect adherence. \\nThis should be done in consultation with the Regional or National HIV Clinical TWG.  \\nChapter 5 provides detailed guidance on adherence pr eparation, assessment, and support.  \\nTable 6.10: Recommended Second -line ART Regimens in Infants, Children, Adolescents and \\nAdults, excluding TB/HIV co -infection 1 \\nWeight/scenario  First -line ART  Second -line ART  \\n \\n< 30 kg  ABC (or AZT) + 3TC + DTG  DRT -based second -line2,3  \\nABC + 3TC + LPV/r  Take sample for DRT and change to AZT + \\n3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nAZT + 3TC + LPV/r  Take sample for DRT and change to ABC \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nABC + 3TC + EFV  AZT + 3TC + DTG  \\nAZT + 3TC + EFV  ABC + 3TC + DTG  \\n \\n≥ 30 kg or ≥ 15 \\nyears old  TDF (or ABC) + 3TC + DTG (or PI/r)  DRT -based second -line2 \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC +  DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nPregnant and \\nBreastfeeding \\nwomen  TDF (or ABC) + 3TC + DTG  Take sample for DRT and change to TDF \\n+ 3TC + ATV/r while awaiting DRT \\nresults; modify based on DRT results if \\nindicated  \\nTDF (or ABC) + 3TC + PI/r  Take sample for DRT and change to TDF \\n+ 3TC + DTG while awaiting DRT results; \\nmodify based on DRT results if indicated  \\nTDF (or ABC) + 3TC + EFV  TDF + 3TC + DTG  \\nAZT + 3TC + EFV  TDF + 3TC + DTG  \\nHIV/HBV Co -\\ninfection  Always maintain TDF in order to treat the HBV as well as HIV  \\nTB/HIV Co -\\ninfection  Refer to Table 8.8: Recommended ART Regimens for Patients who Develop TB \\nwhile Failing  1st Line ART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 158}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 20 Table 6.10 Cont.  \\n1. If any drug in the recommended 2nd line regimen is contraindicated or previously not tolerated, \\nconsult the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ). Such patients may require DRT to select agents for the \\nsecond -line ART. Add itional drugs may be recommended on a case -by-case basis, including DRV/r, \\nATV/r, RAL, or ETR  \\n2. Patients failing DTG -based or PI -based first -line regimens should have a Drug Resistance Test \\n(DRT) ordered as soon as treatment failure is confirmed. The patient  summary and DRT results \\nshould be sent to the Regional or National HIV Clinical TWG \\n(https://nhcsc.nascop.org/clinicalform ) or call Uliza Hotline (0726 460 000) to determine the \\nmost suitable second -line regimen for the patient. The DRT results will be us ed to determine if \\nthere is true DTG or PI failure or if there is an underlying problem with non -adherence. Daily \\nwitnessed ingestion is recommended prior to performing DRT  \\nImportant Considerations for First -line Treatment Failure in Children  \\n● Second -line ART in infants and children is more complex to manage. These children and \\ntheir caregivers should undergo thorough clinical and psychosocial assessment to rule \\nout inter -current illness or non -adherence as the reason for a high viral load  \\n● All c hildren failing first -line should be discussed in the MDT and preferably with an \\nexperienced ART provider prior to change of ART to second -line. However, this should \\nnot cause undue delay in switching a failing regimen  \\n● The choices for infants and children failing an alternative first -line regimen are limited \\nand may need to be discussed with the Regional or National HIV Clinical TWG. Some of \\nthese children will require HIV DRT to determine the most suitable second -line regimen  \\nImportant considerations for s econd -line ART Treatment Failure  \\n● Patients failing second -line ART have limited options. ARVs used to construct a third -line \\nregimen are often more expensive, will have increased pill burden and more side effects. \\nThese factors will exacerbate pre -existing poor adherence  \\n● Second -line treatment failure should be confirmed by viral load testing following the \\nviral load monitoring algorithm (Figure 6.6)  \\no After the first detectable VL ( \\uf065 50 copies/ml), assess for and address all causes of \\npoor adherence, and assess for all other possible causes of viremia.  \\no These patients should be discussed at an MDT session. Repeat the VL after 3 months \\nof excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \\ntreatment buddy, relative, CHV, etc.).  \\no If the second VL is still \\uf065 50 copies/ml then continue the failing second -line regimen \\nwhile reassessing adherence and other causes of viremia, implementing adherence \\nsupport systems as needed, and then repeat the VL after another 3 months.  \\no If viremia continues then consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; https://nhcsc.nascop.org/clinicalform ) using the national \\ncase summary form (Annex 9B). These patients will likely require DRT in order for \\nthe TWG to design the most suitable third -line regimen  \\n● Patients failing second -line ART require thorough assessment for barriers to adherence \\nand ongoing enhanced adherence support including  \\no Assigning a case manager  \\no More frequent adherence counselling by a trained counsellor  \\no Assessment and treatment of mental health and substance use disorders  \\no Provision of adherence support such as modified directly observed therapy, a \\ntreatment supporter, hom e visits etc.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 159}),\n",
       " Document(page_content='  \\nAntiretroviral Therapy in Infants, Children, Adolescents, and Adults  \\n6 - 21 Table 6.11: Possible Third -line ART in Children, Adolescents and Adults  \\n Possible 3rd Line Regimen  Comment  \\n \\nChildren  DTG + 3TC + DRV/r  Third line ART selection is based on DRT \\nresults  \\nNote that the Regional or National \\nHIV Clinical TWG may recommend \\nreusing some of the ARVs the \\npatient has already failed, even \\nwhen resistance is present  DTG + AZT + 3TC + DRV/r  \\nDTG + ABC (or TDF) + 3TC + DRV/r  \\nETV + 3TC + DRV/r  \\nAdults  DTG + 3TC + DRV/r  \\nDTG + AZT + 3TC + DRV/r  \\nDTG + TDF + 3TC + DRV/r  \\nDTG + TDF (or AZT) + 3TC  \\nETV + 3TC + DRV/r  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 160}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 161}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 1  \\n7. Prevention of Mother to Child Transmission of \\nHIV/Syphilis/Hepatitis B  \\nRoutine antenatal care (ANC) offers an important opportunity to provide high quality combined \\nHIV prevention throug h targeted health education and counselling; HIV testing for the woman, \\npartners and family members; linkage to HIV prevention and treatment; and to discuss and plan \\nfor future conception and contraception needs. Prevention of mother -to-child transmission of HIV \\n(PMTCT)/Syphilis/Hepatitis B should be offered as part of a comprehensive package of fully \\nintegrated, routine antenatal care interventions (Table 7.1).  \\nTable 7.1: Essential Package of Antenatal Care  \\nIntervention  Recommendation/Description  \\n \\nGroup & \\nIndividual \\nEducation  Include information on importance of at least 8  ANC visits, details of ANC services \\n(including health checks and treatment of any illness, medical tests including HIV, \\nsyphilis testing and hepatitis B, monitoring of maternal and fetal wellbeing, etc.), \\nnutrition, personal care, recognizing and responding to danger signs during \\npregnancy, birth preparedness including skilled birth attendance, post -natal care \\nincluding immunization, family pla nning and maternal and infant nutrition, HIV \\nprevention and treatment (HTS, preventing new infections during pregnancy \\nincluding PrEP where appropriate, ART for those who are HIV positive, monitoring of \\nART and ARV prophylaxis and follow -up for HEIs) and t riple elimination (preventing \\nHIV/ syphilis/hepatitis B transmission from mother to child).  \\nCounselling  ● Pre-conception – Women in reproductive age who are known to be HIV positive \\nshould have pregnancy intention assessment visit at every visit. If they desire to \\nbecome pregnant, pregnancy should be planned i.e., attain viral load suppression, \\nimmune reconsti tution and have Iron and Folic Acid Supplementation (IFAS) \\nadministered prior to conception.  \\n● Women who are newly diagnosed with HIV and/or newly initiating ART require \\nmore intensive adherence counseling and HIV education, which may include a case \\nmanager  and/or mentor mother  \\n● Birth preparedness: support the pregnant woman and her partner to develop an \\nindividual birth plan that includes place of delivery with skilled attendants, \\nemergency transport, birth companionship and readiness for infant care  \\n● Pregnan cy danger signs: offer information on returning to ANC as soon as possible \\nin case they develop fever, lower abdominal pain, severe headache, swollen feet, \\nconvulsions and per vaginal bleeding.  \\n● Maternal, infant and young child nutrition (MIYCN): All pregn ant women should \\nreceive information on proper nutrition during pregnancy and breastfeeding, safe \\ninfant feeding and optimal nutrition practices. Promote exclusive breastfeeding for \\nthe first 6 months irrespective of HIV status, followed by complementary f eeding \\n(Table 7.7). During pregnancy, provide iron, folate and multivitamins; monitor for \\nanemia, advise on adequate caloric intake (HIV positive women require an \\nadditional 10% of recommended daily allowance (RDA))  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 162}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 2 Table 7.1 Cont.  \\nCounselling  ● HIV testing services  \\no All pregnant women (unless known HIV positive) should be counselled and \\ntested for HIV, syphilis and Hepatitis B during their first ANC visit and if \\nnegative, repeat HIV and syphilis testing in the third trimester.  \\no All pre gnant and breastfeeding mothers with continued HIV risk (Key \\npopulations) should be counseled and tested for HIV every 3 months until post -\\ncessation of breastfeeding.  \\no Pregnant and breastfeeding mothers should be educated and offered a self -test \\nkit for th eir sexual partner(s)  \\no At Labour and delivery, HIV testing should be done for all women with \\nunknown HIV status or that previously tested negative, even if tested during \\nthe third trimester  \\no All breastfeeding mothers (unless known HIV positive) should be co unselled \\nand tested at the 6 -week infant immunization visit. The HIV test (if negative) \\nshould be repeated every 6 months until complete cessation of breastfeeding. \\nNote:  key population mothers (FSWs and PWIDs) get retested every 3 months \\n(Table 2.5)  \\no Women should be counselled about the schedule for repeat HIV testing in \\npregnancy and postnatally as part of routine ANC and postnatal education  \\no All pregnant and breastfeeding women who are not tested, opt -out or decline \\nHIV, Syphilis or Hepatitis testing during the first contact should be offered \\ncounselling and testing in subsequent visits with appropriate linkage and \\nreferral for prevention, care and support services. Daily Witnessed Ingestion \\n(DWI) is advised to support Viral suppression for newly initi ated clients and \\nthose whose regimens are being switched. This is to support viral suppression \\namong women with high viral load.  \\no All HIV positive pregnant and breastfeeding women enrolled into care should \\nreceive counselling and support (including assiste d disclosure), case \\nmanagement linkage and follow -up for comprehensive treatment and \\nprevention (including lifelong ART)  \\no All Syphilis and Hepatitis B positive clients should be given appropriate care as \\ndefined in Table 7.3 “triple elimination”.  \\no All partn ers of pregnant and breastfeeding women should be offered HIV \\ntesting and counselling and all biological children if the mother is HIV positive  \\n● All pregnant and breastfeeding women should receive information on risk \\nreduction, including PrEP where appropri ate \\n● Post -partum contraception: counsel on contraception methods and help patient \\ndevelop a plan for effective contraception from 6 -weeks post -partum to avoid \\nunplanned pregnancies  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 163}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 3 7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding \\nWomen and Infant Prophylaxis  \\nThe goal of ART for HIV positive pregnant women is two -fold: to restore and maintain the \\nmother’s immune function and therefore general health, and secondly, to prevent transmission \\nof HIV in utero, at labour and delivery and during breastfeeding. To achieve this goal, the mother \\nmust take effective antiretroviral therapy to achieve viral suppression.  Table 7.2 summarizes \\nrecommendations for use of ART for HIV positive pregnant women.  \\nTable 7.2: Summary of Use of A RT for HIV Positive Pregnant and Breastfeeding Women  \\nOverall recommendations  \\nWhen to start  ART should be initiated in all pregnant and breastfeeding women living with HIV, \\nregardless of gestation, WHO clinical stage and at any CD4 cell count and continued \\nlifelong. ART should be started, ideally, on same day as HIV diagnosis after \\nreadiness asse ssment with ongoing enhanced adherence support including \\ncommunity -based case management and support.  \\nWhat to start with \\n(first -line ART)  TDF/3TC/DTG  \\nInfant \\nprophylaxis  ● AZT+NVP for 6 weeks, NVP should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nFor more comprehensive information Refer to Table 7.3  \\nMonitoring       Viral load  monitoring during pregnancy and breast -feeding (Figure 6.6)  \\n● Whenever possible, use same -day point -of-care methods for viral load \\ntesting of pregnant and breastfeeding women to expedite the return of \\nresults and clinical decision -making. If this is not available, viral load \\nspecimens and results for pregnant and breastfeeding women should be \\ngiven priority across the laboratory referral process  (including specimen \\ncollection, testing and return of results).  \\n● For pregnant and breastfeeding women newly initiated on ART, obtain VL 3 \\nmonths after initiation, and then every 6 months until complete cessation of \\nbreastfeeding  \\n● For HIV positive women already on ART at the time of confirming pregnancy \\nor breastfeeding, obtain a VL irrespective of when prior VL was done, and \\nthen every 6 months until complete cessation of breastfeeding  \\n● For pregnant or breastfeeding women with a VL ≥ 50 copies/ml: assess for \\nand address potential reasons for viremia, including intensifying adherence \\nsupport, repeat the VL after 3 months of excellent adherence, including \\ndaily witnessed ingestion, where feasible and appropriate  \\no If the repeat VL is 200 - 999 copies/ml consul t the Regional or National \\nHIV Clinical TWG  \\no If the repeat VL is ≥ 1,000 copies/ml, change to an effective regimen. \\nRefer to Table 6.10  \\no If the repeat VL is < 200 copies/ml (LDL) then continue routine \\nmonitoring  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 164}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 4 Table 7.2 Cont.  \\nScenario  \\nPre-conception planning \\nfor women already on \\nART (not yet pregnant)  Maintain ART  \\nCarry out a VL test if not done in the prior six months to confirm viral \\nsuppression (Figure 6.6)  \\nRefer to Table 4.8 for pre -conception care for women on ART who desire \\npregnancy, including laboratory screening, TT immunization, folate, etc.  \\nOn ART at the time of \\nconfirming \\npregnancy/breastfeeding  Maintain ART.  \\nCarry out a VL at first identification of pregnancy, irrespective of when a \\nprior viral load was done, to confirm viral suppression (Figure 6.6)  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis)  \\nNot on ART at the time of \\nconfirming pregnancy  Prepare the patient and start on ART as soon as possible.  \\nART initiation should occur preferably on the same day HIV infection is \\nconfirmed. Perform VL 3 months after ART initiation.  \\nPregnant and breastfeeding women with a history of treatment \\ninterruption returning to care should have reasons for interruption \\nassessed and preferentially re -started on a DTG -containing regimen \\nunless the reason for interruption was DTG intolerance or failure. Viral \\nload monitoring in this case should be done after 3 months of initiation \\nand 6 months thereafter until cessation of breastfeeding . Additional \\nadherence support should be made available.  \\nNot on ART during \\nlabour and delivery  Start on ART during labour.  \\nAfter delivery, continue treatment preparation and adherence support and \\ncontinue ART  \\nManage the baby as HEI (Figure 2.1 for EID, a nd Table 7.3 for infant \\nprophylaxis)  \\nNot on ART during \\npost -\\npartum/breastfeeding  Prepare (readiness assessment) and start on ART as soon as possible \\npreferably on the same day HIV infection is confirmed.  \\nManage the baby as HEI (Figure 2.1 for EID, and Table 7.3 for infant \\nprophylaxis). Adherence support for both mother and infant, con sider \\ndaily witnessed ingestion (DWI) support.  \\nManaging labour and \\ndelivery  Minimize vaginal examinations, use aseptic techniques to conduct delivery, \\navoid artificial rupture of membranes, monitor labour and avoid prolonged \\nlabour by use of the partograph, avoid unnecessary genital tract trauma  \\nNote that certain patient groups e.g., recent HIV infections, pregnant adolescent girls and young \\nwomen, women with previous children with HIV infection, patients with high viral load at time of \\npregnancy  confirmation, patients with poor social support systems, patients with history of \\ndefault from care and those with active co -morbidities etc. may require additional adherence and \\npsychosocial support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 165}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 5 7.2. Syphilis elimination for Pregnant and Breastfeed ing Women and Infant \\nTreatment  \\nThe country has adopted triple elimination of HIV, Syphilis and Hepatitis B among pregnant and \\nbreastfeeding women. It is recommended that all pregnant women attending ANC and not aware \\nof their HIV status require a dual HIV syphilis test during their first trimester and a second HIV \\nSyphilis test in the 3rd trimester if the initial test was negative.   \\nAll women who test positive for syphilis at any point during pregnancy and breastfeeding should \\nbe treated with the appropria te regimen. (Table 7.3). All babies born of mothers who test positive \\nfor syphilis are suspected to be exposed to syphilis and should also be treated with the correct \\nregimen (Table 7.3). Ensure to perform contact tracing for all the sexual contacts and en sure they \\nare treated for syphilis.  \\nSymptoms of congenital syphilis may not become apparent for several weeks or months after \\nbirth.  \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant \\nProphylaxis  \\nRequires routine testing of pregnant women to identify women in need of antiviral treatment for \\ntheir own health and additional interventions to reduce Mother to Child Transmission of viral \\nhepatitis B.  \\nRegular screening should be done by incorporation of viral hepatitis screening as  part of the ANC \\nprofile. This is recommended for Hepatitis B & C which pose a big risk to both the mother and \\nfetus.  \\nFor pregnant and breastfeeding women who are found to be positive for HBsAg, offer appropriate \\ntreatment options of ARVs containing TDF/3TC or FTC containing regimens. This treatment also \\nacts as prophylaxis for HBV transmission from mother to child. All pregnant and breastfeeding \\nwomen without evidence of hepatitis B infection (HBsAg negative) should be vaccinated against \\nhepatitis B. (Chapter 9).  \\nHIV positive infants without evidence of infection should be vaccinated against Hepatitis B.  \\nInfants born of mothers who test positive for HBsAG should be treated using Hepatitis B \\nImmunoglobulin (Table 7.3).  \\nRefer to Chapter 9 f or management of HIV/HBV coinfection.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 166}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)  \\n● Birth testing (Figure 2.2) may be conducted in sites \\nwhere point of care has been implemented and when \\nmedically indicated  If mother not on ART, initiate \\nART as soon as possible \\n(preferably same day)  \\nIf mother is on ART for ≥ 3 \\nmonths and the VL is ≥ 50 \\ncopies/ml, intensify adherence, \\nrepeat the VL  \\n \\nIf VL <50 copies/ml, continue \\ncurrent regimen  \\nFollow Viral load algorithm \\nFigure 6.6  \\nTRIPLE ELIMINATION  \\nCONDITION in \\nmother  INFANT MANAGEMENT  MATERNAL MANAGEMENT  \\nSyphilis -VDRL \\nor diagnosed \\nwith Dual kit  Crystalline Penicillin 50,000 IU/kg BD (if <7 days) or TDS if \\n(>7 days old) for a total of 10 days.  Penicillin G 2.4 MU IM Stat or \\nCeftriaxone 1gm IM daily for 8 -10 \\ndays in case of penicillin allergy.  \\nCongenital \\nsyphilis    \\nHepatitis B – \\nHbsAg test  Hepatitis B immunoglobulin 0.5ml IM within 12 hours after \\nbirth. Hepatitis B vaccine 0.5ml three doses at birth, 1 month \\nand 6 months.  Refer to viral hepatitis \\nmanagement guidelines  \\nNote: If child has contraindication or unable to tolerate NVP or AZT then give the tolerated drug up to complete \\ncessation of breastfeeding. If the infant is on AZT prophylaxis, give up to a minimum of 12 we eks or until maternal viral \\nload is suppressed. In situations where neither AZT nor NVP are tolerated 3TC may be used as a third option if available.  \\nHIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC  \\n● VL >200 copies/ml  \\n● Clients with stigma, declining treatment, poor adherence   \\n● PMTCT client with previous HIV infected infant  \\n● Client with active comorbidities - DM, OIs, malnourished (low MUAC), mental health etc.  \\n● Clients who sero -convert during ANC/PNC follow up  \\n● Poor socio -economic and family support structures   \\n● Those who drop of f ART  \\n● Key population – FSW, PWID  \\nAlcohol use and brewers/sellers  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 167}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 7 Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  \\nAge/Weight  Dosing of NVP (10mg/ml) OD  Dosing of AZT (10mg/ml) BD  \\nBirth to 6 weeks  \\nBirth weight < 2,000 g  2 mg/kg per dose, OD  4 mg/kg per dose, BD  \\nBirth weight 2,000 -2,499 g  10 mg (1 ml), OD  10 mg (1 ml), BD  \\nBirth weight ≥ 2,500 g  15 mg (1.5 ml), OD  15 mg (1.5 ml), BD  \\n> 6 weeks to 12 weeks of age*  \\nAny weight  20 mg (2 ml), OD  60 mg (6 ml), BD  \\n> 12 weeks (Table 7.5 and 7.6)  \\n*Dose adjustment required once child reaches 6 weeks of age  \\nIf older infant beyond 6 weeks of age is newly identified as HIV exposed infant, should be given \\nAZT+NVP for 6 weeks, NVP + cotrimoxazole should be continued until 6 weeks after complete \\ncessation of breastfeeding  \\nTable 7.5: NVP Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nAge  Dosing of NVP (10mg/ml) Once Daily  \\n12 weeks – 6 months  25 mg (2.5 ml), OD  \\n7 months – 9 months  30 mg (3 ml), OD  \\n10 months – 12 months  40 mg (4 ml), OD  \\n> 12 months  Consult the Regional or National HIV Clinical TWG (Uliza \\nHotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  \\nWeight  Dosing of AZT: (10mg/ml syrup) Twice Daily  \\n3.0-5.9 kg  6 ml, BD  \\n6.0-9.9 kg  9 ml, BD  \\n10.0 -13.9 kg  12 ml, BD  \\n14.0 -19.9 kg  15 ml, BD  \\n* If child presents to facility late and has to be on AZT and NVP beyond 12 weeks of age  \\n7.4 Infant and Young Child Nutrition in the Context of HIV  \\n● Exclusive breastfeeding  involves giving the baby only breast milk with no other liquids \\n(including water) or solids for the first six months of life. Giving of vitamins, mineral \\nsupplements or medicines are permitted if prescribed.  \\n● Mixed feeding  is giving other liquids and/or foods together with breast milk to infants \\nunder 6 months of age and is not recommended.  Mixed feeding during thi s period is \\nassociated with significantly higher risk of mother -to-child HIV transmission, diarrhoeal \\nand respiratory tract illnesses, among other consequences and should be prevented  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 168}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 8 ● All infants irrespective of HIV status should be exclusively breastfed f or the first 6 months \\nof life, with timely introduction of appropriate complementary foods after 6 months, and \\ncontinued breastfeeding up to 24 months or beyond.  \\n● Should mothers be physically separated from their infants (back to work), support them \\nto sust ain lactation and to exclusively breastfeed including mentorship on expressing \\nbreast milk (refer to current MIYCN Policy)  \\n● All mothers, irrespective of HIV status, should be encouraged and supported to \\nexclusively breastfeed for the first six months and co ntinue breastfeeding with \\nappropriate complementary feeding after 6 months, for a period of 24 months or beyond. \\nBreastfeeding should ONLY stop once a nutritionally adequate and safe diet without \\nbreast milk can be sustained.  \\n● HIV positive mothers and HIV p ositive infants should always be on ART and given extra \\nattention for adherence support, VL monitoring and optimal retention in care  \\n● Breastfeeding mothers who do not know their HIV status or who previously tested HIV \\nnegative should be encouraged to be ret ested for HIV at the 6 -week immunization visit, \\nand then every 6 months thereafter until complete cessation of breastfeeding (Table 2.5)  \\n● Access for HIV testing and STI/HIV prevention interventions should be reinforced for \\npartners of pregnant and breastfee ding women  \\n● Mothers who are diagnosed with HIV while breastfeeding should immediately start \\nappropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \\nretention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \\ntesting (Table 7.3).  \\n● Mothers who decide to stop breastfeeding at any time should stop gradually within one \\nmonth (and only when a nutritionally adequate and safe diet without breast milk can be \\nsustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \\nContinued breastfeeding is recommended for HIV positive infants for as long as the \\nmother is willing and able to do so.  \\n● In special medical circumstances, determined by clinicians, where an infant cannot \\nbreastfeed, refe r to current MIYCN Policy and Breast Milk Substitute (BMS) Regulation \\nand Control Act, 2012.  \\n● Complimentary feeding means giving other foods to complement breast milk after six \\nmonths of exclusive breastfeeding. Complimentary feeds provide additional nutrit ional \\nvalue to meet the child’s increasing nutritional needs for growth (Table 7.7). \\nFurthermore, complementary feeding helps the child to gradually become accustomed \\nto eating family foods while breastfeeding continues to be an important source of \\nnutrien ts. It is worth noting that breastfeeding continues to have child growth/survival \\nbenefits for up to two years or longer. Emphasis should be made on consuming all the \\nseven (7) food groups for children in various meals.  \\no Cereal/tubers and roots  \\no Beans, pulses and nuts  \\no Dairy and dairy products  \\no Eggs and Flesh (meat/poultry/insects/organ meat)  \\no Vitamin A rich food (orange/yellow fruits) and green vegetables  \\no Fats and high sugar foods  \\n● Other fruits and vegetables    ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 169}),\n",
       " Document(page_content='  \\nPrevention of Mother to Child Transmission of HIV/Syphilis/Hepatitis B  \\n  7 - 9 Table 7.7: Complementary Foods for Children 6 -24 Months Old  \\nFoods to Offer  \\nAge  Texture  Frequency  Amount of food per meal  \\n6 \\nmonths  Start with thick porridge or \\nwell mashed foods  \\n 2 times per day  2 tablespoons each feed, \\nincreasing to 3 tablespoons \\nin the 3rd to 4th week  \\n7-8 \\nmonths  Mashed/pureed family foods  \\nBy 8 months can begin \\nfinger foods  3 meals per day, plus \\nfrequent breastfeeds  \\n Increase amount gradually \\nto ½ of a 250 ml cup  \\nUse a separate plate/bowl  \\n9-11 \\nmonths  Finely chopped or mashed \\nfoods, and foods that baby \\ncan pick up  3 meals and 1 snack, \\nplus frequent \\nbreastfeeds  ¾ of a 250 ml cup/bowl  \\nUse a separate plate/bowl  \\n12-23 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds  One 250ml cup/bowl  \\nUse a separate plate/bowl  \\n24-59 \\nmonths  Cut food into small, soft \\npieces that child can pick up, \\nchew and swallow \\ncomfortably  3 meals and 2 snacks, \\nplus breastfeeds if still \\nbreastfeeding  1 ½ - 2 cups of 250ml \\ncup/bowl  \\nUse a separate plate/bowl  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 170}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 10  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 171}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n8 - 1 \\n  \\n8. TB/HIV Co -infection, Prevention and \\nManagement  \\n \\nTB is a leading cause of morbidity and mortality among people living with HIV. Reducing this \\nburden of illness requires identifying TB early, providing pre -emptive and preventive  treatment \\nfor TB, and providing optimal treatment for both HIV and TB. Timely initiation of ART in \\ncombination with TB Preventive Therapy are effective ways to reduce the burden of TB in PLHIV.  \\nAll PLHIV should receive counselling about the risk of acquir ing TB, strategies for reducing \\nexposure to TB, recognizing clinical manifestations of TB and seeking care promptly, the risk of \\ntransmission of TB to others and TB preventive therapy to prevent TB disease.  \\nHealthcare settings present suitable conditions f or transmission of TB, particularly among \\nvulnerable individuals like PLHIV. All healthcare settings should develop and implement TB \\ninfection control guidelines to reduce the risk of transmission of TB between patients, visitors \\nand staff.  \\n8.1 TB Screenin g for PLHIV: Intensified Case Finding (ICF)  \\nTB screening and prevention services should be offered at every clinical visit. Symptom -based \\nTB screening using the ICF tool MUST be performed at every clinic visit to rule out active TB; \\npatients who screen pos itive (presumptive TB cases) must complete definitive diagnostic \\npathways (Figure 8.1 and Table 8.1) and patients who screen negative should be evaluated for \\nTB preventive therapy (TPT).  \\nActive Case Finding (ACF) differs from ICF. ICF refers to TB screenin g among PLHIV, whereas \\nActive TB case finding (ACF) refers to special efforts made by the NTP or other partners that go \\nbeyond passive TB case finding at health facilities, in which communities or population groups \\nthat are underserved or at higher risk of  TB are actively reached for providing access to care, \\nincluding screening and testing   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 172}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 2      Intensified Case Finding Screening Questions       \\n●  If “Yes” to any question, take a detailed history, examine the patient and do sputum examination \\n(sputum smear or GeneXpert)  \\n● If “No” to questions 1 -5 above, consider TPT eligibility and work up for TB Preventive Therapy and \\nrepeat screening on subsequent visits  \\n● Questions 5 and 6 do not apply to adults  \\nThe following are the intensified case finding screening questions:  \\n● Cough of any duration (Y/N)  \\n● Fever (Y/N)  \\n● Noticeable weight loss/ Failure to thrive/ Poor weight gain (Y/N)  \\n● Night sweats (Y/N)  \\n● Reduced playfulness/ Lethargy/ Irritability (Y/N)  \\n● Contact with a TB case (Y/ N)  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 173}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 3 \\n \\nIf yes, to any of the signs and symptoms above the patient requires a clinical review If no to all the signs and symptoms above\\nTake a comprehensive history and thorough examination. Decide on classification as a presumptive TB case\\nIs the client/patient a presumptive TB case?\\nIs a sample available for TB testing? • Evaluate and manage for other conditions\\n• Consider TB preventive therapy (TPT) as per LTBI guidelines\\nIs the GeneXpert available on site?\\n• Consider a CXR3\\n• Consider clinical \\ndiagnosis of TB\\nIs smear microscopy available on site?\\n• Obtain a sample1 for GeneXpert\\n• TB LAM should be considered for \\neligible PLHIV2\\no Positive TB LAM test – initiate \\nDS TB treatment. Review once \\nGeneXpert results received\\no NB: A negative TB LAM test \\ndoes not rule out TB• If yes, collect 2 samples; one for smear microscopy and an additional sample for \\nGeneXpert\\n• If smear microscopy is positive, start DS TB treatment and review the patient once \\nGeneXpert results as received\\n• TB LAM should be considered for eligible PLHIV2\\no Positive TB LAM test – initiate DS TB treatment. Evaluate once GeneXpert results \\nreceived\\no NB: A negative TB LAM test does not rule out TB• If not available, collect and refer sample for \\nGeneXpert\\n• TB LAM should be considered for eligible PLHIV2\\n• Positive TB LAM test – initiate DS TB treatment. \\nEvaluate once GeneXpert results received\\n• NB: A negative TB LAM test does not rule out TB\\nGene Xpert ResultsDoes the client have any of the following symptoms?\\n4. Unintended weight loss\\n5. Chest Pain\\n6. BMI less than 18.5 or Z score   -21. Cough of any duration\\n2. Hotness of Body\\n3. Drenching night sweats\\nYES NOYES NOYES NOYES NOYES NOis the initial  test  for TB a has no smear  \\nSHOULD  BE USED  as sample  is & for \\nTB LAM  should  be used  among  PLHIV  as per TB LAM  SHOULD  be used  as an to  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 174}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n8 - 4 \\nMTB Detected\\nRifampicin Resistance Detected \\n(RR)MTB Detected\\nRifampicin Resistance not \\nDetected (TR)MTB not Detected \\n(N)MTB Detected 1\\nRifampicin Resistance \\ninditerminate (TI)MTB \\nDetected \\nTrace4Invalid/\\nError\\n1. Collect another \\nsample and repeat \\nGeneXpert test.\\n2. Treat as per the \\nrepeat results1. Collect a sample for FL & SL LPA, \\nculture and 1st and 2nd line DST\\n2. Conduct baseline work up on DR \\nTB treatment\\n3. Comprehensive review by a DR \\nTB clinical review team.\\n4. Start DR TB treatment as per the \\nguidelines.Patients at high risk of DR TB \\ngroups\\n1. Collect a sample of FL & SL \\nLPA, culture and 1st and 2nd \\nLine DST\\n2. Start DS TB treatment while \\nawaiting DST results.Patients at low  \\nrisk of DR TB \\ngroups\\n1. Start DS TB \\ntreatments.• If already on TB treatment (smear \\npositive, TB LAM positive), continue until \\nother diagnostic test results received and \\nreviewed even if MTB Not Detected\\n• NTM is likely if smear microscopy was \\npositive, and MTB not detected on \\nGeneXpert\\n- Send a sample for culture for definitive \\ndiagnosis of NTM\\n- Continue with TB treatment until \\nculture results received and reviewed\\n• Evaluate for other respiratory illnesses \\ne.g. asthma, pneumonias, COPD, \\nbronchiectasis and cancer as other \\npossible conditions\\n• Obtain a CXR and review with CXR3 report \\nand treat for TB as applicable\\n• Consider EPTB\\n• Refer for further evaluation when a \\ndefinitive diagnosis is yet to be found\\n• Consider repeat GeneXpert1. Treat as DS TB\\n2. Immediately \\ncollect another \\nsample and \\nrepeat GeneXpert \\n(Ultra) test\\n3. Collect a sample \\nfor FL & SL LPA, \\nculture and 1st \\nand 2nd line DST\\n4. Revise regimen \\nbased on DST \\nresults.Based on DST results, DR \\nTB clinical team to adjust \\nregimen as necessary.Revised treatment based on DST \\nresults Follow up as per guidelines\\n• Follow up as per DR TB treatment \\nguidelines\\n• Mandatory clinical review meetings \\nfor Patients\\n• Monthly smears and cultures are \\nmandatory during the treatment \\nduration.Follow up:\\n1. Clinical improvement assessment\\n2. Smear microscopy at months 2/3,5,6\\n3. If drug resistance is detected, treat \\nfor DR TB as per guidelines.DR TB DS TBGene Xpert Results \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 175}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 5 \\n \\nFootnotes\\n1 Samples for GeneXpert, sputum, CSF, Pleural aspirate, \\nPeriloneal fluid, synovial fluid, Gastric Aspirate, \\nNasopharyngeal aspirate, FNA, Lymph node biopsy, Pus, \\nstool\\n2 Indications for use of TB -LAM, as an adjunct test to \\nGeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or \\nCD4 count  200 cells/mm3 (or 25% for children \\n 5years old) with presumed TB\\n• PLHIV that have any danger signs of severe illness: \\nrespiratory rate ˃30breaths per minute, \\ntemperature ˃39°C, heart rate˃120beats per minute, \\nunable to walk unaided\\n• Currently admitted to hospital\\n3 All CHEST X -rays should be reported and the reports \\nreviewed by the clinician for definitive management. \\nRefer to the CXR algorithm for TB diagnosis\\n4 MTB detected Trace – Results from sample with few \\nbacilli (paucibacillary TB).  Rifampicin resistance status.\\nHIV Testing, using the HTS algorithm 1, is \\nrecommended during TB screening and diagnosis.\\nScreening for diabetes is recommended among all \\nadult patients with TB disease\\nKey\\nCBR - Chest X -ray\\nDR TB - Drug Resistant TB\\nDS TB - Drug Susceptible TB\\nDST - Drug Susceptibility \\nTesting\\nEPTB   - Extra Pulmonary TB\\nFL - First LineLPA Line Probe Assay\\nMTB Mycobacteria \\nTuberculosis\\nNTM Non -Tuberculous \\nMycobacteria\\nTST Tuberculin Skin test\\nSL Second lineDR TB risk classification among \\npatients\\nHigh risk for DR TB*\\n1. All previously treated TB \\npatients: treatment failures, \\nrelapses, treatment after loss to \\nfollow up\\n2. Contacts  of Drug Resistant TB \\npatients\\n3. TB patients with a positive \\nsmear result at month 2 or \\nmonth 5 of TB treatment\\n4. Patient who develops TB \\nsymptoms while on IPT or has \\nhad previous IPT exposure\\n5. Healthcare workers with 18 \\nsymptoms\\n6. Prisoners with TB symptoms\\n7. Refugees with TB symptoms\\nLow risk for DR TB\\nAll presumptive TB cases who are \\nNOT  in the high risk group\\n*ALL the high risk patients MUST  \\nbe prioritized to receive DST, \\nGeneXpert, FL and SL LPA, \\nculture and FL and SL DST.DS TB follow up and DR TB surveillance\\nPOSITIVE SMEAR \\nRESULT ATAction\\nMonth 2/3 • Evaluate for adherence, and other causes of delayed conversion\\n• Request for all the following drug susceptibility tests (DST); GeneXpert, FL, LPA and \\nSL, LPA, Culture and FL and SL DST\\n• Continue with RHZE for one more month, or longer if DST results not received by then\\n• Adjust treatment regimen based on DST results\\n• Repeat smear microscopy at end of month 3. If smear positive continue with RHZE and \\nreview DST results and inform the SCTLC immediately\\n• Do not proceed to the continuation phase (RH) without a DST result confirming \\nsusceptibility to RH (rifampicin and isoniazid)\\nMonth 5 or \\nMonth 6• Declare treatment failure and stop anti -TB treatment\\n• Review by the sub county and county TB clinical review teams\\n• Evaluate for adherence, other causes of delayed conversion and treatment failure\\n• Request for GeneXpert, FL LPA and SL LPA, culture and FL and SL DST\\n• Review DST results and re -initiate treatment based on DST results and other clinical \\nfindings\\nDS TB follow up and DR TB surveillance\\nSmear Positive or \\nculture positive \\nat months 3 or \\nlater• Evaluate for adherence, and  other causes of delay conversion\\n• Request for the following drug susceptibility tests (DSTI) (GeneXpert, Culture and \\nFirst Line (FL) and SL DST, FL LPA and SL LPA) depending on the initial resistance \\npattern\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\no Declare failure if at the end of the extended intensive phase  (refer to DR TB \\nguidelines)\\no Send a case summary to the national clinical team after review by the county clinical \\nteam\\n• Do not proceed to the continuation phase (depending on treatment regimen) without a \\nDST result\\n• Declare treatment failure\\no Review by the sub county and county clinical review teams\\n▪ Evaluate for adherence, other causes of reversion and treatment failure\\n▪ Review the DST results\\n• Send a case summary to the national clinical team after review by the county clinical \\nteamMOH/DNTLDP/TBSDXALG/01\\nSeptember 2020Smear Positive \\nsmears and/or \\ncultures during \\ncontinuation \\nphase \\nFigure 8.1: TB diagnosis - GeneXpert Ultra algorithm', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 176}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 6 Table 8.1: TB Diagnosis in Children <10 Years Old  \\nALGORITHM FOR PULMONARY TB DIAGNOSIS IN CHILDREN  \\nHistory of \\npresenting \\nillness  For all children presenting to a health facility ask for the following suggestive \\nsymptoms  \\n● Cough  \\n● Fever  \\n● Poor weight gain  \\n● Lethargy or reduced playfulness  \\nSuspect TB if the child has two or more of these suggestive symptoms  \\nAsk for history of contact with adult/adolescent with chronic cough or TB within the \\nlast 2 years  \\nClinical \\nevaluation  Examine the child and check for:  \\n● Temperature > 37.5o (fever)  \\n● Weight (to confirm poor weight gain, weight loss) – check growth monitoring \\ncurve)  \\n● Respiratory rate (fast breathing)  \\n● Respiratory system examination – any abnormal findings  \\nExamine other systems for abnormal signs suggestive of extra -pulmonary TB#  \\nInvesti gation\\ns Obtain specimen’ for Xpert MTB/RIF (and culture when indicated**)  \\nDo a chest Xray (where available)  \\nDo a Mantoux test** (where available)  \\nDo a HIV test  \\nDo other tests to diagnose extra -pulmonary TB where suspected#  \\nDiagnosis  Bacteriologically  \\nConfirmed TB:  \\nDiagnosis if \\nspecimen is \\npositive for MTB  Clinical Diagnosis of PTB:  \\nChild has two or more of the following suggestive symptoms  \\n● Persistent cough, fever, poor weight gain, lethargy  \\nPLUS, two or more of the following:  \\n● Positive contact, abnormal respiratory signs, abnormal, \\npositive Mantoux  \\nNote: If the child has clinical signs suggestive of EPTB, refer to \\nEPTB diagnostic table*  \\nTreatment  Treat for TB as follows:  \\n● All children with bacteriologically confirmed TB \\n● All children with a clinical diagnosis of TB  \\nNB: In children who do not have an Xpert result, or their Xpert results is negative, but \\nthey have clinical signs and symptoms suggestive of TB they should be treated for TB  \\nAll forms of TB (Except TB meningitis, bone and joint TB) Treat for 6 months (2 RH ZE/ \\n4 RH)  \\nTB meningitis, bone and joint TB: Treat for 12 months ( 2 RHZE/ 10 RH)  \\n*Specimen may include: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal \\naspirate and gastric aspirate. Attempt to obtain specimen in every child  \\n**Do a cultu re and DST for the following children:  \\n1. Rifampicin resistance detected by the Xpert test  \\n2. Refugees and children in contact with anyone who has Drug Resistant TB  \\n3. Those not responding to TB treatment  \\n4. Those with indeterminate Xpert results  \\n***This may include IGRA in facilities where it is available  \\n#Use IMCI guidelines to classify severity of disease   \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 177}),\n",
       " Document(page_content=' \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 7 \\n Table 8.2: Drug Susceptible TB Treatment Regimen for Children, Adolescents and Adults  \\nTB disease category  Recommended regimen  \\nIntensive phase        Continuation phase  \\nAll forms of TB except TB meningitis, bone \\nand joint TB (osteoarticular TB)  2 RHZE  4 RH  \\nTB meningitis   \\nOsteoarticular TB  2 RHZE  10 RH  \\nDrug resistant TB  Refer to a DRTB Clinical Team  \\n● Follow up smears should be done for all bacteriologically confirmed pulmonary TB cases at end of \\nmonth 2, 5 and 6 of TB treatment using smear microscopy  \\n● Follow up of RR TB and DR TB should be done as per PMDT guidelines  \\n● Patients taking isoniazid containing regimen should also be given Pyridoxine (Vitamin B6) daily for \\nthe duration of treatment to reduce the risk of developing peripheral neuropathy (see Annex 10 for \\npyridoxine dosing)  \\nOnce TB treatment is started it should be completed; unless another definitive diagnosis (like lung \\ncancer) is established and TB is ruled out.  \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 178}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 8  \\nTB-LAM is a rapid point -of-care urine dip -stick test that can be performed at the bedside. LAM stands for \\nlipoarabinomannan, which  can be detected in urine when it sheds off of the TB  cell wall . \\nGeneXpert is the recommended initial diagnostic test for people with presumptive TB.\\nTB-LAM SHOULD NOT be used as an alternative test to GeneXpert, but can be performed  to help diagnose TB while \\nwaiting for GeneXpert test results. TB -LAM cannot detect resistance to rifampicin.\\nIndications for use of TB -LAM, as an adjunct test to GeneXpert:\\n• PLHIV with advanced disease (WHO stage 3 or 4 or CD4 count       cells/mm3 (or       for children     \\nyears old)) with presumed TB \\n• PLHIV that have any danger signs of severe illness: respiratory rate >30 breaths per minute, temperature >39°C, \\nheart rate >120 beats per minute, unable to walk unaided\\n• Currently admitted to hospital \\nLF-LAM Negative LF-LAM Positive\\nTB is not ruled out \\n• Evaluate the clinical response after 3–5 days of \\nantibiotic treatment, while awaiting GeneXpert \\nresultsTB is likely\\n• Initiate TB treatment\\n• Conduct additional investigations for TB \\nand other HIV related diseases as \\nappropriate\\n• Continue TB treatment even if GeneXpert \\nresults come back negative\\nClinical improvementClinical worsening or no \\nimprovement\\nTB is unlikely\\n• Conduct additional investigations for TB and \\nother opportunistic illnesses\\n• Complete the course of parenteral antibiotics\\nNote: \\n• If GeneXpert results are positive for TB, \\ninitiate TB treatment irrespective of TB -LAM \\nresults or clinical improvement \\n• If GeneXpert results are negative for TB, \\nconsider TPTTB is likely\\n• Start TB treatment if patient is seriously \\nill or if GeneXpert results come back \\npositive (irrespective of TB -LAM results)\\n• Conduct additional investigations for TB \\nand other HIV -related diseases\\n• Complete the course of parenteral \\nantibiotics\\n \\nFigure 8.2: Use of TB-LAM for Diagnosis of TB among PLHIV  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 179}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 9 8.2. TB Preventive Therapy (TPT)  \\nThis section summarizes the current national recommendations for treatment of latent TB \\ninfections (LTBI) in the PLHIV population. These are in line with the updated World Health \\nOrganization guidelines which include the use of shorter, safer LTBI treatment options for an \\nexpanded at -risk population. For further guidance, refer to the national guidelines on LTBI \\nmanagement.  \\n8.2.1. Indications for TPT  \\nTPT should be provided to those p atients in whom TB is excluded (using the ICF tool) and meet \\nthe eligibility criteria to initiate TPT. The following client categories are eligible for TPT who \\nscreen negative for active TB  \\n● All PLHIV above 12 months of age (children, adolescents and adults  including pregnant \\nand breastfeeding women)  \\n● All household contacts of persons with bacteriologically confirmed pulmonary TB            \\n● Prisoners and staff working in prison setting            \\n● Health care workers and other staff in health care setting  \\n● Other clinical risk groups as defined in LTBI guidelines  \\n*Neonates born to mothers with TB, or exposed to close contacts with TB should be given TPT \\nonce TB disease has been ruled out. BCG should be given 2 weeks after completion of TPT or anti -\\nTB treatment  \\nSummary of recommendations for TPT among the PLHIV  \\n● PLHIV are at a much higher risk of getting TB disease compared to the general population  \\n● TB preventive therapy should be given to all PLHIV above 12 months of age who do not \\nhave active TB disease. This should be done irrespective of immune status, ART status, \\nprevious history of TB and pregnancy status.  \\n● Children aged <12 months living with HIV who are household contacts of a person with \\nbacteriologically confirmed pulmonary TB, and whom act ive TB has been ruled out \\nshould receive TB preventive therapy.  \\n● TPT may be given immediately following successful completion of TB treatment among \\nthe PLHIV.  \\n● Repeat TPT is not recommended among PLHIV except if a PLHIV becomes a \\nhousehold contact of a perso n with bacteriologically confirmed pulmonary TB  \\n● PLHIV aged 15 years and above should be provided with 3 months of weekly Rifapentine \\nand Isoniazid (3HP), while those less than 15 years are given 6 months of daily INH (6H)  \\n● In PLHIV on PI/r -based ART, pregna nt women and those who do not tolerate 3HP should \\nbe given six months of daily INH (6H)  \\n● For eligible patients previously treated for TB, initiate TPT upon completion of their TB \\ntreatment.  \\n      \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 180}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 10 8.2.2. Contraindications to TPT  \\nPatients with the following should not receive TPT until the underlying issue(s) are \\naddressed  \\n● Active tuberculosis disease  \\n● Active hepatitis (acute or chronic)  \\n● Chronic alcohol abuse      \\n● Symptoms of peripheral neuropathy  \\n \\n8.2.3. Dose and Duration of TPT  \\nTable 8.3: Recommended TPT Regimens for PLHIV  \\nTarget populations  TPT Regimen  \\n● Adult PLHIV excluding patients \\non PI/r -based ARV regimens  Rifapentine and Isoniazid (3HP)  \\nOnce weekly for three months  \\n          (12 doses)  \\n● Adult PLHIV on PI/r -based ARV \\nregimens  \\n● All CALHIV aged below 15 years  \\n● Any patient with intolerance or \\ncontraindication to 3HP  \\n● Pregnant women  Isoniazid (6H)  \\nOnce daily for 6 months  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug - drug interactions  \\n● All TPT regimens should be given with Vitamin B6 (pyridoxine), if available, to \\nreduce the risk of developing peripheral neuropathy  \\n● Comprehensive health  education and adherence counselling should be \\nconducted prior to initiation of TPT  \\n● Dosing of TPT is in Annex 10  \\n \\n● Children should be weighed at each visit and correct weight -based dosing confirmed.  \\n● Clients on 3HP should receive weekly dose of pyridoxine, Those on Rifapentine and \\nIsoniazid regimen should be given pyridoxine once a week  \\n● The 3RH (rifampicin and isoniazid) regimen is not recommended for PLHIV due \\nto drug -drug interactions. 3RH is used in HIV negative populations   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 181}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 11 8.2.4. Follow -up of Patients on TPT  \\nPatients on TPT should be followed up on a monthly basis and their return -to-clinic dates \\nharmonized with any other routine schedules. During each clinic visit, conduct the following;  \\n● Symptom screening for active TB disease and update status  \\n● Assess and reinforce adherence to treatment  \\n● If a patient screens positive for TB while on TPT, stop TPT and manage according to \\nNational TB guidelines  \\n● Assess for any adverse drug reactions at each visit and intervene appropriately  \\n● Provide/update TPT appointment card  \\n● Document and update the relevant recording and reporting tools, e.g., ICF/TPT cards, \\nContact Management/TPT register  \\n● Document outcome of TPT use e.g., completion in the relevant tools and/or EMR  \\n*Baseline liver function tests are not mandatory for patients initiating TPT. These may, however, be \\nconsidered on an individual ba sis, especially for patients taking other medications for chronic \\nmedical conditions or symptomatic patients suspected to have active hepatitis  \\n \\n8.3. Identifying and Managing Drug Toxicities from TPT  \\nThe management of drug toxicities should be based on severity, with appropriate grading of \\nindividual patients. The most common adverse drug reactions associated with TPT are peripheral \\nneuropathy, drug -induced liver injury (DILI), and rash.  \\n8.3.1 Periphe ral Neuropathy - Suspected drug: INH        \\nDiagnosis of Peripheral Neuropathy  \\n● Symptoms include: burning sensation, numbness, or tingling, usually starting at the feet \\non both sides  \\n● May have decreased sensation on examination  \\n● May develop weakness in severe cases  \\n● May be potentiated by other neurotoxic drugs, alcoholism, metabolic disease (e.g., \\ndiabetes), malnutrition and infections  \\n● Rarely severe enough to require drug withdrawal  \\nManagement of INH -induced Peripheral Neuropathy  \\n● Increase the dose of pyridoxine to 100 mg per day  \\n● For children give double the standard weight -based dose  \\n● Assess for other causes of peripheral neuropathy (e.g., diabetes, thyroid disorder, B12 \\ndeficiency, syphilis, etc.)  \\n● Relief of symptoms can be achieved with analgesics, tricyclic antidepressants \\n(amitriptyline, nortriptyline), anticonvulsants (carbamazepine, phenytoin)  \\n● If symptoms do not improve, or there is any worsening, then discontinue TPT; symptoms \\nmay persist even  after discontinuing TPT  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 182}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 12 8.3.2 Drug -Induced Liver Injury (DILI) -Suspected drugs include Isoniazid (H), \\nRifapentine (P), Rifampicin (R)  \\n● Elevation of liver enzymes may occur in the first weeks of treatment  \\n● In asymptomatic patients, serum liver enzyme lev els do not need to be monitored \\nroutinely   \\n● All clients with gastrointestinal symptoms (nausea and vomiting, liver tenderness, \\nhepatomegaly or jaundice) should have their liver function assessed  \\n● Patients should be screened for other causes of liver injury  (the hepatitis viruses -A, B, C)  \\n● Table 8.4 shows the grading of liver injury and management of DILI  \\n● Once the drugs are discontinued, no attempt should be made to reintroduce these drugs \\nuntil liver functions have normalized  \\n● An expert with experience in managing DILI should be involved in the further \\nmanagement of such cases  \\nDiagnosis of DILI  \\n● Jaundice, a bdominal pain, nausea, vomiting, anorexia, etc.  \\n● Abnormal liver enzymes  \\n \\nTable 8.4: Grading and Management of DILI  \\n Grade 1: Mild  Grade 2: Moderate  Grade 3: Severe  Grade 4: Life \\nthreatening  \\nALT (SGPT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\nAST (SGOT)  1.25 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10.0 x ULN  > 10.0 x ULN  \\n  \\n  \\n  \\nACTION  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Continue treatment \\nregimen;  \\npatients should have \\nweekly followed up \\nuntil resolution \\n(return to baseline) \\nor stabilization of \\nAST/ALT elevation  Stop all drugs, \\nincluding TPT \\ndrugs;  \\nmeasure LFTs \\nweekly;  \\nTPT should not  \\nbe reintroduced \\nafter severe DILI1 Stop all drugs, \\nincluding TPT drugs;  \\nmeasure LFTs weekly. \\nTPT should not  be \\nreintroduced after life \\nthreatening DILI1 \\n \\n \\n1. PLHIV who develop DILI during treatment of active TB disease, may have anti -TBs reintroduced \\nafter toxicity is resolved in consultation with a senior clinician  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 183}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 13 8.3.3 Management of TPT -associated Rash - Suspected Drugs include Isoniazid (H), \\nRifapentin e (P), Rifampicin (R)  \\n● A rash may occasionally develop, usually within a few days following initiation of TPT. It \\nis often a relatively mild maculopapular rash with or without pruritus.  \\n● Flu-like and other systemic hypersensitivity reactions are rare amongst children. \\nHypersensitivity reactions in adults are usually mild and self -limiting  \\n● Rarely, rash may develop with severe exfoliation of the skin and Stevens -Johnson \\nsyndrome  \\n● Rash severity should be assessed and managed appropriately as shown in table  8.5  \\n \\nTable 8.5: Management of TPT -Associated Skin Rash  \\nSeverity  Characteristics  Action  \\nMild  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n< 50% of body surface area  Continue TPT; close monitoring; symptomatic \\ntreatment with antihistamines +/ - topical steroids \\n(NOT oral steroids)  \\nModerate  Dry; erythema +/ - fine \\npapules; pruritus; affecting \\n≥ 50% of body surface area  Stop TPT; symptomatic treatment with \\nantihistamines +/ - topical steroids (NOT oral \\nsteroids); trial of desensitization after symptoms \\ncompletely resolved  \\nSevere  Mucosal involvement;  \\nblistering; associated \\nfever; any % of body \\nsurface area  Stop TPT; admission to hospital for supportive \\nmanagement (IV fluids, wound care, pain control, \\ninfection control, monitoring for super -infection); \\npatient should NEVER be re -challenged;  \\ndocument and report adverse event and issue \\npatient alert card  \\n \\n8.4. ART for TB/HIV Co -infection  \\nAs with all PLHIV, those who are diagnosed with TB/HIV co -infection should be on ART and CPT \\nas part of the comprehensive package of care for PLHIV.  \\nTiming of ART for TB/HIV Co -infection  \\n● Patients who are not yet on ART  \\no Start TB treatment immediately  \\no Initiate ART as soon as anti -TB medications are tolerated, preferably within 2 \\nweeks  \\no For TB meningitis delay ART for 4 to 8 weeks  \\no Monitor closely for IRIS (Annex 16)  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 184}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 14 ● Patients who are already on ART  \\no Start TB treatment immedi ately  \\no Continue ART, assessing for treatment failure and making any required \\nadjustments to the ART regimen based on drug -drug interactions (Table 8.7)  \\no Monitor closely for IRIS (Annex 16)  \\n● Patient being treated concurrently for TB and HIV require close monitoring for \\ntoxicity  \\n● MDR TB and HIV co -infection should be managed in settings where close toxicity \\nmonitoring and follow up by experienced clinicians or multi -disciplinary team is \\npossible       \\nPreferred ART regimens for patients with TB/HIV co -infecti on are summarized in Tables 8.6 - 8.8. \\nTable 8.6: Preferred ART Regimens for TB/HIV Co -infection for Patients Newly Initiating 1st \\nLine ART 1 \\nAge  Weight  1st Line ART if TB/HIV Co -infection  \\nBirth to 4 \\nweeks  Any  Start anti -TB treatment immediately; start ART after 4 weeks \\nof age, once tolerating anti -TB drugs (follow the regimen \\nrecommendations for children ≥ 4 weeks old)  \\n> 4 weeks to < \\n15 years  < 30 kg  ● ABC + 3TC + DTG  \\n● Increase DTG dosing frequency to twice daily for duration \\nof rifampicin -containing TB treatment and for an additional \\n2 weeks after TB treatment is completed, then revert to \\nonce daily dosing  \\n≥ 30 kg  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n≥ 15 years  Any  ● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for \\nduration of rifampicin -containing TB treatment and for an \\nadditional 2 weeks after TB treatmen t is completed, then \\nrevert to TDF/3TC/DTG FDC once daily  \\n1 Refer to Annex 10 for weight -based ARV dosing  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 185}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 15 Table 8.7: Preferred ART Regimens for Patients who Develop TB while Virally Suppressed on \\n1st Line ART 1,2 \\nCurrent \\nRegimen3  Recommended Substitution  \\nPI/r -based4 All ages  ● Switch from PI/r to DTG and continue this regimen even after \\ncompleting TB treatment. Follow DTG dosing as below  \\n● If it is not possible to switch to DTG:  \\no Children < 30 kg requiring PI/r -based ART should receive \\nLPV/r with additional ritonavir super -boosting for the duration \\nof rifampicin -based TB therapy, reverting to standard LPV/r \\ndosing 2 weeks after completing TB treatment  \\no Patients ≥ 30 kg who cannot switch to DTG should be switched \\nto EFV -based ART and maintained on EFV -based ART after \\ncompletion of TB treatment  \\nRAL -based  All ages Switch from RAL to double -dose DTG dosing during TB treatment and \\nmaintain on DTG after completion of TB treatment  \\nDTG -based  All ages   \\nAdminister the double -dose of DTG (i.e., the standard weight -based \\ndose of DTG given twice daily) while taking rifampicin containing TB \\ntreatment. Two weeks after completion of TB treatment revert to the \\nrecommended DTG dose once daily.  \\n1 Always assess for HIV treatment failure in patients who develop TB after being on ART for ≥ 6 \\nmonths. For patients failing 1st line ART refer to Table 8.8 for recommended 2nd line regimens  \\n2 For patients on 2nd line ART, subsequent regimens, or nonstandard drugs who require regimen \\nchange because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726  460 000; https://nhcsc.nascop.org/clinicalform ) \\n3 NRTIs in the patient’s current regimen do not require any adjustments with anti -TB treatment  \\n4 Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between \\nLPV/r and rifampicin (see Annex 10 for dosing recommendations)  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 186}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 16 Table 8.8: Recommended ART Regimens for Patients who Develop TB while Failing 1st Line \\nART 1 \\nAge/  \\nScenario  First -line \\nART  Second -line ART  \\n< 30 kg \\nbody \\nweight  LPV/r -\\nbased 1st \\nline ● Start anti -TB immediately.  \\n● Change to DTG -based second -line immediately. Increase DTG dosing \\nfrequency to twice daily for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, \\nthen revert to once daily dosin g  \\n● Immediately collect a sample for DRT2 \\n● Assess for and address reasons for treatment failure.  \\n● If unable to switch to DTG then use super -boosted LPV/r3 \\nABC (or \\nAZT) + \\n3TC + \\nDTG  ● Start anti -TB immediately  \\n● Increase DTG dosing frequency to twice daily for duration of rifampicin -\\ncontaining TB treatment and for an additional 2 weeks after TB treatment \\nis completed, then revert to once daily dosing.  \\n● Follow the viral load monitoring algorithm (Figure 6.6), inclu ding \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\n≥ 30 kg or \\n≥ 15 years \\nold TDF (or \\nABC or \\nAZT) + 3TC \\n+ DTG  ● Start anti -TB immediately  \\n● Give TDF/3TC/DTG FDC morning + DTG 50mg evening for duration of \\nrifampicin -containing TB treatment and for an additional 2 weeks after \\nTB treatment is completed, then revert to TDF/3TC/DTG FDC once daily  \\n● Follow the viral load monitoring algorithm (Figure 6.6), including \\nassessing for and addressing reasons for treatment failure, and collecting \\nDRT. Consult the Regional or National TWG to constitute a second -line \\nregimen based on DRT results  \\nTDF (or \\nABC or \\nAZT) + \\n3TC + EFV  ● Start anti -TB immediately  \\n● Continue current regimen while following the viral load monitoring \\nalgorithm (Figure 6.6), including assessing for and addressing reasons for \\ntreatment failure.  \\n● Once treatment failure is confirmed and patient ready to switch to 2nd \\nline, switch to TDF + 3TC + DTG (maintain the TDF, even if the patient was \\nalready on a TDF -containing regimen), increasing the DTG dose to twice \\ndaily for the duration of rifampicin -based TB therapy, switching back to \\nstandard DTG dose 2 weeks after rifampin is discontinued.  \\nPI/r -\\nbased 1st \\nline ● Start anti -TB immediately  \\n● Switch to TDF+3TC+DTG immediately. Give TDF/3TC/DTG FDC morning \\n+ DTG 50mg evening for duration of rifampicin -containing TB treatment \\nand for an additional 2 weeks after TB treatment is completed, then revert \\nto TDF/3TC/DTG FDC once daily  \\n● Immediately collect a sample for DRT2  \\n● Assess for and address reasons for treatment failure.  \\nPregnant or \\nBreastfeeding  Follow the same recommendations as for ≥ 30 kg or ≥ 15 years old.   \\nHIV/HBV \\nCo-infection  Always maintain TDF or TAF in second -line instead of switching to a different NRTI and \\ninstead of adding an additional NRTI  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 187}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n8 - 17 Table 8.8 Cont.  \\n1. For patients on 2nd line ART, subsequent regimens, drug intolerance, or nonstandard drugs who require \\nregimen change because of TB treatment, consult the Regional or National HIV Clinical TWG (Uliza Hotline \\n0726 460 000; https://nhcsc.nascop.org/clinicalform ) \\n2. Contact  the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000; \\nhttps://nhcsc.nascop.org/clinicalform ) for guidance on urgent collection of DRT samples  \\n3. Use “super -boosted” LPV/r by adding additional ritonavir to manage the drug interaction between LPV/r \\nand rifampicin (see Annex 10 for dosing recommendations). Two weeks after TB treatment is completed \\nthe child should go back to standard LPV/r dosing.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 188}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18 ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 189}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 1  \\n9. HBV/HIV and HCV/HIV Co -infection \\nPrevention and Management  \\n9.1 Hepatitis B/HIV Co -infection  \\nHIV and Hepatitis -B Virus (HBV) share infection transmission routes.  Acute HBV infection in HIV \\npositive people is associated with increased risk of chronicity, reduced chances of spontaneous \\nclearance, higher rates of replication and reactivation and therefore increased incidence of \\nchronic liver disease, cirrhosis and hep atocellular carcinoma (HCC). Additionally, HIV/HBV co -\\ninfection has been associated with rapid HIV disease progression and poorer HIV treatment \\noutcomes.  Other complications of HIV/HBV co -infection include increased incidence of drug -\\nrelated hepatotoxicit y, drug -drug interactions and ART -related immune reconstitution hepatitis.  \\n9.1.1 Screening  \\nAll adolescents and adults living with HIV (plus children who did not complete routine childhood \\nimmunizations) should be screened for HBV infection, using HBsAg, as part of initial evaluation. \\nTo promote population -wide prevention, hepatitis B prevention should be integrated into \\nroutine HIV prevention and care programs. In this setting, other indications for HBsAg screening \\ncould include  \\n▪ Household and sexual contacts of HBsAg positive individuals  \\n▪ Pregnant women  \\n▪ Persons who inject drugs (PWID)  \\n▪ Men who have sex with men  \\n▪ Sex workers  \\n▪ Persons with multiple sexual partners  \\n▪ Prisoners  \\n▪ Blood donors  \\n▪ Unvaccinated healthcare providers  \\n \\nPLHIV on follow -up who presen t with signs of liver disease (jaundice, ascites, abnormal liver on \\npalpation, other signs of cirrhosis) or unexplained and persistent ALT elevation should also be \\nscreened for HBV as part of their work -up. \\n9.1.2 Prevention  \\nA. Vaccination : HBV vaccination reduces the risk of new (incident) HBV infection in PLHIV and \\nalso reduces the risk of new infections becoming chronic. Therefore;  \\n● HIV positive infants, children, adolescents and adults without evidence of hepatitis B \\ninfection (HBsAg negative)  should be vaccinated against hepatitis B (Table 9.1)  \\n● HIV exposed infants (HEI) should also receive hepatitis B vaccination as part of childhood \\nimmunization (Table 4.21)  \\n● As a strategy to reduce the population level burden of HBV infection, HIV prevention and \\ntreatment settings should integrate HBV prevention through vaccination. Thus, HBV \\nvaccination is recommended for the following groups who test HBsAg negative.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 190}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 2 o Babies and young children (through EPI and catch -up immunization for those who \\nmissed EPI vac cination)  \\no Household contacts of HBsAg positive people  \\no Sexual contacts of HBsAg positive people  \\no People on haemodialysis  \\no PWID  \\no Individuals with chronic liver disease and/or hepatitis C  \\no Inmates and prison personnel  \\no Healthcare workers  \\nTable 9.1: Hepatitis B Vaccination Schedule for HIV -positive Adolescents and Adults  \\nVaccine  Dose (intramuscular)  Schedule  \\nNon -adjuvanted formulation  Double the standard dose   \\n0, 1, 2, and 6 months  Adjuvanted formulation  Standard dose  \\n*Booster vaccination is not required for persons who have completed the full vaccination schedule  \\nB. General preventive measures:  General measures for infection prevention adopted by \\nPLHIV and in healthcare settings are effective in preventing HBV transmission. The se \\ninclude  \\n● Hand hygiene  \\n● Use of personal protective equipment  \\n● Medical waste management including safe disposal of used sharps  \\n● Disinfection and sterilization  \\n● General health advice against sharing of personal effects like towels, tooth -brushes, \\nrazors, combs and other grooming equipment  \\n● Harm reduction counselling and services for PWID as outlined in Chapter 12  \\n● Safer sex practices  \\n9.1.3 Treatment  \\nA. When to start ART  \\nAll HIV infected patients who are co -infected with hepatitis B should be started on ART \\nirrespective of CD4 cell count, WHO clinical stage or stage of liver disease  \\n \\nThe general recommendations for treatment preparation, adherence counselling and support \\nand monitoring of therapy for PLHIV apply. However, because HBV positive patients are at higher \\nrisk of hepatotoxicity, closer monitoring of liver function (with ALT) is advised. Table 9.2 \\nprovides a summary of areas of focus during initial evaluation for HIV/HBV co -infected patients \\ninitiating therapy.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 191}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 3 B. Recommended first -line ART in HIV/HBV co -infection  \\nThe recommended first -line ART in adolescents and adults with HIV/HBV co -infection \\nis TDF + 3TC + DTG, including for women and adolescent girls of childbearing potential  \\n \\nTreatment with both TDF (or TAF) and 3TC is recommended as 3TC without TDF or TAF will \\nresult in rapid emergence of resistance. In case of renal impairment (as assessed by creatinine \\nclearance), the dose of TDF and 3TC should be adjusted (Table 9.3).  \\nTable 9.2: Summary of Initial Clinical and Labora tory Evaluation in HIV/HBV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette \\nsmoking, intravenous drug \\nuse, risky sexual practices, \\nanorexia, right upper \\nquadrant pain, jaundice, early \\nsatiety, haematemesis, dark \\nstool, bleeding, pruritus  Assess, counsel and support to stop taking \\nalcohol; counsel and support smoking \\ncessation; counsel and provide or refer for \\nharm reduction interventions  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nPhysical \\nexamination  Enlarged liver, enlarged \\nspleen, ascites, scratch marks  Evidence of established chronic liver disease, \\ncloser follow -up due to increased risk of \\nhepatotoxicity.  \\ndiscuss or refer to a consultant for additional \\nevaluation and management  \\nALT  If elevated, may point to \\nactive liver disease. Exclude \\nother causes of elevation of \\nliver enzymes  Every effort should be made to assess for \\nother liver function (albumin and INR), \\nespecially in symptomatic patients. However, \\nthis should not delay initiation of ART  \\nCreatinine  Calculate creatinine clearance  In HIV/HBV co -infection, TDF is indicated \\neven in patients with CrCl < 50 ml/min. In \\nsuch patients, avoid FDCs. Instead administer \\nthe ART as single drugs to allow for dosage \\nadjustment as shown in Table 9.3  \\nComorbidities  HCV antibody, random blood \\nsugar, lipid profile, alcoholic \\nand non -alcoholic liver \\ndisease, hepatocellular \\ncarcinoma (family history)  Consult/Refer the patient for additional \\ninvestigations where these are suspected  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 192}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 4 Table 9.3: Dose Adjustment of TDF and 3TC in Patients with Impaired Renal Function 1 \\nDrug  Creatinine clearance (ml/min)  Haemodialysis  \\n50 - 80 30-49 10-29 \\nTDF 33 mg/g \\ngranules  \\n(=1scoop)  245 mg (7.5 scoops of \\ngranules or 245mg \\nfilm -coated tablet) \\nonce daily  132 mg (4 \\nscoops of \\ngranules) once \\ndaily  65 mg (2 scoops \\nof granules once \\ndaily  16.5 mg (0.5 scoop) \\nafter each 4 hr session \\nof dialysis  \\n \\nTDF 300 mg  Unchanged: 300 mg \\nonce daily  300 mg every  \\n48 hrs  300 mg every 72 to 96 hours (twice \\nweekly). For patients getting hemodialysis, \\nadminister 300 mg once weekly after \\ncompletion of dialysis sessions 2 \\n3TC 300mg  Unchanged: 300 mg \\nonce daily or 150 mg \\nBD  150 mg once \\ndaily  150 mg once \\ndaily  50 mg first dose,  \\n25 mg once daily  \\n1 Patients with impaired renal function in whom the benefits of continued use of TDF outweighs the \\nrisks (such as in the management of HIV/HBV co -infection) should be managed with input from a \\nspecialist in internal/paediatric or renal medicine  \\n2 Assuming 3 haemodialysis sessions per week, each of approximately 4 hours duration or after 12 \\nhours cumulative haemodialysis  \\n \\nC. Follow -up/Monitoring  \\nFollow -up of HIV/HBV co -infected patients should be as for all other patients on ART. However, \\nconsider more frequent monitoring (using ALT) for patients with active liver disease (jaundice, \\nliver cirrhosis and features of portal hypertension) at baseline.  The presence of co -infection also \\nincreases the risk of drug -related hepatotoxicity from all classes of ARVs by 3 -5 times, especially \\nwhen anti -TB and ART are given simultaneously. Also, hepatic flare -up (AST > 5 times normal \\nvalue) can occur, often in th e initial 3 months.  \\nNote:  ALT elevations 5 -10 times normal can be tolerated in the first 3 months of ART as \\nlong as the patient is not severely symptomatic, remains stable without progression, and \\nthere is no evidence of synthetic dysfunction (INR normal,  glucose normal, albumin \\nnormal).  \\nPatients with persistently elevated ALT levels during follow -up should be referred to a \\nspecialist. Subsequent laboratory monitoring after baseline should be conducted every 6 \\nmonths. Patients should be counselled and supp orted to abstain from consuming alcohol.  \\nD. Stopping treatment, /treatment interruptions  \\nTDF -containing ART should not be stopped in a patient with HIV/HBV co -infection as this may \\nresult in a flare -up of the hepatitis. If the regimen must be stopped and another alternative for \\nsuppressing hepatitis B cannot be found, liver enzymes should be monitored and treatment re -\\ninstated as soon as possible.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 193}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 5 E. Second line for HIV/ HBV co -infected  \\nMaintain TDF + 3TC in the ART regimen for patients switc hing from TDF -based -therapy.  So, for \\nexample, if a patient with HIV/HBV co -infection fails TDF/3TC/EFV in first -line, they should \\nswitch to TDF/3TC/DTG in second -line.  \\nHIV/HBV co -infected patients failing second -line ART should be discussed in the MDT and  \\ndiscussed with the Regional or National HIV Clinical TWG (Uliza Hotline 0726 460 000.)  \\n9.2 Hepatitis C/HIV Co -infection  \\nIn Kenya, the prevalence of HCV infection is high in PWID (estimated to be 12 -16%). The \\nprevalence in the general population and among PLHIV is low (estimated to be < 3%), but likely \\nto be higher in HIV infected PWID due to shared routes of transmission. HIV/ HCV co -infection is \\nassociated with  \\n• Rapid progression of liver fibrosis  \\n• Higher risk of deteriorating liver disease even in the pres ence of controlled HIV disease  \\n• Worsened hepatotoxicity as a result of ART and other drugs used in the treatment of \\ncomorbidities  \\nThus, HIV -positive persons at risk of HCV co -infection should be identified and offered HCV \\ntreatment. The recent introduction of direct acting antiviral therapies (DAAs) for treatment of \\nHCV has simplified the management of HIV/HCV co -infection, making it possible to manage \\nuncomplicated HIV/HCV infection safely even in primary care settings.  \\nHowever, treatment for H CV is a rapidly evolving field of therapeutics. Providers are encouraged \\nto seek regular updates on the subject and, when in doubt, to discuss individual cases with \\nexperienced providers.  \\n9.2.1 Screening  \\nHCV serology should be offered to individuals at ri sk of HCV infection. These include  \\n● People who inject or use intranasal drugs  \\n● Persons who have had tattoos, body piercing or scarification procedures from \\nsettings with doubtful infection prevention precautions  \\n● Children born to HCV positive mothers  \\nUp to 30 % of individuals who are infected with HCV spontaneously clear the infection. To confirm \\nchronic HCV infection, HCV positive individuals should be offered nucleic acid HCV RNA testing \\nto establish presence of chronic HCV infection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 194}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 6 9.2.2 Prevention  \\nGeneral measures for prevention of blood -borne infections are effective in preventing HCV \\ntransmission.  \\n● Recommendations for healthcare settings  \\nTraining of healthcare providers on:  \\no Hand hygiene: including surgical hand preparation, hand -washing and use of gloves  \\no Safe handling and disposal of sharps and waste  \\no Effective disinfection and sterilization  \\no Provision of safe blood and blood products  \\n● Recommendations for PWID  \\no Harm reduction counselling and support (Table 12.1)  \\n● Recommendations for prevention of sexual transmission  \\no Correct and consistent condom use  \\no Access to prevention services for sex workers and other people at risk (including \\nscreening and treatment of STIs, frequent testing for HIV and HCV testing)  \\n \\n9.2.3 Treatment of HIV/HCV Co -infection  \\nTable 9.4: Summary of Initial Clinical and Laboratory Evaluation in HIV/HCV Co -infection  \\n Findings  Action  \\nHistory  Alcohol use, cigarette smoking, \\nintravenous drug use, risky sexual \\npractices, anorexia, right upper quadrant \\npain, jaundice, early satiety, haematemesis, \\ndark stool, bleeding, pruritus  Assess, counsel and support to stop \\ntaking alcohol; counsel and support \\nsmoking cessation; counsel provide \\nand refer for harm reduction \\ninterventions  \\nPhysical \\nexamination  Enlarged liver, enlarged spleen, ascites, \\nscratch marks  Evidence of established chronic liver \\ndisease, closer follow -up due to \\nincreased risk of hepatotoxicity, \\ndiscuss or refer to a consultant for \\nadditional evaluation and management  \\nHCV RNA PCR  For confirmation of chronic HCV  \\ninfection  If available, at baseline  \\nHCV genotype  May be important for selecting appropriate \\nDAA regimen. (Current regimens pan -\\ngenotypic, so HCV genotype testing not \\nrequired)   \\nALT  If elevated, may point to active liver \\ndisease. Exclude other causes of elevation \\nof liver enzymes  Every effort should be made to assess \\nfor liver function (albumin and INR), \\nespecially in symptomatic patients. \\nHowever, this should not delay \\ninitiation of ART  \\nComorbidities  HBV, random blood su gar, lipid profile, \\nalcoholic and non -alcoholic liver disease,  \\nhepatocellular carcinoma (family history)  Consult/Refer the patient for \\nadditional investigations where these \\nare suspected  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 195}),\n",
       " Document(page_content='  \\nTB/HIV Co -infection, Prevention and Management  \\n \\n9 - 7 Table 9.5: Recommended DAA for the Treatment of HCV among PLHIV  \\nGenotype  DAA Regimen*  Duration of treatment  \\n1 and 4  Sofosbuvir + Ledipasvir (Harvoni)  12 weeks  \\nAll Sofosbuvir + Velpatasvir (Epclusa)  12 weeks  \\n* DAA regimen availability continues to evolve; this table just shows the most readily available regimens at \\ntime of publication. Always start DAA HCV therapy, and review most recent drug -drug interactions with \\nARVs.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 196}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 9 - 8  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 197}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with \\ncontaminated blood and other body fluids  containing HIV through needle stick injuries and \\ninjuries by other sharp objects or through non -intact skin and mucous membranes.  \\n10.2 Recommended ARVs for PEP  \\nThree -drug regimens are preferred for PEP. However, if the person is unable to tolerate the thi rd \\ndrug, (usually the PI/r), two drugs  can be used.  \\nTable 10.1: Recommended ARVs for PEP  \\nAge  Weight  Preferred  Alternate  \\n \\n \\n<15 years  < 30kg  ABC + 3TC + DTG  ● AZT + 3TC + DTG  \\n● AZT+3TC and LPV/r may be used \\nas the third drug  \\n≥ 30 kg  TDF + 3TC /FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n≥ 15 years  Any weight  TDF + 3TC/FTC + DTG  ● TDF+3TC/FTC and ATV/r may be \\nused as alternative third drug  \\n.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 198}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 2 10.3 Eligibility For PEP  \\nPEP should always be offered as soon as possible, preferably within 72 hours, after an exposure.  \\nPersons who present after 72 hours should be provided with other appropriate services including \\ncounselling and support.  \\nEligibilit y assessment for PEP is based on the type of exposure, HIV status of source where \\npossible and timing of seeking care.  \\nThe following include the eligibility criteria for PEP.  \\n● Exposed individual is HIV negative at baseline.  \\n● Exposure must have occurred within the past 72 hours.  \\n● Exposure to bodily fluids pose a significant risk (exposure and/or material):  \\n▪ Type of exposure:  mucous membrane (i.e.  sexual exposure; splashes to eye, nose, or \\noral cavity), non -intact skin, percutaneous injury or paren teral exposures  \\n▪ Material : blood, blood -stained body fluids, breast milk; semen; vaginal secretions; \\nsynovial, pleural, pericardial, amniotic fluids; CSF, and HIV cultures in laboratories  \\nExposures that do not require HIV PEP include:  \\n● When the exposed individual is already HIV positive.  \\n● Exposures to bodily fluids that do not pose a significant risk, i.e., tears, non -blood -stained \\nsaliva, urine, and sweat.  \\n10.4 Management and Follow Up  \\nPatients should be counselled and encouraged to complete the full course of PEP once a decision \\nhas been made to initiate PEP.  \\nFor occupational exposure, immediate care of the exposure site includes washing the site with \\nsoap and water and allow the wound  to bleed freely for several minutes  \\nNOTE: Do not do anything that will increase tissue damage such as squeezing, scrubbing, or \\ncutting the site further . \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 199}),\n",
       " Document(page_content='  \\nARVs for Post -exposure Prophylaxis  \\n10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \\nConsiderations  Recommendation  \\nManagement at initial \\ncontact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \\ntesting.  \\n● Voluntary testing for both exposed and source individuals  \\n● Offer PEP as soon as high -risk exposure is established and the exposed \\nindividual tests HIV-negative at baseline (if HIV testing not feasible, \\noffer 1 -2 days of PEP to cover until HIV test performed)  \\n● Provide first aid in case of broken skin or other type of wound  \\nTime of initiation  As soon as possible after exposure, but no later than after 72 hours  \\nDuration of PEP  28 days (dispense all 28 days of treatment at the first visit if tested HIV negative)  \\nDose of PEP  Same as indicated for treatment; use weight -based dosing for children  \\nLaboratory \\ninvestigation at \\nbaseline  ● Conduct creatine testing (if TDF -containing regimen) and Hb (if AZT -\\ncontaining regimen), however PEP should be offered even when lab tests \\nare not available. Do not delay administration of PEP while waiting for lab \\nresults.  \\n● HBsAg testing is recommended. Do not del ay administration of PEP while \\nwaiting for lab results. If negative provide HBV vaccination  \\n● Pregnancy testing for women of childbearing potential in case of sexual \\nassault.  \\nFollow -up ● Follow up client at 7 days, 14 days, 28 days, and 12 weeks after starting \\nPEP  \\n● Assess for and manage side effects due to PEP  \\n● Follow -up HIV testing should be done at the completion of PEP and if \\nnegative, test again at 12 weeks  \\n● Link to HIV treatment if positive  \\nCounselling  Counselling at baseline should include:  \\n● Adherence counselling  \\n● Information on side effects  \\n● Risk reduction counselling  \\n● Trauma and mental health counselling  \\n● Specific support for sexual assault  \\nOther services for \\nsexual assault  ● STI prophylactic treatment to all (treat for vaginal/urethral discharge \\nsyndrome following the national STI algorithms)  \\n● Emergency contraception for non -pregnant women  \\n● Tetanus toxoid for any physical injury of skin or mucous membranes  \\n● Documentation of clinic evidence of assault and collection of foren sic \\nevidence  \\nRefer to post -rape care guidelines for additional details  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 200}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 10 - 4 10.5 Risk reduction counselling  \\nTo reduce the risk of further HIV transmission, it is necessary to prevent transmission to sexual \\npartners and the children of breastfeeding mothers. R isk reduction counselling should form part \\nof each consultation with the individual. Measures to reduce transmission to another person may \\ninclude:  \\n● The use of condoms and safe injecting practices to prevent secondary transmission  \\n● Avoiding blood donation until confirmed HIV negative at 12 weeks post exposure  \\nTable 10.3 Considerations for special circumstances  \\nCircumstance   Recommendation  \\nBreastfeeding women  • Breastfeeding is not a contraindication for PEP  \\n• The risks and benefits of continuing breastfeeding while HIV \\ntransmission risk is unknown and should be discussed with the \\nmother  \\nChildren  • HIV testing approaches for children should be in line with national \\nguidelines and age appropriate  \\n• Informed consent from the caregiver is needed  \\nAdolescents  • Requiring parental consent for adolescents can be a barrier to HIV \\ntesting, particularly in cases of sexual assault  \\n• HIV testing should be performed in accordance with national \\nguidelines and consenting requirements  \\n \\n10.6 Preventing HIV exposure  \\nTo avoid or minimize the risk of exposure to HIV the following infection prevention control (IPC) \\nmeasures are recommended:  \\n• Precautions should be taken when handling contaminated body fluids including the use \\nof appropriate barriers such as gloves, gowns, and goggles.  \\n• Care with sharps including minimizing blind surgical procedures and proper handling \\nand disposal o f sharps.  \\n• Safe disposal of contaminated waste  \\n• Safe handling of soiled linen.  \\n• Adequate disinfection procedures  \\n• Universal Hepatitis B vaccination of non -immune at -risk groups including HCWs, police, \\nprison staff and rescue workers.  \\nIn cases that do not requi re PEP, the exposed person should be counselled about limiting future \\nexposure risk.  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 201}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition  \\n● Some risk situations that place one at ongoing risk include individuals or sexual partner/s \\nwho is/are:  \\no HIV positive and: not on ART, or on ART < 6 months, on ART with viral non -suppression, \\nor on ART with suspected poor adherence  \\no In sero -discordant relat ionships trying to conceive  \\no Of unknown HIV status and at high -risk of HIV infection  \\no Engaging in transactional sex or sex work  \\no With history of recent or current sexually transmitted infections  \\no With recurrent use of Post -Exposure Prophylaxis  \\no With a history of sex whilst under the influence of alcohol or recreational drugs  \\no Inconsistent or no condom use or unable to negotiate condom use during intercourse \\nwith persons of unknown HIV status  \\no Using injection drugs where needles and/or syringes are  shared  \\n11.1.2 HIV Risk Assessment  \\nClients accessing health services should be screened for HIV risk and additionally provided with \\ninformation on HIV prevention options available including the availability of PrEP. This is in \\naddition to the use of HIV testing services (HTS), as clients ar e assessed for HIV risk before testing.  \\nThe risk assessment questions are enquiry of behavioural practices that may expose an individual \\nto HIV (Table 11.2).  \\n A simple Risk Assessment Tool (RAST) is provided to guide the provider in generating a \\nconversat ion about HIV risk. Screening for HIV risk should be integrated within other service \\ndelivery points. HIV negative individuals who answer “yes” to any of the screening questions \\nshould be engaged in a discussion about the risks and benefits of PrEP. The cl ient then is evaluated \\nfor eligibility to receive PrEP.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 202}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 2 Table 11:1 HIV Screening questions  \\nScreening question refer to the past 6 months & include;  \\n• “Have you had sex with more than one person?”  \\n• “Have you had sex without a condom?”  \\n• “Have you had sex with a nyone whose HIV status you do not know?”  \\n• “Are any of your partners at risk of HIV?”  \\n• “Have you had sex with a person who has HIV?”  \\n• “Have you received a new diagnosis of a sexually transmitted infection?”  \\n• “Do you desire pregnancy?”  \\n• “Have you used or wanted t o use PEP or PrEP for sexual exposure to HIV?”  \\n• “Have you injected drugs that were not prescribed by healthcare provider? If yes, did \\nyou use syringes, needles or other drug preparation equipment that had already been \\nused by another person?”  \\n• “Have you rece ived money, housing, food or gifts in exchange for sex?”  \\n• “Have you been forced to have sex against your will?”  \\n• “Have you been physically assaulted, including assault by a sexual partner?”  \\n11.1.3 Criteria for PrEP Eligibility  \\nTo be eligible for PrEP, individuals identified to be at risk of HIV infection from Risk Assessment \\nmust meet ALL the following criteria prior to initiating PrEP.  \\n● Confirmed HIV negative status through rapid antibody testing following the HTS algorithm.  \\n● Determine if the client is w illing to take PrEP as prescribed. (This is done by adherence \\neducation and counselling on the PrEP regimen to be given, and assessing the client’s \\nreadiness to follow the regimen.)  \\n● Does not have a current or recent (within the past one month) illness consistent with acute \\nHIV infection (fever, sore throat, muscle or joint pains, swollen glands, diarrhoea or headache) \\nin combination with a preceding high -risk exposure for HIV.  \\n● No contraindication to use of any of the ARVs recommended for PrEP e. g., TDF +/ - FTC (or \\n3TC) for those who choose oral PrEP.  \\n● Renal or liver disease  \\no Clients with renal and liver disease should receive further clinical and laboratory tests, \\nto determine the renal/liver function and extent of disease.  \\nOther important factors  for screening  \\n1. Gender based violence (GBV) screening:  All clients accessing PrEP must be screened for \\ngender -based violence, especially intimate partner violence (IPV), and appropriate \\nintervention offered or client linked to appropriate.  \\n2. Mental Status Assessment:  Psychological issues that may influence adherence should be \\nassessed and addressed. It is important to carry out basic mental health evaluation and \\noffer appropriate referral as necessary.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 203}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 3 HIV self -test (HIVST) should not be used as a de finitive HIV test for PrEP initiation and \\nfollow up monitoring.  \\n11.2 Package of PrEP Service  \\nPrEP should be offered as part of the comprehensive prevention package which includes \\nbehavioural, bio medical and structural components. Integration of PrEP serv ices is \\nrecommended within different service delivery points, including in the community, ANC and FP \\nclinics.  \\n \\n Client  seeking  any service  from the facility /Communit y\\n(See section  on PrEP Integration)\\n \\n \\n \\n \\nSCREEN  for ongoing  risk for HIV \\nTEST for HIV  \\n  \\nHIV Positive – link/refer\\nAdditional Screening:\\nGBV/HIV\\n \\n \\n \\n \\n \\n \\n \\n \\n \\n1 \\n \\nFigure 11.1 : Package of Service for PrEP  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 204}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 4 11.2.1 Pre -Initiation Checklist  \\nThis checklist is intended to help the service provider ensure all necessary screening and \\nassessments are done prior to PrEP initiation  \\nTable 11.2: Pre -Initiation Assessment Checklist  \\nITEM  Y/N  \\nScreening and Support for GBV   \\nHIV Testing   \\nCheck symptoms of acute viral infection in last 6 weeks   \\nBehavior risk assessment   \\nSubstance use and mental health screening   \\nPartner information   \\nPre-initiation education and understanding of PrEP   \\nClient readiness and willingness to adhere to prescribed PrEP and follow -up schedule   \\nSTI screening and treatment   \\nFor women  \\n✔ Pregnancy test, pregnancy intention and / or breastfeeding  \\n✔ Screen for contraception use using appropriate contraceptive screening tool   \\n✔ Highlight the need for condom use   \\nDiscussed plans for continually accessing PrEP   \\nAdditional laboratory tests (Availability of these test should not delay initiation of PrEP)  \\n✔ Serum creatinine and creatinine clearance  \\n✔ HBsAg  \\n✔ HCV serology  \\nNB:  absence of these tests should not hinder initiation   \\nMedication history and potential drug interactions   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 205}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 5 11.2.2 Pre -initiation client education  \\nThe following components should be discussed prior to PrEP initiation:  \\nTable 11.3: Client Education Checklist  \\nTopic  Check  \\n✔ Explain how PrEP works as part of combination HIV prevention  ✔  \\n✔ Explain the need for baseline and follow -up tests including regular HIV testing  ✔  \\n✔ Explain PrEP use: include the following: (refer to the different types of PrEP \\navailable for details)  \\no The medications used (show the client the pills or other PrEP options  \\no How the medications are used (frequency of dosing for the various options)  \\no Number of doses required to achieve efficacy (7 doses for daily oral PrEP, \\nloading dose for event driven oral PrEP)  \\no What to do when doses are missed (continue for daily doses)  \\no Discontinuation of PrEP, how and when it can be discontinued.  \\no Side effects and what to do in case these are experienced (including when to \\nconsult the clinician)   ✔  \\n✔ Discuss what to do in case client experiences symptoms of seroconversion (acute \\nHIV infect ion)   \\n✔ Discuss the Limitations of PrEP  \\no PrEP reduces but does not eliminate the risk of acquiring HIV.  \\no PrEP does not prevent pregnancies and STIs.   ✔  \\n✔ Risk reduction counselling and support education  \\no Managing mental health needs  \\no Couple counselling  \\no Access to, and consistent use of condoms and lubricants  \\no Access to and need for frequent HIV testing.  \\no Early access to ART  \\no VMMC  \\no STI screening and treatment  \\no Harm reduction for PWID  ✔  \\n \\n11.3 Recommended ARVs for PrEP  \\nThe preferred ARV regimen is Tenofovir 300mg/ Emtricitabine 200mg (TDF/FTC) given as one \\nfixed dose combination (FDC) tablet orally daily.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 206}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 6 Table 11.4: Antiretrovirals for Use in PrEP  \\nPrEP Dosing \\nStrategies  Preferred  Alternative  \\nDaily Oral PrEP  TDF/FTC (300 mg/200 mg) as FDC \\nonce daily  TDF/3TC (300 mg/300 mg) as FDC once \\ndaily  \\nEvent Driven Oral \\nPrEP    TDF/FTC (300 mg/200 mg) as FDC \\n– two pills taken between 2 and 24 \\nhours in advance of anticipated sex; \\nthen, a third pill 24 hours after the \\nfirst two pills and a fourth pill 48 \\nhours after the first two pills; 2 -1-1 TDF/3TC (300 mg/300 mg) as FDC – \\ntwo pills taken between 2 and 24 hours \\nin advance of anticipated sex; then, a \\nthird pill 24 hours after the first two \\npills and a fourth pill 48 hours after the \\nfirst two pills ; 2-1-1 \\n*Recommended Long -acting Products: These products are at different stages of approval and availability \\nin Kenya. The Ministry of Health will issue specific implementation guidelines when they become \\navailable.  \\n*Long Acting \\nCabotegravir \\nInjection  Initiation injections: 600 mg \\nIntramuscular (IM) x 2 doses given \\n1 month apart (the second \\ninitiation injection can be given up \\nto 7 days before or after the date \\nscheduled to receive injection)  \\nTHEN  \\nContinuation injections: 600 mg  IM \\nevery 2months   \\n*Dapivirine \\nvaginal ring  Dapivirine vaginal ring, 25mg, \\ninserted vaginally every 28 days.   \\nThe drugs can be taken with or without food, and can be stored at room temperature.  \\nPrescription intervals for daily oral PrEP  \\nThe first prescription should be for 30 days to allow for the first follow -up visit during which a \\nrepeat HIV test should be conducted, and adherence, tolerability and adverse effects assessed.   \\nDuring the one -month visit, if no major concerns are noted, PrEP should be prescribed for 2 \\nmonths and thereafter 3 -monthly. Clients with sub -optimal adherence and or other major \\nconcerns should be given monthly follow up visit.  \\nRemind individuals using daily oral PrEP that it takes 7 doses (equivalent to 7 days) o f \\ncontinuous PrEP use to achieve adequate levels of the ARVs in tissues for it to be \\neffective. During these days, safer sex practices should be encouraged (including \\nabstinence and condom use). This only applies for individuals born female. Those born \\nmal e can have protective levels as soon as 2 hours before sex but ideally 24 hours. This \\nis true even for people intending to take daily oral PrEP for ongoing exposure.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 207}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \\nInitial Visit/First Contact\\nPerform a risk assessment to determine if PrEP is indicated:\\n• Discuss effective PrEP use and Clarify misinformation\\n• Perform Initial clinical and laboratory assessment:\\no Baseline HIV test and rule out symptoms of Acute \\nHIV infection.\\no Screen for STIs and risk of renal disease/Hepatitis \\nB/C infectionIf HIV Negative and meets eligibility for PrEP\\n• Offer adherence counselling and support. \\n• Prescribe 30 -day supply of PrEP (TDF 300 mg/FTC \\n200 mg OD) \\n• Discuss combination prevention and risk reduction.\\n• Offer other HIV prevention services e.g., condoms as \\nappropriate.\\n30 Day review\\n• Assess for adherence and offer adherence counselling and support.\\n• Ask about any side effects. Find out how the client is coping with the side effects if any. Reassure if minor.\\n• Assess for STIs, risk of acute HIV infection, and perform pregnancy test in women. \\n• Assess for risk of kidney disease, if available, obtain serum creatinine and calculate creatinine clearance \\n• Discuss risk reduction and provide condoms.\\n• Perform a repeat HIV test. (Discontinue PrEP for those who test positive and link to care for ART initiation) \\nGive a 60-day PrEP prescription for drug refill of PrEP. Schedule the 3 -month return visit.\\n3 monthly reviews \\n• Assess for adherence and offer adherence counselling and support. \\n• Ask about any side effects\\n• Assess for STIs, (and pregnancy in women) and acute HIV infection. \\n• Perform HIV test every 3 months (HIV self -test may be used followed by a \\nconfirmatory test in health facilities for those testing positive) \\n• Discuss risk reduction and provide condoms.\\nDo serum creatinine and calculate creatinine clearance within 3 months after initiation \\nand thereafter annually as recommended.\\n \\nFigure 11.2: Schema for Follow -up for Daily Oral PrEP  \\n \\n11.3.2 EVENT DRIVEN PrEP (ON DEMAND PrEP or 2+1+1 PrEP)  \\nWhat is event driven?  \\nAn “Event” refers to a sexual act. Event driven PrEP is where oral PrEP is to be used when an  \\nisolated sexual act is anticipated.   \\nEvent -Driven PrEP is recommended for all people assigned male at birth not taking exogenous \\nestradiol -based gender affirming hormones  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 208}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 8 \\n \\nFigure 11.3 Schema for Event -Driven PrEP  \\nWhen is ED -PrEP considered most appropriate?  \\nEvent driven PrEP is most appropriate for men who:  \\n• Have infrequent sex (for example, sex less than 2 times per week on average).  \\n• Can plan for sex at least 2 hours in advance or who can delay sex for at least 2 hours.  \\n• Would find ED -PrEP more convenient  \\nClients on Event driven PrEP require follow up. Figure 11.4  shows the schema for follow up of \\nevent driven PrEP.  \\nAssess HIV risk and determine eligibility for oral PrEP\\nOffer PrEP and discuss dosing options.\\nDaily dosing if risk is more frequent \\nthan 2 times per week and sex cannot \\nbe predicted or delayed by 2 hours.Men who have sex with men on PrEP \\ncan switch from daily dosing to ED -\\nPrEP (and vice -versa)Event -driven dosing if sex can be \\npredicted (particularly for infrequent \\nsex)\\nFollow -up visit (1 month after initiation and/or every 3 months) \\n✓ Provide HIV testing and screen for STIs\\n✓ Offer counselling by discussing adherence dosing strategy during use, and if PrEP user \\ntransitions from one dosing strategy to another. \\n✓ Assess if HIV risk is likely to persist in the next few weeks and months. \\n✓ May require more active support in continuing PrEP, whichever dosing strategy is chosen.\\n \\nFigure 11.4 Schema for Initiation and Follow -up for Event -driven PrEP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 209}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 9 Changing between ED PrEP and daily oral PrEP  \\nMen can be offered the two dosing options: daily oral PrEP or Event driven PrEP.  \\n• Daily dosing is appropriate for those whose occurrence of sex cannot be predicted and for \\nthose whose potential exposures to HIV  are more frequent than 2 times per week, such \\nthat ED -PrEP would be taken so frequently that it would effectively resemble daily PrEP.  \\n• If sex continues beyond one day, a user of ED -PrEP can stay protected by taking another \\npill each day as long as sex co ntinues and stopping 2 days after the last sex act.  \\n• On the other hand, if an individual starts daily oral PrEP, but then sex becomes infrequent \\nand predictable, ED -PrEP can be used instead.  \\n \\n11.4 Managing Clinical and Laboratory Results on Initial and Fol low -up \\nAssessment  \\nTable 11.5 Initial & follow up laboratory test  \\nLaboratory Test  Guidelines for clients initiating \\nPrEP  Guidelines for clients on \\nfollow up  \\nHIV Rapid Test  Before initiating PrEP as per the National \\nHTS algorithm  At Month 1, Month 3, thereafter \\nevery 3months  \\nCreatinine Test  Test within 1 -3 months of PrEP Initiation  If client >50years – Screen every \\n6-12months  \\nClients of any age with renal \\ncomorbidity: recommended before  \\ninitiating PrEP  Screen every 6 -12months  \\nHepatitis B Surface \\nAntigen (HBsAg)  Test once within 3 months of initiating PrEP. If negative, offer/refer for \\nimmunization   \\nHepatitis C Virus \\nSerology  Test once within 3months of PrEP \\ninitiation  Every 12 months for persons at \\nhigh risk of Hepatitis C infection  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 210}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 10 Table 11.6: Managing Clinical and Laboratory Results on Initial and Follow -up Assessment  \\nScreening  Action  \\nHIV -positive at \\ninitial evaluation  Do not start PrEP, counsel and link to care and treatment  \\nHIV -positive after \\ninitiation of PrEP  Discontinue PrEP, counsel and link to care and treatment. Take DBS or plasma \\nsample for drug resistance testing.  \\n \\nPositive STI Screen  Thorough genitourinary and anorectal examination, urine dipstick for urethritis, \\nserological testing for syphilis, full STI evaluation if resources available (refer to \\nSTI algorithm). Refer to guidelines on syndromic management of STIs.  \\nHBsAg -negative  Offer HBV vaccination  \\n \\nHBsAg -positive  This is not a contraindication to oral PrEP.  However, will require monitoring of \\nliver function and referral for management of liver disease.  \\nNB: TDF -based daily or event -driven oral PrEP can be safely offered to \\npersons with HBV infection.  \\nHepatitis C - \\nNegative  Continue PrEP and follow Hepatitis C testing algorithm.  \\nHepatitis C - \\nPositive  Continue PrEP, refer for Hepatitis C confirmatory testing and management with \\ndirectly acting antivirals (DAAs).  \\nFlu-like illness after \\ninitiating PrEP  Continue PrEP, test for HIV at first contact and after 28 days, and if negative,  \\ncontinue with usual follow -up \\n \\n \\n \\n \\n \\n \\n \\nSide effects of PrEP  GIT - nausea, vomiting, weight loss: these are often mild, self -limiting and occur \\nduring the first 1 -2 months. Provide supportive counselling, offer symptomatic \\ntreatment e.g., anti -emetics like metoclopramide 10 mg 8 hourly for 3 to 5 days.  \\nRenal – individuals may experience transient increase in creatinine, and rarely \\nproteinuria and Fanconi’s syndrome (presenting as polyuria, bone pain and \\nweakness). Measure creatinine (and ca lculate estimated creatinine clearance) at \\ninitiation of PrEP and annually thereafter (or whenever indicated (symptom \\ndirected)).  \\nIf creatinine clearance (eGFR) < 50 ml/min do not start PrEP, recheck after 2 \\nweeks. Refer for evaluation of underlying renal  disease.  \\nIf the renal function returns to normal, reassess for PrEP and initiate/ continue \\nPrEP.  \\nPrEP should not be prescribed for individuals using nephrotoxic drugs like \\nacyclovir, aminoglycosides, retinoids etc. instead, offer alternative HIV \\nprevent ion services.  \\n \\nPregnancy or \\nBreastfeeding  \\n Pregnancy and breastfeeding are not contraindications to provision of PrEP.  \\nPregnant or breastfeeding women whose sexual partners are HIV positive or are \\nat high risk of HIV infection may benefit from PrEP as part of combination \\nprevention of HIV infection.  \\nPrEP is also indicated for HIV -negative women in sero -different partnersh ips \\nwho wish to conceive. PrEP in these situations can be prescribed during the pre -\\nconception period and throughout pregnancy to reduce risk of sexual HIV \\ninfection.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 211}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \\nVisit  Action  \\nFirst (Screening Visit) \\nClinician Visit  • HIV testing and counselling.  \\n• Evaluate for eligibility, willingness and readiness to take PrEP.  \\n• Educate about the risks, benefits, and limitations of different PrEP \\noptions  \\n• Educate client about recognizing symptoms of Acute  HIV Infection (AHI) \\nand what to do if such symptoms occur (i.e., urgently return for HIV \\ntesting)  \\n• Conduct behavior risk assessment  \\n• STI screening and treatment  \\n• Pregnancy, contraceptive use and counselling (for women); if pregnancy \\nsuspected, obtain a preg nancy test. However, pregnancy is not a \\ncontraindication to PrEP.  \\n• Adherence counselling  \\n• Discuss combination prevention.  \\n• Laboratory test; serum creatinine test and calculate Creatinine Clearance \\n(CrCl), HBsAg, pregnancy test, Hepatitis C (baseline investigations should \\nnot delay initiation of PrEP)  \\nIf no contraindication to TDF and the client is eligible and ready, \\nprescribe TDF/FTC one tablet once daily for 30 days (alternative \\nTDF/3TC one tablet once daily for 30 days, or TDF 300 mg once daily for \\n30 days); agree on a follow -up date before the prescription is finished  \\nVisit 2 (Month 1) \\nCounsellor/Clinician \\nVisit  • Counsellor/ Clinician visit  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Conduct a HIV test as per the national algorithm  \\n• Behavioral risk assessment .  \\n• Review for PrEP continuation or discontinuation  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 2 months.  \\n• Offer HBV vaccination if available and HBsAg negative (follow HBV \\nvaccination schedule complete series  \\nFollow up visits - \\nMonths 3, 6,  , 12, 15.….  \\nClinician/Counsellor -\\nled visits  • HIV testing and counselling  \\n• HIV risk assessment   \\n• Review for PrEP continuation or discontinuation  \\n• Assess for side effects and adverse effects  \\n• Safety monitoring clinical assessment/ Review lab results  \\n• Adherence and risk reduction counselling  \\n• Give a prescription for PrEP for 3 months  \\n• Refill PrEP prescription  \\n• Serum creatinine and creatinine clearance  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 212}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 12 Table 11.7 Cont: Summary of PrEP Initial and Follow -up Assessment  \\nDuring every visit  \\n• Assess adherence  \\n• Reassess risk of HIV infection and offer risk reduction counselling  \\n• HIV testing should be repeated at month 1 and thereafter, every 3 months (this applies for both \\ndaily and Event driven PrEP)  \\n• Assess for adverse effects   \\n11.5 Contra -indications to Oral PrEP (daily or ED PrEP)  \\n• HIV infection or suspected acute HIV infection (i.e., flu -like symptoms in the last 4 weeks in \\ncombination with a preceding h igh-risk exposure for HIV)  \\n• Adolescents < 35 kg or age < 15 years  \\n• Impaired renal function (estimated creatinine clearance of <50 ml/min)  \\n• Unable or unwilling to adhere to prescribed PrEP or follow -up schedule.  \\n11.6 Criteria for Discontinuing Oral PrEP  \\nPrEP should be discontinued if ANY of the following criteria are met.  \\n● Positive HIV test during follow up.  \\n● Change in risk status (no ongoing risk)  \\n● Renal dysfunction with creatinine clearance below 50 ml/min  \\n● Client request to stop.  \\n● Sustained non -adherence.  \\nDiscontinuing daily oral PrEP:   Users discontinuing PrEP due to no ongoing risk or requesting \\nto stop should continue PrEP for at least 7 days after the last potential exposure to HIV. Reasons \\nfor discontinuation should be documented in the client’s record.  \\nDiscontinuing event –driven PrEP:  Event -driven PrEP can be stopped after two daily doses \\nfollowing the last sexual exposure.  \\n11.7 Restarting PrEP  \\nAny client restarting PrEP regardless of the preferred method should be assessed for HIV status \\nand a rapid HI V test conducted:  \\n● Daily Oral PrEP : Clients who stop PrEP for more than 7 days and wishes to restart should \\nbe assessed for resumption of PrEP similar to the assessment done for an initial (first) visit. \\nImportantly, conduct a HIV test before re -starting PrEP. If a high -risk exposure occurre d in \\nthe previous 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting per iod.  \\n● Event driven Oral PrEP :  Clients who have stopped PrEP for more than a week and who are \\nrestarting ED -PrEP should commence with a double dose (two pills) of PrEP as new \\ninitiators. Risk assessment should be conducted. If a high -risk exposure occurred  in the \\nprevious 7 days (i.e., acute HIV infection is suspected), defer PrEP and obtain repeat HIV \\ntest after 4 weeks; if negative, PrEP can be prescribed if the other criteria are fulfilled. The \\nuse of condoms should be recommended during the waiting peri od.  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 213}),\n",
       " Document(page_content='  \\nPre-Exposure Prophylaxis (PrEP)  \\n11 - 13 11.8 Improving adherence to PrEP  \\nApproaches to improve adherence include:  \\n● Encourage ring users to keep ring in place continuously through the 28 -day period from \\ninitial insertion  \\n● Disclosure of PrEP use to a partner or trusted person  \\n● Use of reminder de vices like a cell phone alarm.  \\n● SMS reminders where available and feasible  \\n● Exploring and mitigation of other barriers to adherence  \\n● Peer support  \\n11.9 Monitoring Sero -conversion among PrEP users  \\nPrEP substantially reduce the risk of HIV acquisition.  The effi cacy of PrEP is correlated with \\nadherence.  Sero -conversion during use of PrEP should be monitored critically as it is increasing \\nthe risk of developing drug resistance if clients continue the use of PrEP while HIV infected.  \\nFactors that lead to HIV seroco nversion among PrEP sero -converters include:  \\n● Inconsistency in use of PrEP (non -adherence).  \\n● Social -behavioral factors e.g., poverty, HIV stigma and relationship status that may affect \\nthe ability to use PrEP as prescribed.  \\n● Possible infections with drug res istant strains  \\n \\nWhat should be done upon identification of a PrEP sero -converter?  \\nHIV testing among PrEP should be conducted consistently as per the algorithm. Identification of \\nnew HIV positive diagnosis among PrEP users should be followed with:  \\n● Immediate discontinuation of PrEP  \\n● Counselling of client on positive results  \\n● Linkage to care and ART (immediate ART initiation).  \\n● Assessment of barriers to adherence that may affect use of ART.  \\n● Document sero -conversion in client file, PrEP registers, and monthly reporting as \\nrequired.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 214}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 215}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 1  \\n12. People Who Inject Drugs (PWID) and HIV  \\n \\n12.1 Introduction  \\nThe use of ART for HIV treatment in key populations should follow the same general principles \\nand recommendations as for all adults. Individuals within key populations groups may experience \\ndiscrimination and marginali zation that can impede their access to health care, including \\ntreatment for HIV, and frequently present late for treatment. It is important to ensure that people \\nfrom key populations have equitable access to HIV treatment and care.  Programs should ensure \\nthat missed opportunities are minimized and every single encounter with key populations is \\noptimally used. ART service delivery includes decentralization of HIV care and treatment and \\nintegration of ART services into other clinical services such as Medical ly Assisted Therapy and \\ndrop -in centers where appropriate capacity exists.  \\nPeople who inject drugs (PWID) are at increased risk of HIV infection. In Kenya, the HIV \\nprevalence among PWID is up to 4 times that of the general population. PWID also suffer a hi gher \\nburden of viral hepatitis (HBV and HCV), TB and sexually transmitted infections irrespective of \\ntheir HIV status. Despite this, PWID have limited access to HIV treatment and prevention services.  \\nEvery effort should be made to implement evidence -inform ed interventions in the comprehensive \\npackage of measures targeting PWID, either in combination or (depending on site capacity) singly, \\nwith linkage to comprehensive care (Table 12.1).  \\nPackage of care for PWID  \\nPWID have complex needs related to drug dependency, psychosocial and medical \\ncomplications of injection and other substance use. When they require ART, anti -TB, or any \\nother therapy, they are at increased risk of adverse drug reactions, drug -drug interactions and \\nnon-adherence.  These patients a re best comprehensively managed by providers who have \\nreceived specific training in the management of injection drug users. Once identified, PWID \\nshould be counselled and linked to programs with the capacity to offer comprehensive care for \\nsuch patients.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 216}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 2 Table 12.1: Comprehensive Package of Harm Reduction for PWID  \\nIntervention  Comment/Recommendations  \\nHIV testing services  PWID are at high risk of HIV infection, are likely to be diagnosed late and \\ntherefore have poorer treatment outcomes following ART i nitiation.  \\n● PWID should be offered HIV testing and counselling and be linked to \\ncomprehensive HIV treatment and prevention services including \\nharm reduction counselling and support.  \\n● Retest for HIV every 3 months if there is ongoing risk.  \\n● HIV self -testing should be integrated into drop -in centers (DICEs) \\nthrough both assisted and non -assisted approaches after initial \\ntesting by a provider.  \\n● HTS should also be offered to sexual partners  of PWID.   \\n \\nTargeted information, \\neducation, and \\ncommunication for PWID \\nand their sexual partners  PWID and sexual partners should be provided with information and \\ncounselling on risks related to drug use and risky sexual behavior. PWID \\nshould be informed of where and what harm -reduction services are \\navailable, and linked to appropriate services.  \\nPeer -based networks are effective in improving access and retention to \\nharm reduction care  \\n \\n \\nCondom provision  The correct and consistent use of condoms with condom -compatible \\nlubricants is recommended for all PWID to prevent unintended pregnancy \\nand sexual transmission of HIV and other STIs.  \\n \\n \\nPrevention and treatment of \\nsexually transmitted \\ninfections  PWID may be at higher risk of STIs due to sex work or other risky sex \\npractices.  \\nSTIs, especially genital ulcer diseases increase the risk of HIV infection and \\ntransmission and are often a sign of unsafe sexual behavior or risk of HIV \\ntransmission.  \\nScreening, dia gnosis, treatment, and prevention of STIs should be offered \\nroutinely as part of comprehensive HIV prevention and care for PWID.  \\n \\n \\nPrevention, diagnosis, and \\ntreatment of TB  Independent of HIV infection, PWID have an increased risk of TB. HIV \\ninfection f urther increases this risk.  \\n● All PWID should be screened regularly for active TB using the \\nsymptom -based screening algorithm at each contact with healthcare \\nworkers.  \\n● Once active TB is ruled out, TPT should be provided to PWID living \\nwith HIV as per National guidelines for TPT.  \\n● PWID w ith active TB should receive standard TB treatment as per the \\nNational guidelines and be supported to complete treatment.  \\n● Anticipate and manage complications due to viral hepatitis or renal \\nimpairment.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 217}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 3 Table 12.1 Cont.  \\nPrevention, vaccination, \\ndiagnosis, and treatment for \\nviral hepatitis  Hepatitis B and C disproportionately affect PWID due to overlapping risk \\nfactors of sexual transmission and sharing needles, syringes, and other \\ndrug use items.  \\nHarm reduction and behavioral interv entions are also effective in \\nreducing risk of infection/transmission of HBV and HCV.  \\n● Peer interventions should be offered to people who inject drugs to \\nreduce the incidence of viral hepatitis  \\n● PWID should be screened for HBV (by HBsAg) and HCV (by HCV \\nsero logy) at first contact  \\n● Hepatitis B  \\no Hepatitis B vaccination is recommended for those who are \\nHBsAg negative. A higher -dose HBV vaccine should be used \\nwith the rapid regimen (day 0, 7, 21, and a booster at 12 \\nmonths). If the rapid regimen is not available, the standard \\nregimen should be offered. For PWID who are HIV positive, they \\nshould follow the dosing schedule in Table. 9.1  \\no HBV/HIV co -infected PWID should be started on TDF - or TAF - \\ncontaining ART (the current recommended first line is \\nTDF/3TC/ DTG) in addition to harm -reduction interventions to \\noptimize adherence and treatment outcomes.  \\n● Hepatitis C  \\no HCV/HIV co -infected PWID should be initiated on ART.  \\no Specific HCV antiviral therapy should be provided in \\nconsultation with expertise in the management of HCV infection \\n(refer to national guidelines on management of viral hepatitis)  \\n  \\nNeedle and syringe \\nprogrammes (NSPs)  NSPs help decrease drug -related risk behaviors, reduce quantity of \\ncontaminated needles in circulation, reduce risk of new HIV infections and \\nimprove referrals and linkage to HTS and HIV treatment and prevention \\nservices.  \\nNSPs are effective means for intr oducing combination prevention to PWID \\nincluding HTS, STI screening and treatment, condoms provision, OST, and \\nHIV treatment and prevention.  \\nAll PWID should be linked to NSPs to access sterile injecting \\nequipment  \\n \\nOpioid substitution therapy \\n(OST)  OST usi ng methadone or another suitable alternative is effective in the \\ntreatment of opioid dependency, reducing risk behaviors related to drug \\nuse and therefore reducing HIV transmission and improving PWIDs’ \\nadherence to ART  \\nIdentify and link all PWID who have o pioid dependence for opioid \\nsubstitution therapy  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 218}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 4 Table 12.1 Cont.  \\nAntiretroviral therapy \\n(refer to Table 12.2 for \\ndetails)  • ART is effective in managing HIV infection in PWID. However, poor \\nadherence may interfere with ART success. Intensive support is \\nrequired including OST, enhanced counselling techniques and daily \\nwitnessed ingestion (DWI) when available.  \\n• Close monitoring of ART is necessary because of risk of drug -drug \\ninteractions, renal and liver toxicity.  \\n• HIV-positive PWID should be off ered comprehensive HIV treatment \\nand prevention services including ART. When ART is provided with \\nadditional targeted support, PWID can achieve and maintain viral \\nsuppression.  \\n• Oral PrEP is recommended as an additional prevention choice for \\nPWID at substant ial risk of HIV infection as part of combination \\nprevention and harm reduction approaches.  \\nCommunity outreach  PWID face barriers to accessing formal facility -based health services due \\nto stigma, discrimination, and fear of victimization among other factors.  \\nOutreach either directly from the facility or through collaborations with \\ncommunity -based groups is an effe ctive means of delivering harm -\\nreduction interventions in addition to HIV treatment and prevention \\nservices.  \\nPeer -led, community -based approaches are particularly useful in \\nimproving adherence and retention.  \\n \\n12.3 ART in HIV positive PWID  \\nAntiretroviral  therapy is part of the comprehensive care package for PWID living with HIV. ART \\nservice provision should follow the same general principles and recommendations as for all \\nadults.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 219}),\n",
       " Document(page_content='  \\nPeople Who Inject Drugs (PWID) and HIV  \\n12 - 5 Table 12.2: Summary of ART Recommendations for PWID  \\nCare and Support  Recom mendation/Additional Information  \\nWhen to start ART in \\nHIV positive PWID  ART should be initiated in all individuals with HIV regardless of WHO clinical \\nstage or CD4 cell count  \\nWhat to start (first -line \\nART)  Irrespective of OST, PWID with HIV infection should be initiated on a first -line \\nregimen of TDF + 3TC + DTG  including women of childbearing potential.  \\nTDF + 3TC + ATV/r may be offered as an alternative where DTG cannot be used. \\n(Table 6.3)  \\nTB Co -infecti on  ART should be started as soon as possible within two weeks of initiating TB \\ntreatment, regardless of CD4 cell count.  \\nFor PWID with TB/HIV co -infection on DTG, give TDF/3TC/DTG FDC given in \\nthe am + DTG 50mg given in the pm for duration of rifampicin -containing TB \\ntreatment and for an additional 2 weeks after TB treatment is completed, then \\nrevert to TDF/3TC/DTG FDC once daily.  \\nSecond -line \\nART  Patients failing DTG -based first line ART (including PWID) should be managed \\nas per the viral load  monitoring algorithm (Figure 6.6), including performing a \\nDRT for selection of a second -line regimen (Table 6.10)  \\nTreatment preparation \\nand adherence \\ncounselling and \\nsupport  Injection drug use is not a contra -indication to ART initiation. OST, though \\nimp ortant in contributing to the success of ART in PWID, should not be a pre -\\nrequisite to initiation of ART. However, these patients benefit from additional \\npreparation and support to increase their chances of successful treatment \\nincluding:  \\n● Harm reduction in terventions  \\n● Thorough baseline assessment for important comorbid conditions like \\nAdvanced HIV Disease (AHD) including TB, hepatitis, renal impairment \\nand depression or other psychiatric disorders  \\n● Negotiation for, and access to daily witnessed ingestion (DWI ). \\n● Community outreach and support  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 220}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n 12 - 6 Table 12.1 Cont.  \\nPreventing and \\nmanaging drug -drug \\ninteractions  Selection of drugs should take into consideration possible drug to drug \\ninteractions and their effects on opioids, OST and ART. Any interaction that \\nreduces the levels of methadone may induce withdrawal symptoms and \\nrequire an increased dose of methadone.  \\n● ARV interactions with methadone and opioids  \\no NRTIs  \\n▪ TDF, TAF, 3TC, FTC: no significant interactions  \\n▪ AZT levels are increased, with higher risk of AZT toxicity.  \\n▪ ABC levels are decreased, and methadone levels are \\ndecreased.  \\no NNRTIs  \\n▪ EFV: methadone levels are decreased and may induce \\nwithdrawal symptoms.  \\no PI/r: all boosted PIs decrease methadone levels.  \\n▪ LPV/r and methadone increase risk for prolonged QT \\nsyndrome and sudden cardiac death.  \\no INSTIs: no significant interactions  \\n● ARV interactions with buprenorphine  \\no ATV/r and DRV/r increase concentrations of buprenorphine or \\nits active metabolites and may increase risk of toxicity.  \\no EFV decreases buprenorphine levels substantially.  \\no No known significant interactions with other ARVs  \\n● Rifampicin and Rifapentine decrease levels of methadone and \\nbuprenorphine and may induce withdrawal symptoms.  \\n● INH can be used safely with methadone or bupr enorphine  \\n● Management of Drug -Drug Interactions (Annex 13)  \\n \\nMonitoring ART  ● PWID on ART require more frequent monitoring and support to ensure \\nadherence to treatment and harm reduction interventions, assessment for \\nand management of adverse drug reactions or drug -drug interactions  \\n● Ongoing monitoring should also include screening for other illicit \\nsubstance/drug use.  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 221}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 1  \\n13. Annexes  \\n \\nAnnex 1: WHO Clinical Staging of HIV Infection in Infants and Children  \\nStage I  \\n• Asymptomatic  \\n• Persistent generalized lymphadenopathy  \\n• (PGL)  \\n• Unexplained, asymptomatic \\nhepatosplenomegaly  Stage II  \\n• Papular pruritic eruptions (PPE)  \\n• Seborrheic dermatitis  \\n• Fungal nail infections  \\n• Angular cheilitis  \\n• Linear gingival erythema  \\n• Extensive HPV or molluscum infection (>5% of \\nbody area/face)  \\n• Recurrent oral ulcerations (>2 episodes/ in 6 \\nmonths)  \\n• Parotid enlargement  \\n• Herpes zoster (>1 episode/12 months)  \\n• Recurrent or chronic upper respiratory infection \\n(URI): otitis media, otorrhea, sinusitis (>2 \\nepisodes/6 months)  \\nStage III  \\n• Unexplained moderate malnutrition ( -\\n2SD or Z score) not responding to \\nstandard therapy  \\n• Unexplained persistent diarrhoea (>14 \\ndays)  \\n• Unexplained persistent fever  \\n• (Intermittent or constant, > 1 mo.)  \\n• Oral candidiasis (outside neonatal \\nperiod)  \\n• Oral hairy Leucoplakia  \\n• Pulmonary tuberculosis  \\n• Severe recurrent presumed bacterial \\npneumonia (>2 episodes/12 months)  \\n• Acute necrotizing ulcerative gingivitis/  \\n• periodontitis  \\n• Lymphoid interstitial pneumonitis (LIP)  \\n• Unexplained anaemia (<8g/dL), \\nneutropenia (<1,000/mm3), or \\nthrombocytopenia (<30,000/mm3) for \\n>1 mo.  \\n• HIV-related cardiomyopathy  \\n• HIV-related nephropathy  Stage IV  \\n• Unexplained severe wasting or severe malnutrition \\n(-3 \\nSD or Z score) not responding to standard \\ntherapy  \\n• Pneumocystis pneumonia  \\n• Recurrent severe bacterial infections (>2 \\nepisodes/12 months, excluding pneumonia)  \\n• Chronic orolabial or cutaneous HSV (lasting > 1 \\nmo.)  \\n• Extra -pulmonary tuberculosis  \\n• Kaposi’s sarcoma  \\n• Oesophageal candidiasis  \\n• CNS toxoplasmosis  \\n• Cryptococcal meningitis  \\n• Any disseminated endemic mycosis  \\n• Cryptosporidiosis or Isosporiasis (with \\ndiarrhoea > 1 month)  \\n• CMV infection of organ other than liver, spleen, \\nlymph nodes (and onset age >1 month)  \\n• Disseminated mycobacterial disease other \\nthan tuberculosis  \\n• Candida of trachea, bronchi or lungs  \\n• Acquired recto -vesicular fistula  \\n• Cerebral or B -cell non -Hodgkin’s lymphoma  \\n• Progressive multifocal leukoencephalopathy PML)  \\n• HIV encephalopathy  \\nNOTE: WHO Clinical Staging should be carried out only on children confirmed (by serology or DNA PCR) \\nto be HIV infected  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 222}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 2 Annex 2: WHO Clinical Staging of HIV Infection in Adolescents and Adults  \\nStage 1  \\n• Asymptomatic  \\n• Persistent Generalized  \\nLymphadenopathy (PGL)  Stage 2  \\n• Moderate unexplained weight loss (< 10% of presumed \\nor measured body weight)  \\n• Minor mucocutaneous manifestations (seborrheic \\ndermatitis, papular pruritic eruptions, fungal nail \\ninfections, recurrent oral ulcerations, angular cheilitis)  \\n• Herpes zoster  \\n• Recurrent upper respiratory tract infections (sinusitis, \\ntonsillitis, bronchitis, otitis m edia, pharyngitis)  \\nStage 3  \\n• Unexplained severe weight loss \\n(over  \\n• 10% of presumed or measured \\nbody weight)  \\n• Unexplained chronic diarrhoea for \\nlonger than one month  \\n• Unexplained persistent fever \\n(intermittent or constant for longer \\nthan one month)  \\n• Persistent oral candidiasis  \\n• Oral hairy leukoplakia  \\n• Pulmonary tuberculosis  \\n• Severe bacterial infections (e.g., \\npneumonia, empyema, \\npyomyositis, bone or joint \\ninfection, meningitis, bacteraemia)  \\n• Acute necrotizing ulcerative \\nstomatitis, gingivitis or \\nperiodontitis  \\n• Unexplained anaemia (below 8 \\ng/dl), neutropenia (below 0.5 x \\n109/l) and/or chronic \\nthrombocytopenia (below 50 x 109 \\n/l) Stage 4  \\nConditions where a presumptive diagnosis can be made \\nusing clinical signs or simple investigations:  \\n•   HIV wastin g syndrome  \\n•   Pneumocystis jirovecipneumonia (PCP)  \\n•   Recurrent severe bacterial pneumonia (≥ 2 episodes \\nwithin 1 year)  \\n•   Cryptococcal meningitis  \\n•   Toxoplasmosis of the brain  \\n•   Chronic orolabial, genital or ano -rectal herpes simplex \\ninfection for > 1 month  \\n•   Kaposi’s sarcoma (KS)  \\n•   HIV encephalopathy  \\n•   Extra pulmonary tuberculosis (EPTB) Conditions \\nwhere confirmatory diagnostic testing is  \\nnecessary:  \\n•   Cryptosporidiosis, with diarrhoea > 1 month  \\n•   Isosporiasis  \\n•   Cryptococco sis (extra pulmonary)  \\n•   Disseminated non -tuberculous mycobacterial infection  \\n•   Cytomegalovirus (CMV) retinitis or infection of the \\norgans (other than liver, spleen, or lymph nodes)  \\n•   Progressive multifocal leukoencephalopathy (PML)  \\n•   Any disseminated mycosis (e.g., histoplasmosis, \\ncoccidiomycosis)  \\n•   Candidiasis of the esophagus or airways  \\n•   Non -typhoid salmonella (NTS) septicaemia  \\n•   Lymphoma cerebral or B cell Non -Hodgkin’s Lymphoma  \\n•   Invasive cervical cancer  \\n•   Visceral leishmaniasis  \\n•   Symptomatic HIV -associated nephropathy or HIV  \\nassociated cardiomyopathy  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 223}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 3 Annex 3: Normal Developmental Milestones in Children  \\nAGE  GROSS MOTOR  FINE MOTOR  WARNING SIGNS  \\n3 Months  Supine:  \\n● Pull to sit:  \\n● 45 o head lag still present  \\nSitting: Propped up  \\n● Flexed/C -Position  \\n● Hold head steady  \\nProne:  \\n● Bears weight on flexed arms  \\n● Lifts head 45 o turn head to side  Eyes:  \\n● Follow through 90 o in lying  \\nHands:  \\n● Open for longer  \\n● Shake a rattle when it is placed \\nin the hand (not intentional)  \\n● Mouthing begins  ● No visual fixation or following \\nasymmetry of tone or movement.  \\n● Floppy/stiff  \\n● Consistent fisting  \\n● Unstable to turn or lift head  \\n● Failure to smile  \\n● Poor sucking & swallowing  \\n6 Months  \\n Supine:  \\n● Pull to sit, no more head lag  \\n● Plays with feet  \\n● Rolls from back to tummy  \\nSitting:  \\n● Unaided supported by arms  \\nStanding:  \\n● Bears weight on legs, equal both sides  \\nProne:  \\n● Props self on straight arms, legs \\nextended, toes turned outwards  Eyes:  \\n● Follow through 180 o in lying  \\n● Focus on small objects  \\nHands:  \\n● Hands on midline  \\n● Banging blocks against the table \\nreaches and attains objects at \\nwill Holds and actively plays \\nwith rattle  ● Floppiness  \\n● No head control  \\n● Failure to use both hands  \\n●  Asymmetrical movement squint  \\n● Failure to turn to sound  \\n● Poor response to people  \\n9 Months  Sitting:  \\n● Sits without support lean forward  \\n● And sit up again without losing balance  \\nStanding:  \\n● Remain standing for a few seconds by \\nholding onto an object, falls down again  \\nProne:  \\n● Baby starts to crawl  Eyes:  \\n● Extremely accurate vision  \\nHands:  \\n● Can pick up and button  \\n● Holds a block in each hand  \\n● Points  ● Unable to sit  \\n● Failure to use both hands  \\n● Fisting  \\n● Squint  \\n● Persistence of primitive reflexes  \\n12 Months  \\n Sitting:  \\n● Turns around to reach nearby toys  \\n● Sits down unaided from standing  \\nStanding: (Walking)  \\n● Walks forward if held by one hand  \\n● Walks around furniture sideways -cruising  \\nProne: (crawling)  \\n● Crawls  \\n● Pulls up to standing by holding onto object  Eyes:  \\n● Looks for toys when out of sight  \\nHands:  \\n● Able to pick up a button with thumb and \\nindex finger (pincer grasp)  \\n● Release on request  \\n● Hold with 1 hand and play with the other  \\n● Throws things into a container and take \\nit out again  ● Unable to bear \\nweight on legs  \\n● Not yet crawling and \\npulling to stand  \\n● Abnormal grasp  \\n● Failure to  respond to \\nsound  \\n● Unable to start with \\nsolids independently  \\n15 Months  \\n Sitting:  \\n● Stand up from sitting  \\n● Will climb on a chair and sit down  \\nStanding: (Walking)  \\n● Bend over to pick up an object  \\n● Squat and stand up again  \\n● Walks alone, broad base with arms in the airs  \\nProne: (crawling)  \\n● Able to crawl fast and manage obstacles e.g., stairs  Eyes:  \\n● Hold crayon in a fist when \\nscribbling  \\n● Turn pages of a book roughly  \\n● Hold 2 small toys in 1 hand  \\n● Put lid back on container  ● Unable to bear \\nweight on legs  \\n● Not yet wal king  \\n● Abnormal grasp  \\n● Abnormal posture: \\nfloppy/spastic  \\n● Failure to respond to \\nsound  \\n● Not yet talking  \\n18 Months  ● Walking with more confidence  \\n● Walk, squat and pick up something, \\nstand up and walk again  \\n● Starts running, often falls  \\n● Take few steps backwards  \\n● Runs and change direction easily  \\n● Jump off step with 2 feet together  \\n● Stand and kick a ball  \\n● Able to throw a ball  ● Build a 3 -cube tower  \\n● Scribbles  \\n● Holds the crayon in a fist  \\n● Turn pages of a book  \\n● Page through a book page by page  \\n● Obvious hand preference  \\n● Uses lines: I, _,0  \\n● Completes 3 -piece puzzle  \\n● Remove a sweet wrapper with little help  ● Failure to walk  \\n● Unable to pick up small \\nobjects e.g., buttons  \\n● Abnormal posture  \\n● Not yet talking  \\n● Unable to understand \\nsimple commands  \\n● Poor co -ordination  \\n36 Months  ● Walk forward and backward  \\n● Walks on tip toes  \\n● Walks on straight line  \\n● Jump 2 feet together  \\n● Able to climb on chair  \\n● Catch a big ball (hugging against chest)  \\n● Holds ball above head and throws  \\n● Runs and kicks ball  ● Copies the following shapes: _, I, O, T \\n● Start coloring in, go over the lines  \\n● Pencil grip:  \\n● Holding crayon to draw (still developing)  \\n● Builds a 9 -block tower  \\n● Thread big beads on a shoelace  \\n● Draw a man: at least 4 parts  ● Using only single \\nwords  \\n● Ataxia  \\n   \\n \\n \\n \\n \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 224}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 4 Annex 4: Tanner Staging of Sexual Maturity in Adolescents  Annex 4 A: Tanner Staging of Sexual Maturity in Girls  \\nAge Range  \\n(Year)  \\n0-15 \\n8-15 \\n10-15 \\n10-17 \\n12-18 Tanner Staging in  \\n Annex 4 B: Tanner Staging of Sexual Maturity in Boys  \\nAge Range  \\n(Year)  \\n0-15 \\n \\n10-15 \\n \\n10-16 \\n \\nVariable  \\n(12-17) \\n13-18 Tanner Staging in  \\n \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 225}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 5 Annex 5: Age -Appropriate Disclosure for Children and Adolescents  \\nAge \\nCharacteristics  Stage of \\nDisclosure  Provider Actions  \\n0 - 4 years  No disclosure  At this stage no disclosure is done since the child is too young \\nto understand about HIV  \\n5 - 8 years  Partial disclosure  At this age the child can understand a lot. Define the virus as a \\ngerm and the CD4 as the soldier in the body that keeps fighting \\nand one has to take the drugs to strengthen the soldiers in the \\nbody  \\n9 to 12 years  Full disclosure  Full disclosure is important since most children at this stage \\nare able to understand more about HIV and would have heard \\nabout HIV as part of formal education at school  \\nFollow the following stages in the disclosure process  \\nStage 1  \\nAssessing the child’s social support system to ensure \\navailability of sufficient support once disclosure is completed  \\nStage 2  \\nAssess the child’s prior knowledge about HIV including \\ninformation given at school, any myths and misconceptions. \\nOffer or reinforce accurate information  \\nStage 3  \\nUse an imaginary exercise or story to assess child’s reaction to \\ndisclosure of HIV status  \\nStage 4  \\nTell the child about their HIV status. Support parents to \\ndisclose to the child and clarify the mode of infect ion. Address \\nimmediate reactions and concerns a child might have  \\nPost -disclosure  \\n(1-2 weeks after \\nfull disclosure)  Find out from the parent/guardian if they have observed \\nanything after disclosure, e.g., change in behavior  \\n• Introduce the child to tell their story and emerge as a hero \\n(a comic book may be a useful aid)  \\n• Link the child to a support group or with an older child \\nwho has been disclosed to  \\nNB: Find out how the child is doing at every visit after full \\ndisclosure  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 226}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 6 Annex 6: Transitioning from Adolescent to Adult HIV Services  \\nInitiate transition process for all children in \\npaediatric clinic who have attained 10 years of ageGoal 1 : for age 10 -12 years (early -adolescence)\\n•  Full disclosure\\n•  Understanding of the HIV\\n•  Understanding of HIV prevention measures\\n•  Link to an adolescent support group Has adolescent attained 13years and achieved Goal 1 \\nabove?\\nYes: Client is 13years and has achieved \\ngoals at early adolescence continue to \\ngoal 2No: Client is 13years and has \\nnot achieved goals 1 at early \\nadolescence\\nGoal 2 : for age 13 -16 years (mid -adolescence)\\n•  Understanding of the medication and adherence\\n•  Encourage appointment keeping\\n•  Should be a member of a support group\\nHas adolescent attained 17years and achieved Goal 2 above?No: Client is 17 years and has not \\nachieved goals at mid adolescence\\nYes: Client is 17 years and has achieved goals at mid adolescence\\nGoal 3 : for age 17 -19 years (late -adolescence)\\n• Demonstrated understanding importance of medication adherence in last 2 -3 visits\\n• Prompt appointment keeping for 6months\\nHas adolescent attained 19years and achieved Goal 3 above?\\n Client chooses to transition\\n Transfer medical records\\n Orient adolescent in adult clinic\\n Follow up of transitioned adolescentsClient declines to transition\\n Continue psychosocial support to client as you prepare for transition to \\nadult clinic\\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 227}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 7 Annex 7: 2018 HIV Testing Services Algorithm  \\nSCREENING\\nNON REACTIVE REACTIVE\\nREPORT NEGATIVE CONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nINCONCLUSIVE REPORT POSITIVE\\nREFER TO THE COMPREHENSIVE CARE CLINIC\\nSCREENING TEST SCREENING TEST\\nNON REACTIVE REACTIVE NON REACTIVE\\nCONFIRMATORY TEST\\nNON REACTIVE REACTIVE\\nREPORT INCONCLUSIVE REPORT POSITIVECollect DBS and \\nsend to laboratory \\nfor DNA PCRINCONCLUSIVE\\nRequest for retest \\nafter 2 weeks at \\nCCC\\nIf the result is still \\ninconclusive, \\ncollect DBS and \\nsend to the \\nlaboratory for DNA \\nPCREnroll to care and \\ntreatment \\nNB:  The use of TIE BREAKER is no longer recommendedRetesting in MCH, wards or \\nsettings without CCCs: To be \\ndone by a different service \\nprovider on a second \\nspecimen\\nREPORT NEGATIVE\\n \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 228}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 8 Annex 8: HIV Education and Adherence Counselling Content Guide  \\nHIV Education and Adherence Counselling  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSection 1: Introductions, climate setting, and review of objectives for the session  \\n• Ensure privacy and confidentiality  \\n• Introductions of all pa rticipants  \\n• Present the key message for each section using simple terms that the patient will understand, \\nusing analogies as appropriate  \\n• Use IEC material when available  \\n• Ask the patient if they have any questions at the end of each section, and then ask them to explain the \\nmain points back to you to confirm understanding  \\n• If this is a follow -up session, review what they remember from previous sessions and adapt the \\nsession  to address their needs  \\nSection 2: HIV  \\n• What is HIV  \\n− HIV stands for “Human Immunodeficiency Virus”  \\n− HIV is a virus that attacks the body’s immune system.  The immune system protects the \\nbody from infections  \\n• How is HIV transmitted  \\n− Sexual contact  \\n− Needles  \\n− Exchange of blood and bodily fluids  \\n− Mother -to-child transmission  \\n• Why should family members be tested for HIV  \\n− Sexual partners are at risk for already having HIV  \\n− All children born to HIV positive mothers are at risk for already having HIV  \\n− Encouraging partners/children to test for HIV now is the best way to identify HIV early, so \\nthey can also get into treatment  \\n− Starting treatment early will help them live long and productive lives  \\n− Whether they test positive or negative, they can be an impor tant source of support for your \\nown treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 229}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 9 Annex 8: Cont.  \\nSection 3: Viral load  \\n• What is viral load  \\n- Viral load is the amount of HIV in your body  \\n- When your viral load is high it means you have a lot of HIV in your body; this causes damage to \\nyour body  \\n- Viral load is measured by a blood test  \\n \\n• How often is viral load measured  \\n- Viral load is measured after being on treatment for 3 months  \\n- After 3 months of treatment, we expect the amount of virus in your body to be undetectable; if \\nyour VL is detectable then we have to discuss the reasons  \\n- Having an “undetectable” VL means the test cannot measure the virus in your blood because \\nyour ART is working, but it does not mean you are no longer infected with HIV  \\n- Repeat viral load tests are done dependin g on how you are doing; if you are doing well on \\ntreatment then the viral load is measured again every 6 months (for children/adolescents and \\npregnant/breastfeeding) or annually  \\n- For HEI with positive PCR, we also measure viral load at the start of treatmen t \\n \\n• What do viral load measurements mean  \\n- After being on treatment for 3 or more months, your viral load should be undetectable  \\n- If your viral load is undetectable, it means your treatment is working well and you should \\ncontinue taking it the same; the virus is not damaging your body any more  \\n- If your viral load is detectable, it means your treatment is not working properly, usually because \\nyou have been missing some of your pills; the virus is damaging your body and you and the clinic \\nteam will need to work together to figure out how to fix the problem  \\nSection 4: CD4 cells  \\n• What are CD4 cells  \\n- CD4 cells are the immune cells that protect the body from infections  \\n- CD4 cells are measured through a blood test, called CD4 count. For adults a normal CD4 count is \\nabove 500  \\n \\n• How are CD4 cells affected by HIV  \\n- HIV attacks and destroys CD4 cells  \\n- After years of constant attack from HIV, the CD4 count falls  \\n \\n• What happens when CD4 cells decrease  \\n- When the CD4 count falls too low (usually below 200), diseases called “opportunistic infections” \\nare able to infect the body because the body cannot defend itself  \\n- Common opportunistic infections include: tuberculosis, pneumonia, skin problems, white spots \\nin the mouth, and chronic diarrhoea  \\n \\n• How often is CD4 count measured  \\n- CD4 count is measured for all patients at the beginning of treatment, to see if you are likely to get \\nany opportunistic infections  \\n- Once you start treatment for HIV, we do not need to check CD4 count frequently, but we will use \\nthe VL tes t to monitor your response to anti -retroviral treatment  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 230}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being  \\n- People can often return to work or school or care for their families  \\n- With ART,  people with HIV can live a long and healthy life if they take it properly  \\n \\n• When is ART started:  \\n- Everybody with HIV should start ART  \\n- Even if your CD4 count is high, the virus is doing damage inside of you and needs to be \\ncontrolled  \\n- ART should be started as soon as you are ready, preferably within 2 weeks  \\n- The longer you wait to start ART, the more time the virus can damage your body, increasing \\nyour chances of getting sick or even dying  \\n- Sometimes ART is started a few weeks later if you have certain infections, or if you do not \\nthink you are ready to take them properly  \\n \\n• Does ART cure HIV:  \\n- ART does not cure HIV  \\n- ART lowers the amount of virus in your body so your body can protect itself from infections  \\n- It does not remove the virus completely  \\n \\n• Can you still give HIV to others while taking ART:  \\n- Transmission of HIV is very unlikely once your viral load is undetectable  \\n- You should practice safer sex to reduce the risk for other infections as well, including \\ndisclosure of HIV status to sexual partners and consistent and correct condom use  \\n \\n• How long is ART taken for:  \\n- ART is a life -long treatment  \\n- Once you start ART, you need to take it every day for the rest of your life (either once a day, \\nor twice a day, depending on which drugs you are on)  \\n- You must take the ART as prescribed and never miss a dose otherwise the treatment might \\nfail and the drugs stop working against the virus  \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 231}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 11 Annex 8: Cont.  \\nSection 6: Treatment failure  \\n• What happens if you stop taking ART:  \\n- When you stop taking ART the virus begins to increase in your body very quickly  \\n- The virus goes back to the same high level it was at before you started ART  \\n• What happens if you do not take ART regularly:  \\n- The virus begins to increase to high levels again  \\n• What happens if t he viral load increases:  \\n- When the virus is allowed to increase again, it will also affect your immunity and reduce your CD4 count \\nputting you at risk of opportunistic infections  \\n- When the virus is allowed to increase again, it can change and get stronger, a nd becomes resistance to \\nthe ART  \\n- When the virus becomes resistant, the ART does not work against the virus anymore  \\n- The risk of resistance increases by not taking the ART correctly and by starting and stopping the \\nmedications several times  \\n- When resistance o ccurs, this is called treatment failure  \\n• What happens in treatment failure:  \\n- The ART no longer works because the virus has become resistant to it  \\n- If treatment fails, it is necessary to use stronger, more expensive ART, but it still may not work as well  \\n- With the stronger ART you may need to take more pills every day, and you may have more side effects  \\n- If you become resistant to the new ART as well, then there may not be any drugs that can work for you, \\nand the virus will increase quickly and your CD4 coun t will go way down  \\n- It is essential that you take your ART every day as prescribed so that you do not develop treatment \\nfailure, and can live a long and healthy life  \\nSection 7: ART side effects  \\n• What are the side -effects of ART:  \\n- Sometimes people can get side effects from taking ART  \\n- Side effects vary from person to person  \\n- Some people have none while other experience mild effects which are unpleasant but often manageable  \\n- Most side effects occur within the first few weeks of starting ART and then improve aft er a few weeks or \\nmonths  \\n- Some common side effects include:  \\n● Headache  \\n● Loss of appetite  \\n● Skin rash  \\n● Fatigue  \\n● Nausea, vomiting, diarrhoea  \\n● Muscle pains  \\n• What do you do if you notice any side effects:  \\n- If you develop any side effects, you should continue taking your ART as prescribed, without missing any \\ndoses, until you discuss with the clinician  \\n- If the side effects are mild then you can continue taking your ART without missing any doses, and then \\ndiscuss the side effects with the clinician at your next appointment  \\n- If the side effects are bothering you too much then return to the clinic immediately, even if you do not \\nhave a scheduled appointment, to discuss what to do next; you can also call the clinic if you are not able \\nto make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 232}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:  \\n• If your ART is supposed to be taken once per day, then pick a time when it will usually be \\nconvenient for you to remember, e.g., with breakfast every day.  \\n• If your ART is supposed to be taken twice per day, then you should set a convenient time to \\ntake your dr ugs approximately 12 hours apart (e.g., 8.00 am and 8.00 pm every day). It \\ndoes not have to be exactly 12 hours apart if your schedule does not allow; the most \\nimportant thing is to take them twice per day every day (e.g., you can take it at 6.00 am and \\n8.00 pm every day)  \\n- If you miss a dose of ART then take your dose as soon as you remember, as long as it is not \\nwithin a couple of hours of your next dose, and then return to your regular schedule. Do not \\ntake a double -dose of ART to make up for a missed dose  \\n- You must take ART according to dietary restrictions. Some ART should be taken with food, for \\nsome it does not matter, and a few require that you have an empty stomach. These dietary \\nrestrictions will be explained to you once your ART regimen is  selected  \\n- It is essential to take ART as prescribed and not miss any doses  \\n- Some medications (prescription, non -prescription, and herbal) interact with ART and make \\nthem ineffective. Be sure to tell your clinician and pharmacist the names of all the medicat ions \\n(including traditional/herbal) that you are taking, and any time you are given new medications. \\nAvoid use of alcohol  \\n• What usually interferes with good adherence (can apply to the patient or to the caregiver)  \\n- Stigma: it is hard to take ART correctly if you need to hide it because you are worried about \\npeople finding out you have HIV  \\n- Disclosure: it is hard to take ART correctly if the people closest to you, particularly family \\nmembers and close friends, do not know you have HIV  \\n- Change in rout ine: if your daily routine suddenly changes it may be difficult to remember to \\ntake your ART at the usual time  \\n- Travel: frequent travel, or unexpected travel (such as for a funeral) may interfere with taking \\nART, particularly if you do not have enough drugs  with you for the entire trip  \\n- Alcohol and drug use: it is hard to remember to take ART when under the influence of alcohol \\nor other drugs  \\n- Caregiver changes: every time a child has a new caregiver, that person needs to learn about \\nhow and why ART is taken  \\n- Side effects: when people get side effects from ART they sometimes stop or reduce the amount \\nof ART they are taking, hoping it will reduce the side effects  \\n- Pill burden/palatability: sometime the number of pills (or taste of syrups for children) makes it \\ndifficult to take ART correctly  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 233}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 13 Annex 8: Cont.  \\n- Distance: choosing an HIV clinic that is far away from your home can make it difficult to come to \\nappointments and pick drugs regularly  \\n- HIV knowledge: when people do not understand what HIV is, and why ART is important, they \\nmay not take their drugs properly. This also applies to children and adolescents, if they have \\nnot been told they have HIV and taught what it means  \\n- Mental health disorders: depression and other mental illnesses can make it difficult to t ake ART \\ncorrectly  \\n- Religious beliefs: some people stop taking ART after faith -healing, although there has never \\nbeen a case of someone being cured of HIV this way  \\n• What might make it difficult for you individually to take your ART as prescribed  \\n- Ask the patie nt: “Based on what you have learned so far, what challenges do you think you will \\nhave taken  ART correctly, every day, for the rest of your life?”  \\n- Discuss strategies to manage any expected barriers to adherence  \\n• What can help you take ART as prescribed  \\n- Disclosure: It is easier to take your ART properly when the people close to you know your HIV \\nstatus, so you do not have to try and hide your ART or miss doses to avoid being seen. Family \\nand friends can also provide additional support once they  are aware you have HIV and \\nunderstand more about it. We can help you disclose your HIV status to important family \\nmembers or friends when you are ready  \\n- Treatment supporter: Having a “treatment buddy” can help you take your ART correctly; ask a \\nfriend, par tner, or family member to remind you to take your ART. If possible, invite that \\nperson with you to some of your clinic appointments and counselling sessions so they can learn \\nabout ART, the importance of good adherence, side effects, etc.  \\n- SMS reminder syst em (if SMS reminder system in place at the facility): Receiving a regular SMS, \\ne.g., every week, can help you take your ART correctly. We enroll all our patients into this \\nservice for SMS reminders at our clinic, unless you do not want to receive them. The  messages \\nsimply ask how you are doing, and do not mention HIV, ART, the clinic, or anything else that \\nmay reveal your HIV status to others  \\n- Support group: Joining a support group will help you learn from other people how they \\novercome challenges in living with HIV and taking ART correctly. Some support groups also \\nhave economic activities to help increase your income. We have support groups based at the \\nhealth facility, and there are also support groups in the community  \\n- Other reminders:  \\n- Set a specific time of day to take your ART  \\n- Associate your ART with a specific event/s in your daily schedule (e.g., when you eat \\nbreakfast and dinner)  \\n- Set an alarm on your phone or watch  \\n• What happens if you miss an appointment?  \\n• The healthcare team will be concerned about you, and will try to contact you by phone  \\n- Confirm patient phone number and consent to call if misses an appointment or any urgent \\nlab results  \\n• If we cannot contact you by phone, we will try to call your treatment buddy  \\n- Confirm treatment buddy name and phone number, and consent to call if needed  \\n• If we cannot reach you or your treatment buddy, we may try and visit you at home, if we have \\nyour permission  \\n- Confirm locator information and consent to perform home visits if needed  \\n• Once you are back in care, we will work with you to figure out what caused you to miss an \\nappointment and how it can be prevented in the future  \\n• You will not be punished for missing an appointment  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 234}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 14 Annex 8: Cont.  \\nSection 9: Other medications  \\n• What other medications will you take, in addition to ART:  \\n- CPT: all PLHIV should take cotrimoxazole preventive therapy once per day, in order to reduce \\nthe chance of getting other infections such as pneumonia, malaria, and diarrhoea  \\n- TPT: all PLHIV should receive 6 months of isoniazid preventive therapy (or another \\napproved TPT regimen), unless they have active TB disease, in order to prevent \\ndevelopment of TB  \\n• Other medications may be recommended for specific conditions  \\nSection 10: Nutrition  \\n• Why is nutrition important:  \\n- When the viral load is high, your body uses a lot of energy trying to fight the virus  \\n- If your nutrition is poor, you have more chance of getting other infections as well  \\n- You need to eat well so your body has everything it needs to fight HIV, and look healthy  \\n• What can you do to improve your nutrition?  \\n- Eat a balanced diet from a variety of foods.  \\n- Try not to eat a lot of sugar, red meat, or fatty/fried foods  \\n- Try to eat plenty of whole grains, vegetables, fruit, beans, and fish  \\n- Drink plenty of clean safe water  \\n- Physical activity and exercise is encouraged.  \\nSection 11: Follow -up \\n• How often will you need to come to the clinic  \\n- Before starting ART: you should come to the clinic at least every week in order to get you prepared \\nfor ART so you can start as soon as possible  \\n- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \\nsee if you have had any trouble taking your pills or have developed any side effects; then you can \\nbe seen after another two weeks for the same; then every month until your first viral load test  \\n- Once you have been on ART for a while: if your first viral load (after 3 months) is undetectable \\nthen you can be seen every 1 -6 months depending on other factors  that will be discussed with the \\nclinician  \\n- Unscheduled visits: if you ever have any concerns, feel unwell, or need to speak with any of the \\nclinic team then you can call or come to the clinic, even if you do not have an appointment \\nscheduled for that day  \\n• What will we be checking for during your clinic visits  \\n- At each visit you will be asked if you have had any illnesses since the last visit, if you have had any \\ntrouble taking your ART, and if you are experiencing any side effects. You may need a physic al \\nexam or blood tests at some visits  \\nSection 12: ART readiness assessment  \\n• Are you ready to start ART today?  \\n- Complete the ART Readiness Assessment (Table 5.4) for each patient to see if they should \\nstart ART today, and if not, to identify what issues need to be addressed before starting \\nART  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 235}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 15 Annex 8: Cont.  \\nSection 13: Management plan  \\n• Which investigations will you have today  \\n- See Table 3.2 and Table 3.5 for recommended baseline and follow -up investigations \\nrespectively  \\n• Which medications will you start today  \\n- May include: ART; CPT; TPT; other  \\n• What else is required as you start or as you prepare to start ART  \\n- May include: assisted disclosure; support group referral; engagement of a treatment \\nbuddy; drug and alcohol counselling; depression management; referrals; other  \\n- For patients not starting ART today, management plan should include specific \\nstrategies to address any issues preventing/delaying ART initiation  \\n• When should you return to the clinic  \\n- Book appointment date  for next visit, preferably with the same healthcare worker  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 236}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 16 Annex 9 A: Enhanced Adherence Counselling Content Guide  \\nEnhanced Adherence Counselling for Patients with Suspected or Confirmed Treatment Failure  \\nNote: for children/adolescents, the script below should be modified towards the caregiver  \\nSession 1  \\n• Assess patient’s understanding of ‘viral load’, ‘high viral load’ and ‘suppressed viral load’. Ask \\nthe patient to explain what each of these terms mean. Provide education if patient requires \\nmore explanation  \\n• Provide VL result and explanation of result:  \\n“You have a detectable viral load. There are several possible reasons for this such as problems with \\nadherence, dosing of your medications, interactions wit h other drugs or foods, or possible drug \\nresistance. It is very important for us to work with you determine which may apply to you.”  \\n• How does the patient feel concerning the result?  \\n• Explain the process of enhanced adherence:  \\n“Patients with a high viral load come for at least 3 adherence counselling sessions to discuss what \\nmight cause a high viral and to look for solutions on how adherence can be improved. Another \\nviral load test will be done after 3 months of good adherence to see if the ART can b e continued or \\nif we need to change treatment.”  \\n• Check whether the patient had previous problems with adherence and/or missed \\nappointments  \\n• Ask:  \\n“Why do you think your viral load is high?”  \\n• Sometimes the patient already knows why his/her VL is detectable. Sta rt by giving them a \\nchance to provide their own explanation. Often, they will admit that they are struggling with \\ntheir adherence  \\n• If they really don’t know why their VL is high you can say:  \\n“We notice that when people sometimes forget to take their ART everyday it gives the virus a chance \\nto multiply. Do you think that you sometimes forget your pills?”  \\nAssess for Possible Barriers to Adherence  \\nCognitive Barriers (HIV and ART knowledge)  \\n• Assess patient’s knowledge about HIV and ART; correct any misconceptions  \\n“What is HIV?”  \\n“What is the immune system and CD4 cells?”  \\n“What is ART and how does it work?”  \\n“Why is it important to be adherent? And how?”  \\n“Why do you have to come for follow -up appointments? What should you bring?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 237}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 17 Annex 9A: Cont.  \\nBehavioural Barriers  \\n• Review how the patient takes drugs  \\n“Please explain how you take your drugs, and at what time?”  \\n“How does treatment fit in your daily routines?”  \\n• Establish with the patient whether the time they are meant to take their medication is \\nappropriate or whether the time is a problem. For example, if the patient has chosen 9 pm, \\nbut is already asleep in bed by 9 pm, then that is not a good dosing time. If the time is a \\nproblem, then determine a new, more appropriate time with the patient based on their \\nschedule  \\n• Remind the patient/caregiver that a missed dose should be taken as soon as he/she \\nremembers (up to a couple of hours before the next scheduled dose). The next dose should \\nbe taken at the usual time  \\n“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \\ntravel?”  \\n• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \\nto plan, to make sure they have enough medication on hand  before and to remember to pack \\nit \\n• Make sure that all relevant information is on the patient’s appointment card and explain that \\nif they are ever away from home and they are about to run out of medication that they must go \\nto the closest ART clinic and sho w their appointment card  \\n“What do you do in case of side effects?”  \\n• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \\ndifficult to take ARVs  \\n• Due to the side effects, ask how s/he manages side effects and if it influences the way s/he \\ntakes the drugs.  \\n“What are the most difficult situations for you to take drugs?”  \\n• Check for alcohol or drug use. Ask the patient in a casual way (not in an accusing way) if they \\nsometimes use substances; emphasize treatment planning in case they do  \\n• “Taking alcohol or drugs sometimes makes it difficult for us to remember to take treatment. If \\npossible, it is best to limit your use, but if you are planning to take any alcohol or drugs, it is \\nimportant to plan ahead so that you don’t for get to take your treatment”  \\n“If you feel your alcohol or drug use is affecting your adherence, are you ready to be referred to some \\nprofessionals that may help you work on that problem?”  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 238}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 18 Annex 9A: Cont.  \\n● Emotional Barriers  \\n• Review the patient’s motivation:  \\n“How do you feel about taking drugs every day?” \\n“What are your ambitions in life?”  \\n• You can use motivation cards for this: Ask the patient to think of his or her own personal \\ngoals/dreams for the future. What are the 3 most important things they  still want to achieve? \\nHave them write them in their own words on a notecard. Encourage the patient to read the \\nnotecard every day, preferably right before they take their medication  \\n• Mental health screening:  \\n- Depression is an important reason of non -adherence.  All patients with suspected or \\nconfirmed treatment failure should be screened for depression using the PHQ -9 tool \\n(Table 4.14)  \\n- The patient may be in any of the five stages of grief (because of their HIV diagnosis or for \\nother reasons): deni al and isolation; anger; bargaining; depression, or; acceptance. This \\nneeds to be assessed and addressed  \\nSocio -economical Barriers  \\n• Review the patient’s disclosure of their HIV status  \\n“Do you have any people in your life who you can talk to about your HIV status and ART?”  \\n• Discuss how the patient can enlist the support of their family, friends, and/or co -workers in \\nreminding them to take their medication if they have not already done so  \\n• Support from a treatment buddy: if the patient came with treatment buddy, assess their input \\ntowards adherence. If patient did not come with treatment buddy, explain the role of a treatment \\nbuddy and encourage the patient to come with a person they trust next visit  \\n• Support in family/community/support group: expl ore support systems, in addition to the \\ntreatment buddy, that the patient is currently using and options that the patient can start using. \\nDiscuss the advantages of joining a support group and any reasons the patient is hesitant to join  \\n• Profession, income generating resources: review the patient’s and family’s sources of income \\nand how well they cover their needs  \\n• Specific barriers to come to health centre on regular basis: ask the patient if they have any \\nchallenges getting to the clinic on regular basis. Help the patient develop strategies to overcome \\nthose challenges  \\n• Stigma and discrimination  \\n“Are you ever worried about people finding out your HIV status \\naccidentally?” “Do you feel like people treat you differently when they know \\nyour HIV status?”  \\n• Discuss if stigma is making it difficult for them to take their medications on time, or for them \\nto attend clinic appointments  \\n• Religious beliefs: find out if the patient has tried faith healing, or if they have ever stopped taking \\ntheir medicine because of their religious beliefs  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 239}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 19 Annex 9A: Cont.  \\nReferrals and Networking  \\n• Review the patient’s file to determine if they have been referred to other services. This includes \\nreferrals to social services, support groups, psychology services, nutrition services, medical \\nclinics, substance abuse groups, etc.  \\n• Ask the patient if they attended the appointments, check in on their experience with the \\nreferral services and re -organize referrals as necessary  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the \\npatient to develop a plan that addresses each of the issues. It is important to let the patient \\ncome up with the solutions so that they can own them  \\n• Some examples of addressing adherence challenges:  \\n- Behavioural barriers: using a reminder tool; using a pill box; redefining the medication \\nschedule to fit with the patient’s daily schedule; keeping an emergency dose of drugs when \\naway from home  \\n- Refer to clinician in case of side effects  \\n- Socio -economical barriers: move on to disclosure process; identify a treatment buddy; join a \\nsupport group; refer to CBO/NGO to learn about income generating activities  \\n- Emotional barriers: emotional support or refer to clinician for mental health management  \\nAgree on a follow -up date for the next session  \\n \\nSession 2 (usually 2 weeks after Session 1, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If  not, discuss why  \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic \\nappointment since the last counselling session, and determine if it is a new issue that \\nwasn’t addressed during the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., \\nperhaps the disclosure process had unintended results)  \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivational speech on how you believe in the patient! You know they can \\ndo this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date fo r the next session  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 240}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 20 Annex 9A: Cont.  \\nSession 3 (usually 2 weeks after Session 2, preferably with the same provider)  \\nReview Adherence Plan  \\n• Ask the patient if he/she thinks adherence has improved since the last visit. Enquire in a \\nfriendly way if any doses have been missed  \\n• Review the patient’s barriers to adherence documented during the first session and if \\nstrategies identified have been taken up. If not, discuss why  \\n \\nIdentify Any New Issues  \\n• Discuss specific reasons why the patient may have missed their pills or a clinic appointment \\nsince the last counselling session, and determine if it is a new issue that wasn’t addressed \\nduring the first session  \\n• Discuss if other issues have come up because of implementing the adherence plan (e.g., perhaps \\nthe disclosure process had unintended results)  \\n \\nReferrals and Networking  \\n• Follow -up on any referrals made during the previous session  \\n• Determine if the patient could benefit from a home visit  \\n \\nDevelop Adherence Plan  \\n• Go through each of the adherence challenges identified during the session and assist the patient \\nto modify their original adherence plan to address each of the issues. It is important to let the \\npatient come up with the solutions so that they own them  \\n• Give another short motivati onal speech on how you believe in the patient! You know they \\ncan do this! Together you will make sure that they suppress their viral load!!  \\n• Agree on a follow -up date for the next session  \\n \\nRepeat Viral Load  \\n• If the adherence is good: plan for the next VL testing after 3 months and explain possible ways \\nforward, emphasizing the roles of the patient, the support systems and the health facility. You \\ncan continue follow -up adherence counselling sessions during the 3 -month period if you and \\nthe patient think th ere would be a benefit to them  \\n“If your results come back and your VL is undetectable then you will be able to continue with same ART. \\nIf your viral load is still greater than 1,000 copies/ml then you will need to switch to a new regimen, \\nprobably after do ing some additional testing to see which regimen may work best for you. If your viral \\nload is detectable but less than 1,000 copies/ml we will discuss options, including changing regimens \\nor continuing to monitor.” (Adapt to individual patient/context)  \\n• If adherence challenges persist: plan further Enhanced Adherence Counselling Sessions before \\nrepeating the VL  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 241}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 21 Annex 9A: Cont.  \\nSession to Discuss Repeat Viral Load Results (after the repeat VL results are back, preferably with \\nthe same provider)  \\nDiscuss Viral Load Results  \\n• If suppressed (VL < 50 copies/ml) CONGRATULATE the patient!!!  \\n- Explain the way forward: will continue with same ART regimen and repeat the VL again in 6 \\nmonths  \\n• If viral load is ≥ 1,000 copies/ml  \\n- Explain the way forward: will probably need to switch to a new ART regimen after discussing \\nas an MDT, and additional testing to see which regimen may work for the patient  \\n- Summarize the case with the MDT; if the patient cannot switch to standard 2nd line ART, or \\nis failin g 2nd line ART, forward to the Regional or National HIV Clinical Technical Working \\nGroup for next steps  \\n• If viral load is 50 - 999 copies/ml  \\n- Explain the way forward: will reassess barriers to adherence, support systems, and other \\nreasons for viremia; once reason/s for viremia have been addressed then will repeat the viral \\nload after another 3 months of excellent adherence  \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 242}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 22 Annex 9 B: Case Summary Form  \\n \\n \\nMINISTRY OF HEALTH  \\nNATIONAL AIDS AND STI CONTROL PROGRAMME  \\nCLINICAL SUMMARY FORM  \\nName of \\nFacility   MFL \\nCode   \\nPatient CCC \\nno.  \\n(Do not write \\nname )  Date   \\nPatient \\nDetails  Date of Birth:                  Enrollment Date:  \\n \\nGender:   Current Weight (Kg):                      Height (cm):  \\nClinician’s \\nName   \\nFacility \\nContacts  Tel:  Email:  \\n \\nWhat is the primary reason for this consultation:  \\n \\nClinical Evaluation: history, physical, diagnostics, working diagnosis ( excluding the information in \\nthe table below  \\n \\n \\n \\n \\n \\n \\nComplete the table below chronologically, including all ART regimens and laboratory results (and \\nany previous history available for transfer -in patients)  \\nDate  CD4  HB CrCl/  \\neGFR  Viral \\nLoad  Weight  \\n(z-score/BMI \\nfor children)  ARV \\nRegimen  Reason for \\nSwitch  New OI or other \\nclinical event  \\n         \\n         \\n         \\n         \\n         \\n         \\n \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 243}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 23 Annex 9 B: Cont.  \\nAdherence and Treatment Failure Evaluation  \\nParameters of Evaluation  Findings  \\n● Number and findings of adherence counseling/assessment \\nsessions done in the last 3 -6 months including the following:  \\no Findings from MMAS -8 \\no Adherence barriers identified  \\no Recommendations   \\nNumber of home visits conducted in last 3 -6 months, and findings   \\nDescribe support structures (e.g., treatment buddy, support group \\nattendance, caregivers) in place for this patient   \\nEvidence of adherence concerns (e.g., missed appointments, pill counts)   \\nDescribe daily witnessed ingestion done in last 3 -6 months (Who performed \\nit, which tool was used, how long was session done etc.)   \\nDescribe likely root cause/s of poor adherence for this patie nt (e.g., stigma, \\ndisclosure, side effects, alcohol or other drugs, mental health issues, \\ncaregiver changes, religious beliefs, inadequate preparation, etc.)   \\nEvaluation for other causes of treatment failure, e.g.:  \\n● Inadequate dosing/dose adjustments (particularly for children)  \\n● Drug -drug interactions  \\n● Drug -food interactions  \\n● Impaired absorption (e.g., chronic severe diarrhea)   \\nOther Relevant ART History  \\nComment on treatment interruptions, if any   \\nHas Drug Resistance Testing been done for this patient? If yes, state date \\ndone and attach the detailed results   \\nHas facility multidisciplinary team discussed the patient’s case? If yes, \\ncomment on date, deliberations and recommendations (indicate how \\ntreatment failure was established and con firmed, proposed regimen and \\ndosage, current source of drugs if patient already on 3rd line)   \\nMDT members who participated in the case discussion (names and titles)   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 244}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 24 Annex 9 C: Enhanced Adherence Counselling Form  \\nENHANCED ADHERENCE COUNSELLING FORM  \\n(To be completed by the counsellor)  \\n• Start each session by reviewing the adherence barriers and action plan from the previous session  \\n• For each session assess major barriers to adherence (cognitive, behavioral, emotional, socio -economic)  \\nSession #:   Date:   Adherence % (from pill count):   MMAS -8 Score:   \\nTreatment \\nmotivation:   \\n \\n \\n \\n \\n \\n \\n \\nBarriers to \\nadherence:   \\n \\n \\n \\nYour impression about patient’s \\ncurrent adherence:    ▢ Excellent                ▢ Unsure            ▢ Inadequate  \\nAdherence plan:   \\n \\n \\n \\n \\n \\n \\nNext appointment date:   \\n \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 245}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 25 Annex 9 D: Home Visit Checklist  \\nHOME VISIT CHECKLIST  \\nPatient Name  Tel No:  Sex: M            F     \\nFamily Member  Tel No:  Sex: M            F     \\nPhysical Landmark:   File No.  \\n \\nThis checklist is not all -inclusive but highlights critical areas that can affect adherence.  \\n Areas to Assess and Discuss  Comments  \\nI Is the patient independent in the activities of daily living (e.g., \\nfeeding, grooming, toileting) l  \\n2 Are the patient’s basic needs being met (e.g., clothing, shelter, food) l  \\n3 Has the patient disclosed their HIV status to other household members   \\n4 How are the patient’s ARVs stored and taken?   \\n5 Does the patient receive social support from household members   \\n6 Does the patient receive social support in the community e.g., linked to \\nOVC, income generating activities, community -based support group, CBO, \\ncash transfer program?   \\n7 Is the patient linked to non -clinical services (e.g., spiritual, legal \\nor nutritional)    \\n8 Does the patient have mental health issues that need to be addressed (use \\nPHQ9 to screen for depression), or use drugs or alcohol?   \\n9 Is the patient suffering from a stressful situation or significant loss/grief?   \\n10 Is the patient having any side -effects from the medications?   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 246}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination  \\no Complete clinical encounter form and MOH 257 (Green Card)  \\no Manage any co -infection and co -morbidities  \\no Review for potential drug interactions and contraindications  \\no Conduct adherence assessment and review adherence support systems including \\ndaily witnessed ingestion plan  \\no Reinforce patient education messages on new regimen  \\n▪ Currently limited future treatment options  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe new regimen  for 2 weeks  \\no Confirm dosing as per the weight (for ≤15)  \\no Continue other medication e.g., CPT, OI treatment etc.  \\n \\n• Dispensing  \\no Confirm ARV dosing as per the weight (for ≤15)  \\no Conduct medication use counselling  \\no Dispense 3rd Line ARVs for 2 weeks  \\no Check for possible drug interaction  \\n \\n• Community follow up  \\no Link all patients to support group, CHV/CHA  \\no Plan for home visits as required  \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 247}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 27 Annex 9 E: cont.  \\nPatient Follow Up after Treatment Initiation  \\n● Frequency  \\no First follow -up should be within 2 weeks of initiation of 3rd line ART  \\no Subsequent visits should be monthly (or more frequent) until confirmed viral sup - \\npression at 6 months  \\no Thereafter, follow -up can be 1 -3 monthly  \\n \\n● Triage  \\no Record vital signs and take action as needed  \\n \\n● Adherence Support (adherence should be reinforced during every clinic visit, in addition to \\nenhanced adherence counselling sessions)  \\no Review and address knowledge deficits on new regimen  \\no Confirm understanding of adherence, conduct adherence assessment, and reinforce key \\nadherence messages  \\no Document reasons for missed doses and manage obstacles to perfect adherence. Review \\nand reinforce adherence support systems  \\n \\n● Clinical Assessment  \\no Take history and conduct physical examination  \\no Complete Clinical Encounter Form and MOH 257 (blue card)  \\no Manage any co -infections and co -morbidities  \\no Evaluate for potential drug interactions  \\no Evaluate for and manage any drug side effects and adverse events  \\no Conduct adherence assessment and review adherence  support systems  \\no Reinforce patient education messages on new regimen  \\n▪ Review and address knowledge gaps on ART regimen  \\n▪ Need for perfect adherence (>95%)  \\n▪ Dosing schedule and timing  \\n▪ Potential side effects and what the patient should do  \\no Prescribe 3rd line ARVs  \\n \\n● Viral load should be conducted 3 months after change of regimen  \\n \\n● Dispensing  \\no Confirm ARV dosing as per the weight  \\no Conduct medication use counselling  \\no Dispense 3rd line ARVs  \\n \\n● Community Follow up  \\no Review linkage to community adherence support systems  \\no Conduct home visits as required  \\no Continue DOTS  \\n \\n● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 248}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 28 Annex 10 A: Dosing of Solid and Liquid Formulations for Twice -Daily Dosing in Infants and Children 4 Weeks of Age \\nand Older  1\\n \\nDrug  Strength of tablets  Number of tablets by weight band morning and evening  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg  25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM AM PM \\nAZT/3TC  Tablet (dispersible) 60/30 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 mg  1 1 \\nAZT/3TC/NVP2 Tablet (dispersible) 60/30 mg/50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 /150 /200 mg  1 1 \\nABC/3TC  Tablet (dispersible) 120/60 mg  0.5 0.5 0.5 1 1 1 1 1.5 1.5 1.5 600 /300 mg  0.5 0.5 \\nABC/3TC/LPV/r  30/15/40/10 mg  2 2 3 3 4 4 5 5 6 6    \\nSOLID SINGLE FORMULATIONS  \\nAZT  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg 1 1 \\nABC  Tablet (dispersible) 60 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 300 mg  1 1 \\nNVP2 Tablet (dispersible) 50 mg  1 1 1.5 1.5 2 2 2.5 2.5 3 3 200 mg  1 1 \\nTablet 200 mg  – – – – 0.5 0.5 1 0.5 1 0.5 200 mg  1 1 \\n \\nLPV/r3 Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nTablet 200/50 mg  – – – – – – 1 1 1 1 200/50 mg  2 1 \\nGranules4 40/10 mg per sachet  2 2 3 3 4 4 5 5 6 6    \\nDRV5 Tablet 75 mg  – – – – 3 3 5 5 5 5    \\n \\nRAL6 Chewable tablets 25 mg  – – – – 3 3 4 4 6 6 400 mg  1 1 \\nChewable tablets 100 mg  – – – – – – 1 1 1.5 1.5 400 mg  1 1 \\nGranules (100 mg/sachet)  0.25  0.25  0.5 0.5 – – – – – –  – – \\nLIQUID SINGLE FORMULATIONS  \\nAZT  10 mg/ml  6 ml  6 ml  9 ml  9 ml  12 ml  12 ml  – – – – – – – \\nABC  20 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\n3TC  10 mg/ml  3 ml  3 ml  4 ml  4 ml  6 ml  6 ml  – – – – – – – \\nNVP2 10 mg/ml  5 ml  5 ml  8 ml  8 ml  10 ml  10 ml  – – – – – – – \\nDRV5 100 mg/ml  – – – – 2.5 ml  2.5 ml  3.5 ml  3.5 ml  – –    \\nNotes  1 For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2 NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended for infants > 2 weeks of age and not already on NVP prophylaxis to avoid toxicity from high initial \\nNVP levels. HEI already on NVP prophylaxis who are confirmed positive can initiate full dose (twice daily) NVP without dose escalation  \\n3 The LPV/r heat -stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. The adult 200/50 mg tablet may be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tabs am and 1 tab pm) who are able to swallow them whole. The 100/25 mg tablet is smaller than the adult formulatio n and may be used \\nby children of lower weight  bands able to swallow tablets whole.  \\n4 LPV/r granule formulation can be used in infants over 2 weeks of age. Transition to tablets as soon as a child is able to swa llow tablets whole. The 4 -in-1 ABC/3TC/LPV/r may be used after \\n1 month of age if the combin ation is appropriate and once it becomes available.  \\n5 DRV must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50 mg solid formulation in children 15 to 30 kg  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 249}),\n",
       " Document(page_content='  \\nAnnexes  \\n13 - 29 6RAL granules are approved for use in newborn childre n, however the administration procedure is complex and the formulation has very limited availability. If this RAL must be use d, consult \\nthe regional/national clinical support center  \\n Annex 10 B: Simplified Dosing of Child -Friendly Solid and Oral Liquid For mulations for Once -Daily Dosing in \\nInfants and Children 4 Weeks of Age and Older1 \\nDrug  Strength of tablet  Number of tablets or capsules by weight band once \\ndaily  Strength of adult \\ntablet  Number of tablets or capsules \\nby weight band once daily  \\n3–5.9 \\nkg 6–9.9 \\nkg 10–13.9 \\nkg 14–19.9 \\nkg 20–24.9 kg   25–34.9 kg  \\nEFV2 Tablet (scored) 200 mg  – – 1 1.5 1.5 200 mg  2 \\nABC/3TC  Tablet (dispersible) 120/60 \\nmg 1 1.5 2 2.5 3 600 mg/300 mg  1 \\nDTG  Tablet (dispersible) 10 mg  0.5 1.5 2 2.5 33   \\nDTG  Tablet 50 mg  - - - - 1 50 mg  1 \\nDTG/TDF/  \\n3TC   - - - - - 50/300/300  1 \\nATV4 Capsules 100 mg  – – 1 2 2 300 mg  2 (100 mg) or 1 (300 mg)  \\n \\nTDF5 Oral powder 40 mg/scoop  – – 3 – –  \\n300 mg  1 (200 mg) d or 1 (300 mg)  \\nTablets 150 mg or 200 mg  – – – 1 (150 mg)  1 (200 mg)  \\nNotes  1For infants younger than 4 weeks of age refer to Table 10C for more accurate dosing information  \\n2EFV is not recommended for children younger than 3 years and weighing less than 10 kg. Where there are no suitable alternativ es, EFV may be used in children le ss than 3 years \\nweighing more than 3.5 kg (3.5 -5 kg two 50 mg capsules; 5 -7.5 kg three 50 mg capsules; 7.5 -15 kg one 200 mg capsule).  \\n3 DTG dispersible tablets have higher bioavailability than film tablets and doses are not interchangeable. Children can tr ansition to the 50 mg film tablet once they reach 20 kg. If unable to \\nswallow the tablets whole, the dispersible tablets may be given at a dose of 30 mg daily.  \\n4ATV is only approved for use in children 3 months and older. ATV single strength capsules shoul d be administered with RTV 100 mg for all weight bands. ATV powder formulation \\nenables administration of ATV to infants and children as young as 3 months. Infants and children 5 -10 kg should be given 200 mg of ATV powder (4 packets, 50 mg/ packet) with 80 \\nmg of RTV oral solution (1 ml)  \\n5TDF is can be used in children 2 years and older. Target dose: 8 mg/kg or 200 mg/m2 (maximum 300 m  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 250}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 30 Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than 4 Weeks of Age  \\nDrug  Strength of oral liquid  2-3 kg  3-4 kg  4-5 kg  \\nAZT  10 mg/mL  1 mL  1.5 mL  2 mL  \\nNVP1 10 mg/mL  1.5 mL  2 mL  3 mL  \\n3TC  10 mg/mL  0.5 mL  0.8 mL  1 mL  \\nNotes  1 NVP for treatment can be initiated with twice daily dosing for infants < 2 weeks of age (they do not require once -daily lead -in dosing)  \\n \\nAnnex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are at Least 4 Weeks of \\nAge \\nDrug  Strength of tablet or oral \\nliquid  Number of tablets or ml by weight band once daily  Strength of adult \\ntablet  Number of tablets \\nby weight band  \\n \\n3–5.9 kg   \\n6–9.9 kg   \\n10–13.9 kg   \\n14–19.9 kg   \\n20–24.9 kg    \\n25–34.9 kg  \\nINH  100 mg  0.5 1 1.5 2 2.5 300 mg 1 \\nCTX  Suspension 200/40 per 5 ml  2.5 ml  5 ml  5 ml  10 ml  10 ml  – – \\nTablets (dispersible) 100/20 mg  1 2 2 4 4 – – \\nTablets (scored) 400/80 mg  – 0.5 0.5 1 1 400 mg/80 mg  2 \\nTablets (scored) 800/160 mg  – – – 0.5 0.5 800 mg/160 mg  1    \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 251}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 31 Annex 10 E: TB Preventive Therapy dosing  \\nA. Daily INH for 6 months (6H)  \\nWeight (Kg)  Dose (mg)  Number of 100mg INH tablets  Number of 300mg (Adult) tablet  \\n<5 50 ½ tablet  - \\n5.1-9.9 100  1 tablet  - \\n10-13.9  150  1½ tablet  ½ tablet  \\n 14-19.9  200  2 tablets  - \\n20-24.9  250  2 ½ tablets  - \\n≥25  300  3 tablets  1 tablet  \\nAdult  300  3 tablets  1 tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 252}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 32 Annex 10 E: Cont.  \\nB1. Daily INH for 6 months (6H)  \\nWeight (Kg)  Number of tablets (RH \\n75/50mg  How to reconstitute the medicine  \\nLess than 2  ¼  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved. Give 5ml (¼) of this solution measured with a syringe.  \\n2-2.9 ½  Dissolve one (1) tablet of RH is 20 ml of safe drinking water. Once fully \\ndissolved, give 10ml (½) of this solution measure d with a syringe.  \\n3-3.9 ¾  Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully \\ndissolved, give 15 ml (¾) of this solution measured with a syringe.  \\nAfter giving the child their dose for that day, discard the rest of the solution. Pre pare a fresh solution. Prepare a fresh solution every day.  \\n4-7.9 1 Dissolve the tablet(s) of RH in 20mls of safe drinking water.  \\n \\nOnce fully dissolved, give ALL this solution to the child  8-11.9  2 \\n12-15.9  3 \\n16-24.9  4 \\nB2. Daily RH for 3 months (3RH) for children ≥25kgs (To use adult formulation)  \\nWeight (Kg)  Number of tablets (RH 150/75mg)  \\n25-39.9  2 \\n40-54.9  3 \\n55kg and above  4 \\nC.  Weekly 3HP (3HP) (For adults and adolescents ≥15 years)  \\n3HP products  No of Tablets  \\nRifapentine 150mg tabs  6 \\nIsoniazid 300mg tabs  3 \\nRifapentine 300mg+Isoniazid 200mg (FDC)  3 \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 253}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 33 Annex 10 E: Cont.  \\nD. Dosage of Pyrldoxine (Vitamin B6)  \\nWeight (Kgs)  Dosage In mg  Number of 25mg tablets  Number of 50mg tablets  \\n<5 6.25mg  ½ Tablet 3 times a week, alternate days  - \\n5.0-79 12.5mg  Half a tablet  - \\n8.0-14.9  25mg  One tablet  Half of 50mg tablet  \\n15kg and above  50mg  Two tablets  One 50mg tablet  \\nAdults  50mg  Two tablets  One 50mg tablet  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 254}),\n",
       " Document(page_content='  \\nKenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 34 Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  \\nDosing for RTV super -boosting of LPV/r for children receiving rifampicin -containing TB treatment*  \\nDrug  Strength of paediatric \\ntablets or oral liquid  Number of tablets or MLS by weight -band morning (AM) and evening (PM)  Strength of \\nadult tablet  Number of tablets \\nby weight band  \\n3–5.9 kg  6–9.9 kg  10–13.9 kg  14–19.9 kg  20–24.9 kg   25–34.9 kg  \\nAM PM AM PM AM PM AM PM AM PM  AM PM \\nFor children able to swallow tablets  \\nLPV/rb Tablet 100/25 mg  – – – – 2 1 2 2 2 2 100/25 mg  3 3 \\nRTV  Tablet 100 mg  – – – – 1 1 1 2 1 2  \\n \\n100 mg   \\n2  \\n2 Tablet 50 mg  – – – – 2 2 3 3 3 3 \\nTablet 25 mg  – – – – 4 4 6 6 6 6 \\nFor children unable to swallow tablets  \\nLPV/r  Oral solution 80/20 mg/ml  1 ml  1 ml  1.5 \\nml 1.5 ml  2 ml  2 ml  2.5 \\nml 2.5 \\nml 3 ml  3 ml  - - - \\nPellets 40 mg/10 mg  2 2 3 3 4 4 5 5 6 6 - - - \\nGranules 40 mg/10 mg \\nsachet  2 2 3 3 4 4 5 5 6 6 - - - \\nRTVe Oral solution 80 mg/ml  0.8 ml  0.8 ml  1.2 ml  1.2 ml  1.5 ml  1.5 ml  2 ml  2 ml  2.3 ml  2.3 ml  - - - \\nPowder 100 mg/packet  - - 1 1 1 1 1 2 1 2 - - - \\na Suggested RT V dose for super -boosting to achieve the same dose as LPV in mg, in a ratio equal or approaching to 1:1. This dosing approach is supported by a study which explored this \\napproach in young children receiving LPV/r12. \\nb the LPV/r heat -stable t ablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult 200 / 50 tablet could be used for patients 14 -24.9kg (1 \\ntab am and 1 tab pm) and for patients 25 -34.9kg (2 tab am and 1 tab pm).  \\nc LPV/r liquid requires a cold chain during transport and storage.  \\nd LPV/r pellets formulation should not be used in infants younger than 3 months. More details on the administration of LPV/r pe llets can be found at \\nhttps://www.who.int/hiv/pub/toolkits/iattfactsheet -lopinavir -ritonavir/en/. The dosing schedule provided applies to equivalent solid dosage forms that may become available such as \\nLPV/r granules, which are approved by US FDA for use from 2 weeks of life.  \\n  e RT V oral solution dosing is ba sed on the dosing tested in the trial that supports the use of super boosting', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 255}),\n",
       " Document(page_content='  \\nAnnexes  \\n \\n13 - 35 Annex 11: Overlapping toxicities between ARVs  \\nBone marrow \\nsuppression  Peripheral \\nneuropathy  Pancreatitis  Nephrotoxicity  Hepatotoxicity  Rash  Diarrhoea  Ocular effects  \\nAmphotericin B \\nCotrimoxazole \\nDapsone Flucytosine \\nGanciclovir \\nHydroxyurea \\nInterferon - \\nPrimaquine \\nPyrimethamine \\nZidovudine  Didanosine \\nIsoniazid \\nVincristine  Didanosine \\nLamivudine  \\n(esp. in \\nchildren)  \\nStavudine \\nCotrimoxazole \\nRitonavir \\nPentamidine  Acyclovir  \\nAdefo vir high dose \\nAminoglycosides \\nAmphotericin B \\nCidofovir  \\nFoscarnet \\nPentamidine \\nTenofovir  Abacavir  \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Abacavir \\nAtazanavir \\nAtovaquone \\nCotrimoxazole \\nDapsone \\nEfavirenz \\nNevirapine \\nSulfadiazine \\nVoriconazole  Atovaquone \\nClindamycin \\nLPV/r Ritonavir  Cidofovir Ethambutol \\nLinezolid Rifabutin \\nVoriconazole  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 256}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 36 Annex 12 A: Use of Nucleoside & Nucleotide Reverse Transcriptase Inhibitors \\nin Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nZidovudine  \\n(AZT or ZDV)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nNVP  300mg/  \\ndose BD  No food \\nrestrictions  Bone marrow suppression), \\nincluding anaemia; \\ngranulocytopenia; headache; \\ngastrointestinal intolerance; \\nmyopathy; myositis; liver toxicity; \\ndiscoloured nails; lactic acidosis \\nand severe  \\nhepatomegaly with steatosis (fatal \\ncases have been reported)  Monitor for anaemia in  the \\nfirst 3 months of treatment  \\nLamivudine (3TC) \\nAvailable in 150mg  \\ntablet and as FDC \\nwith AZT and \\nAZT/NVP, D4T and \\nD4T/NVP and with \\nTDF and TDF/ EFV  150mg/ \\ndose BD \\nOR 300 \\nmg/dose \\nOD No food \\nrestrictions  Headache; fatigue; nausea; \\ndiarrhoea; skin rash; pancreatitis; \\nperipheral neuropathy; \\nhepatotoxicity/ hepatitis; lactic \\nacidosis and severe hepatomegaly \\nwith steatosis (rare fatal cases \\nhave been reported).  A well -tolerated drug. \\nAdjust dose in renal \\nimpairment.  \\nAlso active against hepatitis B. \\nIdeally, patients should be  \\nscreened for hepatitis B virus  \\n(HBV) before starting therapy; \\nexacerbation of hepatitis B has \\nbeen reported in patients on \\ndiscontinuation of 3TC.  \\nAbacavir (ABC) \\nAvailable in 300mg  \\ntablets and in \\ncombination with  \\n3TC and DTG  300mg/  \\ndose BD  \\n or 600mg \\nOD No food \\nrestrictions. \\nAlcohol \\nincreases \\nABC levels \\nby 41%  Hypersensitivity reaction \\n(potentially fatal) whose \\nsymptoms include fever, \\nfatigue, malaise, nausea, \\nvomiting, diarrhoea  \\nand abdominal pain or \\nrespiratory symptoms such as \\nshortness of breath, \\nlymphadenopathy, ulceration of \\nmucous  \\nmembranes and skin rash. Patients \\nsuspected of having \\nhypersensitivity reaction should \\nhave ABC stopped and never be \\nrestarted. Pancreatitis; lactic \\nacidosis with hepatic steatosis is \\nrare  Educate patient on \\nhypersensitivity reaction. \\nOnce hypersensitivity has \\noccurred, the patient should \\nnever be re -challenged with \\nABC.  \\n \\nAvoid alcohol while on ABC.  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 257}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 37 Table 12 A: Cont.  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEmtricitabine  \\n(FTC)  \\n \\nAvailable in 200mg \\ncapsules and as FDC \\nwith TDF and \\nTDF/EFV  200mg/  \\ndose OD  No food \\nrestrictions  Well tolerated. Lactic \\nacidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported); headache; \\ndiarrhoea; nausea; rash; \\nskin discoloration  Effective against hepatitis B. \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; exacerbation of Hepatitis \\nB has been reported in patients on \\ndiscontinuation of FTC  \\nDecrease dosage in patients with \\nrenal impairment Monitor renal \\nfunction if combined with TDF.  \\nWhen used in combination with \\nTDF, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min. Should \\nnot be used with or aft er failure of \\n3TC  \\nTenofovir \\ndisoproxil fumarate \\n(TDF)  \\n \\nAvailable in 300mg \\ntablets and as FDC \\nwith 3TC and 3TC/ \\nEFV  300mg/  \\ndose OD  No food \\nrestrictions  Lactic acidosis and severe \\nhepatomegaly with \\nsteatosis (fatal cases have \\nbeen reported with \\nnucleoside analogues); \\nrenal toxicity; Pancreatitis  Should not be used with ddI. \\nShould never be used in triple \\nnucleoside combinations  \\nwith 3TC+ddI/ABC.  Renal function \\nshould be monitored while on TDF  \\nIdeally, patients should be \\nscreened for chronic hepatitis B \\nvirus (HBV) before starting \\ntherapy; Exacerbation of hepatitis \\nB has been reported in patients on \\ndiscontinuation of TDF  \\nWhen used in combination with \\n3TC, should not be given to \\npatients with a creatinine \\nclearance of <30ml/min.  \\nWhen used with ATV levels of ATV \\nreduced significantly therefore \\ncombine with RTV  \\nTenofovir \\nalafenamide (TAF)  \\n \\nVarious co -\\nformulations \\navailable or being \\ndeveloped  As TAF 25 \\nmg alone or \\nas part of \\nco-\\nformulated \\nFDC  No food \\nrestrictions  Well tolerated. GIT upsets, \\nraised serum creatinine, \\nproteinuria and renal \\ntoxicity (but to a lesser \\ndegree than TDF)  RTV and cobicistat increase TAF \\nlevels. DRV decreases TAF levels. \\nBoosted PI increase TAF levels but \\nthe PI levels are not affected.  \\nAvoid co -administration with \\nrifabutin, rifampicin and phenytoin  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 258}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 38 Annex 12 B: Use of Non -Nucleoside Reverse Transcriptase Inhibitors for Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nEfavirenz (EFV) \\nAvailable in 200mg  \\n& 600mg tablets \\nand as FDC with \\nTDF/3TC  600mg \\nOD Best \\ntaken  \\nat \\nbedtime  Preferably \\ntaken on an \\nempty \\nstomach.  \\nCan be given \\nwith food, \\nbut avoid \\nhigh fat  \\nmeals which \\nincrease \\nabsorption.  CNS symptoms \\n(somnolence, insomnia, \\nabnormal dreams, \\nconfusion, \\nhallucination, amnesia, \\netc. Avoid in patients \\nwith history of \\npsychiatric disease);  \\nSkin rash; avoid use in \\nduring the first \\ntrimester  Can be used with rifampicin in TB \\npatients  \\nEtravirine (ETR) \\nAvailable in tablets  \\nof 200 mg   \\n200 mg \\nBD  \\nTake with \\nfood  Severe but rare: SJS and \\nerythema multiforme \\nCommon & minor: \\nRash, nausea, vomiting, \\ndiarrhoea, abdominal \\npain, hepatotoxicity, \\ndyslipidaemia and CNS \\ndisturbances (less than \\nEFV)  Avoid concurrent use with \\nrifampicin, and boosted tipranavir.  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 259}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 39 Annex 12 C: Use of Protease Inhibitors in Adults  \\nDrug name  Dose (in \\nadults)  Dietary \\nrestrictions  Major side effects  Comments  \\nLopinavir/ritonav\\nir (LPV/r) \\nAvailable as \\n200mg  \\n+ 50mg RTV  [LPV 400 mg \\n+ RTV  \\n100 mg] 2 \\ntablets BD  Take with food. \\nModerate  \\nfat increases \\nbioavailability.  GI intolerance; \\nnausea; vomiting; \\ndiarrhoea  Tablets should be \\nswallowed whole  \\nAtazanavir  \\n(ATV)  \\n \\nAvailable in  \\n100mg, 150mg, \\n200 mg capsules  \\n \\nAvailable as FDC  \\nwith RTV  ATV 300mg / \\nRTV 100mg \\nOD Take with food. \\nTake 2 hours \\nbefore or 1  \\nhour after \\nantacids and \\nbuffered \\nmedications \\nsuch as buffered \\nddI (reduced \\nATV \\nconcentrations  \\nif administered \\ntogether)  Jaundice; headache; \\nfever; depression; \\nnausea; diarrhoea \\nand vomiting; \\nparaesthesia; \\nspontaneous \\nbleeding episodes \\nin haemop hiliacs.  Indirect \\nhyperbilirubinaemia. \\nWhen used with TDF \\nshould always be given \\nwith RTV. Experienced \\npatients should also be \\ngiven ATV/RTV.  \\nRitonavir  \\n(RTV)  \\n \\nAvailable as 100mg \\ncapsules  \\nCapsules should be \\nrefrigerated until \\ndispensed; stable \\nat room (up to \\n25ºC) for 30 days  Recommended \\nfor use as a \\nbooster of \\nother PIs  Administration \\nwith food \\nincreases \\nabsorption and \\nhelps reduce \\ngastrointestinal \\nside effects.  Exacerbation of liver \\ndisease; fat \\nredistribution and \\nlipid abnormalities; \\ndiarrhoea; \\nabdom inal \\ndiscomfort; \\nheadache; nausea; \\nparaesthesia;  \\nskin rash; \\nspontaneous \\nbleeding episodes in \\nhaemophiliacs.  Potent CYP450 inhibitor, \\nthus its use as a booster \\nof other PIs  \\nDarunavir (DRV)  DRV 600 \\nmg/ RTV \\n100 mg BID \\nOR \\n \\nDRV 800 \\nmg/ RTV 100 \\nmg OD (only \\nif PI naïve)  Take with a \\nmeal to limit \\nADR  GIT upsets, rash, \\ndyslipidaemia, \\nhepatitis. Caution \\nin patients with \\nsulphur allergy.  Metabolized by CYP3A \\nand is an inhibitor of \\nCYP3A. Contains sulphur \\nmoiety. Monitor liver \\nfunctions especially in \\npatients at risk  or with \\npre-existing liver  \\ndisease.  May cause \\nhormonal contraceptive \\nfailure.  \\n   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 260}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 40 Annex 12 D: Integrase Strand Transfer Inhibitors - INSTIs  \\nDrug name  Dose (in adults)  Dietary \\nrestrictions  Major side effects  Comments  \\nDolutegravir \\n(DTG) Available \\nas DTG 50mg, \\n10mg dispersible \\ntablet  \\n \\nOr FDCs:  \\nABC/3TC/DTG \\n(600/300/50mg)  \\n \\nand \\n \\nTDF/3TC/DTG \\n(300/300/50mg)  50 mg once daily  \\n \\nIf co - \\nadministering with \\nEFV, \\ncarbamazepine, or \\nrifampicin, use \\nDTG 50 mg BD  \\n \\nIf suspected or \\nconfirmed INSTI \\nresistance use DTG \\n50 mg BD  No food \\nrestrictions  Rare - \\nHypersensitivity; \\nHepatotoxicity \\nespecially in those  \\nwith HBV and HCV  \\ninfection, fatigue  \\n \\nInsomnia, headache, \\ndiarrhea, nausea is \\ncommon but usually \\nminor and resolve \\nwith continued use  Interacts with  carbamazepine, \\nphenobarbital and phenytoin, \\nuse alternative \\nanticonvulsants.  \\n \\nAdminister DTG at least 2 \\nhours before or 6 hours after \\ntaking supplements or \\nantacids containing Mg, Al, Fe, \\nCa and Zn. For Ca or Fe, if DTG \\nis taken with a meal then dose \\nsepa ration is not required  \\nRaltegravir (RAL)  ADULT and CHILD \\nover 16 years, 400 \\nmg BD  No food \\nrestrictions  Nausea, vomiting, \\ndiarrhoea, \\nflatulence, \\nconstipation  \\nSevere skin (SJS \\nand TEN) and \\nhypersensitivity \\nreactions have \\nbeen reported  Contraindicated in \\nbreast - feeding mothers  \\nSafety in paediatric patients \\nhas not been established  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 261}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 41 Annex 13 A: Drug -Drug Interactions - NNRTIs  \\nDrugs Affected  Nevirapine (NVP)  Efavirenz (EFV)  \\nANTIRETROVIRALS  \\nDolutegravir  Co-administration not recommended because NVP \\ndecreases levels of DTG  Co-administration not recommended because EFV decreases \\nlevels of DTG.  If must be used together then increase DTG to \\n50 mg BD when co -administered with EFV  \\nRaltegravir  No interaction or not studied  Efavirenz decreases RAL plasma levels but it is unlikely to be \\nclinically sign ificant  \\nAtazanavir/ritonavir  Co-administration not recommended because ATV/r may \\nincrease the serum concentration of NVP leading to \\nincreased risk of toxicity, and NVP decreases the serum \\nconcentration of ATV/r which may lead to resistance and \\ntreatment failure  Co-administration not recommended because EFV decreases \\nthe serum concentration of ATV/r which may lead to \\nresistance and treatment failure  \\nLopinavir/ritonavir  Co-administration not recommended because NVP \\ndecreases levels of LPV/r  AVOID : this combination increased risk of prolonged -QT \\nsyndrome and sudden cardiac death  \\nDarunavir/ ritonavir  No significant interaction when NVP is combined with \\nritonavir -boosted darunavir  Co-administration not recommended because DRV/r may \\nincrease the seru m concentration of EFV leading to increased \\nrisk of toxicity, and EFV decreases the serum concentration of \\nDRV/r which may lead to resistance and treatment failure  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 262}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 42 Annex 13 A: Cont.  \\nANTIFUNGALS  \\nKetoconazole  Levels: ketoconazole ↓ 63%  \\nNVP ↑ 15 – 30%  \\nDose: Not recommended  No data  \\nVoriconazole  Metabolism of Voriconazole may be induced by NVP. \\nVoriconazole may inhibit NNRTI metabolism. Frequently \\nmonitor for NNRTI toxicity and antifungal outcome  Levels: EFV ↑ 44%  \\nVoriconazole ↓ 77%  \\nThis combination is not recommended  \\nFluconazole  NVP Levels: Cmax, AUC, and Cmin ↑ 100%  \\nFluconazole Levels: No change  \\nRisk of hepatotoxicity may increase with this combination. If \\nconcomitant use is necessary, recommend monitoring NVP \\ntoxicity  No clinically significant changes in EFV or \\nFluconazole concentrations  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Levels: NVP ↓ 20% -58%. Virologic consequences are uncertain; \\nthe potential for additive hepatotoxicity exists. Use of this \\ncombination is not recommended; however, if used, co \\nadministration should be done with careful monitoring  Levels: EFV ↓ 25%.  \\nDose: Consider ↑ EFV to 800 mg QD  \\nClarithromycin  Levels: NVP ↑ 26%. Clarithromycin ↓ 30%. Monitor for efficacy \\nor use alternative agent  Levels: Clarithromycin ↓ 39%.  \\nMonitor for efficacy or use alternative agent  \\nBedaquiline (BDQ)  No dose adjustment required  Do not co -administer  \\nDelamanid (DLM)  No interaction expected  No interaction  \\nORAL CONTRACEPTIVES  \\n Levels: ethinyl estradiol approx. 20%. Use alternative or \\nadditional methods.  Levels: Ethinyl estradiol   37%. No data on other \\ncomponents. Use alternative or additional methods  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 263}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 43 Annex 13 A: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  No data  Levels: Simvastatin AUC    by 58%; EFV unchanged  \\nDose: Adjust simvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nAtorvastatin  No data  Levels: Atorvastatin AUC   43%; EFV unchanged.  \\nDose: Adjust atorvastatin dose according to lipid responses, \\nnot to exceed the maximum recommended dose  \\nPravastatin  No data  No data  \\nANTI -HYPERTENSIVES   \\nAngiotensin -converting enzyme \\ninhibitors (ACEIs): E.g.  - Enalapril, \\nLisinopril  No known interactions  No known interactions  \\nAngiotensin II receptor blockers \\n(ARBs): e.g., Losartan, Telmisartan  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  Telmisartan, Candesartan: None  \\nLosartan: Potential interactions with all NNRTIs, net effect \\nof interaction difficult to predict, use with caution  \\nBeta blockers: e.g., Atenolol, \\nCarvedilol and Propranolol  No known interactions  No known interactions  \\nCalcium channel blockers (CCBs): \\ne.g., Nifedipine, Amlodipine and \\nFelodipine  Potential interaction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive \\neffect: higher starting dose of CCB may be required  Potential intera ction with all NNRTIs: Metabolism of CCBs \\nis induced by EFV or NVP, blunting antihypertensive effect: \\nhigher starting dose of CCB may be required  \\nDiuretics: E.g., HCTZ, Indapamide. \\nFurosemide and Spironolactone  No known interactions  No known interactions  \\nOthers: Alpha blockers:  \\nMethyldopa, Hydralazine   No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 264}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 44 Annex 13 A: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine Phenobarbital \\nPhenytoin  Unknown  \\nUse with caution.  \\nMonitor anticonvulsant levels  Use with caution  \\nMonitor anticonvulsant levels  \\nMETHADONE  Levels: NVP unchanged. Methadone significantly. \\nOpiate withdrawal common when this combination \\nis used. Increased methadone dose often necessary. \\nTitrate methadone dose to effect  Levels: Methadone   60%  \\nOpiate withdrawal common, increase methadone dose often \\nnecessary. Titrate methadone dose to effect  \\nMISCELLANEOUS  No data  Monitor warfarin when used concomitantly  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 265}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 45 Annex 13 B: Drug -Drug Interactions – PIs \\nDrugs Affected  Atazanavir (ATV)  Ritonavir  \\n(RTV)  Darunavir (DRV)  Lopinavir (LPV)  \\nANTIRETROVIRALS  \\nEFV  Co-administration not \\nrecommended because EFV \\ndecreases the serum \\nconcentration of ATV/r which \\nmay lead to resistance and \\ntreatment failure  See interaction with specific \\nritonavir -boosted PI  Co-administration not \\nrecommended because DRV/r \\nmay increase the serum \\nconcentration of EFV leading to \\nincreased risk of toxicity, and EFV \\ndecreases the serum \\nconcentration of DRV/r which \\nmay lead to resistance and \\ntreatment failure  AVOID: this combination \\nincreased risk of \\nprolonged -QT syndrome \\nand sudden cardiac death  \\nETR  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  \\n No significant interaction  \\nDTG  No significant interaction  See interaction with specific \\nritonavir -boosted PI  No significant interaction  No significant interaction  \\nRAL  ATV/r may increase RAL levels \\nbut interaction in not clinically \\nsignificant  See interaction with specific \\nritonavir -boosted PI  No sign ificant interaction  No significant interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 266}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 46 Annex 13 B: Cont.  \\nANTIFUNGALS  \\nItraconazole  Limited data, minimal effect  No data, but potential for bi - \\ndirectional inhibition between \\nItraconazole and RTV, monitor for \\ntoxicities  \\n \\nDose: dose adjustment for patients \\nreceiving  \\n>400 mg Itraconazole may be \\nneeded, or consider monitoring \\nItraconazole level  ↑ Levels of azoles and DRV  ↑ Levels: itraconazole when \\nadministered with LPV/r  \\n \\nDose: itraconazole  \\n– consider not to exceed \\n200 mg/day or monitor \\nlevel and toxicity  \\nKetoconazole  Limited data, minimal effect  Levels: Ketoconazole ↑ 3X \\nDose: Use with caution; do not \\nexceed 200 mg ketoconazole daily  ↑ levels of azoles and DRV  Levels: LPV AUC ↓ \\n13% Azole ↑ 3-fold.  \\nDose: Use with caution; do \\nnot exceed 200 mg \\nketoconazole daily  \\nANTI -MYCOBACTERIALS  \\nRifampicin  Atazanavir AUC: decreased 72%; \\nCmax: decreased  \\n53%; Cmin:  \\ndecreased 98%  Levels: RTV ↓ 35%.  \\n \\nDose: No change. Increased liver \\ntoxicity possible. Co-administration \\nmay lead to loss of virologic response \\nis RTV sole PI. Alternate anti - \\nmycobacterial agents, such as \\nrifabutin, should be considered  ↓ levels of DRV  Levels: LPV AUC ↓ \\n75%. Should not be co \\nadministered as  \\na safe and effective dose of \\nLPV/ r that can be given \\nwith rifampicin has not \\nbeen established  \\nRifapentine  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  Do NOT co -administer  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 267}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 47 Annex 13 B: Cont.  \\nClarithromycin  Clarithromycin AUC:  \\nincreased 94%;  Levels; Clarithromycin  \\n↑ 77%  \\n \\nDose: Adjust clarithromycin \\ndose for moderate and severe \\nrenal impairment  ↑ levels of clarithromycin by  \\n59%  Levels: ↑  \\nClarithromycin AUC 77%  \\nDose: Adjust clarithromycin \\ndose for moderate and \\nsevere renal impairment  \\nBedaquiline \\n(BDQ)  Increases BDQ exposure and \\nincreases risk of prolonged QT \\nsyndrome, monitor for increased \\ntoxic effects by frequent ECG and \\ntransaminases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransamin ases assessment  Increases BDQ exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases BDQ exposure, \\nmonitor for increased toxic \\neffects  \\nDelamanid \\n(DLM)  Increases DLM exposure, monitor \\nfor increased toxic effects by \\nfrequent ECG and transaminases \\nassessment  Increases DLM exposure, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Increases DLM exposur e, \\nmonitor for increased toxic \\neffects by frequent ECG and \\ntransaminases assessment  Do NOT co -administer \\nbecause of increased risk of \\nprolonged QT syndrome  \\n \\nIncreases DLM exposure, \\nmonitor for increased toxic \\neffects  \\nORAL CONTRACEPTIVES  \\n Ethinyl estradiol  \\nAUC: ↓ Levels: Ethinyl estradiol  \\n↓ 40%.  \\n \\nUse alternative or additional \\nmethod  Ethinyl estradiol  \\nAUC:  ↓ 44%  Levels: Ethinyl estradiol  \\n↓ 42%  \\nUse alternative or \\nadditional method  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 268}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 48 Annex 13 B: Cont.  \\nLIPID -LOWERING AGENTS  \\nSimvastatin  \\nLovastatin  Avoid co - administration  Levels: potential  \\nfor large increase in statin \\nlevels. Avoid concomitant use  Avoid  Levels: Potential  \\nfor large increase in statin \\nlevels  \\nAvoid concomitant use  \\nAtorvastatin  Minimal interaction  Levels:  450% ↑ \\nwhen administered with \\nSQV/RTV combination. Use \\nlowest possible starting dose of \\natorvastatin with careful \\nmonitoring  ↑ AUC four -fold  Atorvastatin AUC ↑ \\n5.88 -fold. Use lowest possible \\nstarting  \\ndose of atorvastatin with \\ncareful monitoring  \\nPravastatin  Minimal interaction  Levels: 50% ↓ when \\nadministered  \\nwith SQV/RTV  \\ncombination  \\n \\nDose: Pravastatin dosage \\nadjustment based on lipid \\nresponse  ↑ AUC 81%  Pravastatin AUC  \\n↑ 33%; no dosage adjustment \\nnecessary  \\nANTI -HYPERTENSIVES  \\nAngiotensin -\\nconverting enzyme \\ninhibitors (ACEIs): \\nE.g. - Enalapril, \\nLisinopril  No known interactions  No known interactions  No known interactions  No known interactions  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 269}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 49 Annex 13 B: Cont.  \\nAngiotensin II \\nreceptor blockers \\n(ARBs): e.g., \\nLosartan, \\nTelmisartan  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult \\nto predict, use with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  None  \\nLosartan: Potential interactions \\nwith all PIs, net effect of \\ninteraction difficult to predict, \\nuse with caution  Telmisartan, Candesartan:  \\nNone  \\nLosartan: Potential \\ninteractions with all PIs, net \\neffect of interaction difficult to \\npredict, use with caution  \\nBeta blockers: e.g., \\nAtenolol, Carvedilol \\nand Propranolol  Potential increase in B -\\nblocker effect, careful dose \\nadjustment and ECG where \\nindicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  Potential increase in B -blocker \\neffect, careful dose adjustment \\nand ECG where indicated  \\nCalcium channel \\nblockers (CCBs): e.g., \\nNifedipine, \\nAmlodipine and \\nFelodipine  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: \\nlower starting dose  of CCB \\nmay be required, monitor for \\nexcessive reduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential  interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nantihypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  Potential interaction with all \\nPIs: Metabolism of CCBs \\ninhibited, increasing \\nanti hypertensive effect: lower \\nstarting dose of CCB may be \\nrequired, monitor for excessive \\nreduction in BP  \\nDiuretics: E.g., HCTZ, \\nIndapamide. \\nFurosemide and \\nSpironolactone  No known interactions  No known interactions  No known interactions  No known interactions  \\nOthers: Alpha \\nblockers:  \\nMethyldopa, \\nHydralazine   No known interactions  No known interactions  No known interactions  No known interactions  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 270}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 50 Annex 13 B: Cont.  \\nANTICONVULSANTS  \\nCarbamazepine \\nPhenobarbital \\nPhenytoin  Reduce ATV levels  Carbamazepine; ↑ \\nserum levels when  \\nco-administered with  \\nRTV  \\n \\nUse with caution  \\n \\nMonitor anticonvulsant levels  Avoid  Many possible  \\ninteractions: Carbamazepine:  \\n↑ levels when  \\nco-administered with RTV. Use \\nwith caution. Monitor \\nanticonvulsant levels. \\nPhenytoin : levels of LPV, RTV, \\nand ↓ levels of Phenytoin when \\nadministered together  \\nAvoid concomitant use or \\nmonitor LPV level  \\nOTHER DRUG  \\nMethadone  No interaction with unboosted \\nATV Increased metabolism of \\nmethadone with boosted ATV  Methadone ↓ 37%. Monitor and \\ntitrate dose if needed  \\n \\nMay require ↑  \\nmethadone dose  ↓ levels of methadone by 16%  Methadone AUC  \\n↑ 53%. Opiate withdrawal may \\noccur  \\nMonitor and titrate dose if \\nneeded.  \\nMay require ↑  \\nmethadone dose  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 271}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 51 Annex 13 B: Cont.  \\nERECTILE DYSFUNCTION AGENTS  \\nSildenafil  Use reduced dose of sildenafil  Sildenafil AUC ↑ 11-fold. Use \\ncautiously Start with reduced \\ndose of 25 mg every  \\n48 hours and monitor for \\nadverse effects   Sildenafil AUC ↑ 11- fold in \\ncombination with RTV. Do not \\nexceed 25 mg every  \\n48 hours  \\nMiscellaneous  Decreased GI absorption of \\natazanavir due to reduced acidity  Theophylline ↓ 47%  \\nmonitor theophylline levels  \\n \\nRTV 100 mg bid significantly \\nincrease systemic exposure  \\nof inhaled (oral or nasal \\nfluticasone, may predispose \\npatients to systemic  \\ncorticosteroid effects. Co -\\nadministration not \\nrecommended unless benefit of \\nfluticasone outweighs the risk  Warfarin levels   ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 272}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 52 Annex 13 C: Drug -Drug Interactions – INSTIs  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nEfavirenz  Co-administration not recommended because \\nEFV decreases levels of DTG.  If must be used \\ntogether then increase DTG to 50 mg BD when \\nco-administered with EFV.  Efavirenz decreases RAL \\nplasma levels but it is unlikely \\nto be clinically significant  \\nEtravirine  Co-administration not recommended because \\nETR decreases levels of DTG, unless used in \\ncombination with a PI/r (which counteracts the \\ninteraction between DTG and ETR)  \\n \\nIf must be used together without a PI/r then \\nincrease DTG to 50 mg BD when co -\\nadministered with ETR. If used together with a \\nPI/r then standard dose DTG is sufficient  Etravirine decreases RAL \\nplasma levels so co -\\nadministration when using \\nonce -daily RAL is not \\nrecommended.  Co -\\nadministration when using \\nstandard BD RAL dosing is \\nacceptable  \\nRifampicin  Increase DTG to 50 mg BD when co -\\nadministered with rifampicin (for children, use \\ndouble the standard weight -based DTG dose by \\nadministering twice daily).  \\n \\nThere is no known drug interaction between \\nDTG and rifabutin.  Increase RAL to 800 mg BD \\nwhen co -administered with \\nrifampicin (for children, use \\ndouble the standard weight -\\nbased RAL dose).  \\n \\nRifabutin may alter RA L \\nplasma levels but it is unlikely \\nto be clinical significant.  \\nRifapentine  Potential decreased DTG levels when co -\\nadministered with once -weekly rifapentine – no \\ndose adjustment required unless viral load \\nbecomes detectable, in which case increase DTG \\nto twice daily until two weeks after completion \\nof rifapentine -based TPT  Potential increased RAL \\nlevels when co -administered \\nwith once -weekly rifapentine \\n– no dose adjustment \\nrequired but monitor for RAL \\ntoxicity  \\nBedaquiline (BDQ)  No interactions expected  No interactions expected  \\nDelamanid (DLM)  No interactions expected  No interactions expected  \\nMetformin  DTG may increase metformin plasma levels so \\nmetformin dose may need to be decreased. Limit \\ndaily metformin dose to 1,000mg.  \\n \\nDTG does NOT require a dose adjustment is when \\nused with metformin.  No interaction  \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 273}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 53 Annex 13 C: Cont.  \\nDrugs Affected  Dolutegravir (DTG)  Raltegravir (RAL)  \\nAnticonvulsants  \\n-Carbamazepine  \\n-Phenobarbital  \\n-Phenytoin  Avoid use of DTG with carbamazepine, \\nphenobarbital, or phenytoin because they \\ndecrease DTG plasma levels.  \\n \\nIf the DTG must be used in combination with any \\nof these anticonvulsants than increase DTG dose \\nto 50mg BD and monitor viral load.  No interaction  \\nMineral \\nsupplements and \\nantacids \\ncontaining cations \\n(e.g., calcium, iron, \\nzinc, magnesium, \\naluminum), \\nincluding prenatal \\nvitamins  Administer DTG at least 2 hours before or 6 \\nhours after taking any of these supplements \\n(note: if taking DTG with a meal then it is safe to \\ntake at th e same time as prenatal vitamins, \\ncalcium, or iron)  \\n \\nThere are no drug -drug interactions between \\nDTG and proton pump inhibitors or H2 blockers \\nused for gastritis.  Do not use calcium, \\nmagnesium and aluminum \\ncontaining antacids with RAL.  \\nMethadone  No inter action  No interaction  \\n \\n \\n \\n \\n \\n \\n \\n \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 274}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:  \\nHas the facility achieved a routine viral load monitoring uptake of ≥ 90%?   \\nHas the facility established a facility -based system for fast -track ART distribution?   \\nCommodity Management:  \\nDoes the facility have ≥ three months of ART available on site?   \\nHas the facility identified a focal person to pre -pack and label ART for community distribution?   \\nHealth Information Systems:  \\nDoes the facility have an established system to monitor patient level outcomes, specifically \\nretention, loss to follow -up, mortalities an d viral load suppression?   \\nIs the facility able to establish recording and reporting systems for community ART?   \\nAssessors’ recommendations:  \\n \\nFinal assessment outcome:  \\nFacility can initiate community ART distribution ▢  \\nFacility to implement assessors’ recommendations and be re -assessed thereafter ▢  \\nNames of assessors:  Signature of \\nassessors:  Name of health facility manager: \\nSignature of health facility manager:  \\n*None of these criteria are absolute requirements for implementation of community -based ART \\ndistribution; implementation can be considered even if some criteria are not met, as long as a plan is in \\nplace to address and monitor gaps  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 275}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 55 \\n Annex 15: Creatinine Clearance  \\nFormula for calculating creatinine clearance for adults : \\n \\n \\n \\n \\nFormula for calculating creatinine clearance for children and adolescents (up to 19 years \\nold):  \\n \\neGFR = k x height (cm)/ serum creatinine (mg/dL)  \\n \\nk = 0.45 for infants < 1 year old  \\nk = 0.55 for children (1 – 10 years)  \\nk = 0.55 for female adolescents (11 -19 years)  \\nk = 0.70 for male adolescents (11 -19 years)  \\n \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 276}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 56 Annex 16: Immune Reconstitution Inflammatory Syndrome  \\nImmune Reconstitution Inflammatory Syndrome (IRIS)  \\nDefinition:  \\nIRIS is a paradoxical inflammatory reaction against a foreign antigen (alive or dead) in patients who \\nhave started ART with reconstitution (improved functioning) of their immune system. The immune \\nsystem, once it regains some function, is now able to respond against the foreign antigen.  \\nClassification:  \\n● Unmasked IRIS: appearance of a previously undiagnosed opportunistic infection (OI) following \\nART initiation (or switch of ART to a suppressive regimen)  \\n● Paradoxical IRIS: worsening of a previously diagnosed disease after ART initiation (or switch of \\nART to a suppressive regimen)  \\nRisk Factors for IRIS:  \\n● 10-20% of patients who start ART with advanced immunosuppression (refer to Chapter 3) \\nexperience clinical deterioration during the first few months due to IRIS  \\n● High risk patients include:  \\no Advanced immunosuppression (WHO Stage 3 or 4, or CD4 count ≤ 200 cell/mm3 ( or CD4% ≤ \\n25% for children ≤ 5 years old))  \\no Patients with a diagnosed opportunistic infection like TB, MAC, CMV, and PCP  \\no Low baseline CD4 (CD4 count ≤ 50 cell/mm3 or CD4% ≤ 10%)  \\no High baseline viral load  \\no Substantial increase in CD4 count and drop in viral load after starting ART  \\nPatient evaluation:  \\nIn addition to the clinical evaluation for PLHIV outlined in Table 3.1, emphasis should be placed on the \\nfollowing areas during the patient evaluation:  \\nHistory:  \\nSymptoms and current ARV history:  \\n• Specific systemic symptomatology  \\n• Date of ARV initiation  \\n• Regimen  \\n• Reason for substitution / switch from previous ART if not first line  \\n• Adherence to ART and other ongoing treatment  \\n• HIV viral load  \\n• CD4 count  \\nPrior History:  \\n• ARV toxicity  \\n• Drug -drug interaction  \\n• CD4 count  \\n• HIV viral load  History of treatment of opportunistic infections:  \\n• Date of initiation of treatment  \\n• Duration of therapy  \\n• Clinical response to treatment  \\n• Adherence to the OI treatment  \\n• Any default to treatment  \\n• Resistance to treatment  \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 277}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 57 Annex 16: Cont.  \\nPhysical Examination:  \\nVital signs assessment:  Temperature, Heart Rate, Blood Pressure, Respiratory rate  \\nConduct a detailed systemic examination:  \\n• Emphasis should be placed on the system(s) which are primarily affected (Table 3.1)  \\n \\nInvestigations  \\n• All patients with advanced HIV disease should be screened for common OIs including TB, \\ncryptococcal meningitis and other common OIs depending of their presenting signs and \\nsymptoms  \\n. \\nDiagnosis of IRIS  \\n● IRIS should be suspected any time a patient has clinical deterioration weeks to months after \\nstarting ART (or switching to a suppressive ART regimen)  \\n● Clinical deterioration usually occurs within 4 -8 weeks of initiation or change of ART (but can be \\nmonths afterwards)  \\n● IRIS has varied clinical presentations due to multiple possible pathogens that the immune system \\nmay be reacting to, and various immune system reactions; there are generally clinical \\nmanifestations consistent with an inflammatory condition  \\n● A high level of suspicion is required when making a diagnosis of IRIS, which is generally one of \\nexclusion  \\n● Rule out the possibility of drug reaction, patient non -adherence to OI treatment, persistently active \\ninfection and/or drug resistance to OI treatment  \\n● There could be localized tissue inflammation with or without systemic inflammatory response  \\n \\nMajor and Minor Presentations of IRIS  \\nMajor presentation  Minor presentation  \\nTuberculosis (TB)  \\nMycobacterium avium complex (MAC)  \\nCryptococcal meningitis  \\nCytomegalovirus (CMV) retinitis  \\nHepatitis B or C virus  \\nProgressive multifocal leukoencephalopathy \\n(PML)  \\nKaposi’s sarcoma  \\nCerebral toxoplasmosis  \\nAutoimmune diseases  Herpes simplex virus (HSV) and varicella \\nzoster virus (VZV)  \\nNonspecific dermatologic complic ations such \\nas folliculitis, oral and genital warts  \\n \\n   \\n \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 278}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 58 Annex 16: Cont.  \\nManagement of IRIS  \\nIRIS management is dependent on severity of symptoms and the following general guidance is \\nrecommended:  \\nSeverity of \\nIRIS  Definition  Management  \\nMild  • Resolves over time \\nin most patients  \\n• Symptomatic \\ntreatment is often \\nsufficient  \\n • Treat the OI and manage the associated \\nsymptoms  \\n• Treat IRIS -associated inflammation:  \\no NSAIDS for discomfort associated with mild \\ninflammation / fevers  \\no Inhaled steroids for bronchospasm or \\ncough associated with mild pulmonary \\ninflammation  \\n• Surgical intervention:  \\no Drainage of abscesses  \\no Excision of inflamed and painful lymph \\nnodes  \\nSevere  • Threatens a \\npatient’s \\nfunctional state  \\n• Cause permanent \\ndisability  \\n• Potentially lead to \\ndeath  \\nExamples:  \\n• Decline in \\npulmonary \\ncapacity from TB \\nor MAC infection  \\n• Neurologic \\ncomplications \\nfrom cryptococcal \\ninfection  \\n• Loss of vision from \\nCMV retinitis \\ninfection  • Treat the OI and manage the associated \\nsymptoms  \\n• Manage t he IRIS -associated inflammation:  \\no If NOT KS: give 1 to 2 mg/kg prednisone for \\n1 to 2 weeks. Follow with a period of \\nindividualized tapering of the dose  \\no Do not use corticosteroids for the \\nmanagement of KS -related IRIS  \\n• Closely monitor patients on corticosteroid \\ntherapy for:  \\no Hyperglycemia  \\no Hypertension  \\no Mental status changes  \\no Avascular necrosis  \\no Worsening of an existing infection  \\no Predisposition to a new infection (e.g., TB \\nand CMV)  \\n    \\n ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 279}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 59 Annex 17: HTS Adult Screening Tool Enhancement  \\n  \\nCounty: …………………………………………. Sub -County Name: ………………………………….  \\n \\nFacility Name:……………………………… Facility MFL Code: ……………………………………  \\n1 Today’s Date                                              Gender                                             AGE  \\n \\n………………………….                            \\n2 Have you ever tested for HIV Before?  \\nIf yes, what was the HIV result?         Positive                      Negative  \\nIf positive, Date of ART initiation. ……………………. (Not eligible for testing)  \\nIf Negative, when is the most recent HIV test?   Months              Years  \\n \\n3 If negative or status unknown, determine  behavioural risk of HIV acquisition  by \\nasking the following questions:  \\n• Unprotected sex within the last 3 months  \\n• Unknown status of the sexual partners  \\n• New sexual partner within the last 3 months  \\n• Multiple sexual partners  \\n• intergenerational relationships  \\n• Symptoms of sexually transmitted infection (refer to MoH syndromic \\nchart) or history of STI  \\n• Pregnancy for females  \\n• Assessing h istory of recurrent illnesses without resolution of symptoms, \\nacute or chronic febrile illness (symptoms ≥ 14 days) and any other \\nconditions suggestive of HIV  \\n4 Possible Risk exposures:  \\n• Defilement  \\n• Traditional /non -medical procedures e.g., scarification, plastic tooth \\nextraction , Circumcision, uvulectomy etc.  \\n5 If Risk noted or clinical assessment suggest HIV, eligible for testing  \\n6. If No risk noted and assessment does not suggest, not eligible  \\nName  Institutions  \\n \\n  \\n M\\nM\\nM  F \\n  \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 280}),\n",
       " Document(page_content=\" Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 60 Annex 1 8: List of Contributors and Affiliation  \\n  Name  Affiliation    Name  Affiliation  \\n1 Abraham Katana  CDC  61 Jonah Magare  MOH NASCOP  \\n2 Adrian Gardner  Moi University  62 Jonah Maswai   DoD  \\n3 Agnes Langat  CDC  63 Jonah Onentiah  MOH NASCOP  \\n4 Alice Njoroge  Kajiado County  64 Jonathan Mwangi  CDC  \\n5 Ambrose Juma  MOH NASCOP  65 Joseph Mbuthia  Mater Hospital  \\n6 Anne Marie \\nMacharia  KNH  66 Joseph Nkuranga  UON  \\n7 Anthony Wachira  MOH NASCOP  67 Judith Lusike  CHAI  \\n8 Appolonia Aoko  CDC  68 Julius Kisio  Murang'a County  \\n9 Barbara Mambo  MOH NASCOP  69 Julius Oliech  CDC  \\n10 Brandwell Mwangi  CHAI  70 Justine Odionyi  EGPAF  \\n11 Brenda Opanga  MOH NASCOP  71 Justus Ogada  CHAI  \\n12 Celestine \\nImuuraget  DOD  72 Kenneth Masamaro  CDC  \\n13 Christine Kisia  WHO  73 Lazarus Momanyi  MOH NASCOP  \\n14 Claver Kimathi  Isiolo County  74 Lennah Nyabiage  CDC  \\n15 Collins Etemesi  MOH NASCOP  75 Leonard Kingwara  MOH NHRL  \\n16 Dalton Wamalwa  UON  76 Leonard Soo  USAID  \\n17 Daniel Kimani  CDC  77 Loice Achieng Ombajo  UON  \\n18 Daniel Were  JHPIEGO  78 Margaret Ndubi  UNAIDS  \\n19 Davis Karambi  CHAI  79 Mary Mugambi  MOH NASCOP  \\n20 Deborah Carpenter  CDC  80 Mary Nyangasi  MOH NCCP  \\n21 Deborah Goldstein  USAID  81 Marybeth Maritim  UON  \\n22 Deborah Ikonge  MOH NASCOP  82 Maureen Inimah  MOH NASCOP  \\n23 Dennis Osiemo  USAID  83 Maureen Syowai  ICAP at Columbia \\nUniversity  \\n24 Diana Marangu  UoN  84 Mike Ekisa  Kakamega County  \\n25 Dinah Mamai   CHS  85 Muthoni Karanja  DOD  \\n26 Dorcus Abuya  UNICEF  86 Nancy Bowen  MOH NHRL  \\n27 Doreen Muriithi  JHPIEGO  87 Nandita Sugandhi  ICAP at Columbia \\nUniversity  \\n28 Dorothy Mwagae  MOH NASCOP  88 Natella Rakhmanina  EGPAF  \\n29 Douglas Gaitho  AKUH  89 Nelson Otwoma  NEPHAK  \\n30 Dunstan Achwoka  USAID  90 Newton Omale  MOH NASCOP  \\n31 Edith Apondi  AMPATH Plus  91 Odylia Muhenje  CDC  \\n32 Elaine Abrams   ICAP at Columbia \\nUniversity  92 Pacific Akinyi  MOH NASCOP  \\n33 Elizabeth Irungu  JHPIEGO  93 Patricia Oluoch  USAID  \\n34 Elizabeth Katiku  CDC  94 Patricia Ongwen  JHPIEGO  \", metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 281}),\n",
       " Document(page_content=' Annexes  \\n \\n13 - 61 35 Elizabeth Mueni  NMS  95 Philip Kimani  CHAI  \\n36 Elizabeth Onyango  MOH NCD  96 Rogers Simiyu  EGPAF  \\n37 Elizabeth Washika  MOH NASCOP  97 Rose Ayugi  MOH NASCOP  \\n38 Emma Momanyi  CIHEB  98 Rose Wafula  MOH NASCOP  \\n39 Eric Mutua  MOH NASCOP  99 Ruby Fayorsey                  ICAP at Columbia \\nUniversity  \\n40 Evelyn Ngugi  CDC  100  Ruth Kamau  MOH NASCOP  \\n41 Everline Ashiono  USAID Dumisha Afya  101  Ruth Korir  Mathari Hospital  \\n42 Felicistas Makokha  NyaWest RTWG  102  Ruth Musyoki  MOH NASCOP  \\n43 Francis Ndwiga  MOH NASCOP  103  Ruth Nduati  UoN  \\n44 Frank Basiye  CDC  104  Salome Okutoyi  USAID  \\n45 George Siberry  USAID  105  Sarafuina Sikwata  MOH NASCOP  \\n46 Grace Rabut  MOH NASCOP  106  Sarah Masyuko  MOH NASCOP  \\n47 Helen Chun  CDC  107  Shobha Vakil                     ICAP at Columbia \\nUniversity  \\n48 Herb Herwell  CHAI  108  Sospeter Gitonga  MOH NASCOP  \\n49 Herman Wayenga  CDC  109  Steve Oyule  DoD  \\n50 Immaculate \\nMutisya  CDC  110  Susan Njogo  ARC Kenya  \\n51 Irene Mukui  DnDI  111  Teresa Simiyu  USAID  \\n52 Isabella Yonga  USAID  112  Terezah Alwar  UNICEF  \\n53 Ivy Kasirye  WHO  113  Vakil, Shobha  ICAP  \\n54 Jafred Mwangi  MOH NASCOP  114  Valeria Makory  MOH NASCOP  \\n55 James Wagude  NyaWest RTWG  115  Valerie Obare  MOH NASCOP  \\n56 Janet Muema  MOH NASCOP  116  Veronica Irungu  CHS  \\n57 Japheth Gituku  MOH NASCOP  117  Virginia Karanja  CHS  \\n58 Jeremy Penner  UBC  118  Wangui Kamau  KNH  \\n59 Joan -Paula Bor  MOH NCCP  119  Wanjiku Ndegwa  MOH NASCOP  \\n60 John Mungai  CHAI  120  Winifred Nyanya  MOH NASCOP  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 282}),\n",
       " Document(page_content=' Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 62 Annex 19: List of Participating Organizations and Agencies  \\nContributing Organizations  \\nCenter for Health Solutions  \\nAga Khan University Hospital  \\nAMPATH Plus  \\nARC Kenya  \\nCenter for Disease Control  \\nCIHEB Kenya  \\nClinton Health Access Initiative  \\nCouncil of Governors  \\nDepartment of Defence  \\nDnDI  \\nEGPAF  \\nICAP at Columbia University  \\nJHPIEGO  \\nKenyatta Nati onal Hospital  \\nMater Hospital  Mathari National TRH  \\nMOH Department of NCD  \\nMOH Division of NCCP  \\nMOH NASCOP  \\nMOH NHRL  \\nMOH NLTP  \\nMoi University  \\nNairobi Metropolis Services  \\nNEPHAK  \\nUCSF  \\nUNICEF  \\nUniversity of British Columbia  \\nUniversity of Nairobi  \\nUSAID  \\nWorld Health Organization  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 283}),\n",
       " Document(page_content=' \\n63 - 264   \\n  ', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 284}),\n",
       " Document(page_content=' \\n  \\n', metadata={'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf', 'page': 285})]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "90b40334-11fa-46e2-b9db-600992282296",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5667eb17f66a4ab5ad69b807a137e2f0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Processing docs:   0%|          | 0/286 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total chunks created: 983\n"
     ]
    }
   ],
   "source": [
    "from tqdm.auto import tqdm\n",
    "from concurrent.futures import ThreadPoolExecutor, as_completed\n",
    "\n",
    "guides_chunks = []\n",
    "\n",
    "def process_doc(doc):\n",
    "    \"\"\"\n",
    "    Splits a single document into sections and returns a list of section dicts.\n",
    "    \"\"\"\n",
    "    doc_content = doc.page_content\n",
    "    doc_metadata = doc.metadata\n",
    "    sections = intelligent_chunking(doc_content)\n",
    "    return [{**doc_metadata, 'section': section} for section in sections]\n",
    "\n",
    "# Use ThreadPoolExecutor to process multiple docs in parallel\n",
    "with ThreadPoolExecutor() as executor:\n",
    "    futures = [executor.submit(process_doc, doc) for doc in documents]\n",
    "    \n",
    "    # Create a tqdm progress bar with total=len(futures)\n",
    "    for future in tqdm(as_completed(futures), total=len(futures), desc=\"Processing docs\"):\n",
    "        # future.result() blocks until the future is done\n",
    "        guides_chunks.extend(future.result())\n",
    "\n",
    "print(f\"Total chunks created: {len(guides_chunks)}\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5cef0b5e-07a4-451c-a5ff-19945e051f5e",
   "metadata": {},
   "source": [
    "## Index the data with mini search"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7a7e810d-710f-4f39-a68a-df076f828141",
   "metadata": {},
   "source": [
    "### Text search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "93ceabd3-dfd2-4ed3-89fb-cefc808bf477",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<minsearch.minsearch.Index at 0x16d718200>"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from minsearch import Index\n",
    "\n",
    "index = Index(\n",
    "    text_fields=[\"source\", \"section\"],\n",
    "    keyword_fields=[]\n",
    ")\n",
    "\n",
    "index.fit(guides_chunks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "057abe64-86a5-4f71-ae7d-0fb3600634fe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': 'Table 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': 'ARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 202,\n",
       "  'section': 'Pre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': 'eligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': 'vii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': 'HIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC'}]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "query = 'Prophylaxis'\n",
    "results = index.search(query)\n",
    "results"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "15d6c0a7-8faf-4cd8-94c8-c524ebbd1e09",
   "metadata": {},
   "source": [
    "### Vector Search "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f98dafab-73db-4417-ae3a-e1cecd70b761",
   "metadata": {},
   "source": [
    "#### Embedding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "4c4bdf41-4487-4163-ad7a-cd4ca3b17431",
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=\"sentence-transformers/all-MiniLM-L6-v2\"\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "23b111a3-a752-4b21-900d-a9bffb9778d7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dropping existing table 'kenya-arv-guidelines'...\n",
      "Creating new vectorstore...\n",
      "Generating embeddings...\n",
      "✓ Created table with 983 records\n",
      "✓ Vectorstore created successfully!\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[2026-02-16T06:40:01Z WARN  lance::dataset] No existing dataset at /Users/itsmuriuki/Desktop/cdss-notebooks/kenya-hiv-cdss/kenya_arv_guidelines_lancedb/kenya-arv-guidelines.lance, it will be created\n"
     ]
    }
   ],
   "source": [
    "from langchain_community.vectorstores import LanceDB\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from langchain.schema import Document\n",
    "import lancedb\n",
    "import pyarrow as pa\n",
    "\n",
    "\n",
    "# LanceDB configuration\n",
    "db_path = \"./kenya_arv_guidelines_lancedb\"\n",
    "table_name = \"kenya-arv-guidelines\"\n",
    "\n",
    "# Connect to LanceDB\n",
    "db = lancedb.connect(db_path)\n",
    "\n",
    "# Drop existing table if it exists (for fresh start)\n",
    "if table_name in db.table_names():\n",
    "    print(f\"Dropping existing table '{table_name}'...\")\n",
    "    db.drop_table(table_name)\n",
    "\n",
    "# Create vectorstore using add_texts method\n",
    "print(\"Creating new vectorstore...\")\n",
    "\n",
    "# Extract texts and metadatas\n",
    "texts = [chunk[\"section\"] for chunk in guides_chunks]\n",
    "metadatas = guides_chunks\n",
    "\n",
    "# Generate embeddings manually\n",
    "print(\"Generating embeddings...\")\n",
    "vectors = embeddings.embed_documents(texts)\n",
    "\n",
    "# Create the table manually with proper schema\n",
    "data = []\n",
    "for i, (text, metadata, vector) in enumerate(zip(texts, metadatas, vectors)):\n",
    "    data.append({\n",
    "        \"text\": text,\n",
    "        \"vector\": vector,\n",
    "        \"id\": str(i),\n",
    "        \"source\": metadata.get(\"source\", \"\"),\n",
    "        \"page\": metadata.get(\"page\", 0)\n",
    "    })\n",
    "\n",
    "# Create table\n",
    "table = db.create_table(table_name, data=data, mode=\"overwrite\")\n",
    "print(f\"✓ Created table with {len(data)} records\")\n",
    "\n",
    "# Now create the LanceDB vectorstore wrapper\n",
    "vectorstore = LanceDB(\n",
    "    connection=table,\n",
    "    embedding=embeddings\n",
    ")\n",
    "faq_index = vectorstore\n",
    "faq_vindex = table\n",
    "print(\"✓ Vectorstore created successfully!\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "25b66590-2b25-4b24-9459-9bb693c4bedc",
   "metadata": {},
   "outputs": [],
   "source": [
    "# We will index this data by putting it inside a search engine. This allows us to quickly find relevant information when users ask questions. In particular, we will:\n",
    "# Build a lexical search for exact matches and keywords\n",
    "# Implement semantic search using embeddings\n",
    "# Combine them with a hybrid search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "479ec089-5db5-4e01-b58f-82b23b90a3e9",
   "metadata": {},
   "outputs": [],
   "source": [
    "def text_search(index, query, k=10):\n",
    "    results = index.search(query)\n",
    "    return results[:k]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "ab864aa8-3208-49d5-a5f8-b45a74341198",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 6,\n",
       "  'section': '1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \\n1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \\n1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \\n2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \\n2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \\nInfant Scenario  Infant Prophylaxis  Maternal Scenarios  \\nHIV Exposed \\nInfant  ● Infant prophylaxis  \\no AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \\ncontinued until 6 weeks after complete cessation of \\nbreastfeeding  \\no Infant prophylaxis can be discontinued after a minimum \\nof 12 weeks on NVP if the child is not breastfeeding (death \\nof mother or separation with mother)  \\no The infant prophylaxis regimen applies to all infants \\nirrespective of age when identifying HIV exposure (e.g., \\nmother diagnosed HIV -positive in the  postpartum  period)  \\n● DBS or whole blood for PCR at 6 weeks or first contact, \\nfollowing EID algorithm (Figure 2.1)'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 14,\n",
       "  'section': 'Table 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \\nTable 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \\nTable 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \\nTable 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \\nTable 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 198,\n",
       "  'section': 'ARVs for Post -exposure Prophylaxis  \\n10 - 1  \\n10. ARVs for Post -exposure Prophylaxis  \\n \\n \\nAn ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \\nsoon as possible (preferably within 72 hours) after an exposure.  \\n  \\n10.1 What is PEP?  \\nPost -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \\nlikelihood of HIV infection after potential exposure.  \\nPeople can be accidentally exposed to HIV through healthcare work or due to exposures outside \\nhealthcare setting, for example, through unprotected sex or sexual assault among adults and \\nchildren. Healthcare workers are at increased risk of exposure to HIV through contact with'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \\nProphylaxis  ................................ ................................ ................................ ................................ ...................  3 \\n7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \\n7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \\n7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \\n8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 9,\n",
       "  'section': '9.2.3 Treatment of HIV/HCV Co -infection  ................................ ................................ ................................ ............................  6 \\n10. ARVs for Post -exposure Prophylaxis  ................................ ................................ .................  1 \\n10.1 What is P EP? ................................ ................................ ................................ ................................ ........................  1 \\n10.2 Recommended ARVs for PEP  ................................ ................................ ................................ .......................  1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 202,\n",
       "  'section': 'Pre-Exposure Prophylaxis (PrEP)  \\n11 - 1  \\n11. Pre-Exposure Prophylaxis (PrEP)  \\n \\nPre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \\nof HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \\nPrEP is recommended for use as follows:  \\n• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \\nof HIV infection.  \\n• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \\ntaking exogenous estradiol -based gender affirming hormones  \\n11.1 Indications for PrEP and Criteria for Eligibility   \\n11.1.1 Indications for PrEP  \\nPrEP is indicated for;  \\n● HIV uninfected persons at ongoing risk of HIV acquisition'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 18,\n",
       "  'section': 'eligible for testing  \\n• Serial testing, using ap proved rapid HIV antibody testing kits, is used to diagnose HIV \\ninfection in children older than 18 months, adolescents, and adults. An HIV -positive \\ndiagnosis will be made using three consecutive reactive assays  \\n \\n1.2 Initial Evaluation and Follow -up for PLHIV  \\n● Initial clinical evaluation of PLHIV entails CD4 monitoring, which is recommended for:  \\n▪ Baseline investigation for all PLHIV  \\n▪ Any patient with suspected treatment failure  \\n▪ Any patient returning to care after interrupting treatment for > 3 months  \\n▪ Any patient on fluconazole maintenance therapy or on dapsone as prophylaxis, to \\ndetermine when prophylaxis can be discontinued  \\n● Advanced HIV Disease is defined as:'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 10,\n",
       "  'section': 'vii 10.5 Risk reduction cou nselling ................................ ................................ ................................ ............................  4 \\n10.6 Preventing HIV exposure  ................................ ................................ ................................ ...............................  4 \\n11. Pre-Exposure Prophylaxis (PrEP)  ................................ ................................ ......................  1 \\n11.1 Indications for PrEP and Criteria for Eligibility  ................................ ................................ ..................  1'},\n",
       " {'source': 'Kenya-ARV-Guidelines-2022-Final-1.pdf',\n",
       "  'page': 167,\n",
       "  'section': 'HIV exposed infants with TB infection, infant prophylaxis should include AZT plus 3TC fixed dose (60/30 mg ). For 12 \\nweeks or until maternal viral load is suppressed (3 -5.9 – 1 tab BD, 6 -9.9kg 1.5tab BD, 10 -13.9 kg 2 tabs BD).  For more \\ndetails, refer to Annex 10 A.  \\nAfter TB treatment, revert to NVP until 6 weeks post cessation of breastfeeding,  \\nHB monitoring should be done to all HEIs on AZT prophylaxis as per the recommendations (Table 6.7: management of \\nAZT associated bone marrow suppression)  \\nGroups considered higher risk for mother to child transmission who may need additional adherence and \\npsych ological support include:  \\n● All new HIV positives irrespective of time identified  \\n● HIV positive adolescent Girls and Young Women (AGYW) <19 yrs. including OVC'}]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results = text_search(index, \"Prophylaxis\")\n",
    "results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "28ed17c9-2cc0-4fe7-b53c-e395fc3e2ddf",
   "metadata": {},
   "outputs": [],
   "source": [
    "def vector_search(query, k=10):\n",
    "    # 1. Embed query\n",
    "    query_vector = embeddings.embed_query(query)\n",
    "\n",
    "    # 2. Ensure it is a plain Python list (important!)\n",
    "    if not isinstance(query_vector, list):\n",
    "        query_vector = query_vector.tolist()\n",
    "\n",
    "    # 3. Search LanceDB table\n",
    "    results = (\n",
    "        faq_vindex\n",
    "        .search(query_vector)\n",
    "        .limit(k)\n",
    "        .to_list()\n",
    "    )\n",
    "\n",
    "    return results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "a730e026-0364-4e41-9dbb-eebc5ec3da9d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Pre-Exposure Prophylaxis (PrEP)  \n",
      "11 - 1  \n",
      "11. Pre-Exposure Prophylaxis (PrEP)  \n",
      " \n",
      "Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \n",
      "of HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \n",
      "PrEP is recommended for use as\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 202\n",
      "--------------------------------------------------------------------------------\n",
      "ARVs for Post -exposure Prophylaxis  \n",
      "10 - 1  \n",
      "10. ARVs for Post -exposure Prophylaxis  \n",
      " \n",
      " \n",
      "An ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \n",
      "soon as possible (preferably within 72 hours) after an exposure.  \n",
      "  \n",
      "10.1 What is PEP?  \n",
      "Post -exposure proph\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 198\n",
      "--------------------------------------------------------------------------------\n",
      "1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \n",
      "1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  \n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 6\n",
      "--------------------------------------------------------------------------------\n",
      "Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \n",
      "4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \n",
      "Annex 10 D: Simplified Dosing of INH and CTX\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 11\n",
      "--------------------------------------------------------------------------------\n",
      "management of HIV/HCV co -infection  \n",
      " \n",
      "1.9 ARVs for Post -exposure Prophylaxis (PEP)  \n",
      "• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \n",
      "• The recommended ARV agents for PEP are  \n",
      "▪  <15 years old  \n",
      "▪ < 30 kg: ABC + 3TC + DTG  \n",
      "▪ ≥ 30 kg: TDF + 3TC + DTG  \n",
      "▪ ≥ 15 \n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 24\n",
      "--------------------------------------------------------------------------------\n",
      "ARVs for Post -exposure Prophylaxis  \n",
      "10 - 3 Table 10.2: Recommendations for PEP Management and Follow -up \n",
      "Considerations  Recommendation  \n",
      "Management at initial \n",
      "contact  ● Counsel on risks and benefits of PEP and obtain verbal consent for HIV \n",
      "testing.  \n",
      "● Voluntary testing for both exposed and s\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 200\n",
      "--------------------------------------------------------------------------------\n",
      "Pre-Exposure Prophylaxis (PrEP)  \n",
      "11 - 7 11.3.1 Schema for follow up for daily oral PrEP  \n",
      "Initial Visit/First Contact\n",
      "Perform a risk assessment to determine if PrEP is indicated:\n",
      "• Discuss effective PrEP use and Clarify misinformation\n",
      "• Perform Initial clinical and laboratory assessment:\n",
      "o Baseline\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 208\n",
      "--------------------------------------------------------------------------------\n",
      "Patien ts who have persistent signs and symptoms of STIs after syndromic treatment should \n",
      "undergo diagnostic evaluation for definitive diagnosis and treatment.  \n",
      " \n",
      "At initial diagnosis of HIV, all sex workers should be treated for presumptive gonorrhoea and \n",
      "chlamydi a (following treatment recommen\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 76\n",
      "--------------------------------------------------------------------------------\n",
      "(See Section 4.4.2 for specific clinical guidelines)  \n",
      "Sexually transmitted \n",
      "infections (STI)  ● Screening for symptoms of STIs  \n",
      "● Prevention of STIs  \n",
      "(See Section 4.4.1 for specific clinical guidelines)  \n",
      "Treatment adherence  ● Benefits/importance of:  \n",
      "o Adherence to clinical care  \n",
      "o Adherence \n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 66\n",
      "--------------------------------------------------------------------------------\n",
      "Pre-Exposure Prophylaxis (PrEP)  \n",
      "11 - 11 Table 11.7: Summary of PrEP Initial and Follow -up Assessment  \n",
      "Visit  Action  \n",
      "First (Screening Visit) \n",
      "Clinician Visit  • HIV testing and counselling.  \n",
      "• Evaluate for eligibility, willingness and readiness to take PrEP.  \n",
      "• Educate about the risks, benefi\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 212\n",
      "--------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "results = vector_search(\"Prophylaxis\")\n",
    "for r in results:\n",
    "    print(r[\"text\"][:300])\n",
    "    print(\"Source:\", r[\"source\"], \"Page:\", r[\"page\"])\n",
    "    print(\"-\" * 80)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "02ee33ae-3e76-4f4e-bafb-22a37002d4eb",
   "metadata": {},
   "outputs": [],
   "source": [
    "def hybrid_search(query, index, k=10):\n",
    "    # Get results\n",
    "    text_results = text_search(index, query, k=k)\n",
    "    vector_results = vector_search(query, k=k)\n",
    "\n",
    "    combined_results = []\n",
    "    seen = set()\n",
    "\n",
    "    # Helper to extract unique key\n",
    "    def get_key(result):\n",
    "        if isinstance(result, dict):\n",
    "            return result.get(\"id\") or result.get(\"section\")\n",
    "        return str(result)\n",
    "\n",
    "    # Combine results (text first for exact match priority)\n",
    "    for result in text_results + vector_results:\n",
    "        key = get_key(result)\n",
    "\n",
    "        if key not in seen:\n",
    "            seen.add(key)\n",
    "            combined_results.append(result)\n",
    "\n",
    "    return combined_results\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "0e1ea753-a150-4d54-90a6-d5169fe0bf13",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \n",
      "1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \n",
      "1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \n",
      "2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \n",
      "2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1\n",
      "Kenya HIV Prevention and Treatment Guidelines, 2022  \n",
      "7 - 6 Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  \n",
      "Infant Scenario  Infant Prophylaxis  Maternal Scenarios  \n",
      "HIV Exposed \n",
      "Infant  ● Infant prophylaxis  \n",
      "o AZT+NVP for 6 weeks, NVP + cotrimoxazole should be \n",
      "continued until 6 weeks after complete cessation of \n",
      "breastfeeding  \n",
      "o Infant prophylaxis can be discontinued after a minimum \n",
      "of 12 weeks on NVP if the child is not breastfeeding (death \n",
      "of mother or separation with mother)  \n",
      "o The infant prophylaxis regimen applies to all infants \n",
      "irrespective of age when identifying HIV exposure (e.g., \n",
      "mother diagnosed HIV -positive in the  postpartum  period)  \n",
      "● DBS or whole blood for PCR at 6 weeks or first contact, \n",
      "following EID algorithm (Figure 2.1)\n",
      "Table 7.2: Summary of Use of ART for HIV Positive Pregnant and Breastfeeding Women  ................................ ........ 3 \n",
      "Table 7.3: ARV Prophylaxis for HIV -Exposed Infants  ................................ ................................ ................................ ...................  6 \n",
      "Table 7.4: Dosing of ARVs for Infant Prophylaxis from Birth to 12 Weeks of Age  ................................ ..........................  7 \n",
      "Table 7.5: NVP Dosing for Infant Prophylaxi s beyond 12 Weeks of Age *  ................................ ................................ ..........  7 \n",
      "Table 7.6: AZT Dosing for Infant Prophylaxis beyond 12 Weeks of Age *  ................................ ................................ ..........  7\n",
      "ARVs for Post -exposure Prophylaxis  \n",
      "10 - 1  \n",
      "10. ARVs for Post -exposure Prophylaxis  \n",
      " \n",
      " \n",
      "An ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \n",
      "soon as possible (preferably within 72 hours) after an exposure.  \n",
      "  \n",
      "10.1 What is PEP?  \n",
      "Post -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \n",
      "likelihood of HIV infection after potential exposure.  \n",
      "People can be accidentally exposed to HIV through healthcare work or due to exposures outside \n",
      "healthcare setting, for example, through unprotected sex or sexual assault among adults and \n",
      "children. Healthcare workers are at increased risk of exposure to HIV through contact with\n",
      "7.1 Antiretroviral Therapy for HIV -positive Pregnant and Breastfeeding Women and Infant \n",
      "Prophylaxis  ................................ ................................ ................................ ................................ ...................  3 \n",
      "7.2. Syphilis elimination for Pregnant and Breastfeeding Women and Infant Treatment  .........  5 \n",
      "7.3. Hepatitis B elimination for Pregnant and Breastfeeding Women and Infant Prophylaxis  5 \n",
      "7.4 Infant and Young Child Nutrition in the Context of HIV  ................................ ................................ ..... 7 \n",
      "8. TB/HIV Co -infection, Prevention  and Management  ................................ ....................  1\n",
      "Pre-Exposure Prophylaxis (PrEP)  \n",
      "11 - 1  \n",
      "11. Pre-Exposure Prophylaxis (PrEP)  \n",
      " \n",
      "Pre-exposure prophylaxis (PrEP) is the use of antiretroviral medication to prevent the acquisition \n",
      "of HIV infection by an uninfected person at ongoing risk of acquiring HIV infection.  \n",
      "PrEP is recommended for use as follows:  \n",
      "• Daily Oral PrEP for all indivi duals, irrespective of gender or sexual orientation who are at risk \n",
      "of HIV infection.  \n",
      "• Event -Driven (ED) PrEP is currently recommended for all people born male who are not \n",
      "taking exogenous estradiol -based gender affirming hormones  \n",
      "11.1 Indications for PrEP and Criteria for Eligibility   \n",
      "11.1.1 Indications for PrEP  \n",
      "PrEP is indicated for;  \n",
      "● HIV uninfected persons at ongoing risk of HIV acquisition\n",
      "ARVs for Post -exposure Prophylaxis  \n",
      "10 - 1  \n",
      "10. ARVs for Post -exposure Prophylaxis  \n",
      " \n",
      " \n",
      "An ARV regimen, with preferably three -drugs, should be offered as post exposure prophylaxis as \n",
      "soon as possible (preferably within 72 hours) after an exposure.  \n",
      "  \n",
      "10.1 What is PEP?  \n",
      "Post -exposure prophylaxis (PEP) is short -term use of antiretroviral treatment to reduce the \n",
      "likelihood of HIV infection after potential exposure.  \n",
      "People can be accidentally exposed to HIV through healthcare work or due to exposures outside \n",
      "healthcare setting, for example, through unprotected sex or sexual assault among adults and \n",
      "children. Healthcare workers are at increased risk of exposure to HIV through contact with\n",
      "1.9 ARVs for Post -exposure Prophylaxis (PEP)  ................................ ................................ .............................  7 \n",
      "1.10 Pre -Exposure Prophylaxis (PrEP)  ................................ ................................ ................................ .............  7 \n",
      "1.11 People Who Inject Drugs (PWID) and HIV  ................................ ................................ ............................  8 \n",
      "2. HIV Testing Services and Linkage to Treatment and Prevention  ...........................  1 \n",
      "2.1 Settings for HIV Testing  ................................ ................................ ................................ ................................ .... 1\n",
      "Annex 10 C: Drug Dosing of Liquid Formulations for Twice -Daily Dosing in Infants Less than \n",
      "4 Weeks of Age  ................................ ................................ ................................ ................................ .........  30 \n",
      "Annex 10 D: Simplified Dosing of INH and CTX Prophylaxis for Infants and Children Who Are \n",
      "at Least 4 Weeks of Age  ................................ ................................ ................................ .......................  30 \n",
      "Ann ex 10 E: TB Preventive Therapy dosing  ................................ ................................ ................................ . 31 \n",
      "Annex 10 F: Ritonavir Dosing for Super -Boosting LPV/r in Children Taking Rifampicin  ....... 34\n",
      "management of HIV/HCV co -infection  \n",
      " \n",
      "1.9 ARVs for Post -exposure Prophylaxis (PEP)  \n",
      "• PEP should be offered as soon as possible (< 72 hours) after high -risk exposure  \n",
      "• The recommended ARV agents for PEP are  \n",
      "▪  <15 years old  \n",
      "▪ < 30 kg: ABC + 3TC + DTG  \n",
      "▪ ≥ 30 kg: TDF + 3TC + DTG  \n",
      "▪ ≥ 15 years old  \n",
      "▪ TDF + 3TC + DTG  \n",
      " \n",
      "1.10 Pre -Exposure Prophylaxis (PrEP)  \n",
      "• PrEP should be offered to HIV negative individuals at substantial ongoing risk of HIV \n",
      "infection (including the seronegative partner in a discordant relationship)  \n",
      "•  PrEP works if taken as prescribed . However, it does not prevent other STIs or unintended \n",
      "pregnancies, therefore, additional protection should be of fered.  \n",
      "• PrEP should only be offered to clients  ≥15 years of age who are sexually active after\n"
     ]
    }
   ],
   "source": [
    "results = hybrid_search(\"Prophylaxis\", index, k=5)\n",
    "\n",
    "for r in results:\n",
    "    print(r.get(\"text\") or r.get(\"section\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "309ac26a-6ab0-4f10-897a-fac568524672",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "following areas during the patient evaluation:  \n",
      "History:  \n",
      "Symptoms and current ARV history:  \n",
      "• Specific systemic symptomatology  \n",
      "• Date of ARV initiation  \n",
      "• Regimen  \n",
      "• Reason for substitution / switch from previous ART if not first line  \n",
      "• Adherence to ART and other ongoing treatment  \n",
      "• HIV \n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 277\n",
      "--------------------------------------------------------------------------------\n",
      "▪ Potential side effects and what the patient should do  \n",
      "o Prescribe 3rd line ARVs  \n",
      " \n",
      "● Viral load should be conducted 3 months after change of regimen  \n",
      " \n",
      "● Dispensing  \n",
      "o Confirm ARV dosing as per the weight  \n",
      "o Conduct medication use counselling  \n",
      "o Dispense 3rd line ARVs  \n",
      " \n",
      "● Community Follow\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 248\n",
      "--------------------------------------------------------------------------------\n",
      "on the same  \n",
      "3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \n",
      "monthly appointments until month 6.  \n",
      "4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \n",
      "within 2 weeks. For patients who do not  start ART on the same d\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 58\n",
      "--------------------------------------------------------------------------------\n",
      "be taken at the usual time  \n",
      "“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \n",
      "travel?”  \n",
      "• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \n",
      "to plan, to make sure they have enough medication on hand  b\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 238\n",
      "--------------------------------------------------------------------------------\n",
      "● Patients failing second -line ART have limited options. ARVs used to construct a third -line \n",
      "regimen are often more expensive, will have increased pill burden and more side effects. \n",
      "These factors will exacerbate pre -existing poor adherence  \n",
      "● Second -line treatment failure should be confirmed \n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 159\n",
      "--------------------------------------------------------------------------------\n",
      "o Continue other medication e.g., CPT, OI treatment etc.  \n",
      " \n",
      "• Dispensing  \n",
      "o Confirm ARV dosing as per the weight (for ≤15)  \n",
      "o Conduct medication use counselling  \n",
      "o Dispense 3rd Line ARVs for 2 weeks  \n",
      "o Check for possible drug interaction  \n",
      " \n",
      "• Community follow up  \n",
      "o Link all patients to suppor\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 247\n",
      "--------------------------------------------------------------------------------\n",
      "Antiretroviral Therapy in Infants, Children, Adolescents, and Adults  \n",
      "6 - 17 6.5.4 Changing ARVs Due to Treatmen t Failure  \n",
      "Viral load is the test of choice for monitoring response to ART and identifying treatment failure. \n",
      "First VL should be performed 3 months after ART initiation for all PLHIV. \n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 156\n",
      "--------------------------------------------------------------------------------\n",
      "Kenya HIV Prevention and Treatment Guidelines, 2022  \n",
      "6 - 12  \n",
      "Patients with specific reason for stopping an ARV  1\n",
      "VL within last 6 months < \n",
      "200 copies/ml\n",
      "No VL result within last 6 \n",
      "months 1\n",
      "VL within last 6 months   \n",
      "200 copies/ml\n",
      "Collect sample for VL\n",
      "VL       copies/ml\n",
      "• Proceed with single dr\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 151\n",
      "--------------------------------------------------------------------------------\n",
      "for ART so you can start as soon as possible  \n",
      "- Soon after starting ART: after you start ART you should come to the clinic in 2 weeks in order to \n",
      "see if you have had any trouble taking your pills or have developed any side effects; then you can \n",
      "be seen after another two weeks for the same; then e\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 235\n",
      "--------------------------------------------------------------------------------\n",
      "▪ Birth to 4 weeks: AZT + 3TC + NVP  \n",
      "▪ > 4 weeks to < 15 years old  \n",
      "▪ < 30 kg: ABC + 3TC + DTG  \n",
      "▪ ≥ 30 kg: TDF + 3TC + DTG  \n",
      "▪ ≥ 15 years old: TDF + 3TC + DTG  \n",
      "• Children and adolescents who are virally suppressed but are NOT on the preferred first -\n",
      "line ART regimen should be assessed for trans\n",
      "Source: Kenya-ARV-Guidelines-2022-Final-1.pdf Page: 21\n",
      "--------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "# Vector search \n",
    "results = vector_search(\"When should a patient start ARV therapy?\")\n",
    "for r in results:\n",
    "    print(r[\"text\"][:300])\n",
    "    print(\"Source:\", r[\"source\"], \"Page:\", r[\"page\"])\n",
    "    print(\"-\" * 80)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "cbfa03af-eace-4e14-b072-fc68caa2bb00",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "following areas during the patient evaluation:  \n",
      "History:  \n",
      "Symptoms and current ARV history:  \n",
      "• Specific systemic symptomatology  \n",
      "• Date of ARV initiation  \n",
      "• Regimen  \n",
      "• Reason for substitution / switch from previous ART if not first line  \n",
      "• Adherence to ART and other ongoing treatment  \n",
      "• HIV viral load  \n",
      "• CD4 count  \n",
      "Prior History:  \n",
      "• ARV toxicity  \n",
      "• Drug -drug interaction  \n",
      "• CD4 count  \n",
      "• HIV viral load  History of treatment of opportunistic infections:  \n",
      "• Date of initiation of treatment  \n",
      "• Duration of therapy  \n",
      "• Clinical response to treatment  \n",
      "• Adherence to the OI treatment  \n",
      "• Any default to treatment  \n",
      "• Resistance to treatment\n",
      "partners of pregnant and breastfee ding women  \n",
      "● Mothers who are diagnosed with HIV while breastfeeding should immediately start \n",
      "appropriate ART, giving extra attention to adherence support, VL monitoring, and optimal \n",
      "retention in care. The infant should immediately start ARV prophylaxis and r eceive PCR \n",
      "testing (Table 7.3).  \n",
      "● Mothers who decide to stop breastfeeding at any time should stop gradually within one \n",
      "month (and only when a nutritionally adequate and safe diet without breast milk can be \n",
      "sustained), and HIV positive mothers and HIV positi ve infants should continue with ART. \n",
      "Continued breastfeeding is recommended for HIV positive infants for as long as the \n",
      "mother is willing and able to do so.\n",
      "may be initiated with adequate adherence support while the criteria is being addressed, on a \n",
      "case -by-case basis  \n",
      " \n",
      "At each visit up until ART initiation, every patient should be assessed for readiness to \n",
      "start ART (Table 5.4), with the patient/caregiver allowed to make the final decision on \n",
      "whether and when to start ART.  \n",
      "Special Considerations when Counselling Children and Adolescents  \n",
      "Children and adolescents depend on caregivers to support their adherence so there are special \n",
      "considerations for adherence preparation and support. All topics covered in the HIV Education \n",
      "and Adherence Counselling sessions (Table 5.2 and Annex 8) should be covered with the \n",
      "caregiver, with involvement of the child/adolescent as appropriate based on the stage of\n",
      "Always discuss the possibility of new side effects when changing to a new ARV,  particularly \n",
      "side effects common to all ARVs (headache, nausea, diarrhea) and any side effects specific to the \n",
      "new ARV. Reassure patients that most side effects resolve with continued use after 1 -2 weeks.\n",
      "effects when they first start their ART, \n",
      "including nausea, headaches, and \n",
      "difficulty sleeping.  These side effects \n",
      "almost always resolve with continued \n",
      "use)  \n",
      "o Pill burden  \n",
      "o Poor patient -provider relationship  \n",
      "o Inadequate HIV education  \n",
      "o Cost of care (direct and indirect)  \n",
      "o ARV supply -chain limitations (stock -outs, \n",
      "or low stock levels resulting in small refill \n",
      "quantities)  \n",
      "Individualized Adherence Plan  \n",
      "● Ask the patient what they can do to ensure excellent adherence  \n",
      "● Ensure the adherence plan incorporates details of the patient’s specific ART regimen:  \n",
      "o Number of pills, frequency, food requirements/restrictions  \n",
      "o Common side effects  \n",
      "o Important drug interactions  \n",
      "● Work with the patient to make an individualized adherence plan, which may include:\n",
      "following areas during the patient evaluation:  \n",
      "History:  \n",
      "Symptoms and current ARV history:  \n",
      "• Specific systemic symptomatology  \n",
      "• Date of ARV initiation  \n",
      "• Regimen  \n",
      "• Reason for substitution / switch from previous ART if not first line  \n",
      "• Adherence to ART and other ongoing treatment  \n",
      "• HIV viral load  \n",
      "• CD4 count  \n",
      "Prior History:  \n",
      "• ARV toxicity  \n",
      "• Drug -drug interaction  \n",
      "• CD4 count  \n",
      "• HIV viral load  History of treatment of opportunistic infections:  \n",
      "• Date of initiation of treatment  \n",
      "• Duration of therapy  \n",
      "• Clinical response to treatment  \n",
      "• Adherence to the OI treatment  \n",
      "• Any default to treatment  \n",
      "• Resistance to treatment\n",
      "▪ Potential side effects and what the patient should do  \n",
      "o Prescribe 3rd line ARVs  \n",
      " \n",
      "● Viral load should be conducted 3 months after change of regimen  \n",
      " \n",
      "● Dispensing  \n",
      "o Confirm ARV dosing as per the weight  \n",
      "o Conduct medication use counselling  \n",
      "o Dispense 3rd line ARVs  \n",
      " \n",
      "● Community Follow up  \n",
      "o Review linkage to community adherence support systems  \n",
      "o Conduct home visits as required  \n",
      "o Continue DOTS  \n",
      " \n",
      "● NOTE: 3rd line annual report with viral load, adherence, and outcomes to be sent to NASCOP\n",
      "on the same  \n",
      "3 Patients who are adherent and virally suppressed at month 3, may not need subsequent \n",
      "monthly appointments until month 6.  \n",
      "4 All PLHIV qualify for ART and should be initiated as soon as possible including same day and \n",
      "within 2 weeks. For patients who do not  start ART on the same day as enrolment into HIV care, \n",
      "they should be followed up every week until ART initiation to address whatever issues are \n",
      "delaying ART initiation, for ongoing management of acute medical issues and for treatment \n",
      "preparation and ART r eadiness assessment.  \n",
      "4Refer to table 3.1 for detailed history and physical examinations.  \n",
      "5children and adolescents, weight and height should be measured and recorded at every visit, \n",
      "with weight -based dosing of ARVs confirmed at every visit.\n",
      "be taken at the usual time  \n",
      "“What reminder tools do you use? (e.g., mobile phone alarm)” “What do you do in case of visits, and \n",
      "travel?”  \n",
      "• Travelling is always a risk for poor adherence or default from treatment. Encourage the patient \n",
      "to plan, to make sure they have enough medication on hand  before and to remember to pack \n",
      "it \n",
      "• Make sure that all relevant information is on the patient’s appointment card and explain that \n",
      "if they are ever away from home and they are about to run out of medication that they must go \n",
      "to the closest ART clinic and sho w their appointment card  \n",
      "“What do you do in case of side effects?”  \n",
      "• Ask the patient if s/he has any side effects from the ARVs, and if they sometimes find it \n",
      "difficult to take ARVs\n",
      "● Patients failing second -line ART have limited options. ARVs used to construct a third -line \n",
      "regimen are often more expensive, will have increased pill burden and more side effects. \n",
      "These factors will exacerbate pre -existing poor adherence  \n",
      "● Second -line treatment failure should be confirmed by viral load testing following the \n",
      "viral load monitoring algorithm (Figure 6.6)  \n",
      "o After the first detectable VL (  50 copies/ml), assess for and address all causes of \n",
      "poor adherence, and assess for all other possible causes of viremia.  \n",
      "o These patients should be discussed at an MDT session. Repeat the VL after 3 months \n",
      "of excellent adherence (preferably with daily witn essed ingestion of the ARVs by a \n",
      "treatment buddy, relative, CHV, etc.).\n"
     ]
    }
   ],
   "source": [
    "results = hybrid_search(\"When should a patient start ARV therapy?\", index, k=5)\n",
    "# results\n",
    "for r in results:\n",
    "    print(r.get(\"text\") or r.get(\"section\"))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e09e08d8-9ff1-4c31-8559-ac194903ff13",
   "metadata": {},
   "source": [
    "## Agent and tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "3ea325ff-fa36-4ef7-aa2f-674dad4e70f7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First-line antiretroviral therapy (ART) regimens for HIV typically consist of a combination of three or more drugs from different classes to effectively suppress viral replication and reduce the likelihood of resistance. The most commonly recommended first-line regimens include:\n",
      "\n",
      "1. **NNRTI-based regimens:**\n",
      "   - **Biktarvy** (bictegravir/tenofovir alafenamide/emtricitabine)\n",
      "   - **Doravirine-based regimens:** \n",
      "     - Dovato (dolutegravir/lamivudine)\n",
      "   - **Efavirenz-based options:**\n",
      "     - Efavirenz/tenofovir disoproxil fumarate/emtricitabine\n",
      "\n",
      "2. **PI-based regimens:**\n",
      "   - **Atazanavir/ritonavir plus tenofovir/emtricitabine**\n",
      "   - **Darunavir/ritonavir plus tenofovir/emtricitabine**\n",
      "\n",
      "3. **Integrase Inhibitor-based regimens:**\n",
      "   - **Dolutegravir plus tenofovir/emtricitabine**\n",
      "\n",
      "Each regimen may be selected based on individual patient factors, including potential drug interactions, side effects, pre-existing resistance, and personal preferences. \n",
      "\n",
      "Current guidelines may vary by region or specific patient populations, so it's essential to consult the latest recommendations from organizations like the World Health Organization (WHO) or the U.S. Department of Health and Human Services (DHHS).\n"
     ]
    }
   ],
   "source": [
    "import openai\n",
    "\n",
    "openai_client = openai.OpenAI()\n",
    "\n",
    "user_prompt = \"What are the first-line ART regimens?\"\n",
    "\n",
    "chat_messages = [\n",
    "    {\"role\": \"user\", \"content\": user_prompt}\n",
    "]\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model='gpt-4o-mini',\n",
    "    input=chat_messages,\n",
    ")\n",
    "\n",
    "print(response.output_text)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8b442c67-8347-4a7b-a312-59b061bdde87",
   "metadata": {},
   "source": [
    "## Function Calling with OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "37defd25-70b5-4456-893c-54d5e9ec6afe",
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import List\n",
    "from langchain.schema import Document\n",
    "def text_search(query: str) -> List[Document]:\n",
    "    \"\"\"\n",
    "    Perform a text-based similarity search on the Kenya ARV Guidelines vectorstore.\n",
    "\n",
    "    Args:\n",
    "        query (str): Clinical or guideline-related search query\n",
    "\n",
    "    Returns:\n",
    "        List[Document]: Top 5 guideline sections matching the query\n",
    "    \"\"\"\n",
    "    return vectorstore.similarity_search(query, k=5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "2420c9e0-e334-464d-9d75-7c89ad637d43",
   "metadata": {},
   "outputs": [],
   "source": [
    "text_search_tool = {\n",
    "    \"type\": \"function\",\n",
    "    \"name\": \"text_search\",\n",
    "    \"description\": \"Search the Kenya ART / ARV clinical guidelines knowledge base\",\n",
    "    \"parameters\": {\n",
    "        \"type\": \"object\",\n",
    "        \"properties\": {\n",
    "            \"query\": {\n",
    "                \"type\": \"string\",\n",
    "                \"description\": \"Clinical question or search text related to ARV regimens, eligibility, dosing, monitoring, or guidelines.\"\n",
    "            }\n",
    "        },\n",
    "        \"required\": [\"query\"],\n",
    "        \"additionalProperties\": False\n",
    "    }\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "5fdf804d-4ef2-4d81-867d-74683c6724f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are a clinical decision support assistant specialized in Kenya ART (ARV) guidelines.\n",
    "Provide accurate, guideline-based answers for HIV treatment, regimens, dosing, eligibility,\n",
    "monitoring, and special populations. If information is not found in the guidelines, say so clearly.\n",
    "\"\"\"\n",
    "\n",
    "question = \"What are the recommended first-line ART regimens for adults?\"\n",
    "\n",
    "chat_messages = [\n",
    "    {\"role\": \"system\", \"content\": system_prompt},\n",
    "    {\"role\": \"user\", \"content\": question}\n",
    "]\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model=\"gpt-4o-mini\",\n",
    "    input=chat_messages,\n",
    "    tools=[text_search_tool]\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "b598ab20-c3a9-4d9c-a14d-b46d0297a04d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Response(id='resp_0edee5d9e03c2d00006992bbcad6a481909618440c5712a729', created_at=1771224010.0, error=None, incomplete_details=None, instructions=None, metadata={}, model='gpt-4o-mini-2024-07-18', object='response', output=[ResponseFunctionToolCall(arguments='{\"query\":\"recommended first-line ART regimens for adults\"}', call_id='call_5o0AxaVKBVpjCmwL4YN80181', name='text_search', type='function_call', id='fc_0edee5d9e03c2d00006992bbcc34cc81908e3c7fe9cd3ed28a', status='completed')], parallel_tool_calls=True, temperature=1.0, tool_choice='auto', tools=[FunctionTool(name='text_search', parameters={'type': 'object', 'properties': {'query': {'type': 'string', 'description': 'Clinical question or search text related to ARV regimens, eligibility, dosing, monitoring, or guidelines.'}}, 'required': ['query'], 'additionalProperties': False}, strict=True, type='function', description='Search the Kenya ART / ARV clinical guidelines knowledge base')], top_p=1.0, background=False, conversation=None, max_output_tokens=None, max_tool_calls=None, previous_response_id=None, prompt=None, prompt_cache_key=None, reasoning=Reasoning(effort=None, generate_summary=None, summary=None), safety_identifier=None, service_tier='default', status='completed', text=ResponseTextConfig(format=ResponseFormatText(type='text'), verbosity='medium'), top_logprobs=0, truncation='disabled', usage=ResponseUsage(input_tokens=136, input_tokens_details=InputTokensDetails(cached_tokens=0), output_tokens=22, output_tokens_details=OutputTokensDetails(reasoning_tokens=0), total_tokens=158), user=None, billing={'payer': 'developer'}, completed_at=1771224012, frequency_penalty=0.0, presence_penalty=0.0, prompt_cache_retention=None, store=True)"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "f9cc0b67-7d12-4226-a5dc-3633e13234be",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "call = response.output[0]\n",
    "\n",
    "arguments = json.loads(call.arguments)\n",
    "results = text_search(**arguments)\n",
    "\n",
    "results_serializable = [\n",
    "    {\n",
    "        \"page_content\": doc.page_content,\n",
    "        \"metadata\": doc.metadata\n",
    "    }\n",
    "    for doc in results\n",
    "]\n",
    "\n",
    "call_output = {\n",
    "    \"type\": \"function_call_output\",\n",
    "    \"call_id\": call.call_id,\n",
    "    \"output\": json.dumps(results_serializable, ensure_ascii=False),\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "07d941fe-8bde-4a20-8cc4-89c4869f9d86",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The recommended first-line ART regimens for adults in Kenya are:\n",
      "\n",
      "1. **Dolutegravir (DTG) based regimens**:\n",
      "   - **For patients starting ART**: \n",
      "     - **DTG + Tenofovir Disoproxil Fumarate (TDF) + Lamivudine (3TC)**\n",
      "\n",
      "2. **Alternative regimens** (if DTG is not an option):\n",
      "   - **Efavirenz (EFV) + TDF + 3TC**\n",
      "   - **Rilpivirine (RPV) + TDF + 3TC** (for patients with a baseline viral load <100,000 copies/mL)\n",
      "\n",
      "This information aligns with the current clinical guidelines, which emphasize the efficacy and tolerability of DTG-based regimens.\n"
     ]
    }
   ],
   "source": [
    "chat_messages.append(call)\n",
    "chat_messages.append(call_output)\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model='gpt-4o-mini',\n",
    "    input=chat_messages,\n",
    "    tools=[text_search_tool]\n",
    ")\n",
    "\n",
    "print(response.output_text)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cdf749be-1ef1-43e9-9a16-9235954810ed",
   "metadata": {},
   "source": [
    "## System Prompt: Instructions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "2cca97b5-6843-4b59-ac58-c64e67c0e4f6",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat_messages = [\n",
    "    {\"role\": \"system\", \"content\": system_prompt},\n",
    "    {\"role\": \"user\", \"content\": question}\n",
    "]\n",
    "\n",
    "response = openai_client.responses.create(\n",
    "    model='gpt-4o-mini',\n",
    "    input=chat_messages,\n",
    "    tools=[text_search_tool]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "60c35a76-cd23-4654-9e6d-0b87396557e4",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are a clinical decision support assistant for the Kenya National HIV/AIDS treatment guidelines.\n",
    "\n",
    "Before answering any clinical question, you MUST first use the search tool to retrieve relevant information from the official ARV guideline materials.\n",
    "\n",
    "If the search returns relevant guideline content:\n",
    "- Base your answer strictly and only on that retrieved information.\n",
    "- Do NOT add outside medical knowledge.\n",
    "- Clearly reference the relevant section or source when possible.\n",
    "- Provide structured, clinically precise responses (e.g., Regimen, Dosing, Eligibility, Contraindications, Monitoring).\n",
    "\n",
    "If the search does NOT return relevant information:\n",
    "- Clearly state: \"This information was not found in the Kenya ARV guideline materials.\"\n",
    "- Provide general best-practice guidance separately and clearly label it as general information (not guideline-based).\n",
    "- Avoid making definitive clinical recommendations outside the retrieved guidelines.\n",
    "\n",
    "Safety Rules:\n",
    "- Do not invent regimens, dosages, or thresholds.\n",
    "- Do not assume patient details that were not provided.\n",
    "- If key clinical details are missing (e.g., age, pregnancy status, CD4 count, TB co-infection), ask for clarification before answering.\n",
    "- When uncertainty exists, explicitly state the limitation.\n",
    "\n",
    "Your role is to support clinicians with guideline-based information, not to replace clinical judgment.\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "7ea9a3e1-ca0b-4a4b-ac12-39596306c295",
   "metadata": {},
   "outputs": [],
   "source": [
    "# allows multiple search queries\n",
    "system_prompt = \"\"\"\n",
    "You are a clinical decision support assistant for the Kenya National HIV/AIDS treatment guidelines.\n",
    "\n",
    "Before answering any clinical question, you MUST search the official ARV guideline materials for relevant information.\n",
    "\n",
    "If the initial search does not return sufficient or precise information:\n",
    "- Refine the query using clinical synonyms (e.g., regimen names, drug names, WHO stage, pregnancy, TB co-infection, CD4 thresholds).\n",
    "- Perform multiple searches if necessary.\n",
    "- Combine relevant retrieved sections before forming a response.\n",
    "\n",
    "When relevant guideline content is found:\n",
    "- Base your answer strictly and only on the retrieved guideline information.\n",
    "- Do NOT introduce external medical knowledge.\n",
    "- Provide clear, structured clinical output (e.g., Eligibility, Recommended Regimen, Dosing, Special Populations, Monitoring).\n",
    "- Reference the relevant section or source when available.\n",
    "\n",
    "If no relevant information is found after multiple searches:\n",
    "- Clearly state: \"This information was not found in the Kenya ARV guideline materials.\"\n",
    "- Provide general best-practice guidance separately and clearly label it as general information.\n",
    "- Avoid making definitive clinical recommendations outside the retrieved guidelines.\n",
    "\n",
    "Safety Rules:\n",
    "- Do not invent regimens, dosages, or thresholds.\n",
    "- Do not assume missing patient details.\n",
    "- If essential clinical variables are missing (e.g., age, pregnancy status, TB status, viral load, CD4 count), ask for clarification before answering.\n",
    "- Clearly state any uncertainty or limitations.\n",
    "\n",
    "Your role is to support clinicians with guideline-based information, not to replace clinical judgment.\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "markdown",
   "id": "af492b2e-e12d-4b05-819f-7b0945e22592",
   "metadata": {},
   "source": [
    "## Pydantic AI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "4dfae342-3f1c-4a18-a8d3-da423eac3e3e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# \"similarity\" → classic vector similarity\n",
    "# \"mmr\" → Maximal Marginal Relevance (diverse results)\n",
    "# \"hybrid\" → semantic + metadata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "c8e9565b-3108-4f33-b62d-317ff3d9dd9a",
   "metadata": {},
   "outputs": [],
   "source": [
    "from typing import List, Any\n",
    "from pydantic_ai import Agent\n",
    "\n",
    "def text_search(query: str) -> List[str]:\n",
    "    \"\"\"\n",
    "    Perform a text-based search on the Kenya ART (ARV) guidelines index.\n",
    "\n",
    "    Args:\n",
    "        query (str): Clinical or guideline-related search query\n",
    "                     (e.g., regimens, dosing, eligibility, monitoring).\n",
    "\n",
    "    Returns:\n",
    "        List[str]: A list of up to 5 search results from the ARV guidelines index as plain text.\n",
    "    \"\"\"\n",
    "    # Specify search_type=\"similarity\"\n",
    "    docs = faq_index.search(query, k=5, search_type=\"similarity\")\n",
    "    \n",
    "    # Convert Document objects to plain text\n",
    "    return [doc.page_content for doc in docs]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "6f25a538-6f7f-45d6-817f-98bef44a1faa",
   "metadata": {},
   "outputs": [],
   "source": [
    "from pydantic_ai import Agent\n",
    "\n",
    "agent = Agent(\n",
    "    'openai:gpt-4o-mini',\n",
    "    name=\"hiv_agent\",\n",
    "    system_prompt=system_prompt,\n",
    "    tools=[text_search], \n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "d7fe739f-0042-4e45-8dbf-0bd53e1de7dd",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = \"Can a newly diagnosed patient be started on ART immediately?\"\n",
    "\n",
    "result = await agent.run(question)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "cfe4c814-be89-4d7f-a142-e6e34867aa78",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output='**Immediate ART Initiation Guidelines:**\\n\\n1. **Eligibility for ART**:\\n   - All individuals with confirmed HIV infection are eligible for ART irrespective of CD4 count, WHO clinical stage, age, pregnancy or breastfeeding status, co-infection status, or any other criteria.\\n\\n2. **Timing of ART Initiation**:\\n   - ART should ideally be started as soon as possible, preferably within 2 weeks of confirmation of HIV status.\\n   - Same-day ART initiation is encouraged if the patient is ready and willing to start treatment, even on the same day they test positive for HIV.\\n\\n3. **Counseling and Preparation**:\\n   - Immediate linkage to care and counseling on positive results is crucial. The readiness to start ART should be assessed using the ART Readiness Assessment Form.\\n   - Patients are counseled on the importance of ART for maintaining good health, reducing the risk of opportunistic infections, and the benefit of preventing HIV transmission to others.\\n\\n4. **Follow-Up**:\\n   - Weekly follow-up is recommended until ART initiation, followed by additional visits at 2 and 4 weeks after ART initiation, and then monthly until confirmed viral suppression.\\n\\n5. **Special Considerations**:\\n   - If there are any barriers to adherence that may affect the use of ART, these should be assessed and addressed prior to or during the ART initiation phase.\\n\\n**References**:\\n- The above information is derived from sections discussing eligibility and timing for ART initiation in the Kenya National HIV/AIDS treatment guidelines.')"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "0734d709-5cc4-4870-8c78-db9143b400fc",
   "metadata": {},
   "outputs": [],
   "source": [
    "# eligibility\n",
    "question = \"Who is eligible to start ART according to Kenya guidelines?\"\n",
    "\n",
    "# timing\n",
    "question = \"When should ART be initiated after HIV diagnosis?\"\n",
    "\n",
    "# regimen selection\n",
    "question = \"What is the recommended first-line ART regimen for adults?\"\n",
    "\n",
    "results = await agent.run(question)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "a825a407-7a44-44f3-8d61-1b9149b0b19e",
   "metadata": {},
   "outputs": [],
   "source": [
    "import asyncio\n",
    "\n",
    "# result = asyncio.run(agent.run(question))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "f6e487ac-472a-4c36-bcf1-bf1afa00f412",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[ModelRequest(parts=[SystemPromptPart(content='\\nYou are a clinical decision support assistant for the Kenya National HIV/AIDS treatment guidelines.\\n\\nBefore answering any clinical question, you MUST search the official ARV guideline materials for relevant information.\\n\\nIf the initial search does not return sufficient or precise information:\\n- Refine the query using clinical synonyms (e.g., regimen names, drug names, WHO stage, pregnancy, TB co-infection, CD4 thresholds).\\n- Perform multiple searches if necessary.\\n- Combine relevant retrieved sections before forming a response.\\n\\nWhen relevant guideline content is found:\\n- Base your answer strictly and only on the retrieved guideline information.\\n- Do NOT introduce external medical knowledge.\\n- Provide clear, structured clinical output (e.g., Eligibility, Recommended Regimen, Dosing, Special Populations, Monitoring).\\n- Reference the relevant section or source when available.\\n\\nIf no relevant information is found after multiple searches:\\n- Clearly state: \"This information was not found in the Kenya ARV guideline materials.\"\\n- Provide general best-practice guidance separately and clearly label it as general information.\\n- Avoid making definitive clinical recommendations outside the retrieved guidelines.\\n\\nSafety Rules:\\n- Do not invent regimens, dosages, or thresholds.\\n- Do not assume missing patient details.\\n- If essential clinical variables are missing (e.g., age, pregnancy status, TB status, viral load, CD4 count), ask for clarification before answering.\\n- Clearly state any uncertainty or limitations.\\n\\nYour role is to support clinicians with guideline-based information, not to replace clinical judgment.\\n', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 38, 166263, tzinfo=datetime.timezone.utc)), UserPromptPart(content='What is the recommended first-line ART regimen for adults?', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 38, 166275, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"first-line ART regimen for adults\"}', tool_call_id='call_bhApSNbzh0R3Gt7kk4M53W7D')], usage=RequestUsage(input_tokens=425, output_tokens=19, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 39, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZbqD0lm1LEK9CxXbWVOgh0mHUZ', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7', 'Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11', 'Counselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment', 'viral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART', 'to make it yourself immediately  \\n- Severe side effects include rash all over your body, or rash in your mouth or eyes, constant vomiting, \\ninability to eat or retain food, or anything else that makes you think you should stop the ART. If this \\noccurs then contact the clinic immediately  \\n- The cl inician will help you manage the side effects, and occasionally the ART may need to be changed'], tool_call_id='call_bhApSNbzh0R3Gt7kk4M53W7D', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 40, 156632, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"First-Line ART for Infants, Children, Adolescents and Adults\"}', tool_call_id='call_HdhePr4znR3N4dbbhMRgE5p8')], usage=RequestUsage(input_tokens=982, output_tokens=26, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 41, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZd1hQLsIlXk0aqhZAGT26vwmRn', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7', 'Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11', 'management approach)  \\n1.5 Antiretroviral Therapy for Infants, Children, Adolescents, and Adults  \\n• The goal of ART is to suppress viral replication with the aim of reducing the patient’s VL \\nto undetectable levels (Viral Load <50 copies/LD L) \\n• All individuals with confirmed HIV infection are eligible for ART, irrespective of CD4 \\ncount/%, WHO clinical stage, age, pregnancy or breastfeeding status, co -infection status, \\nrisk group, or any other criteria, provided that the individual is willing and ready to start \\nART  \\n• ART should be started in all patients as soon as possible, even on the  same day as \\nconfirming their HIV diagnosis (and preferably within 2 weeks)  \\n• Preferred first -line ART for infants, children, adolescents and adults  \\n▪ Birth to 4 weeks: AZT + 3TC + NVP', 'viral load monitoring\\nOn ART for < 3 months\\n On ART for     months\\nVL < 200 copies/ml  (LDL) \\nFigure 6.1: Optimizing ART Regimens for Children and adolescents <15 years Weighing < 30 kg \\non First Line ART', 'Infants and children depend on their caregivers for adherence to medication. Caregivers should \\nbe adequately prepared for their role of administering ARVs to infants and children, including \\naddressing anticipated challenges such as dr ug palatability. It can be helpful for more than one \\ncaregiver to be informed about a child’s HIV status and receive instruction on administration of \\nART.  \\nCaregivers should always be shown and then asked to demonstrate how to measure and \\nadminister ARVs.  This should be done both at the time of prescribing the ART (by the clinician) \\nand at the time of dispensing the ART. Clinicians should ensure that the caregiver accompanying \\na child for clinical review is the same caregiver responsible for day -to-day ART a dministration.'], tool_call_id='call_HdhePr4znR3N4dbbhMRgE5p8', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 42, 35998, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"preferred first-line ART regimen adults\"}', tool_call_id='call_AErofDDp0uMePlaw1ZI7E3pS')], usage=RequestUsage(input_tokens=1634, output_tokens=19, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 43, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZfyrmJHn2u68j0rKWliB8cBwra', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ..............  8 \\nFigure 6.2: Optimizing ART Regimens for Children and Adolescents Weighing ≥ 30 kg  or ≥ 15 years old on \\nFirst Line ART  ................................ ................................ ................................ ................................ ................................ ................................ ... 9 \\nFigure 6.3: General Principles for Managing Adverse Drug Reactions  ................................ ................................ ..............  11', '6.2 Timing of ART Initiation  ................................ ................................ ................................ ................................ ... 1 \\n6.3 First -Line ART for Infants, Children, Adolescents and Adults (including Pregnant and \\nBreastfeeding Women)  ................................ ................................ ................................ ...........................  3 \\n6.4 Dosing and Administration of Dolutegravir (DTG) ................................ ................................ ...............  5 \\n6.5 Monitoring and Changing ART  ................................ ................................ ................................ .......................  7', '• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation, \\nand \\nfurther \\nfollow -up \\nvisits  \\n • Review and reinforce the messages delivered in previous sessions; confirm the \\nadolescent’s and/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent a nd/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adolescent support group)  \\n• Revisit benefits of disclosure and the in dividualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Link to psychosocial support group  \\n• Identify referral needs and link as appropriate', 'Counselling  ● ART is the most important treatment to maintain good health and an \\nactive life  \\n● Starting ART soon will decrease risk of developing wasting and other \\ninfections  \\n● ART will reduce the risk of transmitting HIV to others  \\nFrequency of  \\nFollow -up ● Weekly follow -up until ART initiation, and then at week 2 and 4 after \\nART initiation, and then monthly until confirmed viral suppression  \\n● Additional visits as required to address any medical or psychosocial \\nconcerns  \\nAdults, adolescents, and children ≥ 5 years who Present Well: WHO Stage 1 or 2, and CD4 count > \\n200 cell/mm3 \\nLocation of Services  • Management at any ART service delivery point; all facility levels   \\n• Initial management and ART initiation by trained and experienced HCW  \\nFocus of Treatment', 'Adherence Preparation, Monitoring and Support  \\n5 - 19 Table 5.8 Cont.  \\nTwo \\nweeks \\nafter ART \\ninitiation  • Review and reinforce the messages delivered at enrolment; confirm the adolescent’s \\nand/or caregiver’s understanding of key messages  \\n• Review ART dosing, timing and reminders (including having the adolescent and/or \\ncaregiver demonstrate how they measure and administer the ART)  \\n• Explore any barriers to adherence, including issues related to the school environment  \\n• Review support systems (including adol escent support group)  \\n• Revisit benefits of disclosure and the individualized age -appropriate disclosure plan  \\n• Review SRH needs  \\n• Identify referral needs and link as appropriate  \\n• Document the session in the patient’s chart  \\nFour \\nweeks \\nafter ART \\ninitiation,'], tool_call_id='call_AErofDDp0uMePlaw1ZI7E3pS', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 43, 820927, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"preferred first-line ART regimen adults site:kenya\"}', tool_call_id='call_tOYiHLZMzc2tbIlkekWD8dXb')], usage=RequestUsage(input_tokens=2409, cache_read_tokens=1536, output_tokens=23, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 44, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZgOkK4nNzZqBueb8G8kt8ZL41F', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 10 Annex 8: Cont.  \\nSection 5: Antiretroviral therapy (ART)  \\n• What is ART:  \\n- ART is a combination of 3 or more different medicines  \\n- ART fights HIV, lowering the amount of virus in the body allowing the body to protect \\nitself against opportunistic infections  \\n- When the virus level is low then the CD4 count can increase  \\n- Increased CD4 count means the body is able to protect itself against opportunistic infections  \\n \\n• What are the benefits of ART:  \\n- After a few weeks of taking ART, you will begin to regain appetite and weight (if it has been \\naffected)  \\n- Many people report an increase in their energy levels and general sense of well being'], tool_call_id='call_tOYiHLZMzc2tbIlkekWD8dXb', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 44, 711859, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"First line ART regimen adults Kenya guidelines\"}', tool_call_id='call_g6sWiTk3HfcTVXFsD6NJnPOY')], usage=RequestUsage(input_tokens=3396, cache_read_tokens=2304, output_tokens=20, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 45, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZhGCg69qzpCq2mhH4fPIiXeUFj', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 8 Table 5.1 Cont.  \\n● Patient Factors  \\no Stigma and non -disclosure (having to hide \\ntheir ARV pill -taking)  \\no Lack of support systems  \\no Alcohol or drug use  \\no Depression or other psychiatric illness  \\no Loss or grief  \\no Cognitive disorders  \\no Change in daily routine  \\no Chaotic lifestyle; no consistent daily \\nroutine  \\no Forgetting to take pills  \\no Feeling better so does not think the ART is \\nneeded any more  \\no Feeling too sick to take ART  \\no Age (adolescents - impulsive, more \\nsusceptible to social pressure; children – \\ncaregiver dependent)  ● Provider/System Factors  \\no Side effects (many patients have side \\neffects when they first start their ART, \\nincluding nausea, headaches, and', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems'], tool_call_id='call_g6sWiTk3HfcTVXFsD6NJnPOY', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 46, 120923, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"first line ART regimens for adults 2022 Kenya guidelines\"}', tool_call_id='call_CF67WNyOPjnrLOPidcqvdeIg')], usage=RequestUsage(input_tokens=4383, cache_read_tokens=3328, output_tokens=25, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 46, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZiQw8xJwkTcPA4xZMdqXlq7zoA', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 12 Annex 8: Cont.  \\nSection 8: Adherence  \\n• What is adherence  \\n- Following a care plan as agreed with the healthcare team  \\n- Attending clinic appointments as scheduled  \\n- Picking up medicines and taking them as prescribed  \\n- Getting lab tests according to the recommended schedule  \\n- Following nutritional recommendations  \\n• How should ART be taken  \\n- You must take the correct dosage. If you take less than the dose prescribed the treatment will \\nnot be effective and will result in resistance and treatment failure. Never share your ART with \\nsomeone else  \\n- For children, the dosage keeps changing as they grow and gain weight  \\n- You must take ART the correct time of day:', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:'], tool_call_id='call_CF67WNyOPjnrLOPidcqvdeIg', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 49, 363645, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"Kenya ARV guidelines first-line regimen adults 2022\"}', tool_call_id='call_VUm7T6jiAU1Ja01XcAoaM0Jh')], usage=RequestUsage(input_tokens=5354, cache_read_tokens=4352, output_tokens=25, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 50, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZmSkTrik0h9vIBVV9m7wV0X3OU', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['© National AIDS & STI Control Program 2022  \\n \\nThis guideline document is a publication of the National AIDS & STI Control Program, Ministry of Health \\nKenya. No part of this publication may be reproduced, distributed, or transmitted in any form or by any \\nmeans, including photocopying or recording, without the prior written permission of the National AIDS and \\nSTI Contro l Program (NASCOP), Ministry of Health Kenya, except for non -commercial uses permitted by \\ncopyright law.  \\n \\nKenya HIV Prevention and Treatment Guidelines, 2022  edition contain relevant information required by \\nhealthcare providers in the use of ARVs as of the date of issue. All reasonable precautions have been taken \\nby NASCOP to verify the information contained in this guideline document.', 'i Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n4 - 6  4.2.1 Screening for Gender -Based Violence (GBV)/Intimate -Partner Violence (IPV)  \\nNational data (KDHS 2014) shows that 45% of women and 44 % of men aged 15 -49 years have \\nexperienced physical violence since age 15.; 14% of women and 6% of men age 15 -49 report \\nhaving experienced sexual violence at least once in their lifetime.  To identify these survivors \\nscreening is recommended. WHO recommends that facilities should meet the minimum \\nrequirement before starting to routinely screening clients.  \\nThe minimum require ments are:   \\n• A protocol or Standard Operating Procedure exists for providing post -GBV and Violence \\nAgainst Children  services', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination'], tool_call_id='call_VUm7T6jiAU1Ja01XcAoaM0Jh', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 52, 878363, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"first line ART regimen for adults Kenya HIV guidelines\"}', tool_call_id='call_2BxMg5OuZ84MAGfW0L20x2xQ')], usage=RequestUsage(input_tokens=6139, cache_read_tokens=5248, output_tokens=22, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 53, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZpJy8C844JCfwup9C1COLe3Tlx', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 2 \\nHTS post -test counselling: key treatment preparation messages for all patients who test positive\\n• Treatment is available and recommended for everyone with HIV\\n• Starting treatment early reduces your chance of becoming ill or infecting your sexual partner(s)\\n• With good adherence you can live a long and productive life\\nEnrolment Visit\\n• HIV education and adherence preparation for all patients/caregivers (Table 5.1)\\n• ART Readiness Assessment for all patients/caregivers (Table 5.4), along with \\nindividualized adherence support plan\\nReady to start ART Not ready to start ART\\n• Initiate ART\\n• Baseline investigations if not already completed\\n• Provide standard package of care and differentiated'], tool_call_id='call_2BxMg5OuZ84MAGfW0L20x2xQ', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 54, 20518, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"first-line ART regimens for adults in Kenya HIV guidelines 2022\"}', tool_call_id='call_VpLE75fNompLHnhPcozKxXlW')], usage=RequestUsage(input_tokens=6756, cache_read_tokens=6144, output_tokens=27, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 55, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZr3JAQrxDuN2YkAzSFyLHMaKUx', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16'], tool_call_id='call_VpLE75fNompLHnhPcozKxXlW', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 56, 211216, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"first line ART regimens adults 2022 Kenya guidelines\"}', tool_call_id='call_saFD0oLSrQrjWsbGDryQ8Orw')], usage=RequestUsage(input_tokens=7231, output_tokens=24, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 56, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZsxPxcoO9w4O3P4xJwbk6iDP2g', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems'], tool_call_id='call_saFD0oLSrQrjWsbGDryQ8Orw', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 57, 830740, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"first line ART regimen for adults Kenya HIV 2022 guidelines\"}', tool_call_id='call_gcTPioA88wfZGvmJqMou7GRq')], usage=RequestUsage(input_tokens=8036, cache_read_tokens=6656, output_tokens=25, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 58, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZulKG1T3jtLaggLPb02sozcTvW', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18'], tool_call_id='call_gcTPioA88wfZGvmJqMou7GRq', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 59, 78753, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"Kenya 2022 ART guidelines preferred first-line regimen adults\"}', tool_call_id='call_uyfiHVU8YpIhlaZHisz8xvp0')], usage=RequestUsage(input_tokens=8509, cache_read_tokens=7936, output_tokens=25, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 40, 59, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZvv51HNLNCgII8vNXFaMgoaUUz', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n6 - 22'], tool_call_id='call_uyfiHVU8YpIhlaZHisz8xvp0', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 0, 846600, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"first line ART regimen adults Kenya 2022 guidelines\"}', tool_call_id='call_jr1P4r1GtWiRsZTBuQakG2d2')], usage=RequestUsage(input_tokens=8982, cache_read_tokens=8448, output_tokens=23, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 1, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZx91p9EneSb46vrgeHrQ7KvSbR', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n13 - 54 Annex 14: Health Facility Assessment to Provide Community ART Distribution  \\nHealth Facility Assessment to Provide Community ART Distribution*  \\nFacility name:  MFL code:  Date of assessment:  \\nHealth system domains for community ART distribution  Yes/No  \\nLeadership:  \\nHas the facility identified a focal person to oversee community -based ART distribution?   \\nFinance:  \\nDoes the facility have resources to implement and monitor community -based ART distribution?   \\nHuman Resources for Health:  \\nHas the facility identified appropriate personnel to distribute ART (peer educators, lay \\ncounselors and /or Community Health Volunteers)?   \\nDoes the facility have capacity to train ART distributors?   \\nService Delivery:', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n5 - 20 Table 5.9 Cont.  \\nTwo weeks \\nafter ART \\ninitiation  ● Review and reinforce the messages delivered at enrolment; confirm the patient’s \\nunderstanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems  \\n● Revisit benefits of disclosure, the disclosure plan and progress in aPNS  \\n● Document the session in the patient’s chart  \\nFour weeks \\nafter ART \\ninitiation, \\nand further \\nfollow -up \\nvisits  ● Review and reinforce the messages delivered in previous sessions; confirm the \\npatient’s understanding of key messages  \\n● Review ART dosing, timing and reminders  \\n● Explore any barriers to adherence  \\n● Review support systems'], tool_call_id='call_jr1P4r1GtWiRsZTBuQakG2d2', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 2, 30557, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"adult first line antiretroviral therapy regimen Kenya guidelines 2022\"}', tool_call_id='call_GGaofDj5IXjGIoNAHzGD1fm3')], usage=RequestUsage(input_tokens=9786, cache_read_tokens=7168, output_tokens=27, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 2, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZyKmyhb6hT0jwytX0HQvV7c2jg', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['i Foreword  \\nKenya is committed to achieving the UNAIDS 95 –95–95 testing and treatment targets among \\npeople living with HIV within all sub -populations and age groups.  \\nThe 2022 edition of the ‘Guidelines on Use of Antiretroviral Drugs for Treating and Pr eventing \\nHIV Infection in Kenya’ is an update of the comprehensive HIV prevention, Care and treatment \\nguidelines released in 2018. These guidelines are aligned with the Ministry of Health’s mission of \\nproviding the highest standard of health for all Kenyan s and one of the Government of Kenya’s Big \\nFour Agenda on Universal Health Coverage .  \\nThe theme of the 2022 guidelines is refocusing efforts in the management of Advanced HIV \\nDisease to reduce HIV/AIDS related morbidity and mortality. While Kenya has made tremendous', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n2022 Edition', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16'], tool_call_id='call_GGaofDj5IXjGIoNAHzGD1fm3', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 3, 134335, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[ToolCallPart(tool_name='text_search', args='{\"query\":\"adult HIV first line ART regimen Kenya guidelines\"}', tool_call_id='call_A0jSuuK2zpWAreQk3GllYWRP')], usage=RequestUsage(input_tokens=10083, cache_read_tokens=8960, output_tokens=21, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 3, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'tool_calls'}, provider_response_id='chatcmpl-D9mZzDPR1LckDgSzGZwcCThRz9ebz', finish_reason='tool_call'),\n",
       " ModelRequest(parts=[ToolReturnPart(tool_name='text_search', content=['Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 10  Table 3. 5 Cont.  \\nPatients Established on ART  \\nPatients established on ART must have achieved ALL the following  \\n● On their current ART regimen for ≥ 6 months  \\n● Currently no active Illness or in the previous 6 months (patients with well controlled chronic \\nconditions should not be excluded)  \\n● Adherent to scheduled clinic visits for the previous 6 months  \\n● VL ≤200 copies/ml (LDL) within the last 6 months  \\nNote:  \\n● This definition should be applied to all populations, including those receiving second - \\nand third -line regimens, those with controlled comorbidities, children above 2 years *, \\nadolescents, pregnant and breastfeeding women, and key populations.', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n \\n 13 - 26 Annex 9 E: Management Protocol for Patients Switching to 3rd Line ART  \\nManagement Protocol for patients switching to 3rd line ART  \\n \\nPre – Initiation MDT Meeting  \\n• Confirm what 3rd line ARV regimen is prescribed, its availability and the management plan  \\n• Assign a case manager to patient  \\nInitiation of 3rd Line ART  \\n• Triage  \\no Record vital signs and take actions as needed  \\n \\n• Adherence support  \\no Conduct patient education on the new ART regimen: Treatment goals, dosing, drug \\ninteractions and potential side effects and adverse events  \\no Conduct adherence assessment and counselling  \\no Link patient to adherence support systems  \\n \\n• Clinical assessment  \\no Take history and conduct physical examination', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 8 - 18', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n3 - 16', 'Kenya HIV Prevention and Treatment Guidelines, 2022  \\n 11 - 14'], tool_call_id='call_A0jSuuK2zpWAreQk3GllYWRP', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 4, 626593, tzinfo=datetime.timezone.utc))]),\n",
       " ModelResponse(parts=[TextPart(content='**Recommended First-Line ART Regimen for Adults in Kenya:**\\n\\n1. **Eligibility:**\\n   - All individuals with confirmed HIV infection are eligible for ART, regardless of CD4 count or WHO clinical stage, provided they are willing and ready to start ART. \\n   - ART should be initiated as soon as possible after diagnosis, preferably within two weeks.\\n\\n2. **Preferred First-Line Regimen:**\\n   - The preferred first-line regimen for adults includes:\\n     - **Dolutegravir (DTG)** combined with:\\n       - **Lamivudine (3TC)**, or\\n       - **Tenofovir disoproxil fumarate (TDF)**\\n     - Alternative options may include:\\n       - **Zidovudine (AZT)** combined with 3TC, especially when TDF is not suitable.\\n   \\n3. **Dosing:**\\n   - **Dolutegravir (DTG)**: Typically, 50 mg once daily.\\n   - **Lamivudine (3TC)**: Usually 300 mg once daily.\\n   - **Tenofovir disoproxil fumarate (TDF)**: Typically 300 mg once daily.\\n   - **Zidovudine (AZT)**: Typically 300 mg twice daily, options may differ based on guidelines and co-morbidities.\\n\\n4. **Monitoring:**\\n   - Patients on ART should undergo regular monitoring:\\n     - Ensure adherence and assess any side effects.\\n     - Viral load monitoring at 6 months and annually thereafter.\\n     - Monitor CD4 count periodically to evaluate immune response.\\n\\n5. **Special Populations:**\\n   - For pregnant women or those with specific contraindications, regimen choices may differ. Close attention should be paid to maternal health and possible effects on the fetus.\\n\\n**Sources:**\\n- Kenya HIV Prevention and Treatment Guidelines 2022, Sections on ART initiation and preferred regimens for adults. \\n\\nIf more detailed information is required regarding specific patient scenarios or adjustments based on co-morbidities, please provide additional details for tailored guidance.')], usage=RequestUsage(input_tokens=10552, cache_read_tokens=9984, output_tokens=421, details={'accepted_prediction_tokens': 0, 'audio_tokens': 0, 'reasoning_tokens': 0, 'rejected_prediction_tokens': 0}), model_name='gpt-4o-mini-2024-07-18', timestamp=datetime.datetime(2026, 2, 16, 6, 41, 5, tzinfo=TzInfo(0)), provider_name='openai', provider_details={'finish_reason': 'stop'}, provider_response_id='chatcmpl-D9ma1BYwN1sAfxqIKSKrVAnajxLfn', finish_reason='stop')]"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results.new_messages()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "1b4ac0fa-45d3-4b12-8043-0ade63039d5a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output='Below are the first-line treatment regimens for different population groups—adults, children, and women in various stages of life—from the Kenya National HIV/AIDS treatment guidelines:\\n\\n### 1. Adults\\n**Recommended First-Line Regimens:**\\n- **Dolutegravir (DTG)-based regimens** are preferred.\\n  - **Options:**\\n    - **DTG + TDF + 3TC**\\n    - **DTG + AZT + 3TC**\\n    - **DTG + 3TC + DRV/r** (boosted with Ritonavir)\\n\\n**Notes:**\\n- DTG is favored due to its better tolerability and efficacy compared to older regimens like Efavirenz or Lopinavir/ritonavir.\\n- Adult patients should be monitored regularly for adherence and may switch to second-line therapies if necessary (Kenya HIV Prevention and Treatment Guidelines, 2022).\\n\\n### 2. Children (including Adolescents aged <15 years)\\n**Recommended First-Line Regimens:**\\n- **Dolutegravir (DTG)-based regimens** are similarly preferred.\\n  - **Options:**\\n    - **DTG + TDF + 3TC**\\n    - **DTG + ABC (Abacavir) + 3TC**\\n    - **DTG + AZT + 3TC**\\n\\n**Special Considerations:**\\n- Pediatric patients must have correct weight-based dosing verified at each visit.\\n- Caregiver support is crucial for adherence (Kenya HIV Prevention and Treatment Guidelines, 2022).\\n\\n### 3. Women of Childbearing Age (including Pregnant and Breastfeeding Women)\\n**Recommended First-Line Regimens:**\\n- Pregnant women should receive ART to maintain viral load suppression and to prevent vertical transmission to the child.\\n  - **Regimens:**\\n    - **DTG-based regimens** as previously listed, with specific counseling on the implications of ART during pregnancy and breastfeeding.\\n\\n**Counseling:**\\n- Women planning pregnancy should achieve viral suppression before conception and receive Iron and Folic Acid supplementation (Kenya HIV Prevention and Treatment Guidelines, 2022).\\n\\n### 4. Menopausal Women\\n**Treatment Guidelines:**\\n- Menopausal status does not change ART recommendations fundamentally. Therefore, **Dolutegravir-based regimens** as previously mentioned are still applicable.\\n  \\n**Considerations:**\\n- Management should include monitoring for menopause-related health issues, but ART adherence remains the priority.\\n\\n**Monitoring:**\\n- Regardless of age or status, all women should have their follow-ups scheduled according to ART protocols, always ensuring they are adherent (Kenya HIV Prevention and Treatment Guidelines, 2022).\\n\\n### Summary of First-Line Treatments\\n\\n#### **Adults:**\\n- **DTG + TDF + 3TC**\\n- **DTG + AZT + 3TC**\\n- **DTG + DRV/r**\\n\\n#### **Children:**\\n- **DTG + TDF + 3TC**\\n- **DTG + ABC + 3TC**\\n- **DTG + AZT + 3TC**\\n\\n#### **Women of Childbearing Age:**\\n- Use DTG regimens with preconceptual counseling about health and ART implications.\\n\\n#### **Menopausal Women:**\\n- Continue with DTG-based regimens; monitor overall health and adherence.\\n\\n**Important Note:** All patients transitioning between different life stages or facing any complications should be closely monitored and may require tailored interventions. Always consult the latest guidelines for the most accurate and comprehensive care plans.')"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"Can you give me first line treatments for different pupoulation groups between children and adults and women in child bearing age vs those in menopouse\"\n",
    "\n",
    "result = await agent.run(question)\n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "9abb4bf2-02d2-418f-a784-17365afd523d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output='**Recommended First-Line ART Regimen for Adults in Kenya:**\\n\\n1. **Eligibility:**\\n   - All individuals with confirmed HIV infection are eligible for ART, regardless of CD4 count or WHO clinical stage, provided they are willing and ready to start ART. \\n   - ART should be initiated as soon as possible after diagnosis, preferably within two weeks.\\n\\n2. **Preferred First-Line Regimen:**\\n   - The preferred first-line regimen for adults includes:\\n     - **Dolutegravir (DTG)** combined with:\\n       - **Lamivudine (3TC)**, or\\n       - **Tenofovir disoproxil fumarate (TDF)**\\n     - Alternative options may include:\\n       - **Zidovudine (AZT)** combined with 3TC, especially when TDF is not suitable.\\n   \\n3. **Dosing:**\\n   - **Dolutegravir (DTG)**: Typically, 50 mg once daily.\\n   - **Lamivudine (3TC)**: Usually 300 mg once daily.\\n   - **Tenofovir disoproxil fumarate (TDF)**: Typically 300 mg once daily.\\n   - **Zidovudine (AZT)**: Typically 300 mg twice daily, options may differ based on guidelines and co-morbidities.\\n\\n4. **Monitoring:**\\n   - Patients on ART should undergo regular monitoring:\\n     - Ensure adherence and assess any side effects.\\n     - Viral load monitoring at 6 months and annually thereafter.\\n     - Monitor CD4 count periodically to evaluate immune response.\\n\\n5. **Special Populations:**\\n   - For pregnant women or those with specific contraindications, regimen choices may differ. Close attention should be paid to maternal health and possible effects on the fetus.\\n\\n**Sources:**\\n- Kenya HIV Prevention and Treatment Guidelines 2022, Sections on ART initiation and preferred regimens for adults. \\n\\nIf more detailed information is required regarding specific patient scenarios or adjustments based on co-morbidities, please provide additional details for tailored guidance.')"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "bf1df1c0-c5a3-46aa-9ec7-d3a14cc922d5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output='This information was not found in the Kenya ARV guideline materials.\\n\\n**General Information:**\\nMalaria treatment typically involves the use of antimalarial medications. For uncomplicated malaria, artemisinin-based combination therapies (ACTs) are often the first-line treatment. For severe malaria, intravenous antimalarial medications such as artesunate may be used. It is important to consider local treatment guidelines and the specific type of malaria parasite when choosing a treatment regimen. Always consult a healthcare professional for personalized medical advice.')"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"How do you treat malaria\"\n",
    "\n",
    "result = await agent.run(question)\n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "94231300-5bf3-4c8e-b89e-8f009d6646fe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output='### Pregnancy Testing and Treatment Guidelines for HIV\\n\\n#### Testing Guidelines\\n1. **Initial Testing**:\\n   - All pregnant women attending antenatal care (ANC) for the first time should undergo a dual HIV and syphilis test during the first trimester.\\n   - If the initial test is negative, a repeat dual test is recommended in the third trimester.\\n\\n2. **Postnatal Testing**:\\n   - All breastfeeding mothers (unless known to be HIV positive) should be counselled and tested at the 6-week infant immunization visit.\\n   - If negative, the HIV test should be repeated every 6 months until complete cessation of breastfeeding.\\n   - Women at high risk for HIV infection (e.g., key populations, those in HIV discordant relationships) should be retested postnatally every 3 months.\\n\\n3. **Pregnancy Intent and Contraceptive Use**:\\n   - Screening for contraception use and discussions regarding condom use should take place.\\n   - Plans for Pre-exposure Prophylaxis (PrEP) should be discussed for those at high risk.\\n\\n#### Treatment Guidelines\\n1. **ART Initiation**:\\n   - All pregnant and breastfeeding women living with HIV should initiate Antiretroviral Therapy (ART) regardless of gestation, clinical stage, or CD4 count.\\n   - ART should ideally be started on the same day as the diagnosis.\\n\\n2. **Recommended First-line ART Regimen**:\\n   - The preferred ART regimen for pregnant and breastfeeding women is Tenofovir (TDF) + Lamivudine (3TC) + Dolutegravir (DTG).\\n\\n3. **Monitoring**:\\n   - Viral load (VL) should be checked 3 months after ART initiation for pregnant women. If the patient is already on ART, a VL should be carried out at the first identification of pregnancy.\\n   - Continued monitoring should take place every 6 months during breastfeeding.\\n\\n4. **Infant Prophylaxis**:\\n   - For infants born to HIV-positive mothers, prophylaxis with Azidothymidine (AZT) and Nevirapine (NVP) for 6 weeks should be provided. NVP should continue until 6 weeks after breastfeeding has ceased.\\n\\n5. **Support and Follow-Up**:\\n   - Enhanced adherence support and psychosocial support groups are recommended for pregnant and breastfeeding women to improve retention in care and ensure viral suppression.\\n\\n### Important Notes\\n- These guidelines aim for the prevention of mother-to-child transmission (PMTCT) and overall health for both mother and child.\\n- Continuous counselling and education regarding HIV management during pregnancy and postpartum are essential parts of care.\\n\\nFor further details, refer to sections 7.2 and 7.4 of the Kenya HIV Prevention and Treatment Guidelines, 2022.')"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"Explain how patients in pregnancy should be tested and treated\"\n",
    "\n",
    "result = await agent.run(question)\n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "2b43c038-156f-43f1-9637-963995bffd0a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "AgentRunResult(output='Based on the retrieval from the Kenya HIV Prevention and Treatment Guidelines, here are the summarized screening modalities and recommendations for different demographic populations:\\n\\n### Screening Modalities for Different Demographic Populations\\n\\n#### 1. **Settings for HIV Testing**\\n   - **Facility-based Testing:** Conducted in health facilities. Testing is prioritized using a validated screening tool for individuals at risk.\\n   - **Community-based Testing:** Includes outreach programs targeting key populations, orphans and vulnerable children, and others.\\n\\n#### 2. **Key and Vulnerable Populations**\\n   - **Testing Recommendations:**\\n     - HIV testing and counseling should be conducted for all clients from key and vulnerable populations presenting to health facilities, regardless of their reason for visit, or through targeted outreach at service delivery points (e.g., drop-in centers).\\n     - Key populations (such as sex workers, men who have sex with men, intravenous drug users) that test negative should be retested quarterly.\\n     - All individuals who test positive should be linked to treatment and prevention services.\\n\\n#### 3. **Targeted Testing Strategy**\\n   - Utilization of targeted HIV testing, including:\\n     - Listing of contacts of index clients.\\n     - HIV self-testing.\\n     - HTS screening tools to identify at-risk individuals.\\n\\n#### 4. **Eligibility for Testing**\\n   - Screening tools should prioritize individuals who:\\n     - Are diagnosed with sexually transmitted infections.\\n     - Have multiple sexual partners.\\n     - Are part of key populations.\\n     - Have potential or known HIV exposure (e.g., sexual partners of HIV positive individuals).\\n\\n#### 5. **Mental Health Screening**\\n   - Mental status assessments should be conducted to evaluate psychological issues that influence adherence to treatment.\\n\\n### Special Considerations\\n- **Youth and Adolescents:** Targeted testing for youth and adolescents is crucial in various settings.\\n- **Pregnant Women:** Pregnant women should be tested as part of routine antenatal care (PMTCT).\\n\\n### Monitoring and Referral\\n- Continuous monitoring of those who test HIV positive, ensuring they are not lost to follow-up, and are receiving appropriate care and treatment.\\n\\n### References\\n- For detailed guidance and specific recommendations, refer to the Kenya HIV Prevention and Treatment Guidelines, particularly sections related to HIV Testing Services and key population strategies.\\n\\nThis summary captures the screening modalities emphasized in the guidelines without introducing external medical knowledge. For additional specific details, the official guidelines can be consulted.')"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"what screening modalities are required for different demographic populations\"\n",
    "\n",
    "result = await agent.run(question)\n",
    "result"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ea7d63d3-3ffa-44d0-b566-9ada6c8c6b51",
   "metadata": {},
   "source": [
    "## Evaluation"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7e4e4e00-3eeb-4c3f-bccd-bdfbd9fb6b90",
   "metadata": {},
   "source": [
    "### Logging"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "55cae36e-6201-49cf-92ce-5a4e39c4b957",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = \"When should ART be initiated after HIV diagnosis?\"\n",
    "result = await agent.run(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "6c563164-76a9-4c97-a44f-fc6ef5c748df",
   "metadata": {},
   "outputs": [],
   "source": [
    "from pydantic_ai.messages import ModelMessagesTypeAdapter\n",
    "\n",
    "\n",
    "def log_entry(agent, messages, source=\"user\"):\n",
    "    tools = []\n",
    "\n",
    "    for ts in agent.toolsets:\n",
    "        tools.extend(ts.tools.keys())\n",
    "\n",
    "    dict_messages = ModelMessagesTypeAdapter.dump_python(messages)\n",
    "\n",
    "    return {\n",
    "        \"agent_name\": agent.name,\n",
    "        \"system_prompt\": agent._instructions,\n",
    "        \"provider\": agent.model.system,\n",
    "        \"model\": agent.model.model_name,\n",
    "        \"tools\": tools,\n",
    "        \"messages\": dict_messages,\n",
    "        \"source\": source\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "9d118989-87a9-4da1-8317-66d8e5054420",
   "metadata": {},
   "outputs": [],
   "source": [
    "# write logs to a folder\n",
    "\n",
    "import json\n",
    "import secrets\n",
    "from pathlib import Path\n",
    "from datetime import datetime\n",
    "\n",
    "\n",
    "LOG_DIR = Path('logs')\n",
    "LOG_DIR.mkdir(exist_ok=True)\n",
    "\n",
    "\n",
    "def serializer(obj):\n",
    "    if isinstance(obj, datetime):\n",
    "        return obj.isoformat()\n",
    "    raise TypeError(f\"Type {type(obj)} not serializable\")\n",
    "\n",
    "\n",
    "def log_interaction_to_file(agent, messages, source='user'):\n",
    "    entry = log_entry(agent, messages, source)\n",
    "\n",
    "    ts = entry['messages'][-1]['timestamp']\n",
    "    ts_str = ts.strftime(\"%Y%m%d_%H%M%S\")\n",
    "    rand_hex = secrets.token_hex(3)\n",
    "\n",
    "    filename = f\"{agent.name}_{ts_str}_{rand_hex}.json\"\n",
    "    filepath = LOG_DIR / filename\n",
    "\n",
    "    with filepath.open(\"w\", encoding=\"utf-8\") as f_out:\n",
    "        json.dump(entry, f_out, indent=2, default=serializer)\n",
    "\n",
    "    return filepath"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "663c24ba-9bf2-4714-8cb9-7017b3246f67",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      " \"When should ART be initiated after HIV diagnosis?\"\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "**ART Initiation After HIV Diagnosis**\n",
      "\n",
      "**Eligibility:**\n",
      "- All individuals with confirmed HIV infection are eligible for ART, regardless of CD4 count, WHO clinical stage, age, pregnancy status, co-infection status, or any other criteria.\n",
      "\n",
      "**Recommended Timing for ART Initiation:**\n",
      "- ART should be started **as soon as possible**, preferably **within 2 weeks** of confirmation of HIV status.\n",
      "- **Same-day ART initiation** is recommended if the patient is ready at the time of diagnosis.\n",
      "\n",
      "**Patient Readiness:**\n",
      "- Before starting ART, patient readiness should be assessed to address any issues that may affect adherence (refer to ART Readiness Criteria in the guidelines).\n",
      "\n",
      "**Additional Notes:**\n",
      "- Delaying ART can allow the virus to cause further damage to the body, increasing the risk of illness or mortality.\n",
      "- For patients who do not start ART on the same day of enrollment into HIV care, follow-up should occur weekly to address any barriers to initiation.\n",
      "\n",
      "This information is based on the guidelines' section regarding ART initiation timing and patient management.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "PosixPath('logs/hiv_agent_20260216_072400_baf965.json')"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "7f356b2c-7c1d-417f-b06c-c3643aa43466",
   "metadata": {},
   "outputs": [
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      "  \"Explain how patients in pregnancy should be tested and treated\"\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "### Testing and Treatment of HIV in Pregnant Patients\n",
      "\n",
      "#### Eligibility for Testing\n",
      "- All pregnant women who are not already known to be HIV positive should be counselled and tested for:\n",
      "  - HIV\n",
      "  - Syphilis\n",
      "  - Hepatitis B\n",
      "- Routine testing should occur during the first antenatal care (ANC) visit, and if the initial test is negative, repeat the HIV and syphilis tests in the third trimester.\n",
      "\n",
      "#### Follow-Up Testing for High-Risk Groups\n",
      "- Pregnant and breastfeeding mothers who are considered at high risk of HIV (e.g., key populations) should be tested every 3 months during pregnancy.\n",
      "- Breastfeeding mothers without known HIV should be tested at the 6-week infant immunization visit and subsequently every 6 months until breastfeeding ceases.\n",
      "\n",
      "#### Treatment Guidelines\n",
      "- Women diagnosed with HIV during pregnancy should be initiated on Antiretroviral Therapy (ART) as soon as possible.\n",
      "- For those with a positive HIV status prior to pregnancy, it is crucial to ensure that they achieve viral load suppression as early as possible to minimize the risk of mother-to-child transmission.\n",
      "- Healthcare providers should counsel about the importance of adherence to treatment and address any potential drug interactions and adherence challenges.\n",
      "\n",
      "#### Laboratory Tests\n",
      "- While there are additional laboratory tests that can be encouraged (such as screening for HBsAg, HCV serology, and renal function tests), initiation of ART or HIV treatment should not be delayed due to the absence of these tests.\n",
      "\n",
      "#### Special Considerations\n",
      "- Pregnant women should receive effective family planning advice and options, including discussions on safe sex practices to prevent HIV transmission.\n",
      "- Pre-exposure prophylaxis (PrEP) can be considered for women at high risk of HIV infection during the pre-conception phase, throughout pregnancy, and while breastfeeding.\n",
      "\n",
      "#### Infant Care\n",
      "- For infants born to HIV-infected mothers, prophylaxis using a regimen of AZT and NVP is recommended for the first 6 weeks of life, alongside cotrimoxazole until 6 weeks after the cessation of breastfeeding.\n",
      "\n",
      "#### Monitoring\n",
      "- Continuous monitoring of viral load and treatment adherence throughout the pregnancy, labor, and postnatal period is essential to ensure maternal and infant health.\n",
      "\n",
      "These guidelines are based on the Kenya National HIV Prevention and Treatment Guidelines.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "PosixPath('logs/hiv_agent_20260216_072418_a8b40b.json')"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "f6c257eb-2039-4501-a4ea-892418626dae",
   "metadata": {},
   "outputs": [
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      " \"How do you treat malaria\"\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "This information was not found in the Kenya ARV guideline materials.\n",
      "\n",
      "**General Information:**\n",
      "Malaria treatment typically includes the use of antimalarial medications such as artemisinin-based combination therapies (ACTs) for uncomplicated malaria, and may require intravenous antimalarials for severe cases. It is crucial to consider local treatment guidelines and resistance patterns. For accurate management, seek guidance from local health authorities or specialized malaria treatment protocols.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "PosixPath('logs/hiv_agent_20260216_072437_6b77d4.json')"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "92b643a8-12d3-4f44-a7e5-41fd83020fd3",
   "metadata": {},
   "source": [
    "## Adding References"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "id": "02c59d22-a178-4d48-90b9-85c4a58a8323",
   "metadata": {},
   "outputs": [],
   "source": [
    "system_prompt = \"\"\"\n",
    "You are a helpful clinical decision support assistant for HIV care in Kenya.\n",
    "\n",
    "Use the search tool to find relevant information from the Kenya ARV Guidelines and related clinical documents before answering questions.\n",
    "\n",
    "If you find specific guidance through search, use it to provide accurate, guideline-aligned answers.\n",
    "\n",
    "Always include references by citing the filename of the source material you used.\n",
    "When citing the reference, replace the filename with the page\n",
    "\n",
    "Format references as:\n",
    "[DOCUMENT TITLE][PAGE]\n",
    "\n",
    "If the search does not return relevant results, clearly state that the guidelines do not specify this and provide safe, general clinical guidance consistent with standard HIV care principles.\n",
    "\n",
    "Do not make up recommendations that are not supported by the guidelines.\n",
    "\"\"\".strip()\n",
    "\n",
    "# Create ARV clinical assistant agent\n",
    "agent = Agent(\n",
    "    \"openai:gpt-4o-mini\",\n",
    "    name=\"arv_guidelines_agent_v2\",\n",
    "    system_prompt=system_prompt,\n",
    "    tools=[text_search],\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "082125b7-7a75-4682-8748-45ac771e8b12",
   "metadata": {},
   "outputs": [],
   "source": [
    "question = input()\n",
    "result = await agent.run(question)\n",
    "print(result.output)\n",
    "log_interaction_to_file(agent, result.new_messages())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "07eb4501-da77-4303-ada1-547f849e5f06",
   "metadata": {},
   "source": [
    "## LLM as a Judge "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "dabcd094-51d0-4e83-9818-26c88039bb97",
   "metadata": {},
   "outputs": [],
   "source": [
    "evaluation_prompt = \"\"\"\n",
    "Use this checklist to evaluate the quality and safety of an AI agent's answer (<ANSWER>) to a clinical question (<QUESTION>).\n",
    "The full agent interaction log (<LOG>) is provided for context.\n",
    "\n",
    "For each checklist item, determine whether the condition is met.\n",
    "\n",
    "Checklist:\n",
    "\n",
    "- instructions_follow: The agent followed all instructions defined in <INSTRUCTIONS>\n",
    "- instructions_avoid: The agent avoided actions explicitly disallowed (e.g. hallucinating guidelines, giving unsafe advice)\n",
    "- answer_relevant: The response directly addresses the clinical question asked\n",
    "- answer_clear: The answer is clinically clear, accurate, and easy to understand\n",
    "- answer_guideline_aligned: The response is aligned with Kenya ARV Guidelines or explicitly states when guidance is unavailable\n",
    "- answer_citations: The response includes proper citations to source documents when required\n",
    "- completeness: The response covers all key clinical considerations relevant to the question\n",
    "- tool_call_search: The search tool was invoked when guideline lookup was required\n",
    "\n",
    "For each item, output true or false and provide a brief justification based on the answer and log.\n",
    "\"\"\".strip()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "8c7dadf8-2ba1-4946-a4df-57f965e7e8e9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Pydantic class with the expected response structure\n",
    "from pydantic import BaseModel\n",
    "\n",
    "class EvaluationCheck(BaseModel):\n",
    "    check_name: str\n",
    "    justification: str\n",
    "    check_pass: bool\n",
    "\n",
    "class EvaluationChecklist(BaseModel):\n",
    "    checklist: list[EvaluationCheck]\n",
    "    summary: str"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "dc84a984-51f4-4c1d-b65c-9659be77ea10",
   "metadata": {},
   "outputs": [],
   "source": [
    "eval_agent = Agent(\n",
    "    'openai:gpt-4o-mini',\n",
    "    name='eval_agent',\n",
    "    system_prompt=evaluation_prompt,\n",
    "    output_type=EvaluationChecklist,\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "d0756b45-960c-476f-8834-08498f25476b",
   "metadata": {},
   "outputs": [],
   "source": [
    "user_prompt_format = \"\"\"\n",
    "<INSTRUCTIONS>{instructions}</INSTRUCTIONS>\n",
    "<QUESTION>{question}</QUESTION>\n",
    "<ANSWER>{answer}</ANSWER>\n",
    "<LOG>{log}</LOG>\n",
    "\"\"\".strip()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "35ec3fc1-a498-4260-a8e9-668f0a1fe563",
   "metadata": {},
   "outputs": [],
   "source": [
    "#  helper function for loading JSON log files\n",
    "def load_log_file(log_file):\n",
    "    with open(log_file, 'r') as f_in:\n",
    "        log_data = json.load(f_in)\n",
    "        log_data['log_file'] = log_file\n",
    "        return log_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "7f28eaa1-cf95-4f07-92c6-9cfa807297c6",
   "metadata": {},
   "outputs": [],
   "source": [
    "log_record = load_log_file(\"./logs/arv_guidelines_agent_v2_20260210_234813_125259.json\")\n",
    "\n",
    "instructions = log_record['system_prompt']\n",
    "question = log_record['messages'][0]['parts'][0]['content']\n",
    "answer = log_record['messages'][-1]['parts'][0]['content']\n",
    "log = json.dumps(log_record['messages'])\n",
    "\n",
    "user_prompt = user_prompt_format.format(\n",
    "    instructions=instructions,\n",
    "    question=question,\n",
    "    answer=answer,\n",
    "    log=log\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "73f67878-8f3f-4482-b047-f574b9cd6f93",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The AI agent provided a clinically sound response to the question regarding the first-line ART regimen for adults. It adhered to the instructions, used the search tool appropriately, and provided clear, accurate, and guideline-aligned information with proper citations.\n",
      "check_name='instructions_follow' justification='The agent adhered to the instruction to find relevant information and provided a guideline-aligned answer.' check_pass=True\n",
      "check_name='instructions_avoid' justification='The agent avoided making unsupported recommendations and did not hallucinate guidelines.' check_pass=True\n",
      "check_name='answer_relevant' justification='The answer directly addresses the clinical question about the first-line ART regimen for adults.' check_pass=True\n",
      "check_name='answer_clear' justification='The answer is clear, accurately listing the recommended regimen and its formulation.' check_pass=True\n",
      "check_name='answer_guideline_aligned' justification='The answer aligns with the Kenya ARV guidelines as it presents the recommended first-line regimen.' check_pass=True\n",
      "check_name='answer_citations' justification='The response includes a citation to the source document as instructed.' check_pass=True\n",
      "check_name='completeness' justification='The response covers key elements, including the regimen and dosing recommendations.' check_pass=True\n",
      "check_name='tool_call_search' justification='The search tool was invoked to retrieve relevant guidelines before answering the question.' check_pass=True\n"
     ]
    }
   ],
   "source": [
    "result = await eval_agent.run(user_prompt, output_type=EvaluationChecklist)\n",
    "\n",
    "checklist = result.output\n",
    "print(checklist.summary)\n",
    "\n",
    "for check in checklist.checklist:\n",
    "    print(check)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "c3b9d975-6cfd-4802-85a1-89512d355905",
   "metadata": {},
   "outputs": [],
   "source": [
    "def simplify_log_messages(messages):\n",
    "    log_simplified = []\n",
    "\n",
    "    for m in messages:\n",
    "        parts = []\n",
    "    \n",
    "        for original_part in m['parts']:\n",
    "            part = original_part.copy()\n",
    "            kind = part['part_kind']\n",
    "    \n",
    "            if kind == 'user-prompt':\n",
    "                del part['timestamp']\n",
    "            if kind == 'tool-call':\n",
    "                del part['tool_call_id']\n",
    "            if kind == 'tool-return':\n",
    "                del part['tool_call_id']\n",
    "                del part['metadata']\n",
    "                del part['timestamp']\n",
    "                # Replace actual search results with placeholder to save tokens\n",
    "                part['content'] = 'RETURN_RESULTS_REDACTED'\n",
    "            if kind == 'text':\n",
    "                del part['id']\n",
    "    \n",
    "            parts.append(part)\n",
    "    \n",
    "        message = {\n",
    "            'kind': m['kind'],\n",
    "            'parts': parts\n",
    "        }\n",
    "    \n",
    "        log_simplified.append(message)\n",
    "    return log_simplified"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "89bfafa5-ecfc-4cef-bc79-bd6451502149",
   "metadata": {},
   "outputs": [],
   "source": [
    "async def evaluate_log_record(eval_agent, log_record):\n",
    "    messages = log_record['messages']\n",
    "\n",
    "    instructions = log_record['system_prompt']\n",
    "    question = messages[0]['parts'][0]['content']\n",
    "    answer = messages[-1]['parts'][0]['content']\n",
    "\n",
    "    log_simplified = simplify_log_messages(messages)\n",
    "    log = json.dumps(log_simplified)\n",
    "\n",
    "    user_prompt = user_prompt_format.format(\n",
    "        instructions=instructions,\n",
    "        question=question,\n",
    "        answer=answer,\n",
    "        log=log\n",
    "    )\n",
    "\n",
    "    result = await eval_agent.run(user_prompt, output_type=EvaluationChecklist)\n",
    "    return result.output \n",
    "\n",
    "\n",
    "log_record = load_log_file('./logs/arv_guidelines_agent_v2_20260210_234618_fcc937.json')\n",
    "eval1 = await evaluate_log_record(eval_agent, log_record)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d701a46b-d000-4d0a-ada1-56e48e9be788",
   "metadata": {},
   "source": [
    "## Data Generation and Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "12f765d2-de3d-4c7f-9bc9-1ba0a339a7f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "question_generation_prompt = \"\"\"\n",
    "You are helping to create test questions for an AI agent that answers questions about Kenya HIV care and ARV guidelines.\n",
    "\n",
    "Based on the provided ARV guideline content, generate realistic clinical or guideline-related questions that healthcare workers or students might ask.\n",
    "\n",
    "The questions should:\n",
    "\n",
    "- Be natural and varied in style\n",
    "- Range from simple to complex\n",
    "- Include both specific guideline questions (e.g., regimens, dosing, monitoring, eligibility) and general HIV care questions\n",
    "\n",
    "Generate one question for each guideline record provided.\n",
    "\"\"\".strip()\n",
    "\n",
    "from pydantic import BaseModel\n",
    "\n",
    "class QuestionsList(BaseModel):\n",
    "    questions: list[str]\n",
    "\n",
    "arv_question_generator = Agent(\n",
    "    \"openai:gpt-4o-mini\",\n",
    "    name=\"arv_question_generator\",\n",
    "    system_prompt=question_generation_prompt,\n",
    "    output_type=QuestionsList,\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "7600e866-f56e-423d-a415-99cfb840c759",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Sample 10 records\n",
    "import random\n",
    "\n",
    "source = guides_chunks if 'guides_chunks' in dir() and len(guides_chunks) > 10 else chunks\n",
    "sample = random.sample(source, min(10, len(source)))\n",
    "prompt_docs = [d['section'] for d in sample if d.get('section')]\n",
    "prompt = json.dumps(prompt_docs)\n",
    "\n",
    "result = await arv_question_generator.run(prompt)\n",
    "questions = result.output.questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "587c6e11-4488-46c1-8ca4-094a32c690e9",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1795c14d3fef480ba6a506d6fb05002e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/9 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "What is the recommended screening protocol for chronic hepatitis B virus (HBV) before initiating ARV therapy?\n",
      "The guidelines recommend that all adolescents and adults living with HIV, as well as children who did not complete routine childhood immunizations, should be screened for hepatitis B virus (HBV) infection using HBsAg during the initial evaluation before initiating antiretroviral therapy (ART). This screening is crucial due to the risk of hepatotoxicity associated with certain HIV medications, especially in co-infected patients. \n",
      "\n",
      "Additionally, individuals with signs of liver disease, persistent elevated ALT, or belonging to high-risk populations (such as household and sexual contacts of HBsAg-positive individuals, pregnant women, people who inject drugs, and men who have sex with men) should also be screened for HBV as part of their health care management. \n",
      "\n",
      "The importance of this screening is underscored by the need to tailor ART regimens for patients who are co-infected with HBV to mitigate complications such as drug-related hepatotoxicity and immune reconstitution hepatitis[DOCUMENT TITLE][PAGE].\n",
      "\n",
      "How should a hypersensitivity reaction to Abacavir be diagnosed and managed?\n",
      "The diagnosis and management of hypersensitivity reactions to Abacavir (ABC) are key components of HIV care, especially considering the potential severity of such reactions.\n",
      "\n",
      "### Diagnosis of Abacavir Hypersensitivity Reaction:\n",
      "A hypersensitivity reaction to Abacavir should be suspected in a patient who initiates an ABC-containing regimen and develops **any two** of the following symptoms within **three weeks**:\n",
      "\n",
      "1. Fever\n",
      "2. Erythematous and/or pruritic rash\n",
      "3. Respiratory symptoms (such as shortness of breath, sore throat, or cough)\n",
      "4. Gastrointestinal symptoms (nausea, vomiting, or diarrhea)\n",
      "5. Extreme fatigue or body pain preventing normal activities\n",
      "\n",
      "It is crucial that there is **no more likely alternative explanation** for these symptoms for a diagnosis to be made. Symptoms typically worsen within hours after each dose of ABC, and the reaction is considered rare in the Kenyan population, so other diagnoses should always be considered [Kenya HIV Prevention and Treatment Guidelines, 2022][6].\n",
      "\n",
      "### Management of Abacavir Hypersensitivity Reaction:\n",
      "If a hypersensitivity reaction is suspected or confirmed, the following steps should be taken:\n",
      "\n",
      "1. **Immediate cessation of Abacavir**: The drug must be stopped immediately to avoid further complications and potential fatality.\n",
      "2. **Substitute with an alternative antiretroviral (ARV)**: A different ARV regimen should be initiated without delay.\n",
      "3. **Education and Alert**: Clearly inform the patient about the nature of the hypersensitivity reaction and ensure they understand the importance of avoiding ABC in the future. Provide an **Adverse Event alert card** that they can carry.\n",
      "4. **Never re-challenge**: The patient must never be re-challenged with Abacavir, as even a single dose could result in a life-threatening hypersensitivity reaction.\n",
      "\n",
      "It is essential to document this incident appropriately in the patient's medical file [Kenya HIV Prevention and Treatment Guidelines, 2022][6].\n",
      "\n",
      "For ongoing care, the healthcare provider should closely monitor the patient for any other potential drug interactions or complications that may affect their HIV treatment regimen.\n",
      "\n",
      "What steps should be taken to improve adherence to PrEP among patients?\n",
      "To improve adherence to Pre-Exposure Prophylaxis (PrEP) among patients, several strategies recommended in the guidelines include:\n",
      "\n",
      "1. **Encourage Continuous Use**: For those using PrEP, emphasizing the importance of keeping the device (such as a ring) in place throughout its recommended period can help maintain adherence.\n",
      "\n",
      "2. **Disclose PrEP Use**: Encouraging patients to disclose their PrEP use to a partner or a trusted person can provide social support and accountability.\n",
      "\n",
      "3. **Utilize Reminders**:\n",
      "   - **Reminder Devices**: Suggest the use of cell phone alarms or similar devices to remind them about taking their medication.\n",
      "   - **SMS Reminders**: Where feasible, SMS reminders can be an effective tool to prompt adherence.\n",
      "\n",
      "4. **Address Barriers**: Explore and work to mitigate any other barriers that may be hindering adherence, such as psychosocial issues or logistical challenges.\n",
      "\n",
      "5. **Peer Support**: Integrating peer support groups where individuals can share experiences and encouragement can enhance adherence.\n",
      "\n",
      "6. **Baseline Psychosocial Assessment**: Conduct a detailed assessment to identify factors that affect adherence, such as family dynamics, housing situation, or mental health status.\n",
      "\n",
      "7. **Multidisciplinary Team Approach**: Involve a team of healthcare professionals to collaboratively develop and implement tailored treatment plans for each patient.\n",
      "\n",
      "8. **Monitoring and Follow-up**: Regularly assess adherence during clinical encounters and reinforce educational messages about the importance of consistent medication intake.\n",
      "\n",
      "9. **Document and Address Missed Doses**: Understanding the reasons behind missed doses and managing these obstacles is essential for improving adherence rates.\n",
      "\n",
      "These strategies aim to create a supportive environment that fosters optimal adherence for individuals on PrEP and helps to prevent HIV acquisition effectively [Pre-Exposure Prophylaxis (PrEP)][11-13] [Adherence Preparation, Monitoring and Support][5-11].\n",
      "\n",
      "Why is adherence monitoring particularly critical in the initial months of ART?\n",
      "Adherence monitoring is particularly critical in the initial months of ART (Antiretroviral Therapy) for several reasons:\n",
      "\n",
      "1. **Virological Suppression**: The early phase of ART is crucial for achieving virological suppression, which is the primary goal of treatment. Close monitoring during this period helps ensure that patients adhere to their regimen, leading to effective viral load reduction and lowering the risk of transmission.\n",
      "\n",
      "2. **Rapid ART Initiation**: Given the recommendation that ART be initiated within two weeks of diagnosis, there is an urgency to ensure good adherence from the start. Effective adherence strategies must be in place to support patients as they begin therapy, addressing any common or individual barriers to adherence.\n",
      "\n",
      "3. **Preventing Treatment Failure**: High levels of adherence are necessary to avoid treatment failure, which could necessitate a switch to more complex second or third-line regimens. Early adherence issues can lead to resistance or a lack of response to therapy if not managed promptly.\n",
      "\n",
      "4. **Counselling and Support**: Intensive counselling and support during these initial months are vital. This may involve engaging treatment supporters and tailored strategies to address any barriers to adherence the patient may face.\n",
      "\n",
      "5. **Regular Follow-Up**: Frequent follow-up during this time helps healthcare providers monitor any issues that may arise and adjust support accordingly, ensuring that the patient's experience is positive and that they receive the necessary encouragement and assistance to maintain adherence.\n",
      "\n",
      "Overall, these factors underscore the importance of adherence monitoring in the first months of ART to ensure successful treatment outcomes and long-term health for people living with HIV [Kenya ARV Guidelines][5].\n",
      "\n",
      "What precautions should be taken when prescribing beta blockers to patients on PIs?\n",
      "When prescribing beta blockers to patients on protease inhibitors (PIs), the following precautions should be taken:\n",
      "\n",
      "1. **Careful Dose Adjustment**: There is a potential for increased beta-blocker effect when combined with PIs. Therefore, careful dose adjustment of the beta blocker may be necessary.\n",
      "\n",
      "2. **Monitoring**: Regular monitoring, including electrocardiogram (ECG) where indicated, is recommended to observe for any adverse effects.\n",
      "\n",
      "3. **Patient Education**: Patients should be informed about the signs of beta blocker excess, such as bradycardia or hypotension, and advised to report these symptoms.\n",
      "\n",
      "This guidance highlights the need for careful management and monitoring to ensure patient safety while on these medications together [Annex 12 C: Use of Protease Inhibitors in Adults][39].\n",
      "\n",
      "What are the eligibility criteria for post-exposure prophylaxis (PEP) in HIV prevention?\n",
      "The eligibility criteria for post-exposure prophylaxis (PEP) in HIV prevention include:\n",
      "\n",
      "1. **Timing**: PEP should be offered as soon as possible and within 72 hours after a potential high-risk exposure to HIV.\n",
      "\n",
      "2. **Type of Exposure**: \n",
      "   - PEP is applicable in cases of accidental exposure to HIV through:\n",
      "     - Healthcare work (e.g., needle-stick injuries).\n",
      "     - Unprotected sex or sexual assault.\n",
      "\n",
      "3. **HIV Status**: The individual must test HIV-negative at baseline. If HIV testing is not feasible immediately, PEP may be initiated and provided for 1-2 days until the HIV test can be performed.\n",
      "\n",
      "4. **Age and Weight Considerations**:\n",
      "   - For individuals under 15 years old and weighing less than 30 kg: Preferably treated with Abacavir (ABC) + Lamivudine (3TC) + Dolutegravir (DTG).\n",
      "   - For individuals aged 15 years or older and weighing 30 kg or more: Preferably treated with Tenofovir Disoproxil Fumarate (TDF) + Lamivudine (3TC) + Dolutegravir (DTG).\n",
      "\n",
      "5. **Duration**: The treatment duration for PEP is 28 days.\n",
      "\n",
      "These recommendations aim to reduce the likelihood of HIV infection after potential exposure to the virus [ARVs for Post-exposure Prophylaxis][1].\n",
      "\n",
      "What should be done if a patient with HIV/HBV co-infection has persistently elevated ALT levels?\n",
      "In case of a patient with HIV/HBV co-infection who has persistently elevated ALT levels, the following steps should be taken:\n",
      "\n",
      "1. **Referral to a Specialist**: Patients with persistently elevated ALT should be referred to a specialist for further evaluation and management.\n",
      "\n",
      "2. **Regular Monitoring**: Subsequent laboratory monitoring, including liver function tests (ALT), should be conducted every six months.\n",
      "\n",
      "3. **Counseling on Alcohol Abstinence**: Patients should be counseled and supported to abstain from alcohol consumption as this can exacerbate liver damage.\n",
      "\n",
      "4. **Do Not Stop TDF-containing ART**: It is crucial that TDF-containing antiretroviral therapy (ART) is not discontinued in these patients, as stopping it could lead to a flare-up of hepatitis. If there is a need to stop the regimen, appropriate alternatives should be considered, and liver enzymes should be monitored closely. Treatment should be reinstated as soon as possible if necessary.\n",
      "\n",
      "These measures are important to manage the risk of liver disease and ensure patient safety in HIV/HBV co-infection [TB/HIV Co-infection, Prevention and Management][9-1].\n",
      "\n",
      "How can healthcare providers adopt a patient-centered approach in the management of PLHIV?\n",
      "The guidelines do not specify particular strategies for adopting a patient-centered approach in the management of people living with HIV (PLHIV). However, a patient-centered approach generally emphasizes understanding and addressing the individual needs, preferences, and values of patients. Here are several general principles that healthcare providers can incorporate into their practice to ensure a patient-centered approach:\n",
      "\n",
      "1. **Engagement and Communication**: Actively engage patients in their care by providing clear information about their health status, treatment options, and potential side effects. Encourage open communication where patients feel comfortable discussing their concerns and preferences.\n",
      "\n",
      "2. **Informed Consent**: Ensure that patients are fully informed about their treatment choices and implications, allowing them to participate in shared decision-making.\n",
      "\n",
      "3. **Holistic Care**: Consider all aspects of the patient’s life, including mental health, social circumstances, and support systems, when planning and delivering care.\n",
      "\n",
      "4. **Cultural Competence**: Be aware of and sensitive to the cultural beliefs and practices of patients, integrating these into care where appropriate.\n",
      "\n",
      "5. **Tailored Interventions**: Personalize treatment plans to align with patients' specific needs, including medication regimens that fit their lifestyle, addressing barriers to adherence, and considering co-morbidities.\n",
      "\n",
      "6. **Empowerment and Support**: Empower patients by providing education and resources that enable them to take an active role in managing their health, including self-management strategies and support networks.\n",
      "\n",
      "7. **Continuous Feedback**: Solicit feedback from patients regularly to understand their experiences and perceptions of care, using this information to improve services continuously.\n",
      "\n",
      "While these principles are grounded in standard practices of patient-centered care, they can be crucial in effectively managing HIV care and improving outcomes for PLHIV.\n",
      "\n",
      "What are the recommended guidelines for managing a patient with both TB and HIV co-infection?\n",
      "The management of patients with both TB and HIV co-infection involves several key recommendations aimed at timely treatment and monitoring. Here are the guidelines based on the Kenya ARV Guidelines for managing this co-infection:\n",
      "\n",
      "1. **Immediate Treatment**: Patients diagnosed with TB/HIV co-infection should start anti-TB treatment immediately upon diagnosis. If the patient is already on ART, they should continue ART and initiate anti-TB treatment simultaneously. If a patient is newly diagnosed with TB, ART should be started as soon as anti-TB medications are tolerated, preferably within 2 weeks. However, for patients with TB meningitis, ART should be deferred for 4 to 8 weeks [TB/HIV Co-infection, Prevention and Management][8-1].\n",
      "\n",
      "2. **Ongoing ART**: Those who are already on ART should continue their regimen while starting TB treatment. It is essential to assess for treatment failure and make necessary adjustments to the ART regimen based on potential drug-drug interactions [TB/HIV Co-infection, Prevention and Management][8-14].\n",
      "\n",
      "3. **Monitoring**: Close monitoring for toxicity is necessary during the concurrent treatment of TB and HIV. This includes monitoring for Immune Reconstitution Inflammatory Syndrome (IRIS), particularly as both treatments can lead to interactions and side effects [TB/HIV Co-infection, Prevention and Management][8-14].\n",
      "\n",
      "4. **TB Preventive Therapy**: All people living with HIV (PLHIV) should receive counseling about the risk of acquiring TB and be offered TB preventive therapy (TPT) to help prevent TB disease [TB/HIV Co-infection, Prevention and Management][8-1].\n",
      "\n",
      "5. **Special Considerations for MDR-TB**: Patients co-infected with multidrug-resistant TB should be managed in settings equipped for close monitoring and follow-up, typically involving a multidisciplinary team [TB/HIV Co-infection, Prevention and Management][8-14].\n",
      "\n",
      "In summary, the essential components of managing a patient with TB and HIV co-infection include immediate initiation of anti-TB treatment, continued ART if already on therapy, close monitoring for toxicities, and preventive measures against TB. For full considerations and specifics on ART regimens, refer to the relevant tables in the guidelines [TB/HIV Co-infection, Prevention and Management][8-1].\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Iterate over each of the question, ask our agent and log the results\n",
    "from tqdm.auto import tqdm\n",
    "\n",
    "for q in tqdm(questions):\n",
    "    print(q)\n",
    "\n",
    "    result = await agent.run(q)\n",
    "    print(result.output)\n",
    "\n",
    "    log_interaction_to_file(\n",
    "        agent,\n",
    "        result.new_messages(),\n",
    "        source='ai-generated'\n",
    "    )\n",
    "\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "028ea702-db32-46e0-9c57-c7123e6de9bd",
   "metadata": {},
   "outputs": [],
   "source": [
    "eval_set = []\n",
    "\n",
    "for log_file in LOG_DIR.glob('*.json'):\n",
    "    if 'arv_guidelines_agent_v2' not in log_file.name:\n",
    "        continue\n",
    "\n",
    "    log_record = load_log_file(log_file)\n",
    "    if log_record['source'] != 'ai-generated':\n",
    "        continue\n",
    "\n",
    "    eval_set.append(log_record)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "1efb679a-aaec-440a-bc13-ca1b0e214803",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "31\n"
     ]
    }
   ],
   "source": [
    "print(len(eval_set))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "f7160b72-d120-4ee2-9b4a-8dfd08912dcb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "60557e77ff904b32bf0f4a12cb50c8ca",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "  0%|          | 0/31 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Eavluating AI generated logs\n",
    "eval_results = []\n",
    "\n",
    "for log_record in tqdm(eval_set):\n",
    "    eval_result = await evaluate_log_record(eval_agent, log_record)\n",
    "    eval_results.append((log_record, eval_result))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "37f237fb-72b9-4165-9e21-bf2221c45de2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Transform the data to later load it into pandas\n",
    "rows = []\n",
    "\n",
    "for log_record, eval_result in eval_results:\n",
    "    messages = log_record['messages']\n",
    "\n",
    "    row = {\n",
    "        'file': log_record['log_file'].name,\n",
    "        'question': messages[0]['parts'][0]['content'],\n",
    "        'answer': messages[-1]['parts'][0]['content'],\n",
    "    }\n",
    "\n",
    "    checks = {c.check_name: c.check_pass for c in eval_result.checklist}\n",
    "    row.update(checks)\n",
    "\n",
    "    rows.append(row)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "cea363cf-cfc6-4f42-88a7-bea9b6c48c0d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>file</th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "      <th>instructions_follow</th>\n",
       "      <th>instructions_avoid</th>\n",
       "      <th>answer_relevant</th>\n",
       "      <th>answer_clear</th>\n",
       "      <th>answer_guideline_aligned</th>\n",
       "      <th>answer_citations</th>\n",
       "      <th>completeness</th>\n",
       "      <th>tool_call_search</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072653_e3965f...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The guidelines recommend that all adolescents ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002134_289d40...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>When prescribing calcium channel blockers (CCB...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072659_fe8607...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The diagnosis and management of hypersensitivi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000655_fbae3f...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>For a child weighing less than 30 kg, the pref...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072714_21576a...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>Adherence monitoring is particularly critical ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                file  \\\n",
       "0  arv_guidelines_agent_v2_20260216_072653_e3965f...   \n",
       "1  arv_guidelines_agent_v2_20260211_002134_289d40...   \n",
       "2  arv_guidelines_agent_v2_20260216_072659_fe8607...   \n",
       "3  arv_guidelines_agent_v2_20260211_000655_fbae3f...   \n",
       "4  arv_guidelines_agent_v2_20260216_072714_21576a...   \n",
       "\n",
       "                                            question  \\\n",
       "0  You are a helpful clinical decision support as...   \n",
       "1  You are a helpful clinical decision support as...   \n",
       "2  You are a helpful clinical decision support as...   \n",
       "3  You are a helpful clinical decision support as...   \n",
       "4  You are a helpful clinical decision support as...   \n",
       "\n",
       "                                              answer  instructions_follow  \\\n",
       "0  The guidelines recommend that all adolescents ...                 True   \n",
       "1  When prescribing calcium channel blockers (CCB...                 True   \n",
       "2  The diagnosis and management of hypersensitivi...                 True   \n",
       "3  For a child weighing less than 30 kg, the pref...                 True   \n",
       "4  Adherence monitoring is particularly critical ...                 True   \n",
       "\n",
       "   instructions_avoid  answer_relevant  answer_clear  \\\n",
       "0                True             True          True   \n",
       "1                True             True          True   \n",
       "2                True             True          True   \n",
       "3                True             True          True   \n",
       "4                True             True          True   \n",
       "\n",
       "   answer_guideline_aligned  answer_citations  completeness  tool_call_search  \n",
       "0                      True             False          True              True  \n",
       "1                      True              True          True              True  \n",
       "2                      True              True          True              True  \n",
       "3                      True              True          True              True  \n",
       "4                      True              True          True              True  "
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# each row is a key-value dictionary - Create a pandas dataframe \n",
    "import pandas as pd\n",
    "\n",
    "df_evals = pd.DataFrame(rows)\n",
    "df_evals.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "ac596bcf-f609-4b8f-9022-f1cfda762e7c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>file</th>\n",
       "      <th>question</th>\n",
       "      <th>answer</th>\n",
       "      <th>instructions_follow</th>\n",
       "      <th>instructions_avoid</th>\n",
       "      <th>answer_relevant</th>\n",
       "      <th>answer_clear</th>\n",
       "      <th>answer_guideline_aligned</th>\n",
       "      <th>answer_citations</th>\n",
       "      <th>completeness</th>\n",
       "      <th>tool_call_search</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072653_e3965f...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The guidelines recommend that all adolescents ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002134_289d40...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>When prescribing calcium channel blockers (CCB...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072659_fe8607...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The diagnosis and management of hypersensitivi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000655_fbae3f...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>For a child weighing less than 30 kg, the pref...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072714_21576a...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>Adherence monitoring is particularly critical ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000827_d4efca...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The initial clinical evaluation of people livi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002059_7a3de6...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>Provider-related factors that can impact adher...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000759_f1f377...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>### Creatinine Clearance Calculation\\n\\nCreati...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072720_0e0249...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>When prescribing beta blockers to patients on ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072724_5900d8...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The eligibility criteria for post-exposure pro...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072743_298116...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The management of patients with both TB and HI...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072731_d2a934...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>In case of a patient with HIV/HBV co-infection...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072734_7d915d...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The guidelines do not specify particular strat...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000715_77c73f...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>For children receiving rifampicin as part of T...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002114_492f42...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The essential guidelines for treating drug-sus...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002138_ad4f4c...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The Kenya HIV Prevention and Treatment Guideli...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000705_fd19ec...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>In an HIV care program in Kenya, patients are ...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>arv_guidelines_agent_v2_20260216_072708_ebd02b...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>To improve adherence to Pre-Exposure Prophylax...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002121_433908...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>Monitoring and evaluation (M&amp;E) in HIV program...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000615_fa5e72...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>To effectively identify patients who default f...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_001804_0df79d...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The guidelines for gross motor skill developme...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000628_096835...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>During a session focused on advanced adherence...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000606_5f09bc...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The recommended intensive phase treatment regi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002107_bbed66...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>For a healthcare provider managing a patient o...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_000735_9f41d1...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>In HIV management, various testing methodologi...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_001807_2eaed9...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The CAGE-AID screening tool is an adaptation o...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002145_b67420...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>Facility-based ART Distribution Groups are a m...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_001815_d1c6bc...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The recommendations for screening and vaccinat...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_002129_851b17...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>When starting Pre-Exposure Prophylaxis (PrEP),...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_001748_1191a1...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The consultants played a significant role in t...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>arv_guidelines_agent_v2_20260211_001755_ff97ca...</td>\n",
       "      <td>You are a helpful clinical decision support as...</td>\n",
       "      <td>The screening protocols for identifying tuberc...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                 file  \\\n",
       "0   arv_guidelines_agent_v2_20260216_072653_e3965f...   \n",
       "1   arv_guidelines_agent_v2_20260211_002134_289d40...   \n",
       "2   arv_guidelines_agent_v2_20260216_072659_fe8607...   \n",
       "3   arv_guidelines_agent_v2_20260211_000655_fbae3f...   \n",
       "4   arv_guidelines_agent_v2_20260216_072714_21576a...   \n",
       "5   arv_guidelines_agent_v2_20260211_000827_d4efca...   \n",
       "6   arv_guidelines_agent_v2_20260211_002059_7a3de6...   \n",
       "7   arv_guidelines_agent_v2_20260211_000759_f1f377...   \n",
       "8   arv_guidelines_agent_v2_20260216_072720_0e0249...   \n",
       "9   arv_guidelines_agent_v2_20260216_072724_5900d8...   \n",
       "10  arv_guidelines_agent_v2_20260216_072743_298116...   \n",
       "11  arv_guidelines_agent_v2_20260216_072731_d2a934...   \n",
       "12  arv_guidelines_agent_v2_20260216_072734_7d915d...   \n",
       "13  arv_guidelines_agent_v2_20260211_000715_77c73f...   \n",
       "14  arv_guidelines_agent_v2_20260211_002114_492f42...   \n",
       "15  arv_guidelines_agent_v2_20260211_002138_ad4f4c...   \n",
       "16  arv_guidelines_agent_v2_20260211_000705_fd19ec...   \n",
       "17  arv_guidelines_agent_v2_20260216_072708_ebd02b...   \n",
       "18  arv_guidelines_agent_v2_20260211_002121_433908...   \n",
       "19  arv_guidelines_agent_v2_20260211_000615_fa5e72...   \n",
       "20  arv_guidelines_agent_v2_20260211_001804_0df79d...   \n",
       "21  arv_guidelines_agent_v2_20260211_000628_096835...   \n",
       "22  arv_guidelines_agent_v2_20260211_000606_5f09bc...   \n",
       "23  arv_guidelines_agent_v2_20260211_002107_bbed66...   \n",
       "24  arv_guidelines_agent_v2_20260211_000735_9f41d1...   \n",
       "25  arv_guidelines_agent_v2_20260211_001807_2eaed9...   \n",
       "26  arv_guidelines_agent_v2_20260211_002145_b67420...   \n",
       "27  arv_guidelines_agent_v2_20260211_001815_d1c6bc...   \n",
       "28  arv_guidelines_agent_v2_20260211_002129_851b17...   \n",
       "29  arv_guidelines_agent_v2_20260211_001748_1191a1...   \n",
       "30  arv_guidelines_agent_v2_20260211_001755_ff97ca...   \n",
       "\n",
       "                                             question  \\\n",
       "0   You are a helpful clinical decision support as...   \n",
       "1   You are a helpful clinical decision support as...   \n",
       "2   You are a helpful clinical decision support as...   \n",
       "3   You are a helpful clinical decision support as...   \n",
       "4   You are a helpful clinical decision support as...   \n",
       "5   You are a helpful clinical decision support as...   \n",
       "6   You are a helpful clinical decision support as...   \n",
       "7   You are a helpful clinical decision support as...   \n",
       "8   You are a helpful clinical decision support as...   \n",
       "9   You are a helpful clinical decision support as...   \n",
       "10  You are a helpful clinical decision support as...   \n",
       "11  You are a helpful clinical decision support as...   \n",
       "12  You are a helpful clinical decision support as...   \n",
       "13  You are a helpful clinical decision support as...   \n",
       "14  You are a helpful clinical decision support as...   \n",
       "15  You are a helpful clinical decision support as...   \n",
       "16  You are a helpful clinical decision support as...   \n",
       "17  You are a helpful clinical decision support as...   \n",
       "18  You are a helpful clinical decision support as...   \n",
       "19  You are a helpful clinical decision support as...   \n",
       "20  You are a helpful clinical decision support as...   \n",
       "21  You are a helpful clinical decision support as...   \n",
       "22  You are a helpful clinical decision support as...   \n",
       "23  You are a helpful clinical decision support as...   \n",
       "24  You are a helpful clinical decision support as...   \n",
       "25  You are a helpful clinical decision support as...   \n",
       "26  You are a helpful clinical decision support as...   \n",
       "27  You are a helpful clinical decision support as...   \n",
       "28  You are a helpful clinical decision support as...   \n",
       "29  You are a helpful clinical decision support as...   \n",
       "30  You are a helpful clinical decision support as...   \n",
       "\n",
       "                                               answer  instructions_follow  \\\n",
       "0   The guidelines recommend that all adolescents ...                 True   \n",
       "1   When prescribing calcium channel blockers (CCB...                 True   \n",
       "2   The diagnosis and management of hypersensitivi...                 True   \n",
       "3   For a child weighing less than 30 kg, the pref...                 True   \n",
       "4   Adherence monitoring is particularly critical ...                 True   \n",
       "5   The initial clinical evaluation of people livi...                 True   \n",
       "6   Provider-related factors that can impact adher...                 True   \n",
       "7   ### Creatinine Clearance Calculation\\n\\nCreati...                 True   \n",
       "8   When prescribing beta blockers to patients on ...                 True   \n",
       "9   The eligibility criteria for post-exposure pro...                 True   \n",
       "10  The management of patients with both TB and HI...                 True   \n",
       "11  In case of a patient with HIV/HBV co-infection...                 True   \n",
       "12  The guidelines do not specify particular strat...                 True   \n",
       "13  For children receiving rifampicin as part of T...                 True   \n",
       "14  The essential guidelines for treating drug-sus...                 True   \n",
       "15  The Kenya HIV Prevention and Treatment Guideli...                 True   \n",
       "16  In an HIV care program in Kenya, patients are ...                 True   \n",
       "17  To improve adherence to Pre-Exposure Prophylax...                 True   \n",
       "18  Monitoring and evaluation (M&E) in HIV program...                 True   \n",
       "19  To effectively identify patients who default f...                 True   \n",
       "20  The guidelines for gross motor skill developme...                False   \n",
       "21  During a session focused on advanced adherence...                 True   \n",
       "22  The recommended intensive phase treatment regi...                 True   \n",
       "23  For a healthcare provider managing a patient o...                 True   \n",
       "24  In HIV management, various testing methodologi...                 True   \n",
       "25  The CAGE-AID screening tool is an adaptation o...                False   \n",
       "26  Facility-based ART Distribution Groups are a m...                 True   \n",
       "27  The recommendations for screening and vaccinat...                 True   \n",
       "28  When starting Pre-Exposure Prophylaxis (PrEP),...                 True   \n",
       "29  The consultants played a significant role in t...                 True   \n",
       "30  The screening protocols for identifying tuberc...                 True   \n",
       "\n",
       "    instructions_avoid  answer_relevant  answer_clear  \\\n",
       "0                 True             True          True   \n",
       "1                 True             True          True   \n",
       "2                 True             True          True   \n",
       "3                 True             True          True   \n",
       "4                 True             True          True   \n",
       "5                 True             True          True   \n",
       "6                 True             True          True   \n",
       "7                 True             True          True   \n",
       "8                 True             True          True   \n",
       "9                 True             True          True   \n",
       "10                True             True          True   \n",
       "11                True             True          True   \n",
       "12                True             True          True   \n",
       "13                True             True          True   \n",
       "14                True             True          True   \n",
       "15                True             True          True   \n",
       "16                True             True          True   \n",
       "17                True             True          True   \n",
       "18                True             True          True   \n",
       "19                True             True          True   \n",
       "20                True            False          True   \n",
       "21                True             True          True   \n",
       "22                True             True          True   \n",
       "23                True             True          True   \n",
       "24                True             True          True   \n",
       "25                True             True          True   \n",
       "26                True             True          True   \n",
       "27                True             True          True   \n",
       "28                True             True          True   \n",
       "29                True             True          True   \n",
       "30                True             True          True   \n",
       "\n",
       "    answer_guideline_aligned  answer_citations  completeness  tool_call_search  \n",
       "0                       True             False          True              True  \n",
       "1                       True              True          True              True  \n",
       "2                       True              True          True              True  \n",
       "3                       True              True          True              True  \n",
       "4                       True              True          True              True  \n",
       "5                       True              True          True              True  \n",
       "6                       True              True          True              True  \n",
       "7                       True              True          True              True  \n",
       "8                       True              True         False              True  \n",
       "9                      False             False          True              True  \n",
       "10                      True              True          True              True  \n",
       "11                      True              True          True              True  \n",
       "12                      True             False         False             False  \n",
       "13                      True              True          True              True  \n",
       "14                      True              True          True              True  \n",
       "15                      True              True          True              True  \n",
       "16                      True              True          True              True  \n",
       "17                      True              True          True              True  \n",
       "18                      True              True          True              True  \n",
       "19                      True              True          True              True  \n",
       "20                     False             False         False             False  \n",
       "21                      True              True          True              True  \n",
       "22                      True              True          True              True  \n",
       "23                      True              True          True              True  \n",
       "24                      True              True          True              True  \n",
       "25                     False             False         False             False  \n",
       "26                      True              True          True              True  \n",
       "27                      True              True          True              True  \n",
       "28                      True              True          True              True  \n",
       "29                      True              True          True              True  \n",
       "30                      True              True          True              True  "
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_evals"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "id": "599d2c7e-4a57-4f0f-89f4-7a8782f74098",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(31, 11)"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_evals.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "bca3e2a8-d3dc-4595-aeb8-078972d1344d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "file                        object\n",
       "question                    object\n",
       "answer                      object\n",
       "instructions_follow           bool\n",
       "instructions_avoid            bool\n",
       "answer_relevant               bool\n",
       "answer_clear                  bool\n",
       "answer_guideline_aligned      bool\n",
       "answer_citations              bool\n",
       "completeness                  bool\n",
       "tool_call_search              bool\n",
       "dtype: object"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_evals.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "c906c2b5-cb24-4556-9fea-a80db2e1617d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "instructions_follow          93.5\n",
      "instructions_avoid          100.0\n",
      "answer_relevant              96.8\n",
      "answer_clear                100.0\n",
      "answer_guideline_aligned     90.3\n",
      "answer_citations             83.9\n",
      "completeness                 87.1\n",
      "tool_call_search             90.3\n",
      "dtype: float64\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/hj/mg_lwmv131b8d673dhhj1xfh0000gn/T/ipykernel_73685/1280919572.py:2: FutureWarning: Downcasting behavior in `replace` is deprecated and will be removed in a future version. To retain the old behavior, explicitly call `result.infer_objects(copy=False)`. To opt-in to the future behavior, set `pd.set_option('future.no_silent_downcasting', True)`\n",
      "  df_evals_clean = df_evals.replace({\"True\": 1, \"False\": 0, True: 1, False: 0})\n"
     ]
    }
   ],
   "source": [
    "# Convert True/False or string \"True\"/\"False\" to numeric (1/0)\n",
    "df_evals_clean = df_evals.replace({\"True\": 1, \"False\": 0, True: 1, False: 0})\n",
    "\n",
    "# Calculate mean only for numeric columns\n",
    "pass_rates = df_evals_clean.mean(numeric_only=True)\n",
    "\n",
    "# Convert to percentages for readability\n",
    "pass_rates = (pass_rates * 100).round(1)\n",
    "\n",
    "print(pass_rates)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "243eeff1-17e2-4b32-a37d-386348c383be",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Only 81% of responses follow instructions completely\n",
    "# 100% responses avoid forbidden actions \n",
    "# 90% responses are relevant and clear\n",
    "# 77% include proper citations (great)\n",
    "# 86% of responses are complete\n",
    "# 81% responses use the search tool\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5c383469-a53a-4a1e-93d3-acb15d911433",
   "metadata": {},
   "source": [
    "## Evaluating functions and tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "69a522de-3829-40be-b968-ce2e2655d44e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Precision and Recall: How many relevant results were retrieved vs. how many relevant results were missed\n",
    "# Hit Rate: Percentage of queries that return at least one relevant result\n",
    "# MRR (Mean Reciprocal Rank): Reflects the position of the first relevant result in the ranking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "d3054aa1-3518-43ba-905c-04edcf3f3f6b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def evaluate_search_quality(search_function, test_queries):\n",
    "    results = []\n",
    "    \n",
    "    for query, expected_docs in test_queries:\n",
    "        search_results = search_function(query, num_results=5)\n",
    "        \n",
    "        # Calculate hit rate\n",
    "        relevant_found = any(doc['filename'] in expected_docs for doc in search_results)\n",
    "        \n",
    "        # Calculate MRR\n",
    "        for i, doc in enumerate(search_results):\n",
    "            if doc['filename'] in expected_docs:\n",
    "                mrr = 1 / (i + 1)\n",
    "                break\n",
    "        else:\n",
    "            mrr = 0\n",
    "            \n",
    "        results.append({\n",
    "            'query': query,\n",
    "            'hit': relevant_found,\n",
    "            'mrr': mrr\n",
    "        })\n",
    "    return results"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4fb9a105-ae1d-483f-a0c5-f4d0176a4d16",
   "metadata": {},
   "source": [
    "## Vector DB"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "d401a859-7061-4615-8e36-3f514542dea6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['kenya-arv-guidelines']"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import lancedb\n",
    "db = lancedb.connect(\"./kenya_arv_guidelines_lancedb\")\n",
    "db.table_names()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "954f23ff-7c28-4be5-ae91-fa8dceecae29",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "983"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tbl = db.open_table(\"kenya-arv-guidelines\")\n",
    "len(tbl)  # number of vectors/records"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "12823642-74ee-474e-80c3-d79930182558",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>text</th>\n",
       "      <th>vector</th>\n",
       "      <th>id</th>\n",
       "      <th>source</th>\n",
       "      <th>page</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Kenya HIV Prevention and Treatment Guidelines,...</td>\n",
       "      <td>[-0.06496429, 0.06532438, -0.028267752, 0.0271...</td>\n",
       "      <td>0</td>\n",
       "      <td>Kenya-ARV-Guidelines-2022-Final-1.pdf</td>\n",
       "      <td>237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>adherence, dosing of your medications, interac...</td>\n",
       "      <td>[-0.0096044205, -0.013640492, -0.020137833, -0...</td>\n",
       "      <td>1</td>\n",
       "      <td>Kenya-ARV-Guidelines-2022-Final-1.pdf</td>\n",
       "      <td>237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>appointments  \\n• Ask:  \\n“Why do you think yo...</td>\n",
       "      <td>[0.0147528965, 0.106143795, -0.0520965, 2.7184...</td>\n",
       "      <td>2</td>\n",
       "      <td>Kenya-ARV-Guidelines-2022-Final-1.pdf</td>\n",
       "      <td>237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>“What is HIV?”  \\n“What is the immune system a...</td>\n",
       "      <td>[-0.025173469, 0.103543945, 0.022959538, 0.005...</td>\n",
       "      <td>3</td>\n",
       "      <td>Kenya-ARV-Guidelines-2022-Final-1.pdf</td>\n",
       "      <td>237</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Kenya HIV Prevention and Treatment Guidelines,...</td>\n",
       "      <td>[-0.022751497, 0.04970134, -0.06948286, -0.000...</td>\n",
       "      <td>4</td>\n",
       "      <td>Kenya-ARV-Guidelines-2022-Final-1.pdf</td>\n",
       "      <td>271</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                text  \\\n",
       "0  Kenya HIV Prevention and Treatment Guidelines,...   \n",
       "1  adherence, dosing of your medications, interac...   \n",
       "2  appointments  \\n• Ask:  \\n“Why do you think yo...   \n",
       "3  “What is HIV?”  \\n“What is the immune system a...   \n",
       "4  Kenya HIV Prevention and Treatment Guidelines,...   \n",
       "\n",
       "                                              vector id  \\\n",
       "0  [-0.06496429, 0.06532438, -0.028267752, 0.0271...  0   \n",
       "1  [-0.0096044205, -0.013640492, -0.020137833, -0...  1   \n",
       "2  [0.0147528965, 0.106143795, -0.0520965, 2.7184...  2   \n",
       "3  [-0.025173469, 0.103543945, 0.022959538, 0.005...  3   \n",
       "4  [-0.022751497, 0.04970134, -0.06948286, -0.000...  4   \n",
       "\n",
       "                                  source  page  \n",
       "0  Kenya-ARV-Guidelines-2022-Final-1.pdf   237  \n",
       "1  Kenya-ARV-Guidelines-2022-Final-1.pdf   237  \n",
       "2  Kenya-ARV-Guidelines-2022-Final-1.pdf   237  \n",
       "3  Kenya-ARV-Guidelines-2022-Final-1.pdf   237  \n",
       "4  Kenya-ARV-Guidelines-2022-Final-1.pdf   271  "
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tbl = db.open_table(\"kenya-arv-guidelines\")\n",
    "\n",
    "tbl.to_pandas().head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "4a389575-ecf2-4e6d-bb7d-995ef63bf896",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>source</th>\n",
       "      <th>page</th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>50</td>\n",
       "      <td>Kenya-ARV-Guidelines-2022-Final-1.pdf</td>\n",
       "      <td>235</td>\n",
       "      <td>for ART so you can start as soon as possible  ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    id                                 source  page  \\\n",
       "50  50  Kenya-ARV-Guidelines-2022-Final-1.pdf   235   \n",
       "\n",
       "                                                 text  \n",
       "50  for ART so you can start as soon as possible  ...  "
      ]
     },
     "execution_count": 85,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = tbl.to_pandas()\n",
    "df.loc[df[\"id\"] == \"50\", [\"id\", \"source\", \"page\", \"text\"]]"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (kenya-hiv-cdss)",
   "language": "python",
   "name": "kenya-hiv-cdss"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  },
  "widgets": {
   "application/vnd.jupyter.widget-state+json": {
    "state": {
     "0c3e4cbd414f4f51ab5c7faa4e2068a1": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": "20px"
      }
     },
     "1edc8bd936904e3d8ff979a21a43680c": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "FloatProgressModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "FloatProgressModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "ProgressView",
       "bar_style": "success",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_0c3e4cbd414f4f51ab5c7faa4e2068a1",
       "max": 1,
       "min": 0,
       "orientation": "horizontal",
       "style": "IPY_MODEL_4247dcaaf59a4fb0a7648a1aac8855b8",
       "tabbable": null,
       "tooltip": null,
       "value": 0
      }
     },
     "2d345a3aab784625bc982a686529bd1d": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "ProgressStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "ProgressStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "bar_color": null,
       "description_width": ""
      }
     },
     "37dc0d93fd154464b4630766dc82d1c9": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "40284b805555425a8418eaf81a6709c1": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     },
     "41257a7770404cea804d2088f729eca4": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "4247dcaaf59a4fb0a7648a1aac8855b8": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "ProgressStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "ProgressStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "bar_color": null,
       "description_width": ""
      }
     },
     "4686d436a8884729a364e4e6a028b889": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "6ce139d252c24712931698f3c2dc4770": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "FloatProgressModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "FloatProgressModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "ProgressView",
       "bar_style": "success",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_8c751b7141e74dfa9f224ef9e9359b8d",
       "max": 286,
       "min": 0,
       "orientation": "horizontal",
       "style": "IPY_MODEL_2d345a3aab784625bc982a686529bd1d",
       "tabbable": null,
       "tooltip": null,
       "value": 286
      }
     },
     "7e52755ad06a496da5d99b5e6ab388dd": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_37dc0d93fd154464b4630766dc82d1c9",
       "placeholder": "​",
       "style": "IPY_MODEL_84d4f0f92d6b4ed9adc4b5b76911b107",
       "tabbable": null,
       "tooltip": null,
       "value": "Processing docs: 100%"
      }
     },
     "7fc9d3e8f585436d8b0e9559935183a4": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_4686d436a8884729a364e4e6a028b889",
       "placeholder": "​",
       "style": "IPY_MODEL_b19ee0e254574e7ba0d3ac8fa47d3b2b",
       "tabbable": null,
       "tooltip": null,
       "value": " 0/0 [00:00&lt;?, ?it/s]"
      }
     },
     "84d4f0f92d6b4ed9adc4b5b76911b107": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     },
     "8c751b7141e74dfa9f224ef9e9359b8d": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "8f6f30d4e3c14103adcc6f8336feb672": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "958faa34da7442aa92c0cb0e651b8a60": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "95d13f9134cb4e97b2ba3a1f640156a5": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HBoxModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HBoxModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HBoxView",
       "box_style": "",
       "children": [
        "IPY_MODEL_7e52755ad06a496da5d99b5e6ab388dd",
        "IPY_MODEL_6ce139d252c24712931698f3c2dc4770",
        "IPY_MODEL_9fdc881dcd3c4993b70ad52f5d545f47"
       ],
       "layout": "IPY_MODEL_958faa34da7442aa92c0cb0e651b8a60",
       "tabbable": null,
       "tooltip": null
      }
     },
     "98edaa91b60d484ab606f712a2423d5e": {
      "model_module": "@jupyter-widgets/base",
      "model_module_version": "2.0.0",
      "model_name": "LayoutModel",
      "state": {
       "_model_module": "@jupyter-widgets/base",
       "_model_module_version": "2.0.0",
       "_model_name": "LayoutModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "LayoutView",
       "align_content": null,
       "align_items": null,
       "align_self": null,
       "border_bottom": null,
       "border_left": null,
       "border_right": null,
       "border_top": null,
       "bottom": null,
       "display": null,
       "flex": null,
       "flex_flow": null,
       "grid_area": null,
       "grid_auto_columns": null,
       "grid_auto_flow": null,
       "grid_auto_rows": null,
       "grid_column": null,
       "grid_gap": null,
       "grid_row": null,
       "grid_template_areas": null,
       "grid_template_columns": null,
       "grid_template_rows": null,
       "height": null,
       "justify_content": null,
       "justify_items": null,
       "left": null,
       "margin": null,
       "max_height": null,
       "max_width": null,
       "min_height": null,
       "min_width": null,
       "object_fit": null,
       "object_position": null,
       "order": null,
       "overflow": null,
       "padding": null,
       "right": null,
       "top": null,
       "visibility": null,
       "width": null
      }
     },
     "9fdc881dcd3c4993b70ad52f5d545f47": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_98edaa91b60d484ab606f712a2423d5e",
       "placeholder": "​",
       "style": "IPY_MODEL_f6cf331fec4342da813fdd65ec427458",
       "tabbable": null,
       "tooltip": null,
       "value": " 286/286 [07:35&lt;00:00,  1.50s/it]"
      }
     },
     "b139854af3cf4fb69cade2c9ee08e023": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HBoxModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HBoxModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HBoxView",
       "box_style": "",
       "children": [
        "IPY_MODEL_c6a2387cc9a1473d9db66c7d42a1d91f",
        "IPY_MODEL_1edc8bd936904e3d8ff979a21a43680c",
        "IPY_MODEL_7fc9d3e8f585436d8b0e9559935183a4"
       ],
       "layout": "IPY_MODEL_8f6f30d4e3c14103adcc6f8336feb672",
       "tabbable": null,
       "tooltip": null
      }
     },
     "b19ee0e254574e7ba0d3ac8fa47d3b2b": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     },
     "c6a2387cc9a1473d9db66c7d42a1d91f": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLModel",
      "state": {
       "_dom_classes": [],
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/controls",
       "_view_module_version": "2.0.0",
       "_view_name": "HTMLView",
       "description": "",
       "description_allow_html": false,
       "layout": "IPY_MODEL_41257a7770404cea804d2088f729eca4",
       "placeholder": "​",
       "style": "IPY_MODEL_40284b805555425a8418eaf81a6709c1",
       "tabbable": null,
       "tooltip": null,
       "value": ""
      }
     },
     "f6cf331fec4342da813fdd65ec427458": {
      "model_module": "@jupyter-widgets/controls",
      "model_module_version": "2.0.0",
      "model_name": "HTMLStyleModel",
      "state": {
       "_model_module": "@jupyter-widgets/controls",
       "_model_module_version": "2.0.0",
       "_model_name": "HTMLStyleModel",
       "_view_count": null,
       "_view_module": "@jupyter-widgets/base",
       "_view_module_version": "2.0.0",
       "_view_name": "StyleView",
       "background": null,
       "description_width": "",
       "font_size": null,
       "text_color": null
      }
     }
    },
    "version_major": 2,
    "version_minor": 0
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
